<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE sequence-cwu SYSTEM "us-sequence-listing-v1_3-2020-10-08.dtd" [ ]><sequence-cwu id="SEQLST-1"><publication-reference><document-id><country>US</country><doc-number>20230002762</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><number>1</number><sequence-list-new-rules><s100><s160>19</s160></s100><s200><s210>1</s210><s211>13</s211><s212>DNA</s212><s213>Artificial</s213><s220><s223>Oligonucleotide motif</s223></s220></s200><s400> 1gcattggtat tca                                                        13</s400><s200><s210>2</s210><s211>18</s211><s212>DNA</s212><s213>artificial</s213><s220><s223>Oligonucleotide motif</s223></s220></s200><s400> 2tctcccagcg tgcgccat                                                   18</s400><s200><s210>3</s210><s211>16</s211><s212>DNA</s212><s213>artificial</s213><s220><s223>Oligonucleotide motif</s223></s220></s200><s400> 3gagttacttg ccaact                                                     16</s400><s200><s210>4</s210><s211>16</s211><s212>DNA</s212><s213>artificial</s213><s220><s223>TATTTACCTGGTTGTT</s223></s220></s200><s400> 4tatttacctg gttgtt                                                     16</s400><s200><s210>5</s210><s211>13</s211><s212>DNA</s212><s213>artificial</s213><s220><s223>Oligonucleotide motif</s223></s220></s200><s400> 5caatcagtcc tag                                                        13</s400><s200><s210>6</s210><s211>20</s211><s212>DNA</s212><s213>artificial</s213><s220><s223>Primer sequence</s223></s220></s200><s400> 6caactccaga acccagcact                                                 20</s400><s200><s210>7</s210><s211>20</s211><s212>DNA</s212><s213>artificial</s213><s220><s223>Primer sequence</s223></s220></s200><s400> 7cttatcggca ggcaagtgag                                                 20</s400><s200><s210>8</s210><s211>26</s211><s212>DNA</s212><s213>artificial</s213><s220><s223>Primer sequence</s223></s220></s200><s400> 8gcacaagggc ttctcaactg gaagag                                          26</s400><s200><s210>9</s210><s211>2138</s211><s212>DNA</s212><s213>homo sapiens</s213></s200><s400> 9caatgggctg ggccgcgcgg ccgcgcgcac tcgcacccgc tgcccccgag gccctcctgc     60actctccccg gcgccgctct ccggccctcg ccctgtccgc cgccaccgcc gccgccgcca    120gagtcgccat gcagatcccg cgcgccgctc ttctcccgct gctgctgctg ctgctggcgg    180cgcccgcctc ggcgcagctg tcccgggccg gccgctcggc gcctttggcc gccgggtgcc    240cagaccgctg cgagccggcg cgctgcccgc cgcagccgga gcactgcgag ggcggccggg    300cccgggacgc gtgcggctgc tgcgaggtgt gcggcgcgcc cgagggcgcc gcgtgcggcc    360tgcaggaggg cccgtgcggc gaggggctgc agtgcgtggt gcccttcggg gtgccagcct    420cggccacggt gcggcggcgc gcgcaggccg gcctctgtgt gtgcgccagc agcgagccgg    480tgtgcggcag cgacgccaac acctacgcca acctgtgcca gctgcgcgcc gccagccgcc    540gctccgagag gctgcaccgg ccgccggtca tcgtcctgca gcgcggagcc tgcggccaag    600ggcaggaaga tcccaacagt ttgcgccata aatataactt tatcgcggac gtggtggaga    660agatcgcccc tgccgtggtt catatcgaat tgtttcgcaa gcttccgttt tctaaacgag    720aggtgccggt ggctagtggg tctgggttta ttgtgtcgga agatggactg atcgtgacaa    780atgcccacgt ggtgaccaac aagcaccggg tcaaagttga gctgaagaac ggtgccactt    840acgaagccaa aatcaaggat gtggatgaga aagcagacat cgcactcatc aaaattgacc    900accagggcaa gctgcctgtc ctgctgcttg gccgctcctc agagctgcgg ccgggagagt    960tcgtggtcgc catcggaagc ccgttttccc ttcaaaacac agtcaccacc gggatcgtga   1020gcaccaccca gcgaggcggc aaagagctgg ggctccgcaa ctcagacatg gactacatcc   1080agaccgacgc catcatcaac tatggaaact cgggaggccc gttagtaaac ctggacggtg   1140aagtgattgg aattaacact ttgaaagtga cagctggaat ctcctttgca atcccatctg   1200ataagattaa aaagttcctc acggagtccc atgaccgaca ggccaaagga aaagccatca   1260ccaagaagaa gtatattggt atccgaatga tgtcactcac gtccagcaaa gccaaagagc   1320tgaaggaccg gcaccgggac ttcccagacg tgatctcagg agcgtatata attgaagtaa   1380ttcctgatac cccagcagaa gctggtggtc tcaaggaaaa cgacgtcata atcagcatca   1440atggacagtc cgtggtctcc gccaatgatg tcagcgacgt cattaaaagg gaaagcaccc   1500tgaacatggt ggtccgcagg ggtaatgaag atatcatgat cacagtgatt cccgaagaaa   1560ttgacccata ggcagaggca tgagctggac ttcatgtttc cctcaaagac tctcccgtgg   1620atgacggatg aggactctgg gctgctggaa taggacactc aagacttttg actgccattt   1680tgtttgttca gtggagactc cctggccaac agaatccttc ttgatagttt gcaggcaaaa   1740caaatgtaat gttgcagatc cgcaggcaga agctctgccc ttctgtatcc tatgtatgca   1800gtgtgctttt tcttgccagc ttgggccatt cttgcttaga cagtcagcat ttgtctcctc   1860ctttaactga gtcatcatct tagtccaact aatgcagtcg atacaatgcg tagatagaag   1920aagccccacg ggagccagga tgggactggt cgtgtttgtg cttttctcca agtcagcacc   1980caaaggtcaa tgcacagaga ccccgggtgg gtgagcgctg gcttctcaaa cggccgaagt   2040tgcctctttt aggaatctct ttggaattgg gagcacgatg actctgagtt tgagctatta   2100aagtacttct tacacattgc aaaaaaaaaa aaaaaaaa                           2138</s400><s200><s210>10</s210><s211>53384</s211><s212>DNA</s212><s213>homo sapiens</s213></s200><s400> 10caatgggctg ggccgcgcgg ccgcgcgcac tcgcacccgc tgcccccgag gccctcctgc     60actctccccg gcgccgctct ccggccctcg ccctgtccgc cgccaccgcc gccgccgcca    120gagtcgccat gcagatcccg cgcgccgctc ttctcccgct gctgctgctg ctgctggcgg    180cgcccgcctc ggcgcagctg tcccgggccg gccgctcggc gcctttggcc gccgggtgcc    240cagaccgctg cgagccggcg cgctgcccgc cgcagccgga gcactgcgag ggcggccggg    300cccgggacgc gtgcggctgc tgcgaggtgt gcggcgcgcc cgagggcgcc gcgtgcggcc    360tgcaggaggg cccgtgcggc gaggggctgc agtgcgtggt gcccttcggg gtgccagcct    420cggccacggt gcggcggcgc gcgcaggccg gcctctgtgt gtgcgccagc agcgagccgg    480tgtgcggcag cgacgccaac acctacgcca acctgtgcca gctgcgcgcc gccagccgcc    540gctccgagag gctgcaccgg ccgccggtca tcgtcctgca gcgcggagcc tgcggccaag    600gtactccgcc gcgctcctgg gcagctcccc actctctcca tcccagctcg gacctgcttc    660tgcgggactg gtgggcaggt tgaggggcag cgaagcgttg tggggtggcc agggcaactc    720tcggggacag gcaggtgggc cccggggtgg cggatttccg cgggctgcct cggaaccgag    780cttcgcgccc agcccggggc cggttctgcg cccagacgat gccagtacgc ccggcctgca    840ctctggggct cgagacgccg ggcgaccggc catggagtgc cctgagggca accacacagc    900gcggggaccc caggacaaat aagaggaatg ggggcataaa ggaaggagag aagttcagga    960ctgggaattg gcgcctcgca gagcggcttc aggaccacaa gaagtcattt cggttgcttt   1020ttcttctatt tacgtcctcc gtccccttta aaattcactg ctttgatcac gggaccgctc   1080agtgaaaact gtatgtaact cttttggaaa ggaacagtgt ttgccggccc gccccggagt   1140ttctccaaaa agtctacccc gagcagggaa cggtttggca ccgctctcgt ttcggcggcg   1200ttgctgcctg tcttgctttc ctcgttttga gccagcccta caaaaatgaa agtggctcct   1260tttgaataag ctgaatcggg ctttggatca cgaaatctgc agaggcggag aagggaccgg   1320gttagtgatg aggaagaagt ctacccctct gttcctacag ccgcacacag gacctgttct   1380ggcaggggag acggtggtga tgggggaagg agtggaatgg agcaatgtct aactctctcg   1440cgggaccttc cggagagatg ctcctcatct tcaggcagag gccatgtgga aaaataatat   1500cgagttcagc agcggccagc cccgcgttgt aggaaccaga cagcggggct tggcagtgcg   1560cttgggcgca gccgtgccgc tgctgccgga ccccagtgct gcctcctcaa cacgggcagt   1620gccaggagag gggcataggg gagcacagtg cagagggact ggtctagagt ttactttata   1680ggaatatggt tcggtgtgac caactagggc ttagcatagt ttggcttacg tggacgggaa   1740gatgccagag ccgaactggg tgaaattcga gattgcgtat ttcaccaaca caggagcaca   1800gccctcggga aactcagcct agtcaggcag tagagagttg tcccggagag aagtgatcct   1860gcagactcga gaaggggcat gatgatagca cacgtctgtt gagcacccag tctgtgtgcc   1920gggtgtgtta cctctgtgac ctcatttggt caaacgagga ggcagttgct cctctctctc   1980tctttttttt tcttaagaga cagggtctcc ctctgtcgcc catgctggag tgtagtggtg   2040tgatcatggc tcactgcagc ctccgacccc tgggctcaat gattctcctg cttcagcctc   2100ccaagtggct gggactacag gcggatgcca ccacacccag cttctcattc ccgttttaca   2160gatagcggag ctaaggttga aaaacttgcc caaggtcatt cagctggaat ttaaacccag   2220acagcctcat tcagaggagt cagcccagca cttaactcca agggtgtggg agaggggtca   2280ggtgctgtaa atttcctggt gggctggacg tgcatccccc tcagagctgg gaacagcata   2340cacaaagcct aagacttgtt tggaggtgaa tagatcagtg tggctgggga acgttttggg   2400agggcagcag gagtgagcca ggctggtggc ccagagtccc agggctgaag aggctggctg   2460tgccccgtgc cctgtgcgca gatgttcttg aactggagca actcaaagcc tagtgtagtg   2520tagggctgac ctagcagtgg agtgcggaat gcatccaggg tggagagttt agactactgc   2580aataatctgg gtgtgaggcg acaacattga aaaagcatgt ttttgtccaa aacaagccag   2640ctgttactgg tctcgctgtt tgtggtctca tcgcacgggg tcctgagttg ctggcaccat   2700gcgagccgcc taatttattg ctagtgaggc aagttgctta acaagttttg gagttggctg   2760agtccctgtg tggaggaaaa caggtccccc attggccatc gggctcacag cgggcccccg   2820gtgtaccagt gaggggacag ccacagaggg ataagcatgg tggctttgaa aggagggaga   2880gacagagtgg gtacaatgct tttcttatcc ctccctcctt cttttgcaaa tatttattga   2940gctctgtagg gtgtctgaca ccgtttgcat gtttgtctgt ctggcacatc ggaggtactt   3000ggtacgagtg gattagtgaa tgaataaatg aatgaatgaa gacaaacggg aggtgcttgc   3060gatacacagc cattctgttt ttccttagtg gaaggcactg ctttgctgcg ccccctctct   3120ggatctcaca ctccaccctt gacttttcgg aggtgtttcc gaggacaggc gcctgggagc   3180cagcagactt cattcagtcc aagccaggct ccaggactca acagctggtg cccacgggca   3240ggtcacttga cgtcactgtt aaatgaggtg aattggctgc ctgctctggc tggaagattg   3300gcgggagagt cactttagct gccatggaca tgagcctttt ctaggggtgc cacttgacta   3360gaggcctgga gttggagcaa gtcatacacg gatctggaga cagagctctc gaggcaggag   3420cgggtgctgc gatttcaaat attataaggt ggctttgtct ggggcagagc atgccagggg   3480atgagaggta gaaatgtcat cagatcaggg gtccccaggg aggtgactag cactttgggt   3540cacagtagat ctttggatag aggaacatgt caccattcaa aggaaagcac tttcatctgt   3600aagctgttta ttgaatagac ctcagagaac atctctgctc accgctctgg aaatgaaggc   3660aaatcatcta tttcagaagt caatgcactg gcagggtttg gatgggaaag tatacaattc   3720agctagagaa caaagatctg tcatctccag ctgtactggt cagatgatta caaaaaagaa   3780aggaattgaa atactaatag ggtactaata atgagggcta acatatatgt tgtgcttatt   3840ctatgccggg tgcatactaa ttcatttgat cctccggaca gtcctatgag tgagtgctgt   3900agtcttccct gggttacagc tgggcagcta agtcacagag aagtaccttg ctcaggactg   3960gtggtcccac acaactggat ggagagcctc gttcataacc accatgctgt gctgttgaca   4020gagcaacaga gattttaaac caaccccagc taagccccag ctaatagctg aaataaacag   4080ggctccagat ggctgtggct tagagatgga acaggacaga tcacagcctt cactctgcag   4140gctcaggagc ctgaagacaa ggttgcctcc agttgccgtc agtgcagccc tcactaaaga   4200aaagcaaaaa gagccgaggg actgtaggaa ggctgtttcc aagccagaga tccagacaaa   4260ctgctcttga agagagaaag cccttccaga ttcccccatg tcccaaaaga ccagccggga   4320ttccggacct ctgctaaaac atggacaaga agccaggaac gagacctgaa acagacttcc   4380caaacagcag aagcctcatc catttctcct gctagtacat cctccaggaa agcccaccct   4440actccatgca gcagcccaga caagcttgga ggtctgcaag ctgcaggggt gcccagaaac   4500tccacccctg gaggttttta ggatcgcctg ctcctggtct caccccagag cctctaaagg   4560cagaggctgt atgtacatac ctggtgaaga accaagggct tagatggttg ctttacttct   4620tggagccctg gaatgtttgt aaaatttact tttttttttg agacagtgtc tcgttctgtc   4680gcctacgctg gagtgcagtg gcgcgatctc ggctcactgc aagctccacc tcccgggttc   4740atgccattct cctgccttag cctccagagt agctgggact acaggcaccc gccaccacgc   4800ccagctaatt tttttgtatt ttttggtaga gacggggttt caccgtgtta gccaggatgg   4860tctccatctc ctgaccttgt gatccgcccg ctttggcctc ccaaagtgct gggattacag   4920gagtgagcca ctgcacccgt gccaaaatgt actttattta ggtgactctt tcgtgggaac   4980ctcaaacaag caatcattgc tagctgagtg ctgaccctgt actgagctct ggggagacag   5040ggttgaataa aacaaagtca ctgcccacag gtaacttata ttcaatacaa tgggggaaaa   5100tacaatcact gcttccctgg ggttgtattt ttccattgtt aaagtgggca gtttgctcga   5160gagtcatttt cactattggc aattcaaata caccttttgt cagttaaaaa acaagtgtgc   5220cagggacctg agcttcatct tagggcaggg tgggtggaaa catttgtgag tctccagctt   5280ttagtcacct gaaacttgga aacttggagg tcttttgagc agtttatgag tctctgcctg   5340ctctggtcgg ctgccttctt ttattgctct gttggttttg ctaaagagtt aaaatattaa   5400ggcttcataa aattaggaag ttaacaagct caaaaaccaa gtgtttgagt tacttcattc   5460cactgagaga gctgtaaatg ggttgcattg gaacttaaaa taactgcatt gagtaagtga   5520tggtggcggg caccatgagc taactgtggt cagaagcctg atggcctccg ctttggggct   5580ggattctccg tttggagctg tgtgatcctg gatgagtttc atgccttgga ttcagaaatc   5640agactttcca tgagcttata tttcaagtga ataaatagct ctggtcaggc ttaatttgaa   5700gaagaagtaa gcttggcagt gggtgagggt tccttggaag gccaactggg gcggaggggc   5760tgagggcaag cggctctggc ccttcctggg gtgttacctg accaggtaac agctccctcg   5820acctctcgga gcctcggcag tgaggggatt gggccagttg atctctgagg ctccttttaa   5880ctagaatggt ctgggatttt tctaagaaaa caagtctttg aggaggttgt ggtcacctca   5940ttcctaattt aaagcctggg gaggcttcct tatgagctac ttctttttcc taaattattg   6000atggttaaag ccaaggctgg catcgaatag atgtgatcca tcttgagcct ggttgctttg   6060tgtttcagct ttgtactggc tgctgaagtc cccgggagac cacaggggtg acatgttcat   6120ctccaagaga tgagcttcca cgagactcat accccttgct ccttccctgg ggctccaagg   6180cctttgggtc atctgaagtg agataccctt gtgtcatttc atcttttcct tctccacctt   6240ctctgccgtt aaaaaaaaaa gaagaaagag aaaaatccta ttaatagaga aaccgagaag   6300tgtagccatt ctgaatgtgt ttccaaaagg ctcctggaag tggcatggaa gttacagtga   6360ttcagcacta cttggtgacg tgtgcctaga accacagggg gacattagcc aggacaacac   6420gcctcaggac agaagtaagt ggctgcgaag aggcatgtcc atcactgccg gaaagatgca   6480gagttcagtt tttggagtca gtgctgagag ttccatttct aaattcattc agagcattta   6540tttaacacct actgtgtgct cagaagtgta tcaggtatgg ggactcagag gtaagggctg   6600gtggcccctg atctcaaggt actcgtggta gatagtatga tgctcagctt aagggctggg   6660cttctgaagt cggattgcca ttttctggat gtgtggtgtt tcttgggtga cttcatctct   6720aagtctcagt ttccccatca gtaagataag agaagtaata gcagatacat acgtagctct   6780tagggcattg cagaatggaa ggacctcctt atatgaaacg caaagcactg tgcctgatgc   6840attgctagaa ctcaggcaat attagcgtgt tgtcattgtc atcatcatca tcatcatcat   6900catcatcatc atcatcatct tcaaggcact gacaaaggag tcagctgtgt gggaggagtg   6960ctgggacact cttgtctccc tggggatgag gtgggtgggt gggttaggaa atcttcacag   7020agaaggaggg tgatgtgaga cttctgtccg ggagctgact cggaatttgc catctaatat   7080gttggaaaag gttctctggg cagaggtatc caaagtcact ttgcctgtca ccctttgagg   7140tcccagttgt tgcctatatc atgtgaccag tgtgtggctt ctcttgaatt aagagctgca   7200tgtctggact gcctgggatt ttacagatgt catctcgtta actctccctg gagcttgtga   7260cacccaggag atggcagttt atagaagccc tggcaccttc ttgaatgatg cttggtttgg   7320tttctatgca ctgggaattc ctcacaagga aagatttgtc acatcttaag gaaggaaaaa   7380aaggcaaatt tgggagtcca tggataccct attattttag attccaggac aaattgtcga   7440ataagcacgt ttcataaaaa caatcctccg cagcatcccg tgacagcagc tggtccctcg   7500ccacaggata attatgtctc cttgtgcaca caaaagtctc cgagggcata ttgttgtggc   7560tggagtttct gataatttcc aaattgaaca acctcagtcc taatgagtca gaggcttgtg   7620caatattttc aaacctcagg aacatctttt tcattagttg tgcaataaag atggtaggcc   7680tatctctgtg atgagctgtt tttttttctc aaagtttgat gagattcgcc gtagaattcc   7740ttctcacata gtcttgggca agattttacc cgatcttcca acacatgagt catctcatat   7800cctgtgacta agaagagctg tctctttggt gccagttttc taagtgcagt caccacttga   7860tggagacgga tggacacagt tgggattgcc caggcagatg ggcaatcttg ccagctagac   7920ataggggagg gaagcctcaa tgttcagcgg tcacatctgc ttttctgtgg cacagagtga   7980gctatacagg aatattgtat tctccaggac agttagggca gtgggaaatg tcatcaaaca   8040gaacagtgac ccaaagagcc actgccactg ggtgctctgt gggagctggg cactgtgctc   8100attgtgttat gggccttgct ttgttcttac cttgtagcca cccagagagg cagggcatta   8160tccttgcttc ctagctgagg ccacagaaga ggctcctaga ggttagctgt aacttgtcca   8220aggccagcca gtgcaaggag gcagagccag gatttgagcc catgtctgtt tcactcccaa   8280actattcttc agatttcttt aagtcaagtg ttatttagaa atgttttgtt tattcatcaa   8340atatttggtg ggtgtttcca gctatctttc tgttattaat ttctagttta attctattgt   8400gggctgagaa tatattttgt atgatttcta ttctattacg tttgttaggg tgtattttct   8460ggtctagaat gtggtctgtc ttggtgagtg ttccctgtgt gcttgagagg aatgtgtgtt   8520ctgtcattgt tgaatggagt gttctataaa tgtcacttag gtctagtgga ttgatagtgc   8580ggttcaggtc aactgtatcc ttcctgattt tctgcctact gatctatcaa ttcctgaaag   8640agaagtgttg acgtctcctg agtctattct gaaacactga attgcggtct ccatgatgaa   8700ccactagagt tagaaaacct gggtcctagc cccatttggg cctttgggat gactcccttc   8760tgcctcagtt tcctcatcta caacaggggg acaatgatgc tgcctaggag acatcagcag   8820gatactgtga aagtccagtg gcataagggg tatggaggag cttcgtcaac tcctaaagct   8880tcagtgctag gaatcctaaa gcattgaaat ccaaagatat aaggaatatg aaggagtttt   8940gtcaattcct aatgcttcag tgctaggaat cctaaagcat taaagtccaa tgatataagg   9000aatatgaagg agctttgtca actcctaaag cttcaatgct aggaatccta aagcattgaa   9060gtccagtgat ataaggaata tgaaggagtt ttatcaactc ccaatgcttc agtgctagga   9120atcctaaagc actgaagtcc aatgatacaa ggaatatgaa ggagctttgt caactcctaa   9180agcttcagtg ctttaggagt cctaaagcat tgaagctgta agagattagg acctctagtt   9240ggcaattcca gactcttcca ggactcctga tagagccaac accaagaata gtgaagccag   9300aaggatggaa atagtaaaat gcctcctggg tgtcaaagca tgggtctcct ctgggcatgt   9360tctcttgtcc tactgagaca tgatagctct tggccaaagt gactgaactt gaccctctgt   9420ttcaggaagg ccaaatgcag ggttcactac catcatgtcc aagggcagat gcgttggtcc   9480agaacatcag catcccaatc attataccaa gcaaacagcc gtctctgcct gcaccgtgga   9540gagcacacgc tcctcctggg gtggcctgca tcctgtgttc ttctcaggcc gactttctgt   9600ttaatgtttg ctggtcagga aatggcctga gctgaggttc ttcagatccc agtctgacct   9660ttctccacca gcatttgtgg ctctgaaaaa tatagcccag tgtggtttag ccccactgga   9720tgaaacccag taggaaaagt ctgataatag cagaagacgc acaggaggaa gagtgaggat   9780ttgagagcat ctgggaagga ccatgtgcct ggatatcgtt ctgtctgtgg gattctgtga   9840cacttgtcat ttacagtctg ttcccatgga attctcatca ttggccaaac atatagtcct   9900tctgtcctct gaaaaatatc attctgctcc gacctttcac acccatctct gaccacatca   9960actccctgtt tgcatgcatc ttgtggatga aggacaccac tttacctgta aagacactgg  10020tggcttccca aagccaccaa ctgacttgta gagaagacag aatcccagag tatgaaacct  10080gagggtgaag ggtcctggca ggtcctagag ctcaaccctt cacttcacag gtggggaaac  10140tgagggagcc aatgggaaca tgactctcac aagctgcaca gctcatctgt aggggccagt  10200gtggagtctg tttgtcctga gacccagggc tgagcctttg agccctccgc atctcagccg  10260catcctcctg ttggagcagt taggtgtttg ggagaggcca cggtccatgc tcatggtttt  10320cctgtaaggc tggagaaaca ggccttgttc ccttagtctc tctaatcaaa atgaggttgc  10380agaaaaccct tctccctact tctccctaaa ataatttcct tgggttagaa gatgactaaa  10440agactattca tccgatgact gatgtctccc ttcaagagtt ataagcacat ataaatgcct  10500ttgaatggta attataataa ttttgctgaa gggaaaatat cagtataaat atcatggtgg  10560acacatggaa tgaggactga gatgctttca tgtcttttca gctgtggtta gattttcttt  10620aagcagaata tacaagtttt tcctctccta gcataaggac tctttttttt tgtatctttt  10680ctctctactt tttagacatg atggaaaatg catttataca tttgatgaca tattgtacta  10740tctcagttgt ttaaaattat aaatgtaatt taatcatatg aaaaattaag aaaagaagat  10800tcatatttca ccatcatctc cccagaaata tcatttcttt attactatta ttattattat  10860tattattatt attattatta ttattatttt gagacagggt cttgctccat cacccaggct  10920ggagtaaggg gcacgatctt gactccctgc aacctccacc tcccaggttc aagcagttct  10980catgcctcag cctcctcagt agctgggatt acaggcctgc accaccacac ccagctacct  11040tttatatttt taagtagaga cagtttcgcc atgttggcca gactggtctc gaactcctgg  11100cctcaagtga ttggcctgct tcagcctccc aaagtgtggg gattacaggc atgagctacc  11160atgcctggcc taattccatc atttctgtcc caagtgttgc caccgtttgg ttaactgttc  11220ccctgttcac atccatttgg gccaaggttg caatgttaaa caatcctgag atggacattt  11280tcatgtttat ggctatttct gtatctaggg tcattctctt aggagaggta ctaaggagta  11340caaaaactgg gaagaaggat atggaatttt tatggatctg gtataaattg ccaaattatt  11400ttccagaagg gttgtagcca tatttgttgc catcagctct agaatttcaa cctcgtaagt  11460cactgaaaga aattctccca aaatcaatcc ttcaggaata atggaagaag atggtgccaa  11520accccagcca ttctgctcac tgttagattc cttttttggt cttacaggtt acttttattc  11580tcaggttgat ggctcttaga gttgagcaat gtttggggta gaataacgag cacttttaaa  11640acttggttct acctggggag ggggtgagtt gtgatcacag acagtctcac ctgggagggg  11700cttgggtgtt tgtcggcttg tccttctaac actcgtgtct caggcgagca gcctgggacc  11760agtgaggtga cctgaaggct ggaggtcaca agctaagagg cgacagagaa cccaggtctc  11820aggaagccca gcccagagct cgctgcactg agcctctcgg atgccagctc tgtccaggat  11880gcgggaggag gccagactga tttggtctgt tttgaaaagt gatgaaaata tttattcaaa  11940tgttttgtac tcataggcag aagtataaca ggagctgcat atacaaaatt attttctagt  12000agtcacatta aaaaagtaaa aagaaagaac acgattattt ttctttttaa aacagcttta  12060ttgagagata atttacatac tataaaattt acccctttaa agtgtacaat ttgctgttct  12120tatatattca caatcatgca cgtatcacta ccagctccag gacactttca tcaccgtaaa  12180aagaaacccc gtatccatta gtagccaccc catacttctc ctctgcccag ccctaggaaa  12240ccaccggttc attttctatt tctatgaatt tgcttattct ggacatttca tataaatgga  12300atcaaagaat acgtaacggg cttctgtctc ttagcataat gttttcaagg ttgtccacat  12360tgtagcatgg atcattattt cattccattt tatgattaaa aatatgcctt ttaagggata  12420cagggagacc agacgtctat tttatctccc ctccctgatg gggaatccta atttcagcct  12480ggaaagtcac tgcgaaagtc taaactgcag aggtgatact gtttccactg gaagaaactg  12540tagcacctga ctcaggaagc cagcattaaa accaagaata ttctatatgg atggggatta  12600cgcactgaaa ggaaaacatg aggaaatgca cttttcagat ttattagatc atagaacttt  12660tttggagctg gaaaggatgt cggaaaccgt ctagcctacc ccctcatctt accactgagg  12720taactgaggc ccaggaaggg gaagtggctt gttttgggtc cgggaccact cttcatttct  12780tatttgagcc aaagcttcct tctggcgtct gtctctgttt cacaagttcc cctcgcatgg  12840gggctgggta ctgcttggaa gaactggctt cttccttgat acaggggctc gttcaccatc  12900acctccctcc ctcacgtctc ttctgcctct ctgcagcctc aggccctcct cctgcaccag  12960gggggcagac tcaacccggg tgggcactgc ctcccagtcc gtggccagag gctggagggc  13020tagggagact gaacagcccc ggcagctcca gacataacaa cctatgttga ggagtcaggg  13080caggaagcga acccagctga gaaatctgcg aaggtcagga ccagagccag acgcttatca  13140agagcaaagt taatggtttt tgtgaaccga gcagtcagct gtttccccga agataataat  13200agacacatca tgttgggcat tcaggaggca tctgaaaaaa aaaatgtgca gtggaattga  13260ttggaagctt ttccctaatg cataaaatag gccagaaaag actatcaaat gtaacagcac  13320cgatcaaacc caatagatca agcaaggact gaaaaacaca attttttttt tctttgccag  13380tgagtctgaa aagtgatttt caatgacagg cgcctttaaa catagacaac ataaacaaca  13440acatagttgt tctggaagag gcatcttttc ccagtaaagc caaagatgca gatctaggct  13500gtgcttgtga ctgacagcac agtgaggggt tcacagccag ctggccaggt gccccccgaa  13560agcacatttc gaatctactc tatttgagag agactgcctt agccttgttt gggtaagtct  13620tcctccttca cttcacctgc cacagacttt tccaggcacc atctgctgca gtcttggccc  13680agcccctgca acagttactg ctcaaggcac ccgggacatg caggacgggg gagcagcctg  13740aggtctggcg tccggcgagc ttttcccact tggagccgtc tgggagactg tcccggaaag  13800agaggggctg ccaacacttg gaagtgccaa tgtgtgctgc aagtcgaggc caggctcccg  13860gctcccccgc ctcttcctcc ttgattcatt aaaaggaaag aaagaggcca cacgaaactc  13920tcctgaattt catttctttg tttctatgca aaagacagag cgtggtcatt catcattcaa  13980attttagcct ttttaaacaa ataataattc ctgcttgtga attcagtgta ttttaacaag  14040agtaggtctg agggccgttg gccgtgtctt tccttagatt tgcagacagc ggccctgatg  14100gtgcataggg tttcaggttt cctttagacc tcagctggct gcctgggcca ccacttagca  14160atgccattgt ccttcctgtg cattttcttt gcagaattcg aggaaatcca gtcgcacagg  14220cccctctgtg cccatgtccc cggcgccctg gaatgtgcag taccagcagc agcgattaga  14280atgggggtct ggtttcccgg aatgtgcaag gtctggcttc tgtttctgct gcctccatgc  14340cccagaccag tgctgggccg ggctctgggc tggagccgtg gctgacaagt ttccttggaa  14400tttaatggag cgggccagac agcatgcagc cactcaaact gaaaacctgg gaaagaaatg  14460agtgttgtgg ggcagctttg ctgcattcac tgggtcatat atgcttcttt ttcttttcct  14520caggcaaccc ctcttgcaga caggaggccc cctccccttt cgcttcatgc ctcactggcc  14580attaggaacc ttttaaaact gatttctctc ctgaccctca gagagaacat agtccaagtt  14640ccctggagga ggaggaagcg ctctgtgttt ctctgcagtt cacggctcag ttaaatgcag  14700cctacgtgct gtctttcccc actcctctgc ctgctcccgt tgtgcttctc atgatcattc  14760tcaaattcag cgagaaacct cacaaaggga gcttttctta gggaagagtc atccttggcc  14820tcccgaatgt ggaccagccc ctctccccag ctgcacagca tcaggttagt taaccacctg  14880cctccatctg ggtcctgtct ggacaggcct actcacacct gctgcaggca tccaacttgc  14940cctcaggtgc ctgtggctcg tccagagggg tggagcccac attccagtcc tgacaggtaa  15000agttcagtgg cggggaccct gcatttagtg taaagatcaa tattccaggt cctctcttcc  15060tgccacccag cgactggccg tttgcaggca ctcggtccca gttgtcctgg gcctgcagcc  15120cttgcattct ctctgctttg tctctgctat tgcacccctg ccccatcaga aatgcaggtg  15180ggggggcctt ccgctgggac agtgagagac tgggtagtaa ggggagcgct agagggatgg  15240ttgcgcttgc atccagccct gactgcattc gctctccccc gcctctctgt gaaggtgctg  15300agctgtgagt ggaaccaagt ggatgagagt ggccttgggc acctgccgat aaatttcccg  15360gtgtgtcttc tcctcctggg agtcccatct ggatttgggt ctggatttat ttattcagca  15420agtagcctct ttatagttac tttttttttt tttttttttt tgagatggag tttcactttg  15480tcacccaggc tggagtgcac tggcgcaatc ttggctcact gcaagctccg ccttccaggt  15540tcacgccatt ctcctgcctc agcctcccga gtagctggga ccacaggtgc ctgccaccat  15600gcctggctaa ttttttgtat ttttagtaga gactgggttt cactgtgtta gccaggacgg  15660tctcgatctc ctgacctcat gatctgccca ccttggcctc ccaaagcgct gggattacag  15720gtgtgagcca ccatgcccgg cctgtagtta cttttaattt agccatgctc ggggctgaag  15780gggatgccaa agaaatataa gatgagcccc tcagacggct aaagatgaag atgaggcctc  15840cagtatgtac ctcccacata caccccagga aattctgggt gtcactggat tctggacctc  15900ccaaaagctg ctggcacctg gaggatgggg ccccgaggct ggacctcact cctgctgggt  15960tgctggactg ggaaagtact gatggcagct gaggagtgtg tcccagactt cactgagcca  16020ttcccaaaga ttattccaag ttctcctgac actgcactgg aggcctgctg tgctggcctt  16080ctttatttac agtttctgac tggtgtctag cagccctgcc agagagagcg gcagtgtgtc  16140tgcaggcgac caggagaaat gtctcaggct ttagagcagg actttgagca catagctgtg  16200ggggcccagc aggctgtctc ctgcacggtt acttctcctt gtcctttcat ggtcgagagg  16260ttgctgcctg gcccttcaag tgaggatggg acatgctatc cattggcctt aatttccaac  16320ctctgcatga tgcattttat gctcctgcct ttgaaagaac ttttattttc ttgtcattta  16380tgcccagacc ccacatggca gaaggaaggg aggctgggac aggggaggcg gataagctgc  16440cgctgacaga cctgcccagt ttcttagctc atcccggcct ccatcctggt gagcagacac  16500tggcccaatc cagccatatt tttggctgag tttctgtctt cacatctcat ccttaaccct  16560gaatcctggc catagttggt actgggttgt attcttattt gtaatcttta aagtaggaat  16620acctttgctg gtatttaaag tggaagaaat caggtgaaga atcacaagtg atttgcaaac  16680tggaagagac attagaatgt aaatgtgagg aagcgtcagc atgaggggct tgcctgggct  16740gcacagcttg ccttggctgg agtatgcact gttctggcat tgcagagagg atgggtacct  16800tgcctccctg caggtggggg actgtatcag cccccgcaga ctgctcctgg gctcctgagt  16860ttgacagatt tttttttttt ttttttgaga cggactctca ctctgttgcc caggctggag  16920tgcagtggtg cgatctcggc tcactgcaag ctccacctcc tgggttcacg ccattctcct  16980gcctcagcct cccgagtagc tgggactaca ggcgcctgcc accacgcctg gctaattttt  17040tgtattttta gtagagacag ggtttcaccg tgttagccag gatggtctcg atttcctgac  17100ctcatgatct gcctgccttg gcctcccaaa gtgctgggat tacaggcttg agccactcgc  17160ccggctgagt ttgaccagat taaggcagca tctccagtgg cacctgagca gctcctgaga  17220tgcttttctg tgctaaatct ggatttgggg tattaaatca aatgaatttg aaatgcaggc  17280acagctggcc ccatgggcat ggacctgtgc agtcacacct tgccccgtgt tcagaagggt  17340gctgtgcctg ttttaatgct ctgctgttgc tctcttgaga ttcttaataa tttttgaaca  17400aagggcccca catactcatt ttgtactggg tactgcatat tatgtagcta gtcttgaatc  17460taggacagtg cattaaaatg ccattgattg gatcaatctg ctcttgcaac tgatttgaat  17520tttgggaaca tgctgtttcc tgtgaataaa ggaggattca tttcttttcc ctcgaataca  17580ctgcgttctg ttttccaaat tagctctacg tatcaactca gctgagaaat tggaagcggg  17640gattgttctg gctggaaggg aaggttagat tgttaatcct gcatcctggc cctgatctca  17700ccgagtgtga agcatgttcc cacaatggtg tgggctgcgg ggggctggag gctggctgag  17760aaggtgggga ccaaggaggg aggctagcct gggagccaga cagatggggt taggctcttg  17820cttttgccac tcgccagctc tgaggcttag ggcaacatga tttaattctc tgatccttgt  17880ttttttcatc tttctgtaga ctggtgatga gatgcaccct gcaggcttgc aggcttgcag  17940gagtaattaa aggtaatatt tgtgcctatt attgggcttg acatatagta gatgctctac  18000aataaataga tcctattatt cttattgata atattatttt attgctaaca ttgaaggttg  18060ggtgggattt gactagctgg aggcgaggag aatgagatca tccaggccgg aaggaaaaga  18120gacatgaatg cagggggatg gggtggagca ctttggaggt gtggggagag gtctgcaggg  18180tgggagttgt gcattaagga gtcgtgggga gagtggagga atcagtgcca catggtgaat  18240gagaggggat cgtgggcccg aggagatggc gatggctgcg gggatcctgc aggaagttta  18300tgtgccccaa agtggcatta tcagttaggg ggagacactg aagacagagg tgaggcctgc  18360ctgaattagc gtagagtggg attcttggaa gcttcagaag cttgagaaga gccacttgga  18420ggtgttgaaa tgcacctggg agggacgtgg ggacccagct ctgggctgag agctgggaga  18480cggaaacgca ggtgaccttg gccttgaaga tggggcatga tatttagtgc tttatgtgca  18540atctcaccta ggactcccaa gccctttgga gtaggtgata ttagctccgt gttacagaaa  18600gggagactga ggctgaagca gggacattca tgatctgaag tcacacagct gtacggggca  18660gaagtgggca tggaggcatt aacttagagc cgaaaggtgt gacctttctt agtgtggctg  18720gccccacggg gaacgtgtgt gggttggagt acaacttggt gttcctaccc atcccagatg  18780ctctgcgttt gtgaacccca gttgccacat cagggcgggc gagggcagga agctctgcag  18840ggagaaggga caagggacag agccaagaac aggggcagtg ccccagggtc ctgcaggggc  18900aatgaagggg gttggcacac ctgggttagt tgctggccag tgtggggaga gagctggcct  18960gggagtctaa tgggaatgcc agggaaagct gccttggtcc cctaaagtga agcccccatg  19020ctggccatgg agtgttggtg attgagggtc cctgctagtt gtctggccga ggcagcatgt  19080cctataggca tagctctggt gtcctgctgg cgtggcgtga gtgcccctca tgctgggagc  19140cagccctgtg ctctggaggg aggtggtggg aggacaaggg acagtgggac ctgccacctg  19200agcaggaatt ggcaccttct cccactggca ggtccaggtt ttatggaatc tgaaacttgt  19260acaattcagt ataccctctt caagaaaaac acccctcaaa attatgaata taacattagg  19320tatgaaacta ttattgatat agattgaaaa aagaaaatgc ccaaaatgac aaacttcaga  19380aaatagacaa atactgcaaa catcacaaaa tcagaaaaat aagattaaaa aaagctaact  19440gctgaacact ccgtcatctt gaaaatgccc ctctctcctc ctctattttt tggctgtgaa  19500ctctttgctc accttttcat gtgacaatgc ttttgtaata tttcctacag agaaaataga  19560ataatttatt attactttta ttgtttttgg attattatta tgatcaattc aatatttttc  19620tgctacccac acactcactg tcttctgtcc aacctctggc ctgcaccagg ggaaccagca  19680gtttcccctg ccatagggtg tccctggaga ccacacatat agcaggatag atatagcaat  19740ttaactagac acagaaggga cttcaaagcc acaaatatat ctcatttaac ctgaacaaaa  19800tgattatcca gttttacttt tcccttagcc tcttccccca aatgctggca gccaccctga  19860tgggatagat gtgtgacaga gggcaagaga ccgtggcccc aaccagctgc agcttcactc  19920tttcatttct gtatactctc tacaagctgt gatgatagca ctttgctagg gcccctcaca  19980gggcagatgg agggctccac gctgaagctt tgtggatgtt tgctgtctat ccacctctgc  20040tccttgtgcc tatgcaggga ttcaggccca accactgcag agagcccaag agcatcaggc  20100agaggttccc aaactgtcat gattggtggc acctttagta gttgatacgg tttggttgtg  20160tcctcaccca aatctcatct tgaattccca catgttgtgg gagggacccg gttggtggta  20220attgaatcat gggggcagat ctttcccgca ctgttctcat gatagtgaat aagtctccca  20280agatctgttg gctttataaa ggggagtttc cctgcacaag ctctctctct gactgctgcc  20340atccatgtaa gacatgacat gctcctcctt gcctcccacc atgattgtga ggcttcccca  20400gccacgtgga actggaagtc caataaaacc tccttctttt gtaaatcacc cagtctcagg  20460tatgtcttta tcagcagtgt gaaaatggac taatacagta gtgcagtcat tttttcatgg  20520tccccagtaa ggccaaaaaa tacccaacag ttccatttat caattagtgg aggccaaaca  20580atttgataag tatttgtgtc cctataacac agtggtcatt aaaaaaagac attttaattt  20640cattattcaa taagcatgat tacttatgaa tgggatatgt gcacctgttg ggtgtcacat  20700gacctttcaa atcttggagt cagattggac accaccatgc ccatttccag ttcaactctg  20760atttttgtgt ggtacatgct ttttatcaca gtgactgcca gaaatccaac ttcatatgga  20820atcatgaaaa gggatgtagt gtgatctgat ttcaaaacta tgatcaatct agagctagtt  20880tacaaggtgt ctaacagtga tcaagtatca ctgtatttcc ctagaaaacc tgaaatatcg  20940atgaattttc tgtggcactc tggggtccct tggggcacac tatgggaacc atgggattag  21000gaccataagg atatgatttt ggcttcttcc tgcctcagat ctaatcttta cctggcattt  21060ttgccttaaa gatgaaagaa gcatacattt tgatgtattt aaagcacata ttcggccagg  21120tgcggtggct cacacctgta gtcccagcac tttgggtggc tgaggcaggc agatcacaag  21180gttggaagtt tgagaccagc ctgaccaaca tggtgaaacc ccatctctac taaaaataca  21240aaaaatagct gggtgtggtg gcatgtgcct gtaatcccag ctactcagga ggctgaggca  21300ggagaatcac ttgaacccag gaggcagagg ttgcagtgaa ccaagattgc accactgcac  21360tccagcctgg gctacagagc aagactctgt ctcaaaaaaa aaaaaaaaaa aaaaaaagca  21420catattcatt ttgtgcttat tcttttgaga gaaacacaga taaaagccta tcctttaatt  21480catactcccc atactgtgat tttcattttt actgcaacaa attttgttca gtgtgataat  21540gaatgtcaaa cacttaatgc cttgctcttt tcagtaacat gacatattgg agaataatga  21600ctgaagctta tctacactgc ctacgtctgt tttcttccac cttgaaagaa gttgttgaaa  21660gtaattaaga agtattatgt gtaaaactcc agggatgatg tgcttcaagg aagcaacatt  21720tatgaagttg tgtgcttgac tagtagttta taaagaggaa agacgaatca tttattgtct  21780tgggattgaa tcttggcaat ttttaaacta taaagttaca ggaaatgttg gctgctctta  21840atgggccatt tgttgtgtta aaaatcagta atgagaaata tttactaggt aagtggaaag  21900atccatctct ataaattgtt gtaacttacc attttacaaa tcttagttac tcagtttttc  21960tgcttaaaaa tgaaatcatg tagcactgta taagtcattc agttttttat tttggagaat  22020tactctggat tgtctaggct ctgtgctctc cacatatatt tttgaaatag tttgtgaatt  22080tctacaaaaa ctcctgctca gaattttcac tgagagtatg cttaatctat gggttaattt  22140gtgagaaatt gatagcttaa caatagtgaa tcttctgatc tacaagtgtg gtatttctct  22200ccatttattt aggtcttctt tattttgata gcgttttgta gctttcaatg tacagatctt  22260gcaaatatct tgttaaatat ttccctaatt acttgatatt tatttttgat gctgttatag  22320ttatatttta aaaattttga ttccaattgt tgctaataca tagaaatgaa attatttatt  22380gacctcttat cctgtgacat tgataaacgc agtcatatat tcgtagattt ctagaatttt  22440tctatataga ctatcatata tatcatctgc aaataaagac ggttttacat tttcctttcc  22500aatctctatg ccttttgttt ctttctcatg cctcattgtg tggtccatta ctgaacggca  22560gccagttcca gctttctgtt caattaagga gcaggtaaaa tggccaggcc ttgacctttc  22620agggggcttc ccgtcctcat tgccttctgc tgcctcagtt ctggcttaac agaacagtgt  22680ggggaggagg catggtcctt acctactagg gcgttacttg gccttcttca ggttggttgc  22740ttcgtcaggt ttaagagctc acctgggctg cagttcaggc taggttatct gctgacctgg  22800ccctgtctcc cttctgtagt gtctgtgggg tacccttgta agctagggag aagagacaca  22860cgtgaaggcc agaaaaaaca gcctgccaca cagcttccct ggatcatacc ttcgcagtga  22920catgacgacg tcgttaggag gcgccgaggt ggctgagtgg gtctccagac acctcccttt  22980acctctctgc tgtgccactg atgtgtgact tgcttacacc tatgcagagc tgccactgag  23040cagcactgtg gccagtcctt tggattttct tctttctaaa ttgtatgccg tggcttgatc  23100aagcatttca tatacagtag atcatgaaat cagcatagaa aacacattga ggtaggtggt  23160gttaccacat tttatggatg agaggctaac acttggagga gtcaggtaac atgtccaagg  23220ccacacagct agtgagtacc ctgctgaggg tcacactctg gtccatctga ggccagagcc  23280tgtgccagcc ttctcctcat gctgatagac gaggaaacag aaagaaggag cagtggacgc  23340ccccaccctc tgtcccctga accccttgga gagtaggcag tggcagagcc agcctgggcc  23400catctatggg aattctccat cgggattgac tcctctggaa ggaagacagt tgacccacag  23460ttgagatcac agcagatggg ccagccaggg tgtctgtaga ccatcaggca gtggccactc  23520catgtagttt aatggacaag cccttttaat ggaacaggaa tctaacactg aaccaagctg  23580cttttagaca cacttttatt cctcactctg aaatggcgtt tggacaagcc aaatatttct  23640tcttctttca gttgacattt tgtccatctt tgaactgtta gttgatgctt cttctgttta  23700gttattcctg ttctattttc ctgttgccac tagtccaccc agggatggta agaatggaag  23760tcaatggttg ctttttcatc tgagatgcac cacgaaggct tgtcagtcag ccttgtcata  23820tggtctgtgc tcccactgct ccttctttct gtttcctcat ctgcagaatt tggagagtcc  23880tggacctgat ctcaaatttc acatgttatt tatcttcctg cagcacgctg gggagaggaa  23940gagacaggga catagaaggt tggagctgga acagacttca catctcattc cagaggcatt  24000tggtccatct tacagatgag gaaatggagg ctgctcagtg gactgaggct ggaactgggc  24060cttccagtgg ccaggccaga tcctccttga tctcccttgt tgctttcctg gtgggaagac  24120cctggaacca ctttatgtga ctgtgtgaga agggaactgc ctctcatttt acccagcaaa  24180atccaccttc aatccatctt catttttgcc cctggtgtgg gcaaattctc ccatacctaa  24240ttcaggaagc cagaaagagg aagtgagtta atgatcctta gtgggaaggc gctggtaatg  24300gtccttcttg tgagagtttc tgaaacacca cgctgtctct gtgttctggc ctggctggag  24360ttaaacctct tcttggcctt tccccaggaa gctggtctga ggaagcccag atgcgtttgt  24420ttacagctgt ctggtgacat tcgccaggct ctgttttcag aaggaacatt tccattccct  24480tatttacacc tcccattgga gtgctcgggg ggacacacca attatttgca actacctgga  24540aacctaggag ggtagcagat ctgtaggagg ccagtgttga agtgagaagc tgtagatctg  24600gtgacactgt gggcttggga gggcttgccc agatctgtta cttatactct ctattaagaa  24660acttcagtgt ccatggagaa gttatttaaa gtctgcgagc ctcagtttcc ccatatataa  24720tatgggaagg atacctgatt ttcctattcc acatgaaggt agaaaaaatt aaattaaggc  24780agccaatgaa agggttttga aagcaaaaat aataatatga tactgttctg aatttgttaa  24840attattcttc caagtagttg cagatctttt tctgtacctt agaaaaaaac catgctatgt  24900aaaaggagat gattccaatc tttaaataaa gcaactcaga ggtcaggggc taggacagaa  24960aacggccctt tgttcacaga agcgctctca cttccaagaa agcaagcgtg ggagaggcag  25020gtggtcctcc cgatgtccct gtgccccatg gtgtcaagct gggttactat ggcccttcgt  25080gacccagtgc agcagggatg tgggaaccag tgggtgtgaa gctgtgacgg gtcacaagag  25140ggctgggacg tctcacagct tttacttata gcctagagcc tggggaaggg ttgccactct  25200agtgatgaga gaggcgtgtg tgtgtgtgtg tgtatgcgtc tgtatgtatg tgtgcatttg  25260catgtatata tgtgtgactg tatgtatgtg cacatctgtg agtatatgaa tgtgtgtgga  25320agtgtgtata ggtgtttatg tgacagtttg tgtgtaaatg tgggtgtatg tgtgggtgtg  25380tttatgcatg tacatctgtg ggtgtgtatg catagtgtgt atgtgtgagt ttgtgtgtgt  25440gtgtgcattt gcatctctgt gtatatatgc atgtgtgtta ggggcaggca cacaggcctg  25500ttggtaaatg agacacaaaa tacctacaaa atacaaaatg tgagacagga aatacaagcc  25560ccagttactc atttttcagt gcaacagaca taagattacc atgtgaaatt gctatgaaag  25620tttccgaaag cttcctgtca attcgtagtg agcagctagc agaggagtgc gggtccctgg  25680agcctgcttg tgcaacgctg agctagtcca agggggaaga atggggtgca tggctctcag  25740ctgcagacca gcctggaacc tctccagcct gctttagcag agacttgtta agaggtagca  25800gcaggtggca agattaggag ccggagtagt aggctaaggc tgcacttcca gggacacact  25860gcctctgcca ccacccgtgc cacgaaaatg ggagcccagg accctgaatc tctagcagtc  25920cgtttctgaa tcagttacct tgggtatgtg cctctggttg atggaaacta acttgtagcc  25980ctgctgggtg agagcctcac atcgggacat gtgacagctt tgttgaaagt agctttggaa  26040acgcccacca cgtggggcca ctcactgtaa tataaacggt catgcatcac tgagcaacag  26100ggatacgttc tgagaaatgc gtcgttaggc gatttcatca ctgtgggaat gttacagagt  26160gtgcctacgc aaacctagat ggcagagccc actccacacc taggccagat ggcagagcct  26220gttgtttcta ggatgcacgc ccgtacagta ggttactgta ctgaatactg taggcagttg  26280taacaatggt gagtatttgt gtattcaaac atagaaaagg tatagtaaaa acaatggtgt  26340tatggtccgc ggctggctga aacgttatgt ggtgcatgac tgtaggtata aagcattaca  26400gttgtttgat ttttctcttt ttctcaccca cagtcttaag gcacctctta tgccttttgt  26460ctgggatgtc ccgggcaggg ttggaacgtg tggttaaggc atggcggaaa ctgctttggg  26520gacagacgat ggcctcagct tgccttgggg tgtcagtggg aaagatagga gctgcccctt  26580tgccttcgtg tttcttcgta ataatctcag atgtacccgt ctggtgggcc tctcctagaa  26640aaagccccgg tgctctttgc tcctgcggtg tttctcagga gggttgttgc ttctttgtaa  26700tggtggggac tcagggaagg gacgcaggca gagggtgatg ccacatcaaa aagggaccct  26760tggctgggtg tggtggctta cgcctgtaat cctagcactt tgggaggccg aggcaggtgg  26820atcacctgag gtcaggagtt cgagaccagc ctggccaacg tggtgaaacc cggtccctag  26880taaaaataca aaaatacaaa ggtggtgggt gcctgtaatc ccagttactc agtaggctga  26940ggcagaagaa tcgcttgaac cggagaggtg gaggttgtga tgagccaaga ttgcgccatt  27000gcactccagc ctgggtgaca gagtgcgact ccatctaaaa ataaactgaa aaaaaacaaa  27060aaacaaactt gggccatcag cttcttggaa aggctggtgt gaggttgaag catttgctgg  27120tgcctctgct caacgttttt gtggtgaacc tgagcaaaga ggttatcatt agtggatttt  27180actgccttac ctgggtgggc actcccttgg gaggtggatg gacatttgca gctgagccca  27240ggtgggggaa ttgcgctcac tccgccttca gaattccaaa ggctgggcat gcatcttggc  27300ttcctctaac ccatgtcttt ctctaggtgg ccacagcaga gtgtcattaa gtatctattc  27360tttgcttttg ttctcagggc aggaagatcc caacagtttg cgccataaat ataactttat  27420cgcggacgtg gtggagaaga tcgcccctgc cgtggttcat atcgaattgt ttcgcaagta  27480aagagagcct tcctttttcc tataacctcc gaagctttca ccgccactag caaaacatga  27540gagctatttt tgagatacat taaagtgtca aagtgtcact gaatatcttc ctacttaaga  27600taagtgtgtc tcccttagaa cattttccct attcgactat ataaatctac attcttgacc  27660cttctgaatg tttaaagaac ctcgggctct gaagagattc tctaagaata ttttgtaagt  27720ggaagttttt gatgcatgca aaaaattggc aggatgttta gtgtttaaat gctaagcccg  27780atatataaag gagcgatggc taggtgtgtg tggctgttgc acaacccatt aatcaatgcg  27840ttgaagcgtt cattttaagg tgctacaggc ttaagtgtgt actcctttgg attttaggct  27900tccgttttct aaacgagagg tgccggtggc tagtgggtct gggtttattg tgtcggaaga  27960tggactgatc gtgacaaatg cccacgtggt gaccaacaag caccgggtca aagttgagct  28020gaagaacggt gccacttacg aagccaaaat caaggatgtg gatgagaaag cagacatcgc  28080actcatcaaa attgaccacc aggtaagggt gttctcgcct gcagaggtga gttctcagat  28140gccccggaac acccttggca aaggcaccag agctctctga ttgcagctga ttctcggggg  28200gcactgaagc cagtctgagc cagtcacagg agggccttga ggagatgctg agtatggcct  28260gggggtgtgg gagaggaagg ggctcaggaa aacttctgta aggagccaga taaaagtttt  28320taaaataatg ttttaaatgt ttgtcaaaga aagcaataga tttgtaaaga aattagtagg  28380taagtagtga aaattgattc tccttcccat tcccaatcct gtggcaactc ttgttacaga  28440ttttatttat cctccacaga tacatcatgc gttcacaatg aacatagaat ttactgggtt  28500ttagactgag ccatccttaa cttgtcaaca gttactttga aaacaaacca gctctcccaa  28560attggggttt tgcggggtta tgagatgtgt ttcaaaagaa tgtttcgtac tttaaacatc  28620ttggaaaact tgaattaaaa cagagctaat ggatttcttc tttccagacc ttctcagagc  28680ttttagtatg ctagtgtgca cgtggcttgc ctacaaaagg gtgttgactg aactatttgc  28740ccaaattata atcatttgag tatacagctt tttgtggggg caggcagaac tgagacatac  28800caaaatcagt ttgggaaatg ctgtatttga aaatgctttc tatttaaata ttctctttgc  28860aatcattttt gctctgttga tttgcttagc aaagtcttca tgtctgggac aatatccatt  28920tcttactgac tcatcaaaaa cccccactcg acacgtcgat gagagaggtt ttgtttgctg  28980tgtggcatgt tcagtgaaag cgtggtttcc agtttcttca catccttata attttctaga  29040cttcagatgg agggaacaat cagaggaggc tggaatcctg cctctgacca aggaaaagac  29100cagaggctga gccaggtggg gtctcttgtc cagccctctg cttgcctcgc tttacctggg  29160tgtgggctga gtaattccag acaagcgtgg aattaatctg gctgtttgtg ctgttcagtg  29220gcacgctggt tacacctcct tctggaaaca actctgcgtg tgctgtttgg gtggtaggat  29280tccgggtctc cttctccgtc tttttataac atcaagttgc tgcccagctc aggctccttt  29340acggccagtc ttcagaaaac caccagctaa cacatttact accctccttc cccgatgttc  29400ctgtagcttc tctatggctg ggtggccagg catggccgaa gaggctctgg gtagatatag  29460gctctgtgcc cggtgtgtgt aactggcctt gagtgaggct gcagttgtgt gttatttcta  29520ttaggtcact gtggaatttc tagcgacaac taatctttca aagtgtgttt attggtcaca  29580ggattattgg gccagcctct gccttcattc tttttcacct aatctgcata atagctgtgt  29640tatccccatt ttagagaaga agaaacaggg gctcagagaa gtctagtaac ctgtgtgagg  29700ccacacagca aacacctcat gaccctgccc tcctaaggca gcccatggct actgctggag  29760ggatagaggc cggccccgtg gtttgatggg acagcttgac cttaaacagc ccatgggaag  29820gcgggtgcat ctggtttagg aacaggctgc tagaaaggta tccaggatgt ggtagtctca  29880ccggaaggag ccagtcagaa tagcacagcc tgtggccacg cgtgggacct gttcagcctc  29940atggagcttt gggaggcagc cagcagcagg gcatgggctg tgtgcaggcg aggcgctggc  30000ctggacgccg cccccactgc gtaacttcgt gtttggaatg cgtgggcaca taccgtgcgg  30060ctgcttctgg ccgggggata ttcttttcca attttgagcc aaggtggaga ctgtctcctc  30120gtgccatccc tggcatgtcc tggcaagacg tgaacgatct caatagacga gctttgcaga  30180gtgtgtctga cctgactcct gctgtcttgg gagtttagct cttcagccag cagcatgctg  30240tttgacatgt gtttcaagcc ccccaagaaa gggtgcttga aatttaaaat tgaactgatg  30300tggcttttca aaatggaatt ggaaatgaaa ggatattaaa ttgcagacac ccacacaaaa  30360gactggtttc cactgactaa actgcttttt tttgctgata gtagttgaaa gtagggagag  30420taacagcatc tcttccagct ttttctcttt tgttcccttg ttttgatgat gggttatttc  30480gggggaagct ctggctggcc ttgctttgtg tcatcttagg gataacaaag aggatgaaag  30540agatcaggaa aaccgagaag gcagaacaga accagcagaa actgtgcttg aggaatgaaa  30600atcacctaca cggctccttg tcatatgaga ctgtggccca gcctcctgca aagccattta  30660agagtaaccc agtgaagctg gtgagactgc ctgccgcgtc cgtgggccca gtgactaact  30720cggtggctta tcatctgggc ccagctcctc ccctggcatc ctgatttcac ttggaggggc  30780ccccgttgtc cttcataaac atgtttattt cattttattt ttatgttttg agacagagtt  30840ttactgttgc ccaggctgga gtgcagtggc gccatctccg ctcactgcaa cctccacctc  30900caggactcaa gtgattctcc tgcctcagcc tcctgagtgg ctgggactac aggcgtgcac  30960caccatgcct ggctactttt tgtattttta gtagagaccg ggttttgcca tgttggccag  31020gctggtctca aactcctgac ctcaggtgat ccacctgcct cagcctccca aagtgctggg  31080attacaggtg tgagccattg cgcgtggctg taaacgtgat attcttgaga ctttcagtga  31140aataagaatt gccacggaca tctgtggtca ttgtccactt gccactcacc tacccccttt  31200tctggcagca acagccggca tttcacatgt ccatcatcgg acagcgtagg tgggaccatc  31260agtcatggtg tcctaccctc tgtggccaag gagtggacac aggacccagt tagggcaagc  31320agaggctccc cttggaatcg caaagtgaag ctggatgcca cccacagaga ctaacatggt  31380gaagctgctg tagcccctgc tgttgagccc ccagcactgc ctgagttctt gcactttgtg  31440agtccagttt aatatctgct tttcctccca ttcttggagc tcccctcaca tctccagtgg  31500cttgaagttg ccagagatgt ttctgggctt gtgaccaaat gactcctttt ctgcttctca  31560ctgctgagca gacacatgtg cgctcacttt gcctgctgag tcttgggacc cggaagagct  31620tttgggagac aatcacggac cagccccctc ttgcctgccc tgctgtctcc ctccaagcag  31680gaggtgagaa ggtgtccacc tgcagccccg gccaggcatc cctttctgtg cttctgccca  31740aatctgaaat tcccctctcc ttgggaccca cgactggggc cagcctgcct ggggagggaa  31800tcccagctgc agaaagtcgg gacagtgtgc gtgtaaacat gttaatagaa agcagctttg  31860agggcagact agttcagctt cagttacaaa ctctttccaa atgcgtttaa catgagccac  31920tggctgtgcg cagcatatgt caagctttca tccaatggtg gcattttgtc cctgcggggt  31980ttttttttcc tgagcagttt ggggcagggg tggggacagg gagagagaaa agtaaaaaga  32040gagcagtttg gtttcttcag gctggagtac aaggcagagg taatgggatg tattgaagaa  32100ggtaggaggg aaagttactt tagctacagc tatttgtcca gctgtgctga ttaagaaact  32160tggagaaaag catctttgga atcatgtcct tcccatctta tatacagcct ttgcagattt  32220cctgctgttc tgagagagat ctgaactcct taccaggacc ttgagggccc cacctgattg  32280ggcacccctc actctctctg cccctcctcc ccttcccctc ctcccctcct ttctccaccc  32340ccacctgctc tgctcagaca ccccttcctt ggttgcttcc cacaggccag ggctgtcccc  32400tggggccttg gctgttcccc tcccaggagc gcccctctcc agctcctcat gcagccaacc  32460ttcctgtcct tcaggcctct gattaaattc tgccttagac atctctcccc accccgctgt  32520gtgaggtagc gccccatgcc ccagtcccct caactccact gcctcacttt ggggacacat  32580caccccaggg acaactgcat tccactcttg gtttttccct cctcgtctat ttatcacaat  32640ttagagtcgc ctcactcatt tgtcaaatga agttcatctc tgcagctgga ctgcggggtt  32700gggggcacat ccggctgtcg gtcctcaggt aggaggtgct tggcaacctt gttcagagta  32760ggacgttcac agctgtctgc cccggaggaa gcaagggcac ccgccacatg gatggaattg  32820aggggaaggc acccggggct cctgcatcga gcttccctcc tatattcaat gaggaaatga  32880ccctgcagaa ggctggctgc agatgcccct gcctcccggc tttgcctgct tggagtttga  32940tggacacgtg gtcctgtcag ggctacagca ggtctatggt ctttggtaac ggaaagcgct  33000ggtgaaacag tgagctttcc cgtgggtgct tttccctgac gccaacaacc aggtaaatat  33060ttggaaacgg ccttgttgag gcttgtgagg tggttttcct ccctcccctg taggcctgcg  33120ccaccccccc aaccccacgg ccacctttgg gccagatggc acccacagac ctgtttgaag  33180tggccacaga gggagccctc tgggcgctgg ggccgctgtg tttgcagagg gtcctcttac  33240tgctgagctg gctggtgcag tgagaaggaa ggccgacacc cctgatcctc atcaagttca  33300gacgggggtc actgcgggtg aggggcctgg ggccttttac atgtcccggg agctgctgag  33360caggccactc ttctccaggc caccagaact tggccctgcg catggtgaat cttccctgag  33420tcagctgagt gagggggttc aggcagcccc ccgggacatg gcagtggcgg ggagtggact  33480ggggtggtgc ttgccatgac tcacgccggt tctcctcagg caaccggatg gtcagatgcg  33540ctgactcagt ggcctgagct cgtccaaaag cgaatcagag aacacagggc ctgggctcac  33600ccgctgccct cttctggagt catctgtcac tcatcctcat gaaggaagcg cctgggagcc  33660tggaatgcac atcgcactgc cccagctccc ctcttgtttc tgtgtttttc cattttggat  33720tctttccccc aacgccttct gtactgggca ttttgtggtc tcttcttttt ctccgagaac  33780tctgagggct accattgcat ttgctaatga tgccacagac ggtgttgacg ttatgaggct  33840tctattactg tattgatttt taccattttt agggggacgg gaatcaatat ttcatgaggg  33900aatgtgaagc cagacagtga agtagaagct ggcttttatt ttgtgccagg ctttgtccag  33960aggcgggtgg ggacgtggct cctaagctct tgattgcagc tccttctggc ttgggaaacg  34020tttcagttcc ccaaactctc agaactggat cccctgtgtg ttctctggcc cggattcaag  34080aacttagttg attgtcaagg aaattctttg gctatatttt tctcttaata tggtaatgcc  34140ttttttcact ctggcactct cttttcaggg aattggatta agactattat ttatgggtct  34200gacaaagcag ttcccaagtt gttgggactg gatttgttta ggaatgtctc ctgtcctctt  34260cattgagggg ggaatacaaa ttgcttccat ttgacagttt atcaagtgtg tgacagagta  34320tcagagtcca gggttggcca actacagcca gtagtccaaa gctggccctc tgttgttgta  34380aataaagttt tattgggaca tggtcatgct cacttattta ggtagagtgt atggctgcat  34440tcagtctaca ccagcagagt taaatagttg tgatgaagac cacgtggccc gtgaagccaa  34500aaatatttgc ttcctggccc tttacaggaa aaaaattccc agccccagtg gcaggcaatt  34560aacaccttgt cctcgaggag ctgaaagtgg ctggaggcag gaatgcttat aagaaccaag  34620cgaggtgaag cactaggtgg ccgcggcgag caggaagaga agctgatttt gtttgccctt  34680tcgtttgcca gagattgtgg gttctttttt tttttttttt tttttttttt tttttgcaga  34740gatgaagctt tgatcttgtc acaatagcag agggaggcct tatttttgtc tatttctctg  34800tgacattggt agaaaggact ttgtcagaat tccaagctat ttggcaatta tccaattttg  34860agatcctaat ggatctttcg aggtctagtt tgttcattct tttagtgatt ccttgttaat  34920tccctgattt tataaatgtg tgttgaacat ctgtcttggc caaatacttc ttaggtgctg  34980aggatgcagc aatagtgggc aaagccatgg ggcttaagat ctagtgtggg aaatgggtga  35040tgtaaagtaa atatggcgat aagtacagtg cacgaagcaa acaagtgaag gggtagaagg  35100tatcaggctg caaagacagc agatagtgta ggcagggaat cttatctgag ggggtgacat  35160ctaagctgag atggaaagga cagtgagagc cagccaagga aacaagttgg gtgacaagag  35220ttgcaggtgg agttgcttaa tttcccactt ctgctcagcc tgcagatcct ggatcttgga  35280ctaattgcaa actgtcattt cctcgtgagt ttattagaac cctccagaac aagtttctgg  35340ttagctagtt tctctgtgtg ttgtctcatt tcttgttggt tctggttctt tggggttcct  35400actcatactc tggaaagctc cagtgtctta agtagtcagt ctcccaagag tctgaaagca  35460caaagattca caatgatacg atcacctctc aatcatagca gcattgatgc agttccgtag  35520ctggtttcct aaagccatcc agatctcttt ctgtggcaag agagaaataa gaccttctgg  35580tgaattgagg actaattatc ctaataaaca tgcgaattaa cagttccttt ggttaaacaa  35640agcaccagaa tctgataatg ggaacatgtg actcatggta tttccttctt tgctttatct  35700accaggcagc tcacagaaac cactggcctt ccctgtgttc ccattttatg tcataaatat  35760atatttaatt aacttattat aaaaggccct ttgttcattg accatatcaa attattctta  35820tatagaagag gttatacatg ttttaaacat tttaaaataa atctgaaaag aatgctacat  35880cctgggcaac ttccctgcat ttggggctca aagaagctct atgtggttat gggtaatgag  35940gagccagagt gccttcaggg cagttcagca gatgctgaaa ggctgctgtg tgctgttcgc  36000tgggcccacc aaatagagta ggactgagcc cctgtccacc atgacagccg ggagatacaa  36060gctgttccct ttgcctccct gagccctgag ctttatagcc tatagacagc tgaaaagcag  36120gctgcatccg ttacccagtc agttacccag acccaaatgc caggccttgg ctaaccccag  36180ttattaccta attttaatat cccaatggat gttttaagac ctggctggtt cattctttca  36240tttatttact tattcattga ttttgtaaat atttctggag catctgccat ggccacatgc  36300tgttgtagca gcatcagcca ctctgaagtt ggtggatgaa aggggatgca tcaaaggcgc  36360tgatgtatgg aggagacgca agttagactt gaccaagaca atattattcc tcctctggat  36420gccccgaata tatacagtca ttagctgtcg ggcccccatg tggcactgtt gacattttgt  36480ggtttaaaca ctgaagagta agggaatatt ggaaatggca aacatctgat atagtgtaaa  36540ggagactaaa tattttgatg gtgttcataa acaccgagga ggaaagtctt ttcatttttt  36600tcatttgtgt gctctctctt tctctgtttt tgcacactgt cctctgttct ccttctcctt  36660ctctttttcc ttttttctcc cttcatctcc ccatttatct gatctctccc acctgaaccc  36720cttctaccct gctgccctcc tgtccattct accttctcta ctcccctccc tagacagtag  36780taatcacatg tcagttggag aaacatgatg gcaacttggt cacaccgttc ttctcagtct  36840gtatatgtcg gtgatctcag tgcccatctg gcagatcctt cctgccctgg ctcttctgct  36900cactgcgacc acccttgact ttgtgatcac tgataacctt caccttctct aatctaaatc  36960ccaagcttct cactcttggt ccaccacctc ccagccttgt ccgttctgaa ccctgaacgg  37020aagctgaatg gaaccctgaa cggaagggtt ctgaagctgt tcagaaccct gaatggaagc  37080tgaaatatca atgggccatt gcttttcaca gtcctctgtg aaagattact ggccaagcca  37140gcatctggag aattcctggt ccaccacctc cctgtctgga gaagctggaa cagccagctg  37200catgagcatg tgacccgtgt actcacaggc cctgtgccct gagctcgctg ttttaatttt  37260atctttgaat ttgtattttt gtgaataaag ccctatgagc taatggagca tgctcaggga  37320acttggggct ttagctcagg ctggattcct cctgctgcct ccccagtccc tggtcccctg  37380agaactccag ccccatctga ccttcccttc cctgtctcta tgcaggggtc attgctaccc  37440tctatccctg gaaaggatgt aggcacaggg cagttctagg ttccagcttg ggcaccgctt  37500aacatcttgg tggtgcaggg atcaggctga tgataccgtg gttgttctgt gggctactgg  37560gcagggtcaa gccactccca ccctgatcca ggtacctaat gcacccgaca cagaagcggc  37620agtgtccttg gggtcatcca ttatccatgt gttggaggag tgggacccta gggaagatgc  37680ttggctcgac ttccccaccc ctagccaggg cacaatcaga ggtccagggg ctggtgggca  37740caatgccaag tcgtgaggcc tccagtgtct gcgctcactg tcccataaat aaccacagta  37800ataactagca aatcaaaaac attgtgatag gtcgagagag acagcatgtg gaagaaagga  37860aaaagctttc tattttagta cctttaacag tgctttctgt atgctttatg aacaaggagc  37920ctgcattttt attttgcact gggctctgct aattttgtag ctggtcctgc cccctagtag  37980ctcaagtcag caaatctttg gttcatctga gtccacagtc cgctgacccg ccctttttca  38040cagttcctcc cctgcccatg tgctcacttc cctccttacc cagcttggcg cactccctca  38100agcaagtctt tggatgctga catcccccgt aaacaaccct tctgcggcct ggtttgattt  38160tccttaggag acatgcaagt tctatagcac tgtttcttgc tgggtatgga ggatgtgcta  38220ttttgtccat tgcatatttt ttaaagaaaa tgaaaggtta gcataactgt ttccagaagg  38280cacattgaat cactcagttg agtcccagcc agttgctgca atgttagcct ttgaagcaaa  38340cttgaaccaa cacaggacca gcctagaagt cccagcctcc agaaatgatg cagtggattc  38400tgcagattca gcaacaacaa tatttttgta actcaagagc acttagtaat tttcaaagga  38460gagaaagaag taattgactt ggcttattag gttgaaaaag agttgccaac tttttctttg  38520gttttgatgt tattggtttt tttttatttt tcttttctcc aagcttcagg gaatgagatt  38580gaatgagcac tcaagtgcta ctaggcagaa ccctgaatgg aaggaagctg aaataccgat  38640gggtcattgc ttttcacagt cctctatgaa agattactgg ccaagccagc atctggagaa  38700ttctaggaac gccccctcct cttgcagcag tataagtttg cggggatcat ctgaccccat  38760tggggagttg tatgaaaaag gggatttatt ggggaccctg ttgcctgttt ggatcttact  38820tacatttaac tattgtctgc taatggattt tttggaaagc aaccaggttt tccgtaaaga  38880atagctaatt gtcagagctg agatgaccat tggagatcac tgggctcaac tccctaattt  38940tagaggtgct aaaaccgcaa tccagagaag ctaatcaagt ggttcaaggt tgtagactga  39000gttcatatag gaccaagacc cagcccagat gtcctactgt ctgggacagt gttctctcag  39060catacgtgga gcctgagggg gtaatgtgtg tgcgtgtgtg tgcatgtatg catatacaca  39120taggtgtttt gcctaagttt tcacttctgc cccaccttgg ttgatcttgg agaatgagcc  39180tgaggcgcgc tgtcaacctg ggggcctcat tcagcacagg cccaactttt ctgccctggg  39240ggagttccag cagttatggt tcatctgtgg ttcagttatg gaactcacac cacacatagt  39300gcccccaaaa ccgaggctgc gtgcacagac ctcccctccc ttcccgtggt gggcccctgc  39360ttgggttctt cctaaacttc ccctttgccc tgctctgtgt tataccctct ctggtcccct  39420gtccctgtgg agtgatccgg ggcacaaggg cagctgtttc cccgctgacc tctgtgtgcc  39480ctgagcatct gggaggtggg gagcaggctg gtgagaagaa cacctggagt ggaggttggg  39540gtcagggagg gtcccagtcc cggtaccacc cccacctgct gtgggacctg cagtcccctc  39600atcagcagaa cggctatgaa gccatcctgc ccatccacag ggtggtgggt cgtgaaggct  39660gcatacctgg cagagcggga gaagctctgg gaagatgccg gacacgcgcc gtgggagtga  39720tttccctgcc ttgcccagat tctgctccca tcacctgaac ctgcctgtca ccaccatgga  39780actgctgtga ccattgcttt ccttttaagc agattagcag acatctcctg ctccaccctg  39840ccaaacaaac aaacaaacaa gcaaacaaac aaacaaaaat gtgcatgagg gagtatggac  39900ttgtagagtc ttttctaaac attgttaggt gcttgtattg ggatcctctc ttaaaatgaa  39960ccatattccc caggctttgg atgacactca tggttgccca ccctccaact tccttccctg  40020ctggcagagc cctgggtttg ttttagttcc aaccctgacc ccaccgcatt cctgactcag  40080gcaaattcgc agggtccaat gcagtcaggg gagccacgtt ccctcctcca acgagtgctg  40140aggtcgctgc ttgattggat actgccgatg acctacgagg aggagggtgc cagggcgctt  40200ttgggacttt gcttttctgg agagatgctt ccacagcatg gtcatggaca cagtcacgtc  40260ttgatgtgat gtctggaatg gtggtggccg tcttgtggct gtgagaacag gctgaggttg  40320attggatgga gggaaggaag gagccttgtt cttgatgctg tctgtgagcc tttgagttat  40380cagcctggta ccacccagcc cttggacaga tatctactct acatactcca tttggagttt  40440tttttttttt tttttttttt tttttttttt gtcacttgca gttgaaaaca ccctaattga  40500tacacacaaa ctatttttag tgctggtctg tgtttggccc ttatggaaga ctctgggctg  40560agctgcccat ggtgagggag gtggactttg tgttttctta ctgctctgtg tcctggtggc  40620ttgtttgtgt ctctgcccat gagacaaaag ccgagagggc aagggcagat tttcttaatc  40680atatgttccc tgcaccaagc tcataggaga cactcactga atggttgttg agagagttct  40740ctttcacgga ggcaatgttt tgtgaaacga tgctgcttgt tgttgtctgt tggttgtaat  40800atgcatgaac actaagagcc atctttaatc atgctgtggg ccgcctcttc caaggtgtta  40860gcattactcc cactacctgg tcagcatcct gcctatggct aggactttgc aatttacata  40920gatatggtgg ggagacctgg agcccatggc caggactctg acaccctcac tggatctgtt  40980tctacatcta cctggatggc cgtctaggac attagaggat ttgtgtcttc ctaaagtccc  41040tctgttgaga gacttctggc tctgttaaga ggacactatt tagcattgtg agtccctgca  41100ggctgggggc cagtgggcgt ttttcttcta gatgccccct ctcttcttct ggcctcccag  41160gcttcctgct cctgagattg tgagaactgg cctgtgctgg gctcactgca gaaagactgt  41220cgtccccaaa ggttttgcac caaacttgag ctacaagatc ttttaggggg acctgagatc  41280tccgcctggg ctctatgaga gcaggcatgg gttgtttttg ccccgtcact gcagtcatgc  41340ccacacttgc attttctttt ccccccagca gtgtgaggat ctggcatgag gagtgggact  41400cgcgtgccct ctttcttctc ctcttccctc tggccttttc atccgtcagt gggggacaga  41460tgtttgccct gtttacttct aggcttactg tggggctcca gggagatggt gaagtggcca  41520aggagaggag ctgccacctt caagacggcc tgtggccggt gccgctttaa agggagactc  41580agaggtgctt tgctgtgggt ggcgcgggaa ccagcctggg gacagcagtg cagaggcctt  41640ggactcagag tgcgtgggcc ccgcggggct tcacggcgcc tgtggctgtg cacttccagc  41700catatctgtg ctgcatctct tccacattcc cccatggagc tgatgtctag acagctatgg  41760aattaaatgc tcaattaccg agtaggaatt tggccagcag aggtatagct gctgagtaga  41820cagactcgag gtgaggctca cggctgagaa caggccccat ctggctttgg aatgagctga  41880ggtgcccgat gctcctgcag ccagtggctc ctgtggggag ctggggccgt gacccccaaa  41940aggcagcttg acctcatgga ccaccataaa tctggcctgg tcaacatctc tgccagacat  42000cattcccttg caaagatttc tgcctgtgat tggaattctg gatgaacatg tactgggcgt  42060gtgggtctga cagctgggaa gcttgttctc ttgtttagcc aggctgccca tcatctgtaa  42120gcctcagtat ccacatcttt aaaatggggg gaaaatatag ctcaactcct aatggtgcca  42180tgagaatact ttgtcacctg ccaggcaaaa gcttattcct ttcacagaaa tccagggttt  42240acaatgtgag acccctcccc actccgccgc atgtgtctgc ttgctttttt ctgtcttagg  42300gttgcccttc atgagctagg aaatgtctga gtggatgaaa acctaaacga gatgatcact  42360ggtggtgccc attggtgcag cctttgccta aatggctact tacgtagcca catttcctcg  42420tctgtgttca ggtgaggact ggttcctggg cagactgcct gggtttgcat cacgggtgtc  42480catcttgtcg aagcccatgt ggtcacccaa gtgtgactga gccaggcttg cccacggggt  42540gctctgggcc ccattttcgg cagcaggcag cgtcccctgg aggcctggcc ctccccggga  42600gcatggggag tagcgcctat gggcaagcag cctgcagcct ccatccctgc ctgggggctc  42660ccccgcccca gcctcacagc ttctccaaaa gtgtttgtct ccttgccgca tcctctaggc  42720ctgagctcag acggtggaaa agaagagctg gaaggagagt tgcctttcag tctctctgcc  42780ttctgaggtc tcctgagaca tagagcctgg gcctgcctcc ctttctagga ggcgccaagg  42840ggtggtaaga ataggggatg agtgagatgt gaattaggat ccccacagca agccctgcct  42900cgtaactttc tgatgggttt tcaatgtgtg gtgaagcaga cgcctgctgg gcccccttcc  42960tgagttgagt ttgacctcct gcctcctgtc tatctccttg ggcagccagg ccaccccgct  43020ccattaacct gtgccacccc atccctttac ctgtcgcaag cccagccctg aaggcctcaa  43080aggcctggtc ttccagccag tccagggcct gaagggatgg cagtgtccct ggtggacctc  43140ccctggtgtg gcctagtgca catcccagcc ctgcctcctg ccccgcctgc acgccatgag  43200tgctgaagtc atgcctggca ggggctgctg gcccaggccc agagtaaaca cactgcgctg  43260agctcgctgg tgtgctgctg gatgctgatg agcttgagga gtgtgggaag tgagcatggg  43320gctgagtaga gatgcggcag gcctgcacct ccccgcagct gccctgcatg ctccagcctc  43380aggcagccac acagggaaag ggtcacccac tgtcagggca gacctttacc atggctgggt  43440gacacgggct ggctgtggaa aggtgtttgg tggttcccgc tgttggattt gcacaggccc  43500agatgctcac agcaaaacca acacctagat ggtgcttaca ggagccagcg ggtattcaaa  43560gagctgttca gatcttaagt tgcttcattc tcacagtgga ccattgaggt agctgtacgt  43620tagtcccatt ttccagatga gaaaactgag gacctgagtg gtcataagct caggccctca  43680tctaaatcac gcagcctggc cccaggtgtg tgctcttgac catggacagt gctctcctgg  43740tcctcttggt atctgtgatc tgagggacct tcctcctcct cagtctcgta tagtcagttt  43800taggtcttgg actctgtctt catatccctt tctcccttcg tgagctttct cacccagcac  43860cttccttatt tggtgtgtgt tgggggatat ttgtggtgtg gcgtggcact gtgtagtgga  43920tgagagagtc tgtttttccg atcccagtcc caggtttcaa accctgctct gtctcgagtc  43980acccagaatc ttggaccctc agtttcctca tctgttaaat gggcatggtg gtcaccccac  44040ctcatcagct agtgtctgct ccatccctgg tggaggagat gactcaagta acccctgggt  44100tccacctgcc ccaccccact ggtcccctgg ctctttcttt gttgagatag acgaatgtga  44160ggctctggag ttgcagttcc cacgagggct ggggtggctg tctgatttct gggcctggtc  44220catgttgttc agggcagctg ctcgttctaa gtgaataaag gctgaaggaa ctcgggaggt  44280ctgctcggct ccgaggaagg cagagaggga aagggccccg atgccttccc tgatagagct  44340agggaggccc ttctgtggtt ccccccagct ccttggcctg ggtgaccctg gagctggctt  44400ctgttccatt ttgttgtgca gagttgtttg agactcctgg ctttgcctgg cctttgtggg  44460acgctggaga tcagggcttc tggagttggc caattagcct gcccagacca ggaagcacag  44520gtggctgaca gagggccgtt tcaggagagg agagacagcc tacctattcg gtcttgctgt  44580ccccatgctc catccctgcc cctgaccagt gtggccctgt actcagcata ggcgtgcacc  44640tgagtcagta cagttccctg cccgcagagc accccaaata ttccaggcct caggacggat  44700gtgcacatga tgagtcgggg caggtttcac tgcctgtagc ttgggatcct tccctggggc  44760ttggttctct agggccatcc ccagcagtct caccccaaac cctaaattca tgttgtcttc  44820ctctgtctct tggcctcaag gtttcagagt gagtctgtgc tgatagcttc aagatgtgat  44880gagaccccga cttggcctcc agttacctcc ccacggtttc cttggtgtgt gtgtggcttc  44940agtgttcact ggctcccgca cggcttgcaa tgtgtggatt acgggtggga gggaaatcca  45000gtcctgcccg cagcaaaggg atgttagttg tgagctcagt tccccaccgg gcctggtgtt  45060tccaaatagc ccgtcactgt ccctgcttgg ttttccatga tatctgtgcc tttacctatt  45120tggttaaatt aaaccaactc agcaacgcca gccattgtgg tttcagggca agctgcctgt  45180cctgctgctt ggccgctcct cagagctgcg gccgggagag ttcgtggtcg ccatcggaag  45240cccgttttcc cttcaaaaca cagtcaccac cgggatcgtg agcaccaccc agcgaggcgg  45300caaagagctg gggctccgca actcagacat ggactacatc cagaccgacg ccatcatcaa  45360cgtgagcctc tgtccctctg cgggtgggga ttggggcaga gttttgccag ggggagagga  45420gtcagcatag gtcttagccc ctgactttgt tgtagtctgc gtgaagggat ggaactagac  45480caagccatgt ggattctagt gccagcagca tggcaggggt cacatggcgg ggacggtgac  45540accggagcag gtggacagcc agcctcctcc caggaggaag aagttgtatt gggtgcttta  45600gggtgattgc agttggcttc tgggcttcag agagaaaatc tccctgttta cggcacctct  45660aaaactttct gaaaattgtt aaggtcattt ttttccggca aaatattagg ttaatgggaa  45720tgaatctcag agaagaatcg tgccccccac tctaggcacc gtgctcagga aacgaccagg  45780cagggacata gattgaacca tgttatgaca cgatttgtaa ccttttcatt tctgtttaat  45840tgcagtatgg aaactcggga ggcccgttag taaacctggt aaggtctttt aaacctatgt  45900taggtcattt gtttttatct atgtatacgc tgttttttgt ttgtttgttt gttgtttgtt  45960tgtttttgag gcagggggtc ttttcaaaca taaggttgcc aaagtgtatt ataaattcct  46020ttaaaatggc tctgtaaatg tactgcgtgc ttgcaaatga ccctacggat cttttctgga  46080aagagtaagg caggccggag gtgagggttg gaaatgttat gccagagaac acacttgtgt  46140ctcagagtta caggtaaaca ccgtgaaatt cagggccaat gcaggagtaa ggtgaaggtc  46200actaaaaatg ctggccagtc accgaaagca cctcctccaa attaaatctc ctgggctgct  46260gaaggagctg gctgggctca tacacatttt ctcttggcca ggaatcctcc cttaaggcct  46320ggctggaatg aggaggagtt acccacccac aaagatatca cttaagtctt cccttaaata  46380cttgagcaga aaaagtgaag ccttagaaca cagaccagca gagctagagg gcagctctgg  46440ggccatttat agagggcagc tctggggcca tttatagagg gcagctctgg ggccatttat  46500aggggctgtc tttagcaagg cccagtgtga tggcacctcc tagatggtgc cttggcatca  46560ggtactgaca tctcagcact cctgggaagt gtgcacttgg cagctttctc ttcccagcag  46620aggggcagct gtgctcccag ctctgtcctc tgcctccccg cgcagcactt ggggatggag  46680tggagatggc tttgctggta atgaagcatg acagccctaa gctctagggt tgtttccccc  46740tgaagtcagc agagtcatct taagatcatt agacatggga gaagcaggaa ggtgtgggca  46800gccacctaaa ggagtttgag cctttggaaa cgtattcctt gtgaaacagg agcaaatcat  46860atcgtgcatt ttgaaactat ctgtgcttac cgtgaggtga gcacccagtg ccgacctgga  46920gtatgtgcga ttcttccaca gctgcgcgtg gctcgcgctg cctgggtgtc ctgatgcctc  46980tctccctgct gccacgggga tcccctcctt gcatctcccc acttcgatct ctgaaatagc  47040tcagggactt ctttcaggca tattctctct gggtgtgtac ctgccggtaa agcttcacga  47100ttcagtaagc cgtgtccttc ttgcttttca ggacggtgaa gtgattggaa ttaacacttt  47160gaaagtgaca gctggaatct cctttgcaat cccatctgat aagattaaaa agttcctcac  47220ggagtcccat gaccgacagg ccaaaggtag gcaaggccca cacagccctg gggactccgg  47280agatggggcc tgaagctcag ctgccctttg ggacttgggg aagggaaaag cggcagcccc  47340taggactagc caagccgtct ctgatccaga agtgaacggg aatgcacatt actaaatccc  47400tcgcagaagg tcacagacat ttcaccattt ttgtcctctg atcatggcaa tgtcacttga  47460gtcagtctaa tatgtaccag gcatgatcct aggtgacttg tgtacattat ttcactttct  47520ttatgtatgt cacttaattc ttttgcccta tcagttagga attactagtc ccattttgct  47580gatgagaaaa cggttcaggg agatcattct gcaaacgttt attgccccat ctgctctaag  47640tcaagcaggg agcttggcag tggacagctc aactggggcc tggggctcaa caggggcctt  47700tgccggtgtg acttttatgt tctgttgggg gatgggaagg ctgacagtaa ataatcaaac  47760acataagata ctattagtgc tcccaagaaa acggatcagg gtggccgtca agggagcgac  47820tggaggggca gctggtggag atggtgtggc caggaaatgc cttccaagct gaggtctgag  47880tgaggaggaa ccagcgggca gggatgtggg gggaacactc cagaaggaaa gacagaggac  47940tcagcatagt tgagtgagca caaggcccct gaagtggcct gagggccgga gcacagtgac  48000agcatggagt tccccggggt ggaaagaggc caaggccggg cgagcaggct cacagcaggc  48060cgtggtgagg gacctgggtt gcatcctaac gacatttaag aacagggaag tttatgatct  48120gattgatgtc actgaaagga cactctgatg gctgcgggga gtctgctgga ggggttgctg  48180gaagttgggg accggttaag gggctctccc agccatctgg atgagacatg ctggggtctc  48240agacaagggt ggtggcagtg gaggtgggac agaggggtca cattccagat atatatgggg  48300ggtagagcaa gcttggggaa gggccagctg tcaggatgag gccatgagga attaagggtc  48360atgcccaggt acctgaccat taattgaaac aatgggactt tcccaaggtc ccccagaggg  48420gaggggtcca gaccaggatt tgagccgcaa cctcagtgta cccttctgtg gcccttcctg  48480caacctgggg gattgggccc ccggcccctg gtgtccccag cacccccacc aactgggctg  48540accttctgct gtccctttgt tgtctcacca ggaaaagcca tcaccaagaa gaagtatatt  48600ggtatccgaa tgatgtcact cacgtccagg tgggtaaaca ggatgcgtgt ctgtgtctta  48660aattttaata aacctgaact tcagaaggtg ctcacgggca cccctgaaag agaaacctta  48720tgctgcctta agacgtctca gtttctgctt ataatgaagt agcatcggga aagaggacag  48780gtcattagcc ttggcccctt tgtttggttt taacctgtgt ttttgcattc tgagctggtt  48840ttcttcactg gcagcaggcc ctccggtgta gaaggttctg ccctcctctt tgaaggcagg  48900cctgaacagt gtgtgcgtgg tggggctgtt gattcactct ggctcacgtc ttccttaccc  48960cacattctgt tgaaacccac attccaggag ggccccaagc ccctcccgca gctctaggca  49020ctctgctttc gttgctctgc agctcgtggg ccgcggctcc aggaatgcca gggcaggtcc  49080agcgcaggga agtgaatgac tgatgtgctt gttttccccg agctggtgga attgcggcct  49140gtggttggca ggctcatggc atcctggtgt tctaaactgg atgaaaaatt ctggtgtaat  49200ctcatgagtc ctggtagtag actcacctgg catggctaaa actgtcagag gtaaagtagg  49260taaagactag aatatagtaa cagatagatt aatgtgttca ttactatgat gaattaatga  49320ttcactcact gtgaaagtat taatatattt tgatacatgt tatgaatggt ggtccctttc  49380ttagcactcc agaagatgga gccatttgtc aaggttaaag tgtcccctca gttgtttgcc  49440tttggaacta cgaggtgtag ggaaagatgg taagcccttg gtgcccagct tcctgggttc  49500ctgtccctgc tctgatatgt cctgccttgt gaccttggga acgatatgac ccctgagtgc  49560ctcagtttcc tcctcttcag gatagggatg acagcgcagg tgcttctgat gtgtggccag  49620gctcagatca gggagtggtg gcaggggtca ccagccacag tgatgccagc cactatgtat  49680cacacgtact gggccaggtg ccttactggg atgatctcat ctgatcctca caactcatgt  49740tgtagggtac tgttattatc cccattttgc aggtgaggaa atgaaggcac agagaagtta  49800agcaactgtc cgaggtcaca cagctagcaa atggccgagc tagggctgca aaccaggcca  49860accactgtac tttactgact ccttagtaat agctactatt aattaagaaa taataacaat  49920gatgatggct gggtgcggtg gctcacatct gtaatcccag cactttggga ggccaaggcg  49980ggcagatcac ttgaggccag gagttcgaga ccagcctggc caatttgtga aaccctgttt  50040ctactaaaaa tataaaaaat tagccgggct tggtggcagg cacctgtaat cccagctact  50100cgggtggctg aggcaggaga attgcttgaa cccgggatat gtaggttgca gtgaactgag  50160atcgtaccac tgcactccag cctgggcgac agagcaagac tctgtctcaa aaaaaaaaaa  50220ataaataaaa aaaataaata aataataaag cactttcctt gctgttacca agtaaatctt  50280tgactctggt agacaggcaa ttttaatttt aaaataggat cagaattcct ggaggaattt  50340taccttagac ctaaggagaa gacgggaact ggtgagagct gagttttgcg tgaggaaggc  50400ctggtgtttc ttcacactaa cacgggtgct ttttctctgg agcagcaaag ccaaagagct  50460gaaggaccgg caccgggact tcccagacgt gatctcagga gcgtatataa ttgaagtaat  50520tcctgatacc ccagcagaag cgtgagttgg agtcgttttc tcttttccca atattcttgt  50580tgttcctgtg ggggtagcag gaagagggag cgctgttcct tttctactgg ctcagatgat  50640tatgttgatc cttgacagac gtggtcggac gttgcttgtc attcctgctg gccaggcctt  50700ccgacctggc tcggctcggg actcatccat aggagggtgc cttctgtctt caaaagtcct  50760tgctccacga ggaccctcca gatggacaga gcaatagcag actcgtaatg agtctctgag  50820atggcccggc tggccagaga gagggtttca ggaacagtgt ccccaagccc tcacttggtg  50880gtccttttct aggcttcagg acccttctct tcctggagtc ttccagaatg tctctgacaa  50940ttaggcccat acctgtcaac acctccagaa aaataaccca agtgatatca aagtaacatg  51000acaagaagta gctcaaccat ccatcagggt ttgttacctg tattggcgga atatccagag  51060aaaagtgcga gaccagggac cagcaaatgt gccttggggg ctggatctgg cccactgcct  51120gcttttatat ggagctgtgg gctaagaata gtttttgcat tttattttta tttttactta  51180ttttttattt tcataggttt ttgggggaac aggtggtatt tggttacatg agtaagttct  51240ttggtggtga tttgtgaggt tttggtgcac ccatcaccca agcagtgtac actgaaccca  51300atttgtagtc ttttatccct catccctgtc ccagcctttc cccttgagtc cccagagtcc  51360attgtatcat tcttatgcct ttgtgtcctc gtagcttagt tcccacttat gagaacattt  51420aaatggttga aaaaatcctg aaataagaat agtattttgt gacatgttaa atttgtatga  51480aattcaaatt tcagtgtcca ctgtaatttg gtttatgaca tctatggtgg cttttgtgct  51540ggaacagcag agttgagtag cttcaacaga gaccatatgt actgcaaagc ctaaaatatt  51600tcctatggag ccctttacag aaaaagtttg cagacccttg tgctagccca tgaaggacca  51660tgacagcgtt ttgacgctga gctatataag agctacagtt atagtggcaa ccacacaaag  51720gaagtgcctc ttaacagaaa cattccgccc acccctatag gaactgcatt ctgagttgca  51780atacccatta taagcaagtt ggccagatag tggccaacta tctggcagat atctggccaa  51840ctacgtggca gatagtacct ggtacatcct tccccacttt ggggtcaatc ttgacctttg  51900atctccttgg ggtcataaag ccacacaagt gttagtaggc atttctacag tggacacaat  51960ggatgattta gcctaaaaat ctcaaaagga gcccagcatc ctggcacatg catgtaatcc  52020cagctactca ggaggctgaa gcagaaggat cccttgagcc caggagttcg agactagctt  52080gggcaacaat tgagacccca tctcaaaaaa aaaaaaaaaa aaaaaaaaag agtggggaaa  52140aaagaacatt attaaaaaaa aaaaccttaa aaagtaatcc aatctaccga tggtttattt  52200tttattttat tttatttttt ttgagatgga atcccactct gtcacccagg ctggagtgca  52260gtggcacaat cttggctcac tgcaacctcc acctcctggg ttcaagtgaa tctcttgcct  52320cagcctctga gtagctggga ttacaggtgc ccaccaccaa acctggctct tttttttttt  52380ttttttgtaa ttttagtaga gacggggctt caccatgttg gccaggctgg tcttgaactc  52440ctgacctcag gtgatccacc tgcctcagcc tcccaaagtg ctgggattac aggcatgagc  52500caccgtgcct gacccactga tggtttgaat tattctaagt tcgccaccgt ccaatcctgt  52560ttgctctggg cttttaggtt ctaagctgtg cctctgtcca tgtaaagtca gaccaggagg  52620aatggaaaca cgaaacattg ccattgtgtt tccctttgtg ttgcagtggt ggtctcaagg  52680aaaacgacgt cataatcagc atcaatggac agtccgtggt ctccgccaat gatgtcagcg  52740acgtcattaa aagggaaagc accctgaaca tggtggtccg caggggtaat gaagatatca  52800tgatcacagt gattcccgaa gaaattgacc cataggcaga ggcatgagct ggacttcatg  52860tttccctcaa agactctccc gtggatgacg gatgaggact ctgggctgct ggaataggac  52920actcaagact tttgactgcc attttgtttg ttcagtggag actccctggc caacagaatc  52980cttcttgata gtttgcaggc aaaacaaatg taatgttgca gatccgcagg cagaagctct  53040gcccttctgt atcctatgta tgcagtgtgc tttttcttgc cagcttgggc cattcttgct  53100tagacagtca gcatttgtct cctcctttaa ctgagtcatc atcttagtcc aactaatgca  53160gtcgatacaa tgcgtagata gaagaagccc cacgggagcc aggatgggac tggtcgtgtt  53220tgtgcttttc tccaagtcag cacccaaagg tcaatgcaca gagaccccgg gtgggtgagc  53280gctggcttct caaacggccg aagttgcctc ttttaggaat ctctttggaa ttgggagcac  53340gatgactctg agtttgagct attaaagtac ttcttacaca ttgc                   53384</s400><s200><s210>11</s210><s211>18</s211><s212>DNA</s212><s213>artificial</s213><s220><s223>Oligonucleotide sequence motif</s223></s220></s200><s400> 11caaatattta cctggttg                                                   18</s400><s200><s210>12</s210><s211>16</s211><s212>DNA</s212><s213>artificial</s213><s220><s223>Oligonucleotide sequence motif</s223></s220></s200><s400> 12tttacctggt tgttgg                                                     16</s400><s200><s210>13</s210><s211>18</s211><s212>DNA</s212><s213>artificial</s213><s220><s223>Oligonucleotide sequence motif</s223></s220></s200><s400> 13ccaaatattt acctggtt                                                   18</s400><s200><s210>14</s210><s211>20</s211><s212>DNA</s212><s213>artificial</s213><s220><s223>Oligonucleotide sequence motif</s223></s220></s200><s400> 14ccaaatattt acctggttgt                                                 20</s400><s200><s210>15</s210><s211>18</s211><s212>DNA</s212><s213>artificial</s213><s220><s223>Oligonucleotide sequence motif</s223></s220></s200><s400> 15atatttacct ggttgttg                                                   18</s400><s200><s210>16</s210><s211>16</s211><s212>DNA</s212><s213>artificial</s213><s220><s223>Oligonucleotide sequence motif</s223></s220></s200><s400> 16tatttacctg gttgtt                                                     16</s400><s200><s210>17</s210><s211>16</s211><s212>DNA</s212><s213>artificial</s213><s220><s223>Oligonucleotide sequence motif</s223></s220></s200><s400> 17atatttacct ggttgt                                                     16</s400><s200><s210>18</s210><s211>17</s211><s212>DNA</s212><s213>artificial</s213><s220><s223>Oligonucleotide sequence motif</s223></s220></s200><s400> 18atatttacct ggttgtt                                                    17</s400><s200><s210>19</s210><s211>11</s211><s212>DNA</s212><s213>artificial</s213><s220><s223>Oligonucleotide sequence motif</s223></s220></s200><s400> 19tttacctggt t                                                          11</s400></sequence-list-new-rules></sequence-cwu><?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v46-2022-02-17.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.6 2022-02-17" file="US20230002763A1-20230105.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20221221" date-publ="20230105"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20230002763</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>17586175</doc-number><date>20220127</date></document-id></application-reference><us-application-series-code>17</us-application-series-code><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>12</class><subclass>N</subclass><main-group>15</main-group><subgroup>113</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>H</subclass><main-group>21</main-group><subgroup>02</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>15</main-group><subgroup>113</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc><further-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>H</subclass><main-group>21</main-group><subgroup>02</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>2310</main-group><subgroup>11</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>2310</main-group><subgroup>315</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>2310</main-group><subgroup>341</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>2320</main-group><subgroup>34</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>2310</main-group><subgroup>3231</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>2310</main-group><subgroup>3341</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>2310</main-group><subgroup>345</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>2310</main-group><subgroup>335</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>2310</main-group><subgroup>3125</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>2310</main-group><subgroup>346</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>2310</main-group><subgroup>313</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></further-cpc></classifications-cpc><invention-title id="d2e43">SELECTIVE ANTISENSE COMPOUNDS AND USES THEREOF</invention-title><us-related-documents><continuation><relation><parent-doc><document-id><country>US</country><doc-number>16793119</doc-number><date>20200218</date></document-id><parent-grant-document><document-id><country>US</country><doc-number>11236335</doc-number></document-id></parent-grant-document></parent-doc><child-doc><document-id><country>US</country><doc-number>17586175</doc-number></document-id></child-doc></relation></continuation><continuation><relation><parent-doc><document-id><country>US</country><doc-number>16141781</doc-number><date>20180925</date></document-id><parent-status>ABANDONED</parent-status></parent-doc><child-doc><document-id><country>US</country><doc-number>16793119</doc-number></document-id></child-doc></relation></continuation><continuation><relation><parent-doc><document-id><country>US</country><doc-number>15468489</doc-number><date>20170324</date></document-id><parent-status>ABANDONED</parent-status></parent-doc><child-doc><document-id><country>US</country><doc-number>16141781</doc-number></document-id></child-doc></relation></continuation><continuation><relation><parent-doc><document-id><country>US</country><doc-number>14434885</doc-number><date>20150410</date></document-id><parent-status>ABANDONED</parent-status><parent-pct-document><document-id><country>WO</country><doc-number>PCT/US2013/064666</doc-number><date>20131011</date></document-id></parent-pct-document></parent-doc><child-doc><document-id><country>US</country><doc-number>15468489</doc-number></document-id></child-doc></relation></continuation><us-provisional-application><document-id><country>US</country><doc-number>61840722</doc-number><date>20130628</date></document-id></us-provisional-application><us-provisional-application><document-id><country>US</country><doc-number>61760596</doc-number><date>20130204</date></document-id></us-provisional-application><us-provisional-application><document-id><country>US</country><doc-number>61713459</doc-number><date>20121012</date></document-id></us-provisional-application></us-related-documents><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only" applicant-authority-category="assignee"><addressbook><orgname>Ionis Pharmaceuticals, Inc.</orgname><address><city>Carlsbad</city><state>CA</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>Oestergaard</last-name><first-name>Michael</first-name><address><city>Carlsbad</city><state>CA</state><country>US</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>Seth</last-name><first-name>Punit P.</first-name><address><city>Carlsbad</city><state>CA</state><country>US</country></address></addressbook></inventor><inventor sequence="02" designation="us-only"><addressbook><last-name>Swayze</last-name><first-name>Eric E.</first-name><address><city>Encinitas</city><state>CA</state><country>US</country></address></addressbook></inventor></inventors></us-parties><assignees><assignee><addressbook><orgname>Ionis Pharmaceuticals, Inc.</orgname><role>02</role><address><city>Carlsbad</city><state>CA</state><country>US</country></address></addressbook></assignee></assignees></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount, activity, or expression of the target nucleic acid in a cell. In certain embodiments, hybridization results in selective modulation of the amount, activity, or expression of a target Huntingtin gene or Huntingtin transcript in a cell.</p></abstract><description id="description"><?summary-of-invention description="Summary of Invention" end="lead"?><heading id="h-0001" level="1">SEQUENCE LISTING</heading><p id="p-0002" num="0001">The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled CORE0109USC4SEQ.txt, created Dec. 8, 2021, which is 392 Kb in size. The information in the electronic format of the sequence listing is incorporated herein by reference in its entirety.</p><heading id="h-0002" level="1">BACKGROUND</heading><p id="p-0003" num="0002">Antisense compounds have been used to modulate target nucleic acids. Antisense compounds comprising a variety of chemical modifications and motifs have been reported. In certain instances, such compounds are useful as research tools, diagnostic reagents, and as therapeutic agents. In certain instances antisense compounds have been shown to modulate protein expression by binding to a target messenger RNA (mRNA) encoding the protein. In certain instances, such binding of an antisense compound to its target mRNA results in cleavage of the mRNA. Antisense compounds that modulate processing of a pre-mRNA have also been reported. Such antisense compounds alter splicing, interfere with polyadenlyation or prevent formation of the 5&#x2032;-cap of a pre-mRNA.</p><heading id="h-0003" level="1">SUMMARY</heading><p id="p-0004" num="0003">In certain embodiments, the present invention provides oligomeric compounds comprising oligonucleotides. In certain embodiments, such oligonucleotides comprise a region having a gapmer motif. In certain embodiments, such oligonucleotides consist of a region having a gapmer motif.</p><p id="p-0005" num="0004">The present disclosure provides the following non-limiting numbered embodiments:<ul id="ul0001" list-style="none">    <li id="ul0001-0001" num="0000">    <ul id="ul0002" list-style="none">        <li id="ul0002-0001" num="0005">Embodiment 1: A compound comprising a modified oligonucleotide consisting of 12 to 30 linked nucleosides, wherein the linked nucleosides comprise at least 8 contiguous nucleobases of a nucleobase sequence recited in SEQ ID NO: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 1 64, 165, 166, 167, 168, 169, 170, 171, 172, 173, or 174-573.</li>        <li id="ul0002-0002" num="0006">Embodiment 2: The compound of embodiment 1, wherein the modified oligonucleotide comprises at least 10 contiguous nucleobases of a nucleobase sequence recited in SEQ ID NO: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 1 64, 165, 166, 167, 168, 169, 170, 171, 172, 173, or 174-573.</li>        <li id="ul0002-0003" num="0007">Embodiment 3: The compound of embodiment 1, wherein the modified oligonucleotide comprises at least 12 contiguous nucleobases of a nucleobase sequence recited in SEQ ID NO: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 1 64, 165, 166, 167, 168, 169, 170, 171, 172, 173, or 174-573.</li>        <li id="ul0002-0004" num="0008">Embodiment 4: The compound of embodiment 1, wherein the modified oligonucleotide comprises at least 14 contiguous nucleobases of a nucleobase sequence recited in SEQ ID NO: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 1 64, 165, 166, 167, 168, 169, 170, 171, 172, 173, or 174-573.</li>        <li id="ul0002-0005" num="0009">Embodiment 5: The compound of embodiment 1, wherein the modified oligonucleotide comprises at least 16 contiguous nucleobases of a nucleobase sequence recited in SEQ ID NO: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 1 64, 165, 166, 167, 168, 169, 170, 171, 172, 173, or 174-573.</li>        <li id="ul0002-0006" num="0010">Embodiment 6: The compound of embodiment 1, wherein the modified oligonucleotide comprises a nucleobase sequence selected from among SEQ ID NO: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 1 64, 165, 166, 167, 168, 169, 170, 171, 172, 173, or 174-573.</li>        <li id="ul0002-0007" num="0011">Embodiment 7: The compound of embodiment 1, wherein the modified oligonucleotide consists of a nucleobase sequence selected from among SEQ ID NO: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, or 174-573.</li>        <li id="ul0002-0008" num="0012">Embodiment 8: The compound of any of embodiments 1 to 7, wherein the modified oligonucleotide consists of 14 to 26 linked nucleosides.</li>        <li id="ul0002-0009" num="0013">Embodiment 9: The compound of any of embodiments 1 to 7, wherein the modified oligonucleotide consists of 15 to 25 linked nucleosides.</li>        <li id="ul0002-0010" num="0014">Embodiment 10: The compound of any of embodiments 1 to 7, wherein the modified oligonucleotide consists of 16 to 25 linked nucleosides.</li>        <li id="ul0002-0011" num="0015">Embodiment 11: The compound of any of embodiments 1 to 7, wherein the modified oligonucleotide consists of 17 to 25 linked nucleosides.</li>        <li id="ul0002-0012" num="0016">Embodiment 12: The compound of any of embodiments 1 to 7, wherein the modified oligonucleotide consists of 15 to 22 linked nucleosides.</li>        <li id="ul0002-0013" num="0017">Embodiment 13: The compound of any of embodiments 1 to 7, wherein the modified oligonucleotide consists of 15 to 20 linked nucleosides.</li>        <li id="ul0002-0014" num="0018">Embodiment 14: The compound of any of embodiments 1 to 7, wherein the modified oligonucleotide consists of 16 to 20 linked nucleosides.</li>        <li id="ul0002-0015" num="0019">Embodiment 15: The compound of any of embodiments 1 to 7, wherein the modified oligonucleotide consists of 14 linked nucleosides.</li>        <li id="ul0002-0016" num="0020">Embodiment 16: The compound of any of embodiments 1 to 7, wherein the modified oligonucleotide consists of 15 linked nucleosides.</li>        <li id="ul0002-0017" num="0021">Embodiment 17: The compound of any of embodiments 1 to 7, wherein the modified oligonucleotide consists of 16 linked nucleosides.</li>        <li id="ul0002-0018" num="0022">Embodiment 18: The compound of any of embodiments 1 to 7, wherein the modified oligonucleotide consists of 17 linked nucleosides.</li>        <li id="ul0002-0019" num="0023">Embodiment 19: The compound of any of embodiments 1 to 7, wherein the modified oligonucleotide consists of 18 linked nucleosides.</li>        <li id="ul0002-0020" num="0024">Embodiment 20: The compound of any of embodiments 1 to 7, wherein the modified oligonucleotide consists of 19 linked nucleosides.</li>        <li id="ul0002-0021" num="0025">Embodiment 21: The compound of any of embodiments 1 to 7, wherein the modified oligonucleotide consists of 20 linked nucleosides.</li>        <li id="ul0002-0022" num="0026">Embodiment 22: The compound of any of embodiments 1 to 7, wherein the modified oligonucleotide consists of 21 linked nucleosides.</li>        <li id="ul0002-0023" num="0027">Embodiment 23: The compound of any of embodiments 1 to 7, wherein the modified oligonucleotide consists of 22 linked nucleosides.</li>        <li id="ul0002-0024" num="0028">Embodiment 24: The compound of any of embodiments 1 to 23, wherein the nucleobase sequence of the modified oligonucleotide is 90% complementary to SEQ ID NO. 1.</li>        <li id="ul0002-0025" num="0029">Embodiment 25: The compound of any of embodiments 1 to 23, wherein the nucleobase sequence of the modified oligonucleotide is 95% complementary to SEQ ID NO. 1.</li>        <li id="ul0002-0026" num="0030">Embodiment 26: The compound of any of embodiments 1 to 23, wherein the nucleobase sequence of the modified oligonucleotide is 100% complementary to SEQ ID NO. 1.</li>        <li id="ul0002-0027" num="0031">Embodiment 27: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an eeedk-d7-keee motif.</li>        <li id="ul0002-0028" num="0032">Embodiment 28: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an eeeedk-d7-eeee motif.</li>        <li id="ul0002-0029" num="0033">Embodiment 29: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an eeeedk-d7-keee motif.</li>        <li id="ul0002-0030" num="0034">Embodiment 30: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an eeeedk-d7-kkee motif</li>        <li id="ul0002-0031" num="0035">Embodiment 31: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an eeeee-d9-eeeee motif.</li>        <li id="ul0002-0032" num="0036">Embodiment 32: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an eeeeedk-d7-eeeee motif.</li>        <li id="ul0002-0033" num="0037">Embodiment 33: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an eeeeeeeek-d7-eee motif</li>        <li id="ul0002-0034" num="0038">Embodiment 34: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an eeeeeeek-d7-eeee motif.</li>        <li id="ul0002-0035" num="0039">Embodiment 35: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an eeeeek-d7-eee motif.</li>        <li id="ul0002-0036" num="0040">Embodiment 36: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an eeeeek-d7-eeeeee motif.</li>        <li id="ul0002-0037" num="0041">Embodiment 37: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an eeeeek-d7-kee motif.</li>        <li id="ul0002-0038" num="0042">Embodiment 38: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an eeeeek-d7-kke motif</li>        <li id="ul0002-0039" num="0043">Embodiment 39: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an eeeek-d7-eeee motif.</li>        <li id="ul0002-0040" num="0044">Embodiment 40: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an eeeek-d7-eeeeeee motif.</li>        <li id="ul0002-0041" num="0045">Embodiment 41: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an eeeek-d7-keee motif.</li>        <li id="ul0002-0042" num="0046">Embodiment 42: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an eeeek-d7-keeee motif.</li>        <li id="ul0002-0043" num="0047">Embodiment 43: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an eeeek-d7-kke motif</li>        <li id="ul0002-0044" num="0048">Embodiment 44: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an eeeek-d7-kkee motif.</li>        <li id="ul0002-0045" num="0049">Embodiment 45: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an eeeekk-d3-k-d3-keke motif.</li>        <li id="ul0002-0046" num="0050">Embodiment 46: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an eeeekk-d7-kee motif.</li>        <li id="ul0002-0047" num="0051">Embodiment 47: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an eeeekk-d7-keke motif.</li>        <li id="ul0002-0048" num="0052">Embodiment 48: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an eeeekk-d7-kke motif</li>        <li id="ul0002-0049" num="0053">Embodiment 49: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an eeeekk-d7-kkee motif.</li>        <li id="ul0002-0050" num="0054">Embodiment 50: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an eeek-d7-eeeeeeee motif Embodiment 51: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an eeek-d7-keeeee motif.</li>        <li id="ul0002-0051" num="0055">Embodiment 52: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an eeek-d7-kkee motif.</li>        <li id="ul0002-0052" num="0056">Embodiment 53: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an eeek-d7-kkeee motif.</li>        <li id="ul0002-0053" num="0057">Embodiment 54: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an eeek-d8-kee motif.</li>        <li id="ul0002-0054" num="0058">Embodiment 55: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an eeek-d9-keee motif</li>        <li id="ul0002-0055" num="0059">Embodiment 56: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an eeek-d9-keke motif.</li>        <li id="ul0002-0056" num="0060">Embodiment 57: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an eeekk-d7-eeee motif.</li>        <li id="ul0002-0057" num="0061">Embodiment 58: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an eeekk-d7-keee motif.</li>        <li id="ul0002-0058" num="0062">Embodiment 59: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an eeekk-d7-kke motif.</li>        <li id="ul0002-0059" num="0063">Embodiment 60: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an eeekk-d7-kkee motif</li>        <li id="ul0002-0060" num="0064">Embodiment 61: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an eeekk-d7-kkeee motif.</li>        <li id="ul0002-0061" num="0065">Embodiment 62: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an eek-d7-eeeeeeeee motif.</li>        <li id="ul0002-0062" num="0066">Embodiment 63: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an eek-d7-keeeeee motif.</li>        <li id="ul0002-0063" num="0067">Embodiment 64: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an eek-d7-kkeee motif.</li>        <li id="ul0002-0064" num="0068">Embodiment 65: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an eek-d8-kkee motif.</li>        <li id="ul0002-0065" num="0069">Embodiment 66: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an eekk-d8-kee motif.</li>        <li id="ul0002-0066" num="0070">Embodiment 67: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an eekk-d8-kkee motif.</li>        <li id="ul0002-0067" num="0071">Embodiment 68: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an eekk-d8-kkeee motif</li>        <li id="ul0002-0068" num="0072">Embodiment 69: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an ek-d7-eeeeeeeeee motif.</li>        <li id="ul0002-0069" num="0073">Embodiment 70: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an ek-d8-kkeee motif.</li>        <li id="ul0002-0070" num="0074">Embodiment 71: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an ek-d9-kkke motif.</li>        <li id="ul0002-0071" num="0075">Embodiment 72: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an ekek-d6-k-dd-keke motif.</li>        <li id="ul0002-0072" num="0076">Embodiment 73: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an ekek-d8-kkeke motif</li>        <li id="ul0002-0073" num="0077">Embodiment 74: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an ekek-d9-keee motif.</li>        <li id="ul0002-0074" num="0078">Embodiment 75: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an ekek-d9-keke motif.</li>        <li id="ul0002-0075" num="0079">Embodiment 76: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an ekekek-d7-keke motif.</li>        <li id="ul0002-0076" num="0080">Embodiment 77: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an ekekk-d8-keke motif.</li>        <li id="ul0002-0077" num="0081">Embodiment 78: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an ekk-d7-kkeee motif.</li>        <li id="ul0002-0078" num="0082">Embodiment 79: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an ekk-d7-kkeeeee motif.</li>        <li id="ul0002-0079" num="0083">Embodiment 80: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an ekk-d8-kkee motif.</li>        <li id="ul0002-0080" num="0084">Embodiment 81: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an ekk-d8-kkeee motif.</li>        <li id="ul0002-0081" num="0085">Embodiment 82: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an ekk-d8-kkeeee motif.</li>        <li id="ul0002-0082" num="0086">Embodiment 83: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an ekk-d8-kkke motif.</li>        <li id="ul0002-0083" num="0087">Embodiment 84: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an ekk-d9-kke motif</li>        <li id="ul0002-0084" num="0088">Embodiment 85: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an ekkdk-d7-kke motif.</li>        <li id="ul0002-0085" num="0089">Embodiment 86: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an ekkk-d8-kke motif.</li>        <li id="ul0002-0086" num="0090">Embodiment 87: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an ekkk-d9-ke motif.</li>        <li id="ul0002-0087" num="0091">Embodiment 88: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an ekkkk-d7-kke motif.</li>        <li id="ul0002-0088" num="0092">Embodiment 89: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has an ekkkk-d7-kkke motif.</li>        <li id="ul0002-0089" num="0093">Embodiment 90: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has a kkekk-d9-kkekk motif.</li>        <li id="ul0002-0090" num="0094">Embodiment 91: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has a kkkkk-d7-kkkkk motif</li>        <li id="ul0002-0091" num="0095">Embodiment 92: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has a ekkdk-d7-kke motif.</li>        <li id="ul0002-0092" num="0096">Embodiment 93: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has a ekek-d8-kekee motif.</li>        <li id="ul0002-0093" num="0097">Embodiment 94: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has a ekk-f-d8-kke motif.</li>        <li id="ul0002-0094" num="0098">Embodiment 95: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has a ekk-z-d8-kke motif.</li>        <li id="ul0002-0095" num="0099">Embodiment 96: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has a ekk-h-d8-kke motif</li>        <li id="ul0002-0096" num="0100">Embodiment 97: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has a ekk-d2-h-d6-kke motif.</li>        <li id="ul0002-0097" num="0101">Embodiment 98: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has a ekk-d-h-d7-kke motif.</li>        <li id="ul0002-0098" num="0102">Embodiment 99: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has a ekk-d3-f-d5-kke motif.</li>        <li id="ul0002-0099" num="0103">Embodiment 100: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has a ekk-d3-z-d5-kke motif.</li>        <li id="ul0002-0100" num="0104">Embodiment 101: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has a ekk-d3-h-d5-kke motif.</li>        <li id="ul0002-0101" num="0105">Embodiment 102: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has a ekk-d4-h-d4-kke motif.</li>        <li id="ul0002-0102" num="0106">Embodiment 103: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has a ekk-d5-f-d3-kke motif.</li>        <li id="ul0002-0103" num="0107">Embodiment 104: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has a ekk-d5-z-d3-kke motif</li>        <li id="ul0002-0104" num="0108">Embodiment 105: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has a ekk-d5-h-d3-kke motif.</li>        <li id="ul0002-0105" num="0109">Embodiment 106: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has a ekk-d6-f-d2-kke motif.</li>        <li id="ul0002-0106" num="0110">Embodiment 107: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has a ekk-d6-z-d2-kke motif.</li>        <li id="ul0002-0107" num="0111">Embodiment 108: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has a ekk-d6-h-d2-kke motif.</li>        <li id="ul0002-0108" num="0112">Embodiment 109: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has a ekk-d7-f-d-kke motif</li>        <li id="ul0002-0109" num="0113">Embodiment 110: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has a ekk-d7-z-d-kke motif.</li>        <li id="ul0002-0110" num="0114">Embodiment 111: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has a ekk-d7-h-d-kke motif.</li>        <li id="ul0002-0111" num="0115">Embodiment 112: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has a ekk-d8-f-dkke motif.</li>        <li id="ul0002-0112" num="0116">Embodiment 113: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has a ekk-d8-z-kke motif.</li>        <li id="ul0002-0113" num="0117">Embodiment 114: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has a ekk-d8-h-kke motif</li>        <li id="ul0002-0114" num="0118">Embodiment 115: The compound of any of embodiments 1 to 26, wherein the oligonucleotide has a ekk-d9-kke motif.</li>        <li id="ul0002-0115" num="0119">Embodiment 116: The oligomeric compound of any of embodiments 1 to 115 comprising at least one modified internucleoside linkage.</li>        <li id="ul0002-0116" num="0120">Embodiment 117: The oligomeric compound of embodiment 116, wherein each internucleoside linkage is a modified internucleoside linkage.</li>        <li id="ul0002-0117" num="0121">Embodiment 118: The oligomeric compound of embodiment 115 or 116 comprising at least one phosphorothioate internucleoside linkage.</li>        <li id="ul0002-0118" num="0122">Embodiment 119: The oligomeric compound of embodiment 117 wherein each internucleoside linkage is a phosphorothioate internucleoside linkage.</li>        <li id="ul0002-0119" num="0123">Embodiment 120: The oligomeric compound of any of embodiments 1 to 119 comprising at least one methylphosphonate internucleoside linkage.</li>        <li id="ul0002-0120" num="0124">Embodiment 121: The oligomeric compound of any of embodiments 1 to 119 comprising one methylphosphonate internucleoside linkage.</li>        <li id="ul0002-0121" num="0125">Embodiment 122: The oligomeric compound of any of embodiments 1 to 120 comprising two methylphosphonate internucleoside linkages.</li>        <li id="ul0002-0122" num="0126">Embodiment 123: The oligomeric compound of any of embodiments 1 to 120 comprising at least one modified nucleobase.</li>        <li id="ul0002-0123" num="0127">Embodiment 124: The oligomeric compound of embodiment 123, comprising at least one 2-thio-thymidine.</li>        <li id="ul0002-0124" num="0128">Embodiment 125: The oligomeric compound of embodiment 1, having an eeeekk-d7-kke motif and consisting of the nucleobase sequence of SEQ ID NO.: 24.</li>        <li id="ul0002-0125" num="0129">Embodiment 126: The oligomeric compound of any of embodiments 1 to 119 comprising at least one 5&#x2032;-Me-DNA modification.</li>        <li id="ul0002-0126" num="0130">Embodiment 127: The oligomeric compound of any of embodiments 1 to 119 comprising one 5&#x2032;-Me-DNA modification.</li>        <li id="ul0002-0127" num="0131">Embodiment 128: The oligomeric compound of embodiment 126 or 127, wherein the 5&#x2032;-Me-DNA modification is an S-5&#x2032;-Me-DNA.</li>        <li id="ul0002-0128" num="0132">Embodiment 129: The oligomeric compound of embodiment 126 or 127, wherein the 5&#x2032;-Me-DNA modification is an R-5&#x2032;-Me-DNA.</li>        <li id="ul0002-0129" num="0133">Embodiment 130: The oligomeric compound of any of embodiments 126 to 129, wherein the 5&#x2032;-Me-DNA modification is at position 6 from the 5&#x2032;-end.</li>        <li id="ul0002-0130" num="0134">Embodiment 131: The oligomeric compound of any of embodiments 126 to 129, wherein the 5&#x2032;-Me-DNA modification is at position 7 from the 5&#x2032;-end.</li>        <li id="ul0002-0131" num="0135">Embodiment 132: The oligomeric compound of any of embodiments 126 to 129, consisting of the nucleobase sequence of SEQ ID NO.: 3.</li>        <li id="ul0002-0132" num="0136">Embodiment 133: The oligomeric compound of any of embodiments 1 to 132, having an EC<sub>50 </sub>for reduction of expression of target that is at least least two-fold lower than its EC<sub>50 </sub>for reduction of expression of the non-target, when measured in cells.</li>        <li id="ul0002-0133" num="0137">Embodiment 134: The oligomeric compound of any of embodiments 1 to 132, having an ED<sub>50 </sub>for reduction of expression of target that is at least least two-fold lower than its ED<sub>50 </sub>for reduction of expression of the non-target, when measured in an animal.</li>        <li id="ul0002-0134" num="0138">Embodiment 135: A compound consisting of ISIS 572772.</li>        <li id="ul0002-0135" num="0139">Embodiment 136: A pharmaceutical composition comprising an oligomeric compound of any of embodiments 1-135 and a pharmaceutically acceptable carrier or diluent.</li>        <li id="ul0002-0136" num="0140">Embodiment 137: A method comprising contacting a cell with an oligomeric compound of any of embodiments 1-136.</li>        <li id="ul0002-0137" num="0141">Embodiment 138: The method of embodiment 137, wherein the cell is in vitro.</li>        <li id="ul0002-0138" num="0142">Embodiment 139: The method of embodiment 137, wherein the cell is in an animal.</li>        <li id="ul0002-0139" num="0143">Embodiment 140: The method of embodiment 137, wherein the animal is a human.</li>        <li id="ul0002-0140" num="0144">Embodiment 141: The method of embodiment 137, wherein the animal is a mouse.</li>        <li id="ul0002-0141" num="0145">Embodiment 142: A method of administering a pharmaceutical composition of embodiment 136 to an animal.</li>        <li id="ul0002-0142" num="0146">Embodiment 143: The method of embodiment 142, wherein the animal is a human.</li>        <li id="ul0002-0143" num="0147">Embodiment 144: The method of embodiment 143, wherein the animal is a mouse.</li>        <li id="ul0002-0144" num="0148">Embodiment 145: Use of an oligomeric compound of any of embodiments 1-136 for the preparation of a medicament for the treatment or amelioration of Huntington's disease.</li>        <li id="ul0002-0145" num="0149">Embodiment 146: A method of ameliorating a symptom of Huntington's disease, comprising administering an oligomeric compound of any of embodiments 1-136 to an animal in need thereof.</li>        <li id="ul0002-0146" num="0150">Embodiment 147: The method of embodiment 146, wherein the animal is a human.</li>        <li id="ul0002-0147" num="0151">Embodiment 148: The method of embodiment 147, wherein the animal is a mouse.</li>        <li id="ul0002-0148" num="0152">Embodiment 149: A method for reducing the rate of progression of a symptom associated with Huntington's Disease, comprising administering to a human in need thereof a compound of any of embodiments 1-136, and thereby reducing the rate of progression a symptom of Huntington's disease in the human.</li>        <li id="ul0002-0149" num="0153">Embodiment 150: A method for reversing degeneration indicated by a symptom associated with Huntington's disease, comprising administering to a human in need thereof a compound of any of embodiments 1-136, and thereby reversing degeneration indicated by a symptom of Huntington's disease in the human.</li>        <li id="ul0002-0150" num="0154">Embodiment 151: A method for treating a human with Huntington's disease comprising identifying the human with the disease and administering to the human a therapeutically effective amount of the compound of any of embodiments 1-136.</li>        <li id="ul0002-0151" num="0155">Embodiment 152: The method of embodiment 149, wherein the treatment reduces at least one of restlessness, lack of coordination, unintentionally initiated motions, unintentionally uncompleted motions, unsteady gait, chorea, rigidity, writhing motions, abnormal posturing, instability, abnormal facial expressions, difficulty chewing, difficulty swallowing, difficulty speaking, seizure, sleep disturbances, impaired planning, impaired flexibility, impaired abstract thinking, impaired rule acquisition, impaired initiation of appropriate actions, impaired inhibition of inappropriate actions, impaired short-term memory, impaired long-term memory, paranoia, disorientation, confusion, hallucination, dementia, a anxiety, depression, blunted affect, egocentrisms, aggression, compulsive behavior, irritability, suicidal ideation, reduced brain mass, muscle atrophy, cardiac failure, impaired glucose tolerance, weight loss, osteoporosis, and testicular atrophy in the human.</li>        <li id="ul0002-0152" num="0156">Embodiment 153: A method for reducing the rate of progression of a symptom associated with Huntington's Disease, comprising administering to a human in need thereof ISIS 572772, and thereby reducing the rate of progression a symptom of Huntington's disease in the human.</li>        <li id="ul0002-0153" num="0157">Embodiment 154: A method for reversing degeneration indicated by a symptom associated with Huntington's disease, comprising administering to a human in need thereof ISIS 572772, and thereby reversing degeneration indicated by a symptom of Huntington's disease in the human.</li>        <li id="ul0002-0154" num="0158">Embodiment 155: A method for treating a human with Huntington's disease comprising identifying the human with the disease and administering to the human a therapeutically effective amount of ISIS 572772.</li>        <li id="ul0002-0155" num="0159">Embodiment 156: The method of embodiment 153, wherein the treatment reduces at least one of restlessness, lack of coordination, unintentionally initiated motions, unintentionally uncompleted motions, unsteady gait, chorea, rigidity, writhing motions, abnormal posturing, instability, abnormal facial expressions, difficulty chewing, difficulty swallowing, difficulty speaking, seizure, sleep disturbances, impaired planning, impaired flexibility, impaired abstract thinking, impaired rule acquisition, impaired initiation of appropriate actions, impaired inhibition of inappropriate actions, impaired short-term memory, impaired long-term memory, paranoia, disorientation, confusion, hallucination, dementia, a anxiety, depression, blunted affect, egocentrisms, aggression, compulsive behavior, irritability, suicidal ideation, reduced brain mass, muscle atrophy, cardiac failure, impaired glucose tolerance, weight loss, osteoporosis, and testicular atrophy in the human.</li>    </ul>    </li></ul></p><?summary-of-invention description="Summary of Invention" end="tail"?><?detailed-description description="Detailed Description" end="lead"?><heading id="h-0004" level="1">DETAILED DESCRIPTION</heading><p id="p-0006" num="0160">It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed. Herein, the use of the singular includes the plural unless specifically stated otherwise. As used herein, the use of &#x201c;or&#x201d; means &#x201c;and/or&#x201d; unless stated otherwise. Furthermore, the use of the term &#x201c;including&#x201d; as well as other forms, such as &#x201c;includes&#x201d; and &#x201c;included&#x201d;, is not limiting. Also, terms such as &#x201c;element&#x201d; or &#x201c;component&#x201d; encompass both elements and components comprising one unit and elements and components that comprise more than one subunit, unless specifically stated otherwise.</p><p id="p-0007" num="0161">The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. All documents, or portions of documents, cited in this application, including, but not limited to, patents, patent applications, articles, books, and treatises, are hereby expressly incorporated by reference in their entirety for any purpose.</p><heading id="h-0005" level="1">A. Definitions</heading><p id="p-0008" num="0162">Unless specific definitions are provided, the nomenclature used in connection with, and the procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well known and commonly used in the art. Standard techniques may be used for chemical synthesis, and chemical analysis. Certain such techniques and procedures may be found for example in &#x201c;Carbohydrate Modifications in Antisense Research&#x201d; Edited by Sangvi and Cook, American Chemical Society, Washington D.C., 1994; &#x201c;Remington's Pharmaceutical Sciences,&#x201d; Mack Publishing Co., Easton, Pa., 21&#x2032; edition, 2005; and &#x201c;Antisense Drug Technology, Principles, Strategies, and Applications&#x201d; Edited by Stanley T. Crooke, CRC Press, Boca Raton, Fla.; and Sambrook et al., &#x201c;Molecular Cloning, A laboratory Manual,&#x201d; 2<sup>nd </sup>Edition, Cold Spring Harbor Laboratory Press, 1989, which are hereby incorporated by reference for any purpose. Where permitted, all patents, applications, published applications and other publications and other data referred to throughout in the disclosure are incorporated by reference herein in their entirety.</p><p id="p-0009" num="0163">Unless otherwise indicated, the following terms have the following meanings:</p><p id="p-0010" num="0164">As used herein, &#x201c;nucleoside&#x201d; means a compound comprising a nucleobase moiety and a sugar moiety. Nucleosides include, but are not limited to, naturally occurring nucleosides (as found in DNA and RNA) and modified nucleosides. Nucleosides may be linked to a phosphate moiety.</p><p id="p-0011" num="0165">As used herein, &#x201c;chemical modification&#x201d; means a chemical difference in a compound when compared to a naturally occurring counterpart. Chemical modifications of oligonucleotides include nucleoside modifications (including sugar moiety modifications and nucleobase modifications) and internucleoside linkage modifications. In reference to an oligonucleotide, chemical modification does not include differences only in nucleobase sequence.</p><p id="p-0012" num="0166">As used herein, &#x201c;furanosyl&#x201d; means a structure comprising a 5-membered ring comprising four carbon atoms and one oxygen atom.</p><p id="p-0013" num="0167">As used herein, &#x201c;naturally occurring sugar moiety&#x201d; means a ribofuranosyl as found in naturally occurring RNA or a deoxyribofuranosyl as found in naturally occurring DNA.</p><p id="p-0014" num="0168">As used herein, &#x201c;sugar moiety&#x201d; means a naturally occurring sugar moiety or a modified sugar moiety of a nucleoside.</p><p id="p-0015" num="0169">As used herein, &#x201c;modified sugar moiety&#x201d; means a substituted sugar moiety or a sugar surrogate.</p><p id="p-0016" num="0170">As used herein, &#x201c;substituted sugar moiety&#x201d; means a furanosyl that is not a naturally occurring sugar moiety. Substituted sugar moieties include, but are not limited to furanosyls comprising substituents at the 2&#x2032;-position, the 3&#x2032;-position, the 5&#x2032;-position and/or the 4&#x2032;-position. Certain substituted sugar moieties are bicyclic sugar moieties.</p><p id="p-0017" num="0171">As used herein, &#x201c;2&#x2032;-substituted sugar moiety&#x201d; means a furanosyl comprising a substituent at the 2&#x2032;-position other than H or OH. Unless otherwise indicated, a 2&#x2032;-substituted sugar moiety is not a bicyclic sugar moiety (i.e., the 2&#x2032;-substituent of a 2&#x2032;-substituted sugar moiety does not form a bridge to another atom of the furanosyl ring.</p><p id="p-0018" num="0172">As used herein, &#x201c;MOE&#x201d; means &#x2014;OCH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>.</p><p id="p-0019" num="0173">As used herein, &#x201c;2&#x2032;-F nucleoside&#x201d; refers to a nucleoside comprising a sugar comprising fluoroine at the 2&#x2032; position. Unless otherwise indicated, the fluorine in a 2&#x2032;-F nucleoside is in the ribo position (replacing the OH of a natural ribose).</p><p id="p-0020" num="0174">As used herein, &#x201c;2&#x2032;-(ara)-F&#x201d; refers to a 2&#x2032;-F substituted nucleoside, wherein the fluoro group is in the arabino position.</p><p id="p-0021" num="0175">As used herein the term &#x201c;sugar surrogate&#x201d; means a structure that does not comprise a furanosyl and that is capable of replacing the naturally occurring sugar moiety of a nucleoside, such that the resulting nucleoside sub-units are capable of linking together and/or linking to other nucleosides to form an oligomeric compound which is capable of hybridizing to a complementary oligomeric compound. Such structures include rings comprising a different number of atoms than furanosyl (e.g., 4, 6, or 7-membered rings); replacement of the oxygen of a furanosyl with a non-oxygen atom (e.g., carbon, sulfur, or nitrogen); or both a change in the number of atoms and a replacement of the oxygen. Such structures may also comprise substitutions corresponding to those described for substituted sugar moieties (e.g., 6-membered carbocyclic bicyclic sugar surrogates optionally comprising additional substituents). Sugar surrogates also include more complex sugar replacements (e.g., the non-ring systems of peptide nucleic acid). Sugar surrogates include without limitation morpholinos, cyclohexenyls and cyclohexitols.</p><p id="p-0022" num="0176">As used herein, &#x201c;bicyclic sugar moiety&#x201d; means a modified sugar moiety comprising a 4 to 7 membered ring (including but not limited to a furanosyl) comprising a bridge connecting two atoms of the 4 to 7 membered ring to form a second ring, resulting in a bicyclic structure. In certain embodiments, the 4 to 7 membered ring is a sugar ring. In certain embodiments the 4 to 7 membered ring is a furanosyl. In certain such embodiments, the bridge connects the 2&#x2032;-carbon and the 4&#x2032;-carbon of the furanosyl.</p><p id="p-0023" num="0177">As used herein, &#x201c;nucleotide&#x201d; means a nucleoside further comprising a phosphate linking group. As used herein, &#x201c;linked nucleosides&#x201d; may or may not be linked by phosphate linkages and thus includes, but is not limited to &#x201c;linked nucleotides.&#x201d; As used herein, &#x201c;linked nucleosides&#x201d; are nucleosides that are connected in a continuous sequence (i.e. no additional nucleosides are present between those that are linked).</p><p id="p-0024" num="0178">As used herein, &#x201c;nucleobase&#x201d; means a group of atoms that can be linked to a sugar moiety to create a nucleoside that is capable of incorporation into an oligonucleotide, and wherein the group of atoms is capable of bonding with a complementary naturally occurring nucleobase of another oligonucleotide or nucleic acid. Nucleobases may be naturally occurring or may be modified.</p><p id="p-0025" num="0179">As used herein the terms, &#x201c;unmodified nucleobase&#x201d; or &#x201c;naturally occurring nucleobase&#x201d; means the naturally occurring heterocyclic nucleobases of RNA or DNA: the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) (including 5-methyl C), and uracil (U).</p><p id="p-0026" num="0180">As used herein, &#x201c;modified nucleobase&#x201d; means any nucleobase that is not a naturally occurring nucleobase.</p><p id="p-0027" num="0181">As used herein, &#x201c;modified nucleoside&#x201d; means a nucleoside comprising at least one chemical modification compared to naturally occurring RNA or DNA nucleosides. Modified nucleosides comprise a modified sugar moiety and/or a modified nucleobase.</p><p id="p-0028" num="0182">As used herein, &#x201c;bicyclic nucleoside&#x201d; or &#x201c;BNA&#x201d; means a nucleoside comprising a bicyclic sugar moiety.</p><p id="p-0029" num="0183">As used herein, &#x201c;constrained ethyl nucleoside&#x201d; or &#x201c;cEt&#x201d; means a nucleoside comprising a bicyclic sugar moiety comprising a 4&#x2032;-CH(CH<sub>3</sub>)&#x2014;O-2&#x2032;bridge.</p><p id="p-0030" num="0184">As used herein, &#x201c;locked nucleic acid nucleoside&#x201d; or &#x201c;LNA&#x201d; means a nucleoside comprising a bicyclic sugar moiety comprising a 4&#x2032;-CH<sub>2</sub>&#x2014;O-2&#x2032;bridge.</p><p id="p-0031" num="0185">As used herein, &#x201c;2&#x2032;-substituted nucleoside&#x201d; means a nucleoside comprising a substituent at the 2&#x2032;-position other than H or OH. Unless otherwise indicated, a 2&#x2032;-substituted nucleoside is not a bicyclic nucleoside.</p><p id="p-0032" num="0186">As used herein, &#x201c;2&#x2032;-deoxynucleoside&#x201d; means a nucleoside comprising 2&#x2032;-H furanosyl sugar moiety, as found in naturally occurring deoxyribonucleosides (DNA). In certain embodiments, a 2&#x2032;-deoxynucleoside may comprise a modified nucleobase or may comprise an RNA nucleobase (e.g., uracil).</p><p id="p-0033" num="0187">As used herein, &#x201c;RNA-like nucleoside&#x201d; means a modified nucleoside that adopts a northern configuration and functions like RNA when incorporated into an oligonucleotide. RNA-like nucleosides include, but are not limited to 3&#x2032;-endo furanosyl nucleosides and RNA surrogates.</p><p id="p-0034" num="0188">As used herein, &#x201c;3&#x2032;-endo-furanosyl nucleoside&#x201d; means an RNA-like nucleoside that comprises a substituted sugar moiety that has a 3&#x2032;-endo conformation. 3&#x2032;-endo-furanosyl nucleosides include, but are not limited to: 2&#x2032;-MOE, 2&#x2032;-F, 2&#x2032;-OMe, LNA, ENA, and cEt nucleosides.</p><p id="p-0035" num="0189">As used herein, &#x201c;RNA-surrogate nucleoside&#x201d; means an RNA-like nucleoside that does not comprise a furanosyl. RNA-surrogate nucleosides include, but are not limited to hexitols and cyclopentanes.</p><p id="p-0036" num="0190">As used herein, &#x201c;oligonucleotide&#x201d; means a compound comprising a plurality of linked nucleosides. In certain embodiments, an oligonucleotide comprises one or more unmodified ribonucleosides (RNA) and/or unmodified deoxyribonucleosides (DNA) and/or one or more modified nucleosides.</p><p id="p-0037" num="0191">As used herein &#x201c;oligonucleoside&#x201d; means an oligonucleotide in which none of the internucleoside linkages contains a phosphorus atom. As used herein, oligonucleotides include oligonucleosides.</p><p id="p-0038" num="0192">As used herein, &#x201c;modified oligonucleotide&#x201d; means an oligonucleotide comprising at least one modified nucleoside and/or at least one modified internucleoside linkage.</p><p id="p-0039" num="0193">As used herein &#x201c;internucleoside linkage&#x201d; means a covalent linkage between adjacent nucleosides in an oligonucleotide.</p><p id="p-0040" num="0194">As used herein &#x201c;naturally occurring internucleoside linkage&#x201d; means a 3&#x2032; to 5&#x2032; phosphodiester linkage.</p><p id="p-0041" num="0195">As used herein, &#x201c;modified internucleoside linkage&#x201d; means any internucleoside linkage other than a naturally occurring internucleoside linkage.</p><p id="p-0042" num="0196">As used herein, &#x201c;oligomeric compound&#x201d; means a polymeric structure comprising two or more sub-structures. In certain embodiments, an oligomeric compound comprises an oligonucleotide. In certain embodiments, an oligomeric compound comprises one or more conjugate groups and/or terminal groups. In certain embodiments, an oligomeric compound consists of an oligonucleotide.</p><p id="p-0043" num="0197">As used herein, &#x201c;terminal group&#x201d; means one or more atom attached to either, or both, the 3&#x2032; end or the 5&#x2032; end of an oligonucleotide. In certain embodiments a terminal group is a conjugate group. In certain embodiments, a terminal group comprises one or more terminal group nucleosides.</p><p id="p-0044" num="0198">As used herein, &#x201c;conjugate&#x201d; means an atom or group of atoms bound to an oligonucleotide or oligomeric compound. In general, conjugate groups modify one or more properties of the compound to which they are attached, including, but not limited to pharmacodynamic, pharmacokinetic, binding, absorption, cellular distribution, cellular uptake, charge and/or clearance properties.</p><p id="p-0045" num="0199">As used herein, &#x201c;conjugate linking group&#x201d; means any atom or group of atoms used to attach a conjugate to an oligonucleotide or oligomeric compound.</p><p id="p-0046" num="0200">As used herein, &#x201c;antisense compound&#x201d; means a compound comprising or consisting of an oligonucleotide at least a portion of which is complementary to a target nucleic acid to which it is capable of hybridizing, resulting in at least one antisense activity.</p><p id="p-0047" num="0201">As used herein, &#x201c;antisense activity&#x201d; means any detectable and/or measurable change attributable to the hybridization of an antisense compound to its target nucleic acid.</p><p id="p-0048" num="0202">As used herein, &#x201c;detecting&#x201d; or &#x201c;measuring&#x201d; means that a test or assay for detecting or measuring is performed. Such detection and/or measuring may result in a value of zero. Thus, if a test for detection or measuring results in a finding of no activity (activity of zero), the step of detecting or measuring the activity has nevertheless been performed.</p><p id="p-0049" num="0203">As used herein, &#x201c;detectable and/or measureable activity&#x201d; means a measurable activity that is not zero.</p><p id="p-0050" num="0204">As used herein, &#x201c;essentially unchanged&#x201d; means little or no change in a particular parameter, particularly relative to another parameter which changes much more. In certain embodiments, a parameter is essentially unchanged when it changes less than 5%. In certain embodiments, a parameter is essentially unchanged if it changes less than two-fold while another parameter changes at least ten-fold. For example, in certain embodiments, an antisense activity is a change in the amount of a target nucleic acid. In certain such embodiments, the amount of a non-target nucleic acid is essentially unchanged if it changes much less than the target nucleic acid does, but the change need not be zero.</p><p id="p-0051" num="0205">As used herein, &#x201c;expression&#x201d; means the process by which a gene ultimately results in a protein. Expression includes, but is not limited to, transcription, post-transcriptional modification (e.g., splicing, polyadenlyation, addition of 5&#x2032;-cap), and translation.</p><p id="p-0052" num="0206">As used herein, &#x201c;target nucleic acid&#x201d; means a nucleic acid molecule to which an antisense compound is intended to hybridize.</p><p id="p-0053" num="0207">As used herein, &#x201c;non-target nucleic acid&#x201d; means a nucleic acid molecule to which hybridization of an antisense compound is not intended or desired. In certain embodiments, antisense compounds do hybridize to a non-target, due to homology between the target (intended) and non-target (un-intended).</p><p id="p-0054" num="0208">As used herein, &#x201c;mRNA&#x201d; means an RNA molecule that encodes a protein.</p><p id="p-0055" num="0209">As used herein, &#x201c;pre-mRNA&#x201d; means an RNA transcript that has not been fully processed into mRNA. Pre-RNA includes one or more intron.</p><p id="p-0056" num="0210">As used herein, &#x201c;object RNA&#x201d; means an RNA molecule other than a target RNA, the amount, activity, splicing, and/or function of which is modulated, either directly or indirectly, by a target nucleic acid. In certain embodiments, a target nucleic acid modulates splicing of an object RNA. In certain such embodiments, an antisense compound modulates the amount or activity of the target nucleic acid, resulting in a change in the splicing of an object RNA and ultimately resulting in a change in the activity or function of the object RNA.</p><p id="p-0057" num="0211">As used herein, &#x201c;microRNA&#x201d; means a naturally occurring, small, non-coding RNA that represses gene expression of at least one mRNA. In certain embodiments, a microRNA represses gene expression by binding to a target site within a 3&#x2032; untranslated region of an mRNA. In certain embodiments, a microRNA has a nucleobase sequence as set forth in miRBase, a database of published microRNA sequences found at http://microrna.sanger.ac.uk/sequences/. In certain embodiments, a microRNA has a nucleobase sequence as set forth in miRBase version 12.0 released September 2008, which is herein incorporated by reference in its entirety.</p><p id="p-0058" num="0212">As used herein, &#x201c;microRNA mimic&#x201d; means an oligomeric compound having a sequence that is at least partially identical to that of a microRNA. In certain embodiments, a microRNA mimic comprises the microRNA seed region of a microRNA. In certain embodiments, a microRNA mimic modulates translation of more than one target nucleic acids. In certain embodiments, a microRNA mimic is double-stranded.</p><p id="p-0059" num="0213">As used herein, &#x201c;differentiating nucleobase&#x201d; means a nucleobase that differs between two nucleic acids. In certain instances, a target region of a target nucleic acid differs by 1-4 nucleobases from a non-target nucleic acid. Each of those differences is referred to as a differentiating nucleobase. In certain instances, a differentiating nucleobase is a single-nucleotide polymorphism.</p><p id="p-0060" num="0214">As used herein, &#x201c;target-selective nucleoside&#x201d; means a nucleoside of an antisense compound that corresponds to a differentiating nucleobase of a target nucleic acid.</p><p id="p-0061" num="0215">As used herein, &#x201c;allele&#x201d; means one of a pair of copies of a gene existing at a particular locus or marker on a specific chromosome, or one member of a pair of nucleobases existing at a particular locus or marker on a specific chromosome, or one member of a pair of nucleobase sequences existing at a particular locus or marker on a specific chromosome. For a diploid organism or cell or for autosomal chromosomes, each allelic pair will normally occupy corresponding positions (loci) on a pair of homologous chromosomes, one inherited from the mother and one inherited from the father. If these alleles are identical, the organism or cell is said to be &#x201c;homozygous&#x201d; for that allele; if they differ, the organism or cell is said to be &#x201c;heterozygous&#x201d; for that allele. &#x201c;Wild-type allele&#x201d; refers to the genotype typically not associated with disease or dysfunction of the gene product. &#x201c;Mutant allele&#x201d; refers to the genotype associated with disease or dysfunction of the gene product.</p><p id="p-0062" num="0216">As used herein, &#x201c;allelic variant&#x201d; means a particular identity of an allele, where more than one identity occurs. For example, an allelic variant may refer to either the mutant allele or the wild-type allele.</p><p id="p-0063" num="0217">As used herein, &#x201c;single nucleotide polymorphism&#x201d; or &#x201c;SNP&#x201d; means a single nucleotide variation between the genomes of individuals of the same species. In some cases, a SNP may be a single nucleotide deletion or insertion. In general, SNPs occur relatively frequently in genomes and thus contribute to genetic diversity. The location of a SNP is generally flanked by highly conserved sequences. An individual may be homozygous or heterozygous for an allele at each SNP site.</p><p id="p-0064" num="0218">As used herein, &#x201c;single nucleotide polymorphism site&#x201d; or &#x201c;SNP site&#x201d; refers to the nucleotides surrounding a SNP contained in a target nucleic acid to which an antisense compound is targeted.</p><p id="p-0065" num="0219">As used herein, &#x201c;targeting&#x201d; or &#x201c;targeted to&#x201d; means the association of an antisense compound to a particular target nucleic acid molecule or a particular region of a target nucleic acid molecule. An antisense compound targets a target nucleic acid if it is sufficiently complementary to the target nucleic acid to allow hybridization under physiological conditions.</p><p id="p-0066" num="0220">As used herein, &#x201c;nucleobase complementarity&#x201d; or &#x201c;complementarity&#x201d; when in reference to nucleobases means a nucleobase that is capable of base pairing with another nucleobase. For example, in DNA, adenine (A) is complementary to thymine (T). For example, in RNA, adenine (A) is complementary to uracil (U). In certain embodiments, complementary nucleobase means a nucleobase of an antisense compound that is capable of base pairing with a nucleobase of its target nucleic acid. For example, if a nucleobase at a certain position of an antisense compound is capable of hydrogen bonding with a nucleobase at a certain position of a target nucleic acid, then the position of hydrogen bonding between the oligonucleotide and the target nucleic acid is considered to be complementary at that nucleobase pair. Nucleobases comprising certain modifications may maintain the ability to pair with a counterpart nucleobase and thus, are still capable of nucleobase complementarity.</p><p id="p-0067" num="0221">As used herein, &#x201c;non-complementary&#x201d; in reference to nucleobases means a pair of nucleobases that do not form hydrogen bonds with one another.</p><p id="p-0068" num="0222">As used herein, &#x201c;complementary&#x201d; in reference to oligomeric compounds (e.g., linked nucleosides, oligonucleotides, or nucleic acids) means the capacity of such oligomeric compounds or regions thereof to hybridize to another oligomeric compound or region thereof through nucleobase complementarity under stringent conditions. Complementary oligomeric compounds need not have nucleobase complementarity at each nucleoside. Rather, some mismatches are tolerated. In certain embodiments, complementary oligomeric compounds or regions are complementary at 70% of the nucleobases (70% complementary). In certain embodiments, complementary oligomeric compounds or regions are 80% complementary. In certain embodiments, complementary oligomeric compounds or regions are 90% complementary. In certain embodiments, complementary oligomeric compounds or regions are 95% complementary. In certain embodiments, complementary oligomeric compounds or regions are 100% complementary.</p><p id="p-0069" num="0223">As used herein, &#x201c;mismatch&#x201d; means a nucleobase of a first oligomeric compound that is not capable of pairing with a nucleobase at a corresponding position of a second oligomeric compound, when the first and second oligomeric compound are aligned. Either or both of the first and second oligomeric compounds may be oligonucleotides.</p><p id="p-0070" num="0224">As used herein, &#x201c;hybridization&#x201d; means the pairing of complementary oligomeric compounds (e.g., an antisense compound and its target nucleic acid). While not limited to a particular mechanism, the most common mechanism of pairing involves hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleobases.</p><p id="p-0071" num="0225">As used herein, &#x201c;specifically hybridizes&#x201d; means the ability of an oligomeric compound to hybridize to one nucleic acid site with greater affinity than it hybridizes to another nucleic acid site. In certain embodiments, an antisense oligonucleotide specifically hybridizes to more than one target site.</p><p id="p-0072" num="0226">As used herein, &#x201c;fully complementary&#x201d; in reference to an oligonucleotide or portion thereof means that each nucleobase of the oligonucleotide or portion thereof is capable of pairing with a nucleobase of a complementary nucleic acid or contiguous portion thereof. Thus, a fully complementary region comprises no mismatches or unhybridized nucleobases in either strand.</p><p id="p-0073" num="0227">As used herein, &#x201c;percent complementarity&#x201d; means the percentage of nucleobases of an oligomeric compound that are complementary to an equal-length portion of a target nucleic acid. Percent complementarity is calculated by dividing the number of nucleobases of the oligomeric compound that are complementary to nucleobases at corresponding positions in the target nucleic acid by the total length of the oligomeric compound.</p><p id="p-0074" num="0228">As used herein, &#x201c;percent identity&#x201d; means the number of nucleobases in a first nucleic acid that are the same type (independent of chemical modification) as nucleobases at corresponding positions in a second nucleic acid, divided by the total number of nucleobases in the first nucleic acid.</p><p id="p-0075" num="0229">As used herein, &#x201c;modulation&#x201d; means a change of amount or quality of a molecule, function, or activity when compared to the amount or quality of a molecule, function, or activity prior to modulation. For example, modulation includes the change, either an increase (stimulation or induction) or a decrease (inhibition or reduction) in gene expression. As a further example, modulation of expression can include a change in splice site selection of pre-mRNA processing, resulting in a change in the absolute or relative amount of a particular splice-variant compared to the amount in the absence of modulation.</p><p id="p-0076" num="0230">As used herein, &#x201c;modification motif&#x201d; means a pattern of chemical modifications in an oligomeric compound or a region thereof. Motifs may be defined by modifications at certain nucleosides and/or at certain linking groups of an oligomeric compound.</p><p id="p-0077" num="0231">As used herein, &#x201c;nucleoside motif&#x201d; means a pattern of nucleoside modifications in an oligomeric compound or a region thereof. The linkages of such an oligomeric compound may be modified or unmodified. Unless otherwise indicated, motifs herein describing only nucleosides are intended to be nucleoside motifs. Thus, in such instances, the linkages are not limited.</p><p id="p-0078" num="0232">As used herein, &#x201c;sugar motif&#x201d; means a pattern of sugar modifications in an oligomeric compound or a region thereof.</p><p id="p-0079" num="0233">As used herein, &#x201c;linkage motif&#x201d; means a pattern of linkage modifications in an oligomeric compound or region thereof. The nucleosides of such an oligomeric compound may be modified or unmodified. Unless otherwise indicated, motifs herein describing only linkages are intended to be linkage motifs. Thus, in such instances, the nucleosides are not limited.</p><p id="p-0080" num="0234">As used herein, &#x201c;nucleobase modification motif&#x201d; means a pattern of modifications to nucleobases along an oligonucleotide. Unless otherwise indicated, a nucleobase modification motif is independent of the nucleobase sequence.</p><p id="p-0081" num="0235">As used herein, &#x201c;sequence motif&#x201d; means a pattern of nucleobases arranged along an oligonucleotide or portion thereof. Unless otherwise indicated, a sequence motif is independent of chemical modifications and thus may have any combination of chemical modifications, including no chemical modifications.</p><p id="p-0082" num="0236">As used herein, &#x201c;type of modification&#x201d; in reference to a nucleoside or a nucleoside of a &#x201c;type&#x201d; means the chemical modification of a nucleoside and includes modified and unmodified nucleosides. Accordingly, unless otherwise indicated, a &#x201c;nucleoside having a modification of a first type&#x201d; may be an unmodified nucleoside.</p><p id="p-0083" num="0237">As used herein, &#x201c;differently modified&#x201d; mean chemical modifications or chemical substituents that are different from one another, including absence of modifications. Thus, for example, a MOE nucleoside and an unmodified DNA nucleoside are &#x201c;differently modified,&#x201d; even though the DNA nucleoside is unmodified. Likewise, DNA and RNA are &#x201c;differently modified,&#x201d; even though both are naturally-occurring unmodified nucleosides. Nucleosides that are the same but for comprising different nucleobases are not differently modified. For example, a nucleoside comprising a 2&#x2032;-OMe modified sugar and an unmodified adenine nucleobase and a nucleoside comprising a 2&#x2032;-OMe modified sugar and an unmodified thymine nucleobase are not differently modified.</p><p id="p-0084" num="0238">As used herein, &#x201c;the same type of modifications&#x201d; refers to modifications that are the same as one another, including absence of modifications. Thus, for example, two unmodified DNA nucleoside have &#x201c;the same type of modification,&#x201d; even though the DNA nucleoside is unmodified. Such nucleosides having the same type modification may comprise different nucleobases.</p><p id="p-0085" num="0239">As used herein, &#x201c;pharmaceutically acceptable carrier or diluent&#x201d; means any substance suitable for use in administering to an animal. In certain embodiments, a pharmaceutically acceptable carrier or diluent is sterile saline. In certain embodiments, such sterile saline is pharmaceutical grade saline.</p><p id="p-0086" num="0240">As used herein, &#x201c;substituent&#x201d; and &#x201c;substituent group,&#x201d; means an atom or group that replaces the atom or group of a named parent compound. For example a substituent of a modified nucleoside is any atom or group that differs from the atom or group found in a naturally occurring nucleoside (e.g., a modified 2&#x2032;-substituent is any atom or group at the 2&#x2032;-position of a nucleoside other than H or OH). Substituent groups can be protected or unprotected. In certain embodiments, compounds of the present invention have substituents at one or at more than one position of the parent compound. Substituents may also be further substituted with other substituent groups and may be attached directly or via a linking group such as an alkyl or hydrocarbyl group to a parent compound.</p><p id="p-0087" num="0241">Likewise, as used herein, &#x201c;substituent&#x201d; in reference to a chemical functional group means an atom or group of atoms differs from the atom or a group of atoms normally present in the named functional group. In certain embodiments, a substituent replaces a hydrogen atom of the functional group (e.g., in certain embodiments, the substituent of a substituted methyl group is an atom or group other than hydrogen which replaces one of the hydrogen atoms of an unsubstituted methyl group). Unless otherwise indicated, groups amenable for use as substituents include without limitation, halogen, hydroxyl, alkyl, alkenyl, alkynyl, acyl (&#x2014;C(O)R<sub>aa</sub>), carboxyl (&#x2014;C(O)O&#x2014;R<sub>aa</sub>), aliphatic groups, alicyclic groups, alkoxy, substituted oxy (&#x2014;O&#x2014;R<sub>aa</sub>), aryl, aralkyl, heterocyclic radical, heteroaryl, heteroarylalkyl, amino (&#x2014;N(R<sub>bb</sub>)(R<sub>cc</sub>)), imino(&#x2550;NR<sub>bb</sub>), amido (&#x2014;C(O)N(R<sub>bb</sub>)(R<sub>cc</sub>) or &#x2014;N(R<sub>bb</sub>)C(O)R<sub>aa</sub>), azido (&#x2014;N<sub>3</sub>), nitro (&#x2014;NO<sub>2</sub>), cyano (&#x2014;CN), carbamido (&#x2014;OC(O)N(R<sub>bb</sub>)(R<sub>cc</sub>) or &#x2014;N(R<sub>bb</sub>)C(O)OR<sub>aa</sub>), ureido (&#x2014;N(R<sub>bb</sub>)C(O)N(R<sub>bb</sub>)(R<sub>cc</sub>)), thioureido (&#x2014;N(R<sub>bb</sub>)C(S)N(R<sub>bb</sub>)&#x2014;(R<sub>cc</sub>)), guanidinyl (&#x2014;N(R<sub>bb</sub>)C(&#x2550;NR<sub>bb</sub>)N(R<sub>bb</sub>)(R<sub>cc</sub>)), amidinyl (&#x2014;C(&#x2550;NR<sub>bb</sub>)N(R<sub>bb</sub>)(R<sub>cc</sub>) or &#x2014;N(R<sub>bb</sub>)C(&#x2550;NR<sub>bb</sub>)(R<sub>aa</sub>)), thiol (&#x2014;SR<sub>bb</sub>), sulfinyl (&#x2014;S(O)R<sub>bb</sub>), sulfonyl (&#x2014;S(O)<sub>2</sub>R<sub>bb</sub>) and sulfonamidyl (&#x2014;S(O)<sub>2</sub>N(R<sub>bb</sub>)(R<sub>cc</sub>) or &#x2014;N(R<sub>bb</sub>)S&#x2014;(O)<sub>2</sub>R<sub>bb</sub>). Wherein each R<sub>aa</sub>, R<sub>bb </sub>and R<sub>cc </sub>is, independently, H, an optionally linked chemical functional group or a further substituent group with a preferred list including without limitation, alkyl, alkenyl, alkynyl, aliphatic, alkoxy, acyl, aryl, aralkyl, heteroaryl, alicyclic, heterocyclic and heteroarylalkyl. Selected substituents within the compounds described herein are present to a recursive degree.</p><p id="p-0088" num="0242">As used herein, &#x201c;alkyl,&#x201d; as used herein, means a saturated straight or branched hydrocarbon radical containing up to twenty four carbon atoms. Examples of alkyl groups include without limitation, methyl, ethyl, propyl, butyl, isopropyl, n-hexyl, octyl, decyl, dodecyl and the like. Alkyl groups typically include from 1 to about 24 carbon atoms, more typically from 1 to about 12 carbon atoms (C<sub>1</sub>-C<sub>12 </sub>alkyl) with from 1 to about 6 carbon atoms being more preferred.</p><p id="p-0089" num="0243">As used herein, &#x201c;alkenyl,&#x201d; means a straight or branched hydrocarbon chain radical containing up to twenty four carbon atoms and having at least one carbon-carbon double bond. Examples of alkenyl groups include without limitation, ethenyl, propenyl, butenyl, 1-methyl-2-buten-1-yl, dienes such as 1,3-butadiene and the like. Alkenyl groups typically include from 2 to about 24 carbon atoms, more typically from 2 to about 12 carbon atoms with from 2 to about 6 carbon atoms being more preferred. Alkenyl groups as used herein may optionally include one or more further substituent groups.</p><p id="p-0090" num="0244">As used herein, &#x201c;alkynyl,&#x201d; means a straight or branched hydrocarbon radical containing up to twenty four carbon atoms and having at least one carbon-carbon triple bond. Examples of alkynyl groups include, without limitation, ethynyl, 1-propynyl, 1-butynyl, and the like. Alkynyl groups typically include from 2 to about 24 carbon atoms, more typically from 2 to about 12 carbon atoms with from 2 to about 6 carbon atoms being more preferred. Alkynyl groups as used herein may optionally include one or more further substituent groups.</p><p id="p-0091" num="0245">As used herein, &#x201c;acyl,&#x201d; means a radical formed by removal of a hydroxyl group from an organic acid and has the general Formula &#x2014;C(O)&#x2014;X where X is typically aliphatic, alicyclic or aromatic. Examples include aliphatic carbonyls, aromatic carbonyls, aliphatic sulfonyls, aromatic sulfinyls, aliphatic sulfinyls, aromatic phosphates, aliphatic phosphates and the like. Acyl groups as used herein may optionally include further substituent groups.</p><p id="p-0092" num="0246">As used herein, &#x201c;alicyclic&#x201d; means a cyclic ring system wherein the ring is aliphatic. The ring system can comprise one or more rings wherein at least one ring is aliphatic. Preferred alicyclics include rings having from about 5 to about 9 carbon atoms in the ring. Alicyclic as used herein may optionally include further substituent groups.</p><p id="p-0093" num="0247">As used herein, &#x201c;aliphatic&#x201d; means a straight or branched hydrocarbon radical containing up to twenty four carbon atoms wherein the saturation between any two carbon atoms is a single, double or triple bond. An aliphatic group preferably contains from 1 to about 24 carbon atoms, more typically from 1 to about 12 carbon atoms with from 1 to about 6 carbon atoms being more preferred. The straight or branched chain of an aliphatic group may be interrupted with one or more heteroatoms that include nitrogen, oxygen, sulfur and phosphorus. Such aliphatic groups interrupted by heteroatoms include without limitation, polyalkoxys, such as polyalkylene glycols, polyamines, and polyimines. Aliphatic groups as used herein may optionally include further substituent groups.</p><p id="p-0094" num="0248">As used herein, &#x201c;alkoxy&#x201d; means a radical formed between an alkyl group and an oxygen atom wherein the oxygen atom is used to attach the alkoxy group to a parent molecule. Examples of alkoxy groups include without limitation, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentoxy, neopentoxy, n-hexoxy and the like. Alkoxy groups as used herein may optionally include further substituent groups.</p><p id="p-0095" num="0249">As used herein, &#x201c;aminoalkyl&#x201d; means an amino substituted C<sub>1</sub>-C<sub>12 </sub>alkyl radical. The alkyl portion of the radical forms a covalent bond with a parent molecule. The amino group can be located at any position and the aminoalkyl group can be substituted with a further substituent group at the alkyl and/or amino portions.</p><p id="p-0096" num="0250">As used herein, &#x201c;aralkyl&#x201d; and &#x201c;arylalkyl&#x201d; mean an aromatic group that is covalently linked to a C<sub>1</sub>-C<sub>12 </sub>alkyl radical. The alkyl radical portion of the resulting aralkyl (or arylalkyl) group forms a covalent bond with a parent molecule. Examples include without limitation, benzyl, phenethyl and the like. Aralkyl groups as used herein may optionally include further substituent groups attached to the alkyl, the aryl or both groups that form the radical group.</p><p id="p-0097" num="0251">As used herein, &#x201c;aryl&#x201d; and &#x201c;aromatic&#x201d; mean a mono- or polycyclic carbocyclic ring system radicals having one or more aromatic rings. Examples of aryl groups include without limitation, phenyl, naphthyl, tetrahydronaphthyl, indanyl, idenyl and the like. Preferred aryl ring systems have from about 5 to about 20 carbon atoms in one or more rings. Aryl groups as used herein may optionally include further substituent groups.</p><p id="p-0098" num="0252">As used herein, &#x201c;halo&#x201d; and &#x201c;halogen,&#x201d; mean an atom selected from fluorine, chlorine, bromine and iodine.</p><p id="p-0099" num="0253">As used herein, &#x201c;heteroaryl,&#x201d; and &#x201c;heteroaromatic,&#x201d; mean a radical comprising a mono- or poly-cyclic aromatic ring, ring system or fused ring system wherein at least one of the rings is aromatic and includes one or more heteroatoms. Heteroaryl is also meant to include fused ring systems including systems where one or more of the fused rings contain no heteroatoms. Heteroaryl groups typically include one ring atom selected from sulfur, nitrogen or oxygen. Examples of heteroaryl groups include without limitation, pyridinyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isooxazolyl, thiadiazolyl, oxadiazolyl, thiophenyl, furanyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzooxazolyl, quinoxalinyl and the like. Heteroaryl radicals can be attached to a parent molecule directly or through a linking moiety such as an aliphatic group or hetero atom. Heteroaryl groups as used herein may optionally include further substituent groups.</p><p id="p-0100" num="0254">As used herein, &#x201c;huntingtin transcript&#x201d; means a transcript transcribed from a huntingtin gene.</p><p id="p-0101" num="0255">As used herein, &#x201c;Intracerebroventricular&#x201d; or &#x201c;ICV&#x201d; means administration into the ventricular system of the brain.</p><heading id="h-0006" level="1">B. Oligomeric Compounds</heading><p id="p-0102" num="0256">In certain embodiments, the present invention provides oligomeric compounds. In certain embodiments, such oligomeric compounds comprise oligonucleotides optionally comprising one or more conjugate and/or terminal groups. In certain embodiments, an oligomeric compound consists of an oligonucleotide. In certain embodiments, oligonucleotides comprise one or more chemical modifications.</p><p id="p-0103" num="0257">Such chemical modifications include modifications of one or more nucleoside (including modifications to the sugar moiety and/or the nucleobase) and/or modifications to one or more internucleoside linkage.</p><p id="p-0104" num="0258">a. Certain Modified Nucleosides</p><p id="p-0105" num="0259">In certain embodiments, provided herein are oligomeric compounds comprising or consisting of oligonucleotides comprising at least one modified nucleoside. Such modified nucleosides comprise a modified sugar moeity, a modified nucleobase, or both a modified sugar moiety and a modified nucleobase.</p><p id="p-0106" num="0260">i. Certain Modified Sugar Moieties</p><p id="p-0107" num="0261">In certain embodiments, oligomeric compounds of the invention comprise one or more modified nucleosides comprising a modified sugar moiety. Such oligomeric compounds comprising one or more sugar-modified nucleosides may have desirable properties, such as enhanced nuclease stability or increased binding affinity with a target nucleic acid relative to oligomeric compounds comprising only nucleosides comprising naturally occurring sugar moieties. In certain embodiments, modified sugar moieties are substituted sugar moieties. In certain embodiments, modified sugar moieties are bicyclic or tricyclic sugar moieties. In certain embodiments, modified sugar moieties are sugar surrogates. Such sugar surrogates may comprise one or more substitutions corresponding to those of substituted sugar moieties.</p><p id="p-0108" num="0262">In certain embodiments, modified sugar moieties are substituted sugar moieties comprising one or more substituent, including but not limited to substituents at the 2&#x2032; and/or 5&#x2032; positions. Examples of sugar substituents suitable for the 2&#x2032;-position, include, but are not limited to: 2&#x2032;-F, 2&#x2032;-OCH<sub>3</sub>(&#x201c;OMe&#x201d; or &#x201c;O-methyl&#x201d;), and 2&#x2032;-O(CH<sub>2</sub>)<sub>2</sub>O CH<sub>3 </sub>(&#x201c;MOE&#x201d;). In certain embodiments, sugar substituents at the 2&#x2032; position is selected from allyl, amino, azido, thio, O-allyl, O&#x2014;C<sub>1</sub>-C<sub>10 </sub>alkyl, O&#x2014;C<sub>1</sub>-C<sub>10 </sub>substituted alkyl; O&#x2014; C<sub>1</sub>-C<sub>10 </sub>alkoxy; O&#x2014; C<sub>1</sub>-C<sub>10 </sub>substituted alkoxy, OCF<sub>3</sub>, O(CH<sub>2</sub>)<sub>2</sub>SCH<sub>3</sub>, O(CH<sub>2</sub>)<sub>2</sub>&#x2014;O&#x2014;N(Rm)(Rn), and O&#x2014;CH<sub>2</sub>&#x2014;C(&#x2550;O)&#x2014;N(Rm)(Rn), where each Rm and Rn is, independently, H or substituted or unsubstituted C<sub>1</sub>-C<sub>10 </sub>alkyl. Examples of sugar substituents at the 5&#x2032;-position, include, but are not limited to: 5&#x2032;-methyl (R or S); 5&#x2032;-vinyl, and 5&#x2032;-methoxy. In certain embodiments, substituted sugars comprise more than one non-bridging sugar substituent, for example, 2&#x2032;-F-5&#x2032;-methyl sugar moieties (see, e.g., PCT International Application WO 2008/101157, for additional 5&#x2032;, 2&#x2032;-bis substituted sugar moieties and nucleosides).</p><p id="p-0109" num="0263">Nucleosides comprising 2&#x2032;-substituted sugar moieties are referred to as 2&#x2032;-substituted nucleosides. In certain embodiments, a 2&#x2032;-substituted nucleoside comprises a 2&#x2032;-substituent group selected from halo, allyl, amino, azido, O&#x2014;C<sub>1</sub>-C<sub>10 </sub>alkoxy; O&#x2014;C<sub>1</sub>-C<sub>10 </sub>substituted alkoxy, SH, CN, OCN, CF<sub>3</sub>, OCF<sub>3</sub>, O-alkyl, S-alkyl, N(R<sub>m</sub>)-alkyl; O-alkenyl, S-alkenyl, or N(R<sub>m</sub>)-alkenyl; O-alkynyl, S-alkynyl, N(R<sub>m</sub>)-alkynyl; O-alkylenyl-O-alkyl, alkynyl, alkaryl, aralkyl, O-alkaryl, O-aralkyl, O(CH<sub>2</sub>)<sub>2</sub>SCH<sub>3</sub>, O&#x2014;(CH<sub>2</sub>)<sub>2</sub>&#x2014;O&#x2014;N(R<sub>m</sub>)(R<sub>n</sub>) or O&#x2014;CH<sub>2</sub>&#x2014;C(&#x2550;O)&#x2014;N(R<sub>m</sub>)(R<sub>11</sub>), where each Rm and Rn is, independently, H, an amino protecting group or substituted or unsubstituted C<sub>1</sub>-C<sub>10 </sub>alkyl. These 2&#x2032;-substituent groups can be further substituted with one or more substituent groups independently selected from hydroxyl, amino, alkoxy, carboxy, benzyl, phenyl, nitro (NO<sub>2</sub>), thiol, thioalkoxy (S-alkyl), halogen, alkyl, aryl, alkenyl and alkynyl.</p><p id="p-0110" num="0264">In certain embodiments, a 2&#x2032;-substituted nucleoside comprises a 2&#x2032;-substituent group selected from F, NH<sub>2</sub>, N<sub>3</sub>, OCF<sub>3</sub>, O&#x2014;CH<sub>3</sub>, O(CH<sub>2</sub>)<sub>3</sub>NH<sub>2</sub>, CH<sub>2</sub>&#x2014;CH&#x2550;CH<sub>2</sub>, O&#x2014;CH<sub>2</sub>&#x2014;CH&#x2550;CH<sub>2</sub>, OCH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>, O(CH<sub>2</sub>)<sub>2</sub>SCH<sub>3</sub>, O&#x2014;(CH<sub>2</sub>)<sub>2</sub>&#x2014;O&#x2014;N(R<sub>m</sub>)(R<sub>n</sub>), O(CH<sub>2</sub>)<sub>2</sub>O(CH<sub>2</sub>)<sub>2</sub>N(CH<sub>3</sub>)<sub>2</sub>, and N-substituted acetamide (O&#x2014;CH<sub>2</sub>&#x2014;C(&#x2550;O)&#x2014;N(R<sub>m</sub>)(R<sub>n</sub>) where each R<sub>m </sub>and R<sub>n </sub>is, independently, H, an amino protecting group or substituted or unsubstituted C<sub>1</sub>-C<sub>10 </sub>alkyl.</p><p id="p-0111" num="0265">In certain embodiments, a 2&#x2032;-substituted nucleoside comprises a sugar moiety comprising a 2&#x2032;-substituent group selected from F, OCF<sub>3</sub>, O&#x2014;CH<sub>3</sub>, OCH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>, O(CH<sub>2</sub>)<sub>2</sub>SCH<sub>3</sub>, O&#x2014;(CH<sub>2</sub>)<sub>2</sub>&#x2014;O&#x2014;N(CH<sub>3</sub>)<sub>2</sub>, &#x2014;O(CH<sub>2</sub>)<sub>2</sub>O(CH<sub>2</sub>)<sub>2</sub>N(CH<sub>3</sub>)<sub>2</sub>, and O&#x2014;CH<sub>2</sub>&#x2014;C(&#x2550;O)&#x2014;N(H)CH<sub>3</sub>.</p><p id="p-0112" num="0266">In certain embodiments, a 2&#x2032;-substituted nucleoside comprises a sugar moiety comprising a 2&#x2032;-substituent group selected from F, O&#x2014;CH<sub>3</sub>, and OCH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>.</p><p id="p-0113" num="0267">Certain modified sugar moieties comprise a bridging sugar substituent that forms a second ring resulting in a bicyclic sugar moiety. In certain such embodiments, the bicyclic sugar moiety comprises a bridge between the 4&#x2032; and the 2&#x2032; furanose ring atoms. Examples of such 4&#x2032; to 2&#x2032; sugar substituents, include, but are not limited to: &#x2014;[C(R<sub>a</sub>)(R<sub>b</sub>)]<sub>n</sub>&#x2014;, &#x2014;[C(R<sub>a</sub>)(R<sub>b</sub>)]<sub>n</sub>&#x2014;O&#x2014;, &#x2014;C(R<sub>a</sub>R<sub>b</sub>)&#x2014;N(R)&#x2014;O&#x2014; or, &#x2014;C(R<sub>a</sub>R<sub>b</sub>)&#x2014;O&#x2014;N(R)&#x2014;; 4&#x2032;- CH<sub>2</sub>-2&#x2032;, 4&#x2032;-(CH<sub>2</sub>)<sub>2</sub>-2&#x2032;, 4&#x2032;-(CH<sub>2</sub>)<sub>3</sub>-2&#x2032;, 4&#x2032;-(CH<sub>2</sub>)&#x2014;O-2&#x2032; (LNA); 4&#x2032;-(CH<sub>2</sub>)&#x2014;S-2; 4&#x2032;-(CH<sub>2</sub>)<sub>2</sub>&#x2014;O-2&#x2032; (ENA); 4&#x2032;-CH(CH<sub>3</sub>)&#x2014;O-2&#x2032; (cEt) and 4&#x2032;-CH(CH<sub>2</sub>OCH<sub>3</sub>)&#x2014;O-2&#x2032;, and analogs thereof (see, e.g., U.S. Pat. No. 7,399,845, issued on Jul. 15, 2008); 4&#x2032;-C(CH<sub>3</sub>)(CH<sub>3</sub>)&#x2014;O-2&#x2032; and analogs thereof, (see, e.g., WO2009/006478, published Jan. 8, 2009); 4&#x2032;-CH<sub>2</sub>&#x2014;N(OCH<sub>3</sub>)-2&#x2032; and analogs thereof (see, e.g., WO2008/150729, published Dec. 11, 2008); 4&#x2032;-CH<sub>2</sub>&#x2014;O&#x2014;N(CH<sub>3</sub>)-2&#x2032; (see, e.g., US2004/0171570, published Sep. 2, 2004); 4&#x2032;-CH<sub>2</sub>&#x2014;O&#x2014;N(R)-2&#x2032;, and 4&#x2032;-CH<sub>2</sub>&#x2014;N(R)-0-2&#x2032;-, wherein each R is, independently, H, a protecting group, or C<sub>1</sub>-C<sub>12 </sub>alkyl; 4&#x2032;-CH<sub>2</sub>&#x2014;N(R)&#x2014;O-2&#x2032;, wherein R is H, C<sub>1</sub>-C<sub>12 </sub>alkyl, or a protecting group (see, U.S. Pat. No. 7,427,672, issued on Sep. 23, 2008); 4&#x2032;-CH<sub>2</sub>&#x2014;C(H)(CH<sub>3</sub>)-2&#x2032; (see, e.g., Chattopadhyaya, et al., <i>J. Org. Chem., </i>2009, 74, 118-134); and 4&#x2032;-CH<sub>2</sub>&#x2014;C(&#x2550;CH<sub>2</sub>)-2&#x2032; and analogs thereof (see, published PCT International Application WO 2008/154401, published on Dec. 8, 2008).</p><p id="p-0114" num="0268">In certain embodiments, such 4&#x2032; to 2&#x2032; bridges independently comprise from 1 to 4 linked groups independently selected from &#x2014;[C(R<sub>a</sub>)(R<sub>b</sub>)]<sub>n</sub>&#x2014;, &#x2014;C(R<sub>a</sub>)&#x2550;C(R<sub>b</sub>)&#x2014;, &#x2014;C(R<sub>a</sub>)&#x2550;N&#x2014;, &#x2014;C(&#x2550;NR<sub>a</sub>)&#x2014;, &#x2014;C(&#x2550;O)&#x2014;, &#x2014;C(&#x2550;S)&#x2014;, &#x2014;O&#x2014;, &#x2014;Si(R<sub>a</sub>)<sub>2</sub>&#x2014;, &#x2014;S(&#x2550;O)<sub>x</sub>&#x2014;, and &#x2014;N(R<sub>a</sub>)&#x2014;;</p><p id="p-0115" num="0269">wherein:</p><p id="p-0116" num="0270">x is 0, 1, or 2;</p><p id="p-0117" num="0271">n is 1, 2, 3, or 4;</p><p id="p-0118" num="0272">each R<sub>a </sub>and R<sub>b </sub>is, independently, H, a protecting group, hydroxyl, C<sub>1</sub>-C<sub>12 </sub>alkyl, substituted C<sub>1</sub>-C<sub>12 </sub>alkyl, C<sub>2</sub>-C<sub>12 </sub>alkenyl, substituted C<sub>2</sub>-C<sub>12 </sub>alkenyl, C<sub>2</sub>-C<sub>12 </sub>alkynyl, substituted C<sub>2</sub>-C<sub>12 </sub>alkynyl, C<sub>5</sub>-C<sub>20 </sub>aryl, substituted C<sub>5</sub>-C<sub>20 </sub>aryl, heterocycle radical, substituted heterocycle radical, heteroaryl, substituted heteroaryl, C<sub>5</sub>-C<sub>7 </sub>alicyclic radical, substituted C<sub>5</sub>-C<sub>7 </sub>alicyclic radical, halogen, OJ<sub>1</sub>, NJ<sub>1</sub>J<sub>2</sub>, SJ<sub>1</sub>, N<sub>3</sub>, COOJ<sub>1</sub>, acyl (C(&#x2550;O)&#x2014;H), substituted acyl, CN, sulfonyl (S(&#x2550;O)<sub>2</sub>-J<sub>1</sub>), or sulfoxyl (S(&#x2550;O)-J<sub>1</sub>); and each J<sub>1 </sub>and J<sub>2 </sub>is, independently, H, C<sub>1</sub>-C<sub>12 </sub>alkyl, substituted C<sub>1</sub>-C<sub>12 </sub>alkyl, C<sub>2</sub>-C<sub>12 </sub>alkenyl, substituted C<sub>2</sub>-C<sub>12 </sub>alkenyl, C<sub>2</sub>-C<sub>12 </sub>alkynyl, substituted C<sub>2</sub>-C<sub>12 </sub>alkynyl, C<sub>5</sub>-C<sub>20 </sub>aryl, substituted C<sub>5</sub>-C<sub>20 </sub>aryl, acyl (C(&#x2550;O)&#x2014;H), substituted acyl, a heterocycle radical, a substituted heterocycle radical, C<sub>1</sub>-C<sub>12 </sub>aminoalkyl, substituted C<sub>1</sub>-C<sub>12 </sub>aminoalkyl, or a protecting group.</p><p id="p-0119" num="0273">Nucleosides comprising bicyclic sugar moieties are referred to as bicyclic nucleosides or BNAs. Bicyclic nucleosides include, but are not limited to, (A) &#x3b1;-L-Methyleneoxy (4&#x2032;-CH<sub>2</sub>&#x2014;O-2&#x2032;) BNA, (B) &#x3b2;-D-Methyleneoxy (4&#x2032;-CH<sub>2</sub>&#x2014;O-2&#x2032;) BNA (also referred to as locked nucleic acid or LNA), (C) Ethyleneoxy (4&#x2032;-(CH<sub>2</sub>)<sub>2</sub>&#x2014;O-2&#x2032;) BNA, (D) Aminooxy (4&#x2032;-CH<sub>2</sub>&#x2014;O&#x2014;N(R)-2&#x2032;) BNA, (E) Oxyamino (4&#x2032;-CH<sub>2</sub>&#x2014;N(R)&#x2014;O-2&#x2032;) BNA, (F) Methyl(methyleneoxy) (4&#x2032;-CH(CH<sub>3</sub>)&#x2014;O-2&#x2032;) BNA (also referred to as constrained ethyl or cEt), (G) methylene-thio (4&#x2032;-CH<sub>2</sub>&#x2014;S-2&#x2032;) BNA, (H) methylene-amino (4&#x2032;-CH<sub>2</sub>&#x2014;N(R)-2&#x2032;) BNA, (I) methyl carbocyclic (4&#x2032;-CH<sub>2</sub>&#x2014;CH(CH<sub>3</sub>)-2&#x2032;) BNA, (J) propylene carbocyclic (4&#x2032;-(CH<sub>2</sub>)<sub>3</sub>-2&#x2032;) BNA, and (M) 4&#x2032;-CH<sub>2</sub>&#x2014;O&#x2014;CH<sub>2</sub>-2&#x2032; as depicted below.</p><p id="p-0120" num="0000"><chemistry id="CHEM-US-00001" num="00001"><img id="EMI-C00001" he="253.24mm" wi="69.93mm" file="US20230002763A1-20230105-C00001.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00002" num="00002"><img id="EMI-C00002" he="95.50mm" wi="69.93mm" file="US20230002763A1-20230105-C00002.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0121" num="0000">wherein Bx is a nucleobase moiety and R is, independently, H, a protecting group, or C<sub>1</sub>-C<sub>12 </sub>alkyl.</p><p id="p-0122" num="0274">Additional bicyclic sugar moieties are known in the art, for example: Singh et al., <i>Chem. Commun., </i>1998, 4, 455-456; Koshkin et al., <i>Tetrahedron, </i>1998, 54, 3607-3630; Wahlestedt et al., <i>Proc. Natl. Acad. Sci. U.S.A., </i>2000, 97, 5633-5638; Kumar et al., <i>Bioorg. Med. Chem. Lett., </i>1998, 8, 2219-2222; Singh et al., <i>Org. Chem., </i>1998, 63, 10035-10039; Srivastava et al., <i>J. Am. Chem. Soc., </i>129(26) 8362-8379 (Jul. 4, 2007); Elayadi et al., <i>Curr. Opinion Invens. Drugs, </i>2001, 2, 558-561; Braasch et al., <i>Chem. Biol., </i>2001, 8, 1-7; Orum et al., <i>Curr. Opinion Mol. Ther., </i>2001, 3, 239-243; U.S. Pat. Nos. 7,053,207, 6,268,490, 6,770,748, 6,794,499, 7,034,133, 6,525,191, 6,670,461, and 7,399,845; WO 2004/106356, WO 1994/14226, WO 2005/021570, and WO 2007/134181; U.S. Patent Publication Nos. US2004/0171570, US2007/0287831, and US2008/0039618; U.S. patent Ser. Nos. 12/129,154, 60/989,574, 61/026,995, 61/026,998, 61/056,564, 61/086,231, 61/097,787, and 61/099,844; and PCT International Applications Nos. PCT/US2008/064591, PCT/US2008/066154, and PCT/US2008/068922.</p><p id="p-0123" num="0275">In certain embodiments, bicyclic sugar moieties and nucleosides incorporating such bicyclic sugar moieties are further defined by isomeric configuration. For example, a nucleoside comprising a 4&#x2032;-2&#x2032; methylene-oxy bridge, may be in the &#x3b1;-L configuration or in the &#x3b2;-D configuration. Previously, &#x3b1;-L-methyleneoxy (4&#x2032;-CH<sub>2</sub>&#x2014;O-2&#x2032;) bicyclic nucleosides have been incorporated into antisense oligonucleotides that showed antisense activity (Frieden et al., <i>Nucleic Acids Research, </i>2003, 21, 6365-6372).</p><p id="p-0124" num="0276">In certain embodiments, substituted sugar moieties comprise one or more non-bridging sugar substituent and one or more bridging sugar substituent (e.g., 5&#x2032;-substituted and 4&#x2032;-2&#x2032; bridged sugars). (see, PCT International Application WO 2007/134181, published on Nov. 22, 2007, wherein LNA is substituted with, for example, a 5&#x2032;-methyl or a 5&#x2032;-vinyl group).</p><p id="p-0125" num="0277">In certain embodiments, modified sugar moieties are sugar surrogates. In certain such embodiments, the oxygen atom of the naturally occurring sugar is substituted, e.g., with a sulfur, carbon or nitrogen atom. In certain such embodiments, such modified sugar moiety also comprises bridging and/or non-bridging substituents as described above. For example, certain sugar surrogates comprise a 4&#x2032;-sulfer atom and a substitution at the 2&#x2032;-position (see, e.g., published U.S. Patent Application US2005/0130923, published on Jun. 16, 2005) and/or the 5&#x2032; position. By way of additional example, carbocyclic bicyclic nucleosides having a 4&#x2032;-2&#x2032; bridge have been described (see, e.g., Freier et al., <i>Nucleic Acids Research, </i>1997, 25(22), 4429-4443 and Albaek et al., <i>J. Org. Chem., </i>2006, 71, 7731-7740).</p><p id="p-0126" num="0278">In certain embodiments, sugar surrogates comprise rings having other than 5-atoms. For example, in certain embodiments, a sugar surrogate comprises a six-membered tetrahydropyran. Such tetrahydropyrans may be further modified or substituted. Nucleosides comprising such modified tetrahydropyrans include, but are not limited to, hexitol nucleic acid (HNA), anitol nucleic acid (ANA), manitol nucleic acid (MNA) (see Leumann, C J. <i>Bioorg</i>. &#x26; <i>Med. Chem. </i>(2002) 10:841-854), fluoro HNA (F-HNA), and those compounds having Formula VII:</p><p id="p-0127" num="0000"><chemistry id="CHEM-US-00003" num="00003"><img id="EMI-C00003" he="30.56mm" wi="69.85mm" file="US20230002763A1-20230105-C00003.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0128" num="0000">wherein independently for each of said at least one tetrahydropyran nucleoside analog of Formula VII:</p><p id="p-0129" num="0279">Bx is a nucleobase moiety;</p><p id="p-0130" num="0280">T<sub>3 </sub>and T<sub>4 </sub>are each, independently, an internucleoside linking group linking the tetrahydropyran nucleoside analog to the antisense compound or one of T<sub>3 </sub>and T<sub>4 </sub>is an internucleoside linking group linking the tetrahydropyran nucleoside analog to the antisense compound and the other of T<sub>3 </sub>and T<sub>4 </sub>is H, a hydroxyl protecting group, a linked conjugate group, or a 5&#x2032; or 3&#x2032;-terminal group;</p><p id="p-0131" num="0000">q<sub>1</sub>, q<sub>2</sub>, q<sub>3</sub>, q<sub>4</sub>, q<sub>5</sub>, q<sub>6 </sub>and q<sub>7 </sub>are each, independently, H, C<sub>1</sub>-C<sub>6 </sub>alkyl, substituted C<sub>1</sub>-C<sub>6 </sub>alkyl, C<sub>2</sub>-C<sub>6 </sub>alkenyl, substituted C<sub>2</sub>-C<sub>6 </sub>alkenyl, C<sub>2</sub>-C<sub>6 </sub>alkynyl, or substituted C<sub>2</sub>-C<sub>6 </sub>alkynyl; and</p><p id="p-0132" num="0281">each of R<sub>1 </sub>and R<sub>2 </sub>is independently selected from among: hydrogen, halogen, substituted or unsubstituted alkoxy, NJ<sub>1</sub>J<sub>2</sub>, SJ<sub>1</sub>, N<sub>3</sub>, OC(&#x2550;X)J<sub>1</sub>, OC(&#x2550;X)NJ<sub>1</sub>J<sub>2</sub>, NJ<sub>3</sub>C(&#x2550;X)NJ<sub>1</sub>J<sub>2</sub>, and CN, wherein X is O, S or NJ<sub>1</sub>, and each J<sub>1</sub>, J<sub>2</sub>, and J<sub>3 </sub>is, independently, H or C<sub>1</sub>-C<sub>6 </sub>alkyl.</p><p id="p-0133" num="0282">In certain embodiments, the modified THP nucleosides of Formula VII are provided wherein q<sub>1</sub>, q<sub>2</sub>, q<sub>3</sub>, q<sub>4</sub>, q<sub>5</sub>, q<sub>6 </sub>and q<sub>7 </sub>are each H. In certain embodiments, at least one of q<sub>1</sub>, q<sub>2</sub>, q<sub>3</sub>, q<sub>4</sub>, q<sub>5</sub>, q<sub>6 </sub>and q<sub>7 </sub>is other than H. In certain embodiments, at least one of q<sub>1</sub>, q<sub>2</sub>, q<sub>3</sub>, q<sub>4</sub>, q<sub>5</sub>, q<sub>6 </sub>and q<sub>7 </sub>is methyl. In certain embodiments, THP nucleosides of Formula VII are provided wherein one of R<sub>1 </sub>and R<sub>2 </sub>is F. In certain embodiments, R<sub>1 </sub>is fluoro and R<sub>2 </sub>is H, R<sub>1 </sub>is methoxy and R<sub>2 </sub>is H, and R<sub>1 </sub>is methoxyethoxy and R<sub>2 </sub>is H.</p><p id="p-0134" num="0283">Many other bicyclic and tricyclic sugar and sugar surrogate ring systems are known in the art that can be used to modify nucleosides (see, e.g., review article: Leumann, J. C, <i>Bioorganic </i>&#x26; <i>Medicinal Chemistry, </i>2002, 10, 841-854).</p><p id="p-0135" num="0284">In certain embodiments, sugar surrogates comprise rings having more than 5 atoms and more than one heteroatom. For example nucleosides comprising morpholino sugar moieties and their use in oligomeric compounds has been reported (see for example: Braasch et al., Biochemistry, 2002, 41, 4503-4510; and U.S. Pat. Nos. 5,698,685; 5,166,315; 5,185,444; and 5,034,506). As used here, the term &#x201c;morpholino&#x201d; means a sugar surrogate having the following structure:</p><p id="p-0136" num="0000"><chemistry id="CHEM-US-00004" num="00004"><img id="EMI-C00004" he="24.30mm" wi="32.26mm" file="US20230002763A1-20230105-C00004.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0137" num="0000">In certain embodiments, morpholinos may be modified, for example by adding or altering various substituent groups from the above morpholino structure. Such sugar surrogates are referred to herein as &#x201c;modified morpholinos.&#x201d;<br/>Combinations of modifications are also provided without limitation, such as 2&#x2032;-F-5&#x2032;-methyl substituted nucleosides (see PCT International Application WO 2008/101157 Published on Aug. 21, 2008 for other disclosed 5&#x2032;, 2&#x2032;-bis substituted nucleosides) and replacement of the ribosyl ring oxygen atom with S and further substitution at the 2&#x2032;-position (see published U.S. Patent Application US2005-0130923, published on Jun. 16, 2005) or alternatively 5&#x2032;-substitution of a bicyclic nucleic acid (see PCT International Application WO 2007/134181, published on Nov. 22, 2007 wherein a 4&#x2032;-CH<sub>2</sub>&#x2014;O-2&#x2032; bicyclic nucleoside is further substituted at the 5&#x2032; position with a 5&#x2032;-methyl or a 5&#x2032;-vinyl group). The synthesis and preparation of carbocyclic bicyclic nucleosides along with their oligomerization and biochemical studies have also been described (see, e.g., Srivastava et al., <i>J. Am. Chem. Soc. </i>2007, 129(26), 8362-8379).</p><p id="p-0138" num="0285">In certain embodiments, the present invention provides oligonucleotides comprising modified nucleosides. Those modified nucleotides may include modified sugars, modified nucleobases, and/or modified linkages. The specific modifications are selected such that the resulting oligonucleotides possess desirable characteristics. In certain embodiments, oligonucleotides comprise one or more RNA-like nucleosides. In certain embodiments, oligonucleotides comprise one or more DNA-like nucleotides.</p><p id="p-0139" num="0286">ii. Certain Modified Nucleobases</p><p id="p-0140" num="0287">In certain embodiments, nucleosides of the present invention comprise one or more unmodified nucleobases. In certain embodiments, nucleosides of the present invention comprise one or more modified nucleobases.</p><p id="p-0141" num="0288">In certain embodiments, modified nucleobases are selected from: universal bases, hydrophobic bases, promiscuous bases, size-expanded bases, and fluorinated bases as defined herein. 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and 0-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil; 5-propynylcytosine; 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl CH<sub>3</sub>) uracil and cytosine and other alkynyl derivatives of pyrimidine bases, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 2-F-adenine, 2-amino-adenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine, 3-deazaguanine and 3-deazaadenine, universal bases, hydrophobic bases, promiscuous bases, size-expanded bases, and fluorinated bases as defined herein. Further modified nucleobases include tricyclic pyrimidines such as phenoxazine cytidine([5,4-b][1,4]benzoxazin-2(3H)-one), phenothiazine cytidine (1H-pyrimido[5,4-b][1,4]benzothiazin-2(3H)-one), G-clamps such as a substituted phenoxazine cytidine (e.g. 9-(2-aminoethoxy)-H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one), carbazole cytidine (2H-pyrimido[4,5-b]indol-2-one), pyridoindole cytidine (H-pyrido[3&#x2032;,2&#x2032;:4,5]pyrrolo[2,3-d]pyrimidin-2-one). Modified nucleobases may also include those in which the purine or pyrimidine base is replaced with other heterocycles, for example 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine and 2-pyridone. Further nucleobases include those disclosed in U.S. Pat. No. 3,687,808, those disclosed in <i>The Concise Encyclopedia Of Polymer Science And Engineering</i>, Kroschwitz, J. I., Ed., John Wiley &#x26; Sons, 1990, 858-859; those disclosed by Englisch et al., <i>Angewandte Chemie</i>, International Edition, 1991, 30, 613; and those disclosed by Sanghvi, Y. S., Chapter 15<i>, Antisense Research and Applications</i>, Crooke, S. T. and Lebleu, B., Eds., CRC Press, 1993, 273-288.</p><p id="p-0142" num="0289">Representative United States patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include without limitation, U.S. Pat. Nos. 3,687,808; 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121; 5,596,091; 5,614,617; 5,645,985; 5,681,941; 5,750,692; 5,763,588; 5,830,653 and 6,005,096, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.</p><p id="p-0143" num="0290">a. Certain Internucleoside Linkages</p><p id="p-0144" num="0291">In certain embodiments, nucleosides may be linked together using any internucleoside linkage to form oligonucleotides. The two main classes of internucleoside linking groups are defined by the presence or absence of a phosphorus atom. Representative phosphorus containing internucleoside linkages include, but are not limited to, phosphodiesters (P&#x2550;O), phosphotriesters, methylphosphonates, phosphoramidate, and phosphorothioates (P&#x2550;S). Representative non-phosphorus containing internucleoside linking groups include, but are not limited to, methylenemethylimino (&#x2014;CH<sub>2</sub>&#x2014;N(CH<sub>3</sub>)&#x2014;O&#x2014;CH<sub>2</sub>&#x2014;), thiodiester (&#x2014;O&#x2014;C(O)&#x2014;S&#x2014;), thionocarbamate (&#x2014;O&#x2014;C(O)(NH)&#x2014;S&#x2014;); siloxane (&#x2014;O&#x2014;Si(H)<sub>2</sub>&#x2014;O&#x2014;); and N,N&#x2032;-dimethylhydrazine (&#x2014;CH<sub>2</sub>&#x2014;N(CH<sub>3</sub>)&#x2014;N(CH<sub>3</sub>)&#x2014;). Modified linkages, compared to natural phosphodiester linkages, can be used to alter, typically increase, nuclease resistance of the oligonucleotide. In certain embodiments, internucleoside linkages having a chiral atom can be prepared as a racemic mixture, or as separate enantiomers. Representative chiral linkages include, but are not limited to, alkylphosphonates and phosphorothioates. Methods of preparation of phosphorous-containing and non-phosphorous-containing internucleoside linkages are well known to those skilled in the art.</p><p id="p-0145" num="0292">The oligonucleotides described herein contain one or more asymmetric centers and thus give rise to enantiomers, diastereomers, and other stereoisomeric configurations that may be defined, in terms of absolute stereochemistry, as (R) or (S), &#x3b1; or &#x3b2; such as for sugar anomers, or as (D) or (L) such as for amino acids etc. Included in the antisense compounds provided herein are all such possible isomers, as well as their racemic and optically pure forms.</p><p id="p-0146" num="0293">Neutral internucleoside linkages include without limitation, phosphotriesters, methylphosphonates, MMI (3&#x2032;-CH<sub>2</sub>&#x2014;N(CH<sub>3</sub>)&#x2014;O-5&#x2032;), amide-3 (3&#x2032;-CH<sub>2</sub>&#x2014;C(&#x2550;O)&#x2014;N(H)-5&#x2032;), amide-4 (3&#x2032;-CH<sub>2</sub>&#x2014;N(H)&#x2014;C(&#x2550;O)-5&#x2032;), formacetal (3&#x2032;-O&#x2014;CH<sub>2</sub>&#x2014;O-5&#x2032;), and thioformacetal (3&#x2032;-S&#x2014;CH<sub>2</sub>&#x2014;O-5&#x2032;). Further neutral internucleoside linkages include nonionic linkages comprising siloxane (dialkylsiloxane), carboxylate ester, carboxamide, sulfide, sulfonate ester and amides (See for example: <i>Carbohydrate Modifications in Antisense Research</i>; Y. S. Sanghvi and P. D. Cook, Eds., ACS Symposium Series 580; Chapters 3 and 4, 40-65). Further neutral internucleoside linkages include nonionic linkages comprising mixed N, O, S and CH<sub>2 </sub>component parts.</p><p id="p-0147" num="0294">iii. 3&#x2032;-Endo Modifications</p><p id="p-0148" num="0295">In one aspect of the present disclosure, oligomeric compounds include nucleosides synthetically modified to induce a 3&#x2032;-endo sugar conformation. A nucleoside can incorporate synthetic modifications of the heterocyclic base moiety, the sugar moiety or both to induce a desired 3&#x2032;-endo sugar conformation. These modified nucleosides are used to mimic RNA like nucleosides so that particular properties of an oligomeric compound can be enhanced while maintaining the desirable 3&#x2032;-endo conformational geometry. There is an apparent preference for an RNA type duplex (A form helix, predominantly 3&#x2032;-endo) as a requirement of RNA interference which is supported in part by the fact that duplexes composed of 2&#x2032;-deoxy-2&#x2032;-F-nucleosides appear efficient in triggering RNAi response in the <i>C. elegans </i>system. Properties that are enhanced by using more stable 3&#x2032;-endo nucleosides include but aren't limited to modulation of pharmacokinetic properties through modification of protein binding, protein off-rate, absorption and clearance; modulation of nuclease stability as well as chemical stability; modulation of the binding affinity and specificity of the oligomer (affinity and specificity for enzymes as well as for complementary sequences); and increasing efficacy of RNA cleavage. The present invention provides oligomeric compounds having one or more nucleosides modified in such a way as to favor a C3&#x2032;-endo type conformation.</p><p id="p-0149" num="0000"><chemistry id="CHEM-US-00005" num="00005"><img id="EMI-C00005" he="32.94mm" wi="66.72mm" file="US20230002763A1-20230105-C00005.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0150" num="0296">Nucleoside conformation is influenced by various factors including substitution at the 2&#x2032;, 3&#x2032; or 4&#x2032;-positions of the pentofuranosyl sugar. Electronegative substituents generally prefer the axial positions, while sterically demanding substituents generally prefer the equatorial positions (Principles of Nucleic Acid Structure, Wolfgang Sanger, 1984, Springer-Verlag.) Modification of the 2&#x2032; position to favor the 3&#x2032;-endo conformation can be achieved while maintaining the 2&#x2032;-OH as a recognition element, as exemplified in Example 35, below (Gallo et al., Tetrahedron (2001), 57, 5707-5713. Harry-O'kuru et al., J. Org. Chem., (1997), 62(6), 1754-1759 and Tang et al., J. Org. Chem. (1999), 64, 747-754.) Alternatively, preference for the 3&#x2032;-endo conformation can be achieved by deletion of the 2&#x2032;-OH as exemplified by 2&#x2032;deoxy-2&#x2032;F-nucleosides (Kawasaki et al., J. Med. Chem. (1993), 36, 831-841), which adopts the 3&#x2032;-endo conformation positioning the electronegative fluorine atom in the axial position. Other modifications of the ribose ring, for example substitution at the 4&#x2032;-position to give 4&#x2032;-F modified nucleosides (Guillerm et al., Bioorganic and Medicinal Chemistry Letters (1995), 5, 1455-1460 and Owen et al., J. Org. Chem. (1976), 41, 3010-3017), or for example modification to yield methanocarba nucleoside analogs (Jacobson et al., J. Med. Chem. Lett. (2000), 43, 2196-2203 and Lee et al., Bioorganic and Medicinal Chemistry Letters (2001), 11, 1333-1337) also induce preference for the 3&#x2032;-endo conformation. Some modifications actually lock the conformational geometry by formation of a bicyclic sugar moiety e.g. locked nucleic acid (LNA, Singh et al, Chem. Commun. (1998), 4, 455-456), and ethylene bridged nucleic acids (ENA, Morita et al, Bioorganic &#x26; Medicinal Chemistry Letters (2002), 12, 73-76.)</p><p id="p-0151" num="0297">b. Certain Motifs</p><p id="p-0152" num="0298">In certain embodiments, oligomeric compounds comprise or consist of oligonucleotides. In certain embodiments, such oligonucleotides comprise one or more chemical modification. In certain embodiments, chemically modified oligonucleotides comprise one or more modified sugars. In certain embodiments, chemically modified oligonucleotides comprise one or more modified nucleobases. In certain embodiments, chemically modified oligonucleotides comprise one or more modified internucleoside linkages. In certain embodiments, the chemical modifications (sugar modifications, nucleobase modifications, and/or linkage modifications) define a pattern or motif. In certain embodiments, the patterns of chemical modifications of sugar moieties, internucleoside linkages, and nucleobases are each independent of one another. Thus, an oligonucleotide may be described by its sugar modification motif, internucleoside linkage motif and/or nucleobase modification motif (as used herein, nucleobase modification motif describes the chemical modifications to the nucleobases independent of the sequence of nucleobases).</p><p id="p-0153" num="0299">iv. Certain Sugar Motifs</p><p id="p-0154" num="0300">In certain embodiments, oligonucleotides comprise one or more type of modified sugar moieties and/or naturally occurring sugar moieties arranged along an oligonucleotide or region thereof in a defined pattern or sugar motif. Such sugar motifs include but are not limited to any of the sugar modifications discussed herein.</p><p id="p-0155" num="0301">In certain embodiments, the oligonucleotides comprise or consist of a region having a gapmer sugar motif, which comprises two external regions or &#x201c;wings&#x201d; and a central or internal region or &#x201c;gap.&#x201d; The three regions of a gapmer sugar motif (the 5&#x2032;-wing, the gap, and the 3&#x2032;-wing) form a contiguous sequence of nucleosides wherein at least some of the sugar moieties of the nucleosides of each of the wings differ from at least some of the sugar moieties of the nucleosides of the gap. Specifically, at least the sugar moieties of the nucleosides of each wing that are closest to the gap (the 3&#x2032;-most nucleoside of the 5&#x2032;-wing and the 5&#x2032;-most nucleoside of the 3&#x2032;-wing) differ from the sugar moiety of the neighboring gap nucleosides, thus defining the boundary between the wings and the gap. In certain embodiments, the sugar moieties within the gap are the same as one another. In certain embodiments, the gap includes one or more nucleoside having a sugar moiety that differs from the sugar moiety of one or more other nucleosides of the gap. In certain embodiments, the sugar motifs of the two wings are the same as one another (symmetric sugar gapmer). In certain embodiments, the sugar motifs of the 5&#x2032;-wing differs from the sugar motif of the 3&#x2032;-wing (asymmetric sugar gapmer).</p><p id="p-0156" num="0302">v. Certain Nucleobase Modification Motifs</p><p id="p-0157" num="0303">In certain embodiments, oligonucleotides comprise chemical modifications to nucleobases arranged along the oligonucleotide or region thereof in a defined pattern or nucleobases modification motif. In certain embodiments, each nucleobase is modified. In certain embodiments, none of the nucleobases is chemically modified.</p><p id="p-0158" num="0304">In certain embodiments, oligonucleotides comprise a block of modified nucleobases. In certain such embodiments, the block is at the 3&#x2032;-end of the oligonucleotide. In certain embodiments the block is within 3 nucleotides of the 3&#x2032;-end of the oligonucleotide. In certain such embodiments, the block is at the 5&#x2032;-end of the oligonucleotide. In certain embodiments the block is within 3 nucleotides of the 5&#x2032;-end of the oligonucleotide.</p><p id="p-0159" num="0305">In certain embodiments, nucleobase modifications are a function of the natural base at a particular position of an oligonucleotide. For example, in certain embodiments each purine or each pyrimidine in an oligonucleotide is modified. In certain embodiments, each adenine is modified. In certain embodiments, each guanine is modified. In certain embodiments, each thymine is modified. In certain embodiments, each cytosine is modified. In certain embodiments, each uracil is modified.</p><p id="p-0160" num="0306">In certain embodiments, oligonucleotides comprise one or more nucleosides comprising a modified nucleobase. In certain embodiments, oligonucleotides having a gapmer sugar motif comprise a nucleoside comprising a modified nucleobase. In certain such embodiments, one nucleoside comprising a modified nucleobases is in the central gap of an oligonucleotide having a gapmer sugar motif. In certain embodiments, the sugar is an unmodified 2&#x2032;deoxynucleoside. In certain embodiments, the modified nucleobase is selected from: a 2-thio pyrimidine and a 5-propyne pyrimidine</p><p id="p-0161" num="0307">In certain embodiments, some, all, or none of the cytosine moieties in an oligonucleotide are 5-methyl cytosine moieties. Herein, 5-methyl cytosine is not a &#x201c;modified nucleobase.&#x201d; Accordingly, unless otherwise indicated, unmodified nucleobases include both cytosine residues having a 5-methyl and those lacking a 5 methyl. In certain embodiments, the methylation state of all or some cytosine nucleobases is specified.</p><p id="p-0162" num="0308">vi. Certain Nucleoside Motifs</p><p id="p-0163" num="0309">In certain embodiments, oligonucleotides comprise nucleosides comprising modified sugar moieties and/or nucleosides comprising modified nucleobases. Such motifs can be described by their sugar motif and their nucleobase motif separately or by their nucleoside motif, which provides positions or patterns of modified nucleosides (whether modified sugar, nucleobase, or both sugar and nucleobase) in an oligonucleotide.</p><p id="p-0164" num="0310">In certain embodiments, the oligonucleotides comprise or consist of a region having a gapmer nucleoside motif, which comprises two external regions or &#x201c;wings&#x201d; and a central or internal region or &#x201c;gap.&#x201d; The three regions of a gapmer nucleoside motif (the 5&#x2032;-wing, the gap, and the 3&#x2032;-wing) form a contiguous sequence of nucleosides wherein at least some of the sugar moieties and/or nucleobases of the nucleosides of each of the wings differ from at least some of the sugar moieties and/or nucleobase of the nucleosides of the gap. Specifically, at least the nucleosides of each wing that are closest to the gap (the 3&#x2032;-most nucleoside of the 5&#x2032;-wing and the 5&#x2032;-most nucleoside of the 3&#x2032;-wing) differ from the neighboring gap nucleosides, thus defining the boundary between the wings and the gap. In certain embodiments, the nucleosides within the gap are the same as one another. In certain embodiments, the gap includes one or more nucleoside that differs from one or more other nucleosides of the gap. In certain embodiments, the nucleoside motifs of the two wings are the same as one another (symmetric gapmer). In certain embodiments, the nucleoside motifs of the 5&#x2032;-wing differs from the nucleoside motif of the 3&#x2032;-wing (asymmetric gapmer).</p><p id="p-0165" num="0311">vii. Certain 5&#x2032;-Wings</p><p id="p-0166" num="0312">In certain embodiments, the 5&#x2032;-wing of a gapmer consists of 1 to 6 linked nucleosides. In certain embodiments, the 5&#x2032;-wing of a gapmer consists of 1 to 5 linked nucleosides. In certain embodiments, the 5&#x2032;-wing of a gapmer consists of 2 to 5 linked nucleosides. In certain embodiments, the 5&#x2032;-wing of a gapmer consists of 3 to 5 linked nucleosides. In certain embodiments, the 5&#x2032;-wing of a gapmer consists of 4 or 5 linked nucleosides. In certain embodiments, the 5&#x2032;-wing of a gapmer consists of 1 to 4 linked nucleosides. In certain embodiments, the 5&#x2032;-wing of a gapmer consists of 1 to 3 linked nucleosides. In certain embodiments, the 5&#x2032;-wing of a gapmer consists of 1 or 2 linked nucleosides. In certain embodiments, the 5&#x2032;-wing of a gapmer consists of 2 to 4 linked nucleosides. In certain embodiments, the 5&#x2032;-wing of a gapmer consists of 2 or 3 linked nucleosides. In certain embodiments, the 5&#x2032;-wing of a gapmer consists of 3 or 4 linked nucleosides. In certain embodiments, the 5&#x2032;-wing of a gapmer consists of 1 nucleoside. In certain embodiments, the 5&#x2032;-wing of a gapmer consists of 2 linked nucleosides. In certain embodiments, the 5&#x2032;-wing of a gapmer consists of 3 linked nucleosides. In certain embodiments, the 5&#x2032;-wing of a gapmer consists of 4 linked nucleosides. In certain embodiments, the 5&#x2032;-wing of a gapmer consists of 5 linked nucleosides. In certain embodiments, the 5&#x2032;-wing of a gapmer consists of 6 linked nucleosides.</p><p id="p-0167" num="0313">In certain embodiments, the 5&#x2032;-wing of a gapmer comprises at least one bicyclic nucleoside. In certain embodiments, the 5&#x2032;-wing of a gapmer comprises at least two bicyclic nucleosides. In certain embodiments, the 5&#x2032;-wing of a gapmer comprises at least three bicyclic nucleosides. In certain embodiments, the 5&#x2032;-wing of a gapmer comprises at least four bicyclic nucleosides. In certain embodiments, the 5&#x2032;-wing of a gapmer comprises at least one constrained ethyl nucleoside. In certain embodiments, the 5&#x2032;-wing of a gapmer comprises at least one LNA nucleoside. In certain embodiments, each nucleoside of the 5&#x2032;-wing of a gapmer is a bicyclic nucleoside. In certain embodiments, each nucleoside of the 5&#x2032;-wing of a gapmer is a constrained ethyl nucleoside. In certain embodiments, each nucleoside of the 5&#x2032;-wing of a gapmer is a LNA nucleoside.</p><p id="p-0168" num="0314">In certain embodiments, the 5&#x2032;-wing of a gapmer comprises at least one non-bicyclic modified nucleoside. In certain embodiments, the 5&#x2032;-wing of a gapmer comprises at least one 2&#x2032;-substituted nucleoside. In certain embodiments, the 5&#x2032;-wing of a gapmer comprises at least one 2&#x2032;-MOE nucleoside. In certain embodiments, the 5&#x2032;-wing of a gapmer comprises at least one 2&#x2032;-OMe nucleoside. In certain embodiments, each nucleoside of the 5&#x2032;-wing of a gapmer is a non-bicyclic modified nucleoside. In certain embodiments, each nucleoside of the 5&#x2032;-wing of a gapmer is a 2&#x2032;-substituted nucleoside. In certain embodiments, each nucleoside of the 5&#x2032;-wing of a gapmer is a 2&#x2032;-MOE nucleoside. In certain embodiments, each nucleoside of the 5&#x2032;-wing of a gapmer is a 2&#x2032;-OMe nucleoside.</p><p id="p-0169" num="0315">In certain embodiments, the 5&#x2032;-wing of a gapmer comprises at least one 2&#x2032;-deoxynucleoside. In certain embodiments, each nucleoside of the 5&#x2032;-wing of a gapmer is a 2&#x2032;-deoxynucleoside. In a certain embodiments, the 5&#x2032;-wing of a gapmer comprises at least one ribonucleoside. In certain embodiments, each nucleoside of the 5&#x2032;-wing of a gapmer is a ribonucleoside. In certain embodiments, one, more than one, or each of the nucleosides of the 5&#x2032;-wing is an RNA-like nucleoside.</p><p id="p-0170" num="0316">In certain embodiments, the 5&#x2032;-wing of a gapmer comprises at least one bicyclic nucleoside and at least one non-bicyclic modified nucleoside. In certain embodiments, the 5&#x2032;-wing of a gapmer comprises at least one bicyclic nucleoside and at least one 2&#x2032;-substituted nucleoside. In certain embodiments, the 5&#x2032;-wing of a gapmer comprises at least one bicyclic nucleoside and at least one 2&#x2032;-MOE nucleoside. In certain embodiments, the 5&#x2032;-wing of a gapmer comprises at least one bicyclic nucleoside and at least one 2&#x2032;-OMe nucleoside. In certain embodiments, the 5&#x2032;-wing of a gapmer comprises at least one bicyclic nucleoside and at least one 2&#x2032;-deoxynucleoside.</p><p id="p-0171" num="0317">In certain embodiments, the 5&#x2032;-wing of a gapmer comprises at least one constrained ethyl nucleoside and at least one non-bicyclic modified nucleoside. In certain embodiments, the 5&#x2032;-wing of a gapmer comprises at least one constrained ethyl nucleoside and at least one 2&#x2032;-substituted nucleoside. In certain embodiments, the 5&#x2032;-wing of a gapmer comprises at least one constrained ethyl nucleoside and at least one 2&#x2032;-MOE nucleoside. In certain embodiments, the 5&#x2032;-wing of a gapmer comprises at least one constrained ethyl nucleoside and at least one 2&#x2032;-OMe nucleoside. In certain embodiments, the 5&#x2032;-wing of a gapmer comprises at least one constrained ethyl nucleoside and at least one 2&#x2032;-deoxynucleoside.</p><p id="p-0172" num="0318">In certain embodiments, the 5&#x2032;-wing of a gapmer has a nucleoside motif selected from among the following: ADDA; ABDAA; ABBA; ABB; ABAA; AABAA; AAABAA; AAAABAA; AAAAABAA; AAABAA; AABAA; ABAB; ABADB; ABADDB; AAABB; AAAAA; ABBDC; ABDDC; ABBDCC; ABBDDC; ABBDCC; ABBC; AA; AAA; AAAA; AAAAB; AAAAAAA; AAAAAAAA; ABBB; AB; ABAB; AAAAB; AABBB; AAAAB; and AABBB, wherein each A is a modified nucleoside of a first type, each B is a modified nucleoside of a second type, each C is a modified nucleoside of a third type, and each D is an unmodified deoxynucleoside.</p><p id="p-0173" num="0319">In certain embodiments, the 5&#x2032;-wing of a gapmer has a nucleoside motif selected from among the following: AB, ABB, AAA, BBB, BBBAA, AAB, BAA, BBAA, AABB, AAAB, ABBW, ABBWW, ABBB, ABBBB, ABAB, ABABAB, ABABBB, ABABAA, AAABB, AAAABB, AABB, AAAAB, AABBB, ABBBB, BBBBB, AAABW, AAAAA, BBBBAA, and AAABW; wherein each A is a modified nucleoside of a first type, each B is a modified nucleoside of a second type, and each W is a modified nucleoside of either the first type, the second type or a third type.</p><p id="p-0174" num="0320">In certain embodiments, the 5&#x2032;-wing of a gapmer has a nucleoside motif selected from among the following: ABB; ABAA; AABAA; AAABAA; ABAB; ABADB; AAABB; AAAAA; AA; AAA; AAAA; AAAAB; ABBB; AB; and ABAB; wherein each A is a modified nucleoside of a first type, each B is a modified nucleoside of a second type, and each W is a modified nucleoside of either the first type, the second type or a third type.</p><p id="p-0175" num="0321">In certain embodiments, an oligonucleotide comprises any 5&#x2032;-wing motif provided herein. In certain such embodiments, the oligonucleotide is a 5&#x2032;-hemimer (does not comprise a 3&#x2032;-wing). In certain embodiments, such an oligonucleotide is a gapmer. In certain such embodiments, the 3&#x2032;-wing of the gapmer may comprise any nucleoside motif.</p><p id="p-0176" num="0322">In certain embodiments, the 5&#x2032;-wing of a gapmer has a sugar motif selected from among those listed in the following non-limiting tables:</p><p id="p-0177" num="0000"><tables id="TABLE-US-00001" num="00001"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;1</entry></row><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Certain&#x2003;5&#x2032;-Wing&#x2003;Sugar&#x2003;Motifs</entry></row><row><entry>Certain&#x2003;5&#x2032;-Wing&#x2003;Sugar&#x2003;Motifs</entry></row><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="49pt" align="left"/><colspec colname="2" colwidth="42pt" align="left"/><colspec colname="3" colwidth="42pt" align="left"/><colspec colname="4" colwidth="42pt" align="left"/><colspec colname="5" colwidth="42pt" align="left"/><tbody valign="top"><row><entry>AAAAA</entry><entry>ABCBB</entry><entry>BABCC</entry><entry>BCBBA</entry><entry>CBACC</entry></row><row><entry> </entry></row><row><entry>AAAAB</entry><entry>ABCBC</entry><entry>BACAA</entry><entry>BCBBB</entry><entry>CBBAA</entry></row><row><entry> </entry></row><row><entry>AAAAC</entry><entry>ABCCA</entry><entry>BACAB</entry><entry>BCBBC</entry><entry>CBBAB</entry></row><row><entry> </entry></row><row><entry>AAABA</entry><entry>ABCCB</entry><entry>BACAC</entry><entry>BCBCA</entry><entry>CBBAC</entry></row><row><entry> </entry></row><row><entry>AAABB</entry><entry>ABCCC</entry><entry>BACBA</entry><entry>BCBCB</entry><entry>CBBBA</entry></row><row><entry> </entry></row><row><entry>AAABC</entry><entry>ACAAA</entry><entry>BACBB</entry><entry>BCBCC</entry><entry>CBBBB</entry></row><row><entry> </entry></row><row><entry>AAACA</entry><entry>ACAAB</entry><entry>BACBC</entry><entry>BCCAA</entry><entry>CBBBC</entry></row><row><entry> </entry></row><row><entry>AAACB</entry><entry>ACAAC</entry><entry>BACCA</entry><entry>BCCAB</entry><entry>CBBCA</entry></row><row><entry> </entry></row><row><entry>AAACC</entry><entry>ACABA</entry><entry>BACCB</entry><entry>BCCAC</entry><entry>CBBCB</entry></row><row><entry> </entry></row><row><entry>AABAA</entry><entry>ACABB</entry><entry>BACCC</entry><entry>BCCBA</entry><entry>CBBCC</entry></row><row><entry> </entry></row><row><entry>AABAB</entry><entry>ACABC</entry><entry>BBAAA</entry><entry>BCCBB</entry><entry>CBCAA</entry></row><row><entry> </entry></row><row><entry>AABAC</entry><entry>ACACA</entry><entry>BBAAB</entry><entry>BCCBC</entry><entry>CBCAB</entry></row><row><entry> </entry></row><row><entry>AABBA</entry><entry>ACACB</entry><entry>BBAAC</entry><entry>BCCCA</entry><entry>CBCAC</entry></row><row><entry> </entry></row><row><entry>AABBB</entry><entry>ACACC</entry><entry>BBABA</entry><entry>BCCCB</entry><entry>CBCBA</entry></row><row><entry> </entry></row><row><entry>AABBC</entry><entry>ACBAA</entry><entry>BBABB</entry><entry>BCCCC</entry><entry>CBCBB</entry></row><row><entry> </entry></row><row><entry>AABCA</entry><entry>ACBAB</entry><entry>BBABC</entry><entry>CAAAA</entry><entry>CBCBC</entry></row><row><entry> </entry></row><row><entry>AABCB</entry><entry>ACBAC</entry><entry>BBACA</entry><entry>CAAAB</entry><entry>CBCCA</entry></row><row><entry> </entry></row><row><entry>AABCC</entry><entry>ACBBA</entry><entry>BBACB</entry><entry>CAAAC</entry><entry>CBCCB</entry></row><row><entry> </entry></row><row><entry>AACAA</entry><entry>ACBBB</entry><entry>BBACC</entry><entry>CAABA</entry><entry>CBCCC</entry></row><row><entry> </entry></row><row><entry>AACAB</entry><entry>ACBBC</entry><entry>BBBAA</entry><entry>CAABB</entry><entry>CCAAA</entry></row><row><entry> </entry></row><row><entry>AACAC</entry><entry>ACBCA</entry><entry>BBBAB</entry><entry>CAABC</entry><entry>CCAAB</entry></row><row><entry> </entry></row><row><entry>AACBA</entry><entry>ACBCB</entry><entry>BBBAC</entry><entry>CAACA</entry><entry>CCAAC</entry></row><row><entry> </entry></row><row><entry>AACBB</entry><entry>ACBCC</entry><entry>BBBBA</entry><entry>CAACB</entry><entry>CCABA</entry></row><row><entry> </entry></row><row><entry>AACBC</entry><entry>ACCAA</entry><entry>BBBBB</entry><entry>CAACC</entry><entry>CCABB</entry></row><row><entry> </entry></row><row><entry>AACCA</entry><entry>ACCAB</entry><entry>BBBBC</entry><entry>CABAA</entry><entry>CCABC</entry></row><row><entry> </entry></row><row><entry>AACCB</entry><entry>ACCAC</entry><entry>BBBCA</entry><entry>CABAB</entry><entry>CCACA</entry></row><row><entry> </entry></row><row><entry>AACCC</entry><entry>ACCBA</entry><entry>BBBCB</entry><entry>CABAC</entry><entry>CCACB</entry></row><row><entry> </entry></row><row><entry>ABAAA</entry><entry>ACCBB</entry><entry>BBBCC</entry><entry>CABBA</entry><entry>CCACC</entry></row><row><entry> </entry></row><row><entry>ABAAB</entry><entry>ACCBC</entry><entry>BBCAA</entry><entry>CABBB</entry><entry>CCBAA</entry></row><row><entry> </entry></row><row><entry>ABAAC</entry><entry>ACCCA</entry><entry>BBCAB</entry><entry>CABBC</entry><entry>CCBAB</entry></row><row><entry> </entry></row><row><entry>ABABA</entry><entry>ACCCB</entry><entry>BBCAC</entry><entry>CABCA</entry><entry>CCBAC</entry></row><row><entry> </entry></row><row><entry>ABABB</entry><entry>ACCCC</entry><entry>BBCBA</entry><entry>CABCB</entry><entry>CCBBA</entry></row><row><entry> </entry></row><row><entry>ABABC</entry><entry>BAAAA</entry><entry>BBCBB</entry><entry>CABCC</entry><entry>CCBBB</entry></row><row><entry> </entry></row><row><entry>ABACA</entry><entry>BAAAB</entry><entry>BBCBC</entry><entry>CACAA</entry><entry>CCBBC</entry></row><row><entry> </entry></row><row><entry>ABACB</entry><entry>BAAAC</entry><entry>BBCCA</entry><entry>CACAB</entry><entry>CCBCA</entry></row><row><entry> </entry></row><row><entry>ABACC</entry><entry>BAABA</entry><entry>BBCCB</entry><entry>CACAC</entry><entry>CCBCB</entry></row><row><entry> </entry></row><row><entry>ABBAA</entry><entry>BAABB</entry><entry>BBCCC</entry><entry>CACBA</entry><entry>CCBCC</entry></row><row><entry> </entry></row><row><entry>ABBAB</entry><entry>BAABC</entry><entry>BCAAA</entry><entry>CACBB</entry><entry>CCCAA</entry></row><row><entry> </entry></row><row><entry>ABBAC</entry><entry>BAACA</entry><entry>BCAAB</entry><entry>CACBC</entry><entry>CCCAB</entry></row><row><entry> </entry></row><row><entry>ABBBA</entry><entry>BAACB</entry><entry>BCAAC</entry><entry>CACCA</entry><entry>CCCAC</entry></row><row><entry> </entry></row><row><entry>ABBBB</entry><entry>BAACC</entry><entry>BCABA</entry><entry>CACCB</entry><entry>CCCBA</entry></row><row><entry> </entry></row><row><entry>ABBBC</entry><entry>BABAA</entry><entry>BCABB</entry><entry>CACCC</entry><entry>CCCBB</entry></row><row><entry> </entry></row><row><entry>ABBCA</entry><entry>BABAB</entry><entry>BCABC</entry><entry>CBAAA</entry><entry>CCCBC</entry></row><row><entry> </entry></row><row><entry>ABBCB</entry><entry>BABAC</entry><entry>BCACA</entry><entry>CBAAB</entry><entry>CCCCA</entry></row><row><entry> </entry></row><row><entry>ABBCC</entry><entry>BABBA</entry><entry>BCACB</entry><entry>CBAAC</entry><entry>CCCCB</entry></row><row><entry> </entry></row><row><entry>ABCAA</entry><entry>BABBB</entry><entry>BCACC</entry><entry>CBABA</entry><entry>CCCCC</entry></row><row><entry> </entry></row><row><entry>ABCAB</entry><entry>BABBC</entry><entry>BCBAA</entry><entry>CBABB</entry><entry/></row><row><entry> </entry></row><row><entry>ABCAC</entry><entry>BABCA</entry><entry>BCBAB</entry><entry>CBABC</entry><entry/></row><row><entry> </entry></row><row><entry>ABCBA</entry><entry>BABCB</entry><entry>BCBAC</entry><entry>CBACA</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0178" num="0000"><tables id="TABLE-US-00002" num="00002"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;2</entry></row><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Certain&#x2003;5&#x2032;-Wing&#x2003;Sugar&#x2003;Motifs</entry></row><row><entry>Certain&#x2003;5&#x2032;-Wing&#x2003;Sugar&#x2003;Motifs</entry></row><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="56pt" align="left"/><colspec colname="2" colwidth="42pt" align="left"/><colspec colname="3" colwidth="42pt" align="left"/><colspec colname="4" colwidth="42pt" align="left"/><colspec colname="5" colwidth="35pt" align="left"/><tbody valign="top"><row><entry>AAAAA</entry><entry>BABC</entry><entry>CBAB</entry><entry>ABBB</entry><entry>BAA</entry></row><row><entry> </entry></row><row><entry>AAAAB</entry><entry>BACA</entry><entry>CBAC</entry><entry>BAAA</entry><entry>BAB</entry></row><row><entry> </entry></row><row><entry>AAABA</entry><entry>BACB</entry><entry>CBBA</entry><entry>BAAB</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>AAABB</entry><entry>BACC</entry><entry>CBBB</entry><entry>BABA</entry><entry>BBB</entry></row><row><entry> </entry></row><row><entry>AABAA</entry><entry>BBAA</entry><entry>CBBC</entry><entry>BABB</entry><entry>AA</entry></row><row><entry> </entry></row><row><entry>AABAB</entry><entry>BBAB</entry><entry>CBCA</entry><entry>BBAA</entry><entry>AB</entry></row><row><entry> </entry></row><row><entry>AABBA</entry><entry>BBAC</entry><entry>CBCB</entry><entry>BBAB</entry><entry>AC</entry></row><row><entry> </entry></row><row><entry>AABBB</entry><entry>BBBA</entry><entry>CBCC</entry><entry>BBBA</entry><entry>BA</entry></row><row><entry> </entry></row><row><entry>ABAAA</entry><entry>BBBB</entry><entry>CCAA</entry><entry>BBBB</entry><entry>BB</entry></row><row><entry> </entry></row><row><entry>ABAAB</entry><entry>BBBC</entry><entry>CCAB</entry><entry>AAA</entry><entry>BC</entry></row><row><entry> </entry></row><row><entry>ABABA</entry><entry>BBCA</entry><entry>CCAC</entry><entry>AAB</entry><entry>CA</entry></row><row><entry> </entry></row><row><entry>ABABB</entry><entry>BBCB</entry><entry>CCBA</entry><entry>AAC</entry><entry>CB</entry></row><row><entry> </entry></row><row><entry>ABBAA</entry><entry>BBCC</entry><entry>CCBB</entry><entry>ABA</entry><entry>CC</entry></row><row><entry> </entry></row><row><entry>ABBAB</entry><entry>BCAA</entry><entry>CCBC</entry><entry>ABB</entry><entry>AA</entry></row><row><entry> </entry></row><row><entry>ABBBA</entry><entry>BCAB</entry><entry>CCCA</entry><entry>ABC</entry><entry>AB</entry></row><row><entry> </entry></row><row><entry>ABBBB</entry><entry>BCAC</entry><entry>CCCB</entry><entry>ACA</entry><entry>BA</entry></row><row><entry> </entry></row><row><entry>BAAAA</entry><entry>ABCB</entry><entry>BCBA</entry><entry>ACB</entry><entry/></row><row><entry> </entry></row><row><entry>BAAAB</entry><entry>ABCC</entry><entry>BCBB</entry><entry>ACC</entry><entry/></row><row><entry> </entry></row><row><entry>BAABA</entry><entry>ACAA</entry><entry>BCBC</entry><entry>BAA</entry><entry/></row><row><entry> </entry></row><row><entry>BAABB</entry><entry>ACAB</entry><entry>BCCA</entry><entry>BAB</entry><entry/></row><row><entry> </entry></row><row><entry>BABAA</entry><entry>ACAC</entry><entry>BCCB</entry><entry>BAC</entry><entry/></row><row><entry> </entry></row><row><entry>BABAB</entry><entry>ACBA</entry><entry>BCCC</entry><entry>BBA</entry><entry/></row><row><entry> </entry></row><row><entry>BABBA</entry><entry>ACBB</entry><entry>CAAA</entry><entry>BBB</entry><entry/></row><row><entry> </entry></row><row><entry>BABBB</entry><entry>ACBC</entry><entry>CAAB</entry><entry>BBC</entry><entry/></row><row><entry> </entry></row><row><entry>BBAAA</entry><entry>ACCA</entry><entry>CAAC</entry><entry>BCA</entry><entry/></row><row><entry> </entry></row><row><entry>BBAAB</entry><entry>ACCB</entry><entry>CABA</entry><entry>BCB</entry><entry/></row><row><entry> </entry></row><row><entry>BBABA</entry><entry>ACCC</entry><entry>CABB</entry><entry>BCC</entry><entry/></row><row><entry> </entry></row><row><entry>BBABB</entry><entry>BAAA</entry><entry>CABC</entry><entry>CAA</entry><entry/></row><row><entry> </entry></row><row><entry>BBBAA</entry><entry>BAAB</entry><entry>CACA</entry><entry>CAB</entry><entry/></row><row><entry> </entry></row><row><entry>BBBAB</entry><entry>BAAC</entry><entry>CACB</entry><entry>CAC</entry><entry/></row><row><entry> </entry></row><row><entry>BBBBA</entry><entry>BABA</entry><entry>CACC</entry><entry>CBA</entry><entry/></row><row><entry> </entry></row><row><entry>BBBBB</entry><entry>BABB</entry><entry>CBAA</entry><entry>CBB</entry><entry/></row><row><entry> </entry></row><row><entry>AAAA</entry><entry>AACC</entry><entry>CCCC</entry><entry>CBC</entry><entry/></row><row><entry> </entry></row><row><entry>AAAB</entry><entry>ABAA</entry><entry>AAAA</entry><entry>CCA</entry><entry/></row><row><entry> </entry></row><row><entry>AAAC</entry><entry>ABAB</entry><entry>AAAB</entry><entry>CCB</entry><entry/></row><row><entry> </entry></row><row><entry>AABA</entry><entry>ABAC</entry><entry>AABA</entry><entry>CCC</entry><entry/></row><row><entry> </entry></row><row><entry>AABB</entry><entry>ABBA</entry><entry>AABB</entry><entry>AAA</entry><entry/></row><row><entry> </entry></row><row><entry>AABC</entry><entry>ABBB</entry><entry>ABAA</entry><entry>AAB</entry><entry/></row><row><entry> </entry></row><row><entry>AACA</entry><entry>ABBC</entry><entry>ABAB</entry><entry>ABA</entry><entry/></row><row><entry> </entry></row><row><entry>AACB</entry><entry>ABCA</entry><entry>ABBA</entry><entry>ABB</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0179" num="0323">In certain embodiments, each A, each B, and each C located at the 3&#x2032;-most 5&#x2032;-wing nucleoside is a modified nucleoside. For example, in certain embodiments the 5&#x2032;-wing motif is selected from among ABB, BBB, and CBB, wherein the underlined nucleoside represents the 3&#x2032;-most 5&#x2032;-wing nucleoside and wherein the underlined nucleoside is a modified nucleoside. In certain embodiments, the the 3&#x2032;-most 5&#x2032;-wing nucleoside comprises a bicyclic sugar moiety selected from among cEt, cMOE, LNA, &#x3b1;-L-LNA, ENA and 2&#x2032;-thio LNA. In certain embodiments, the the 3&#x2032;-most 5&#x2032;-wing nucleoside comprises a bicyclic sugar moiety selected from among cEt and LNA. In certain embodiments, the the 3&#x2032;-most 5&#x2032;-wing nucleoside comprises cEt. In certain embodiments, the the 3&#x2032;-most 5&#x2032;-wing nucleoside comprises LNA.</p><p id="p-0180" num="0324">In certain embodiments, each A comprises an unmodified 2&#x2032;-deoxyfuranose sugar moiety. In certain embodiments, each A comprises a modified sugar moiety. In certain embodiments, each A comprises a 2&#x2032;-substituted sugar moiety. In certain embodiments, each A comprises a 2&#x2032;-substituted sugar moiety selected from among F, ara-F, OCH<sub>3 </sub>and O(CH<sub>2</sub>)<sub>2</sub>&#x2014;OCH<sub>3</sub>. In certain embodiments, each A comprises a bicyclic sugar moiety. In certain embodiments, each A comprises a bicyclic sugar moiety selected from among cEt, cMOE, LNA, &#x3b1;-L-LNA, ENA and 2&#x2032;-thio LNA. In certain embodiments, each A comprises a modified nucleobase. In certain embodiments, each A comprises a modified nucleobase selected from among 2-thio-thymidine nucleoside and 5-propyne uridine nucleoside. In certain embodiments, each A comprises an HNA. In certain embodiments, each A comprises a F-HNA. In certain embodiments, each A comprises a 5&#x2032;-substituted sugar moiety selected from among 5&#x2032;-Me DNA, and 5&#x2032;-(R)-Me DNA.</p><p id="p-0181" num="0325">In certain embodiments, each B comprises an unmodified 2&#x2032;-deoxyfuranose sugar moiety. In certain embodiments, each B comprises a modified sugar moiety. In certain embodiments, each B comprises a 2&#x2032;-substituted sugar moiety. In certain embodiments, each B comprises a 2&#x2032;-substituted sugar moiety selected from among F, (ara)-F, OCH<sub>3 </sub>and O(CH<sub>2</sub>)<sub>2</sub>&#x2014;OCH<sub>3</sub>. In certain embodiments, each B comprises a bicyclic sugar moiety. In certain embodiments, each B comprises a bicyclic sugar moiety selected from among cEt, cMOE, LNA, &#x3b1;-L-LNA, ENA and 2&#x2032;-thio LNA. In certain embodiments, each B comprises a modified nucleobase. In certain embodiments, each B comprises a modified nucleobase selected from among 2-thio-thymidine nucleoside and 5-propyne urindine nucleoside. In certain embodiments, each B comprises an HNA. In certain embodiments, each B comprises a F-HNA. In certain embodiments, each B comprises a 5&#x2032;-substituted sugar moiety selected from among 5&#x2032;-Me DNA, and 5&#x2032;-(R)-Me DNA.</p><p id="p-0182" num="0326">In certain embodiments, each A comprises a 2&#x2032;-substituted sugar moiety selected from among F, ara-F, OCH<sub>3 </sub>and O(CH<sub>2</sub>)<sub>2</sub>&#x2014;OCH<sub>3 </sub>and each B comprises a bicyclic sugar moiety selected from among cEt, cMOE, LNA, &#x3b1;-L-LNA, ENA and 2&#x2032;-thio LNA. In certain embodiments, each A comprises O(CH<sub>2</sub>)<sub>2</sub>&#x2014;OCH<sub>3 </sub>and each B comprises cEt.</p><p id="p-0183" num="0327">In certain embodiments, each C comprises an unmodified 2&#x2032;-deoxyfuranose sugar moiety. In certain embodiments, each C comprises a modified sugar moiety. In certain embodiments, each C comprises a 2&#x2032;-substituted sugar moiety. In certain embodiments, each C comprises a 2&#x2032;-substituted sugar moiety selected from among F, (ara)-F, OCH<sub>3 </sub>and O(CH<sub>2</sub>)<sub>2</sub>&#x2014;OCH<sub>3</sub>. In certain embodiments, each C comprises a 5&#x2032;-substituted sugar moiety. In certain embodiments, each C comprises a 5&#x2032;-substituted sugar moiety selected from among 5&#x2032;-Me DNA, and 5&#x2032;-(R)-Me DNA. In certain embodiments, each C comprises a bicyclic sugar moiety. In certain embodiments, each C comprises a bicyclic sugar moiety selected from among cEt, cMOE, LNA, &#x3b1;-L-LNA, ENA and 2&#x2032;-thio LNA. In certain embodiments, each C comprises a modified nucleobase. In certain embodiments, each C comprises a modified nucleobase selected from among 2-thio-thymidine and 5-propyne uridine. In certain embodiments, each C comprises a 2-thio-thymidine nucleoside. In certain embodiments, each C comprises an HNA. In certain embodiments, each C comprises an F-HNA.</p><p id="p-0184" num="0328">viii. Certain 3&#x2032;-Wings</p><p id="p-0185" num="0329">In certain embodiments, the 3&#x2032;-wing of a gapmer consists of 1 to 6 linked nucleosides. In certain embodiments, the 3&#x2032;-wing of a gapmer consists of 1 to 5 linked nucleosides. In certain embodiments, the 3&#x2032;-wing of a gapmer consists of 2 to 5 linked nucleosides. In certain embodiments, the 3&#x2032;-wing of a gapmer consists of 3 to 5 linked nucleosides. In certain embodiments, the 3&#x2032;-wing of a gapmer consists of 4 or 5 linked nucleosides. In certain embodiments, the 3&#x2032;-wing of a gapmer consists of 1 to 4 linked nucleosides. In certain embodiments, the 3&#x2032;-wing of a gapmer consists of 1 to 3 linked nucleosides. In certain embodiments, the 3&#x2032;-wing of a gapmer consists of 1 or 2 linked nucleosides. In certain embodiments, the 3&#x2032;-wing of a gapmer consists of 2 to 4 linked nucleosides. In certain embodiments, the 3&#x2032;-wing of a gapmer consists of 2 or 3 linked nucleosides. In certain embodiments, the 3&#x2032;-wing of a gapmer consists of 3 or 4 linked nucleosides. In certain embodiments, the 3&#x2032;-wing of a gapmer consists of 1 nucleoside. In certain embodiments, the 3&#x2032;-wing of a gapmer consists of 2 linked nucleosides. In certain embodiments, the 3&#x2032;-wing of a gapmer consists of 3 linked nucleosides. In certain embodiments, the 3&#x2032;-wing of a gapmer consists of 4 linked nucleosides. In certain embodiments, the 3&#x2032;-wing of a gapmer consists of 5 linked nucleosides. In certain embodiments, the 3&#x2032;-wing of a gapmer consists of 6 linked nucleosides.</p><p id="p-0186" num="0330">In certain embodiments, the 3&#x2032;-wing of a gapmer comprises at least one bicyclic nucleoside. In certain embodiments, the 3&#x2032;-wing of a gapmer comprises at least one constrained ethyl nucleoside. In certain embodiments, the 3&#x2032;-wing of a gapmer comprises at least one LNA nucleoside. In certain embodiments, each nucleoside of the 3&#x2032;-wing of a gapmer is a bicyclic nucleoside. In certain embodiments, each nucleoside of the 3&#x2032;-wing of a gapmer is a constrained ethyl nucleoside. In certain embodiments, each nucleoside of the 3&#x2032;-wing of a gapmer is a LNA nucleoside.</p><p id="p-0187" num="0331">In certain embodiments, the 3&#x2032;-wing of a gapmer comprises at least one non-bicyclic modified nucleoside. In certain embodiments, the 3&#x2032;-wing of a gapmer comprises at least two non-bicyclic modified nucleosides. In certain embodiments, the 3&#x2032;-wing of a gapmer comprises at least three non-bicyclic modified nucleosides. In certain embodiments, the 3&#x2032;-wing of a gapmer comprises at least four non-bicyclic modified nucleosides. In certain embodiments, the 3&#x2032;-wing of a gapmer comprises at least one 2&#x2032;-substituted nucleoside. In certain embodiments, the 3&#x2032;-wing of a gapmer comprises at least one 2&#x2032;-MOE nucleoside. In certain embodiments, the 3&#x2032;-wing of a gapmer comprises at least one 2&#x2032;-OMe nucleoside. In certain embodiments, each nucleoside of the 3&#x2032;-wing of a gapmer is a non-bicyclic modified nucleoside. In certain embodiments, each nucleoside of the 3&#x2032;-wing of a gapmer is a 2&#x2032;-substituted nucleoside. In certain embodiments, each nucleoside of the 3&#x2032;-wing of a gapmer is a 2&#x2032;-MOE nucleoside. In certain embodiments, each nucleoside of the 3&#x2032;-wing of a gapmer is a 2&#x2032;-OMe nucleoside.</p><p id="p-0188" num="0332">In certain embodiments, the 3&#x2032;-wing of a gapmer comprises at least one 2&#x2032;-deoxynucleoside. In certain embodiments, each nucleoside of the 3&#x2032;-wing of a gapmer is a 2&#x2032;-deoxynucleoside. In a certain embodiments, the 3&#x2032;-wing of a gapmer comprises at least one ribonucleoside. In certain embodiments, each nucleoside of the 3&#x2032;-wing of a gapmer is a ribonucleoside. In certain embodiments, one, more than one, or each of the nucleosides of the 5&#x2032;-wing is an RNA-like nucleoside.</p><p id="p-0189" num="0333">In certain embodiments, the 3&#x2032;-wing of a gapmer comprises at least one bicyclic nucleoside and at least one non-bicyclic modified nucleoside. In certain embodiments, the 3&#x2032;-wing of a gapmer comprises at least one bicyclic nucleoside and at least one 2&#x2032;-substituted nucleoside. In certain embodiments, the 3&#x2032;-wing of a gapmer comprises at least one bicyclic nucleoside and at least one 2&#x2032;-MOE nucleoside. In certain embodiments, the 3&#x2032;-wing of a gapmer comprises at least one bicyclic nucleoside and at least one 2&#x2032;-OMe nucleoside. In certain embodiments, the 3&#x2032;-wing of a gapmer comprises at least one bicyclic nucleoside and at least one 2&#x2032;-deoxynucleoside.</p><p id="p-0190" num="0334">In certain embodiments, the 3&#x2032;-wing of a gapmer comprises at least one constrained ethyl nucleoside and at least one non-bicyclic modified nucleoside. In certain embodiments, the 3&#x2032;-wing of a gapmer comprises at least one constrained ethyl nucleoside and at least one 2&#x2032;-substituted nucleoside. In certain embodiments, the 3&#x2032;-wing of a gapmer comprises at least one constrained ethyl nucleoside and at least one 2&#x2032;-MOE nucleoside. In certain embodiments, the 3&#x2032;-wing of a gapmer comprises at least one constrained ethyl nucleoside and at least one 2&#x2032;-OMe nucleoside. In certain embodiments, the 3&#x2032;-wing of a gapmer comprises at least one constrained ethyl nucleoside and at least one 2&#x2032;-deoxynucleoside.</p><p id="p-0191" num="0335">In certain embodiments, the 3&#x2032;-wing of a gapmer comprises at least one LNA nucleoside and at least one non-bicyclic modified nucleoside. In certain embodiments, the 3&#x2032;-wing of a gapmer comprises at least one LNA nucleoside and at least one 2&#x2032;-substituted nucleoside. In certain embodiments, the 3&#x2032;-wing of a gapmer comprises at least one LNA nucleoside and at least one 2&#x2032;-MOE nucleoside. In certain embodiments, the 3&#x2032;-wing of a gapmer comprises at least one LNA nucleoside and at least one 2&#x2032;-OMe nucleoside. In certain embodiments, the 3&#x2032;-wing of a gapmer comprises at least one LNA nucleoside and at least one 2&#x2032;-deoxynucleoside.</p><p id="p-0192" num="0336">In certain embodiments, the 3&#x2032;-wing of a gapmer comprises at least one bicyclic nucleoside, at least one non-bicyclic modified nucleoside, and at least one 2&#x2032;-deoxynucleoside. In certain embodiments, the 3&#x2032;-wing of a gapmer comprises at least one constrained ethyl nucleoside, at least one non-bicyclic modified nucleoside, and at least one 2&#x2032;-deoxynucleoside. In certain embodiments, the 3&#x2032;-wing of a gapmer comprises at least one LNA nucleoside, at least one non-bicyclic modified nucleoside, and at least one 2&#x2032;-deoxynucleoside.</p><p id="p-0193" num="0337">In certain embodiments, the 3&#x2032;-wing of a gapmer comprises at least one bicyclic nucleoside, at least one 2&#x2032;-substituted nucleoside, and at least one 2&#x2032;-deoxynucleoside. In certain embodiments, the 3&#x2032;-wing of a gapmer comprises at least one constrained ethyl nucleoside, at least one 2&#x2032;-substituted nucleoside, and at least one 2&#x2032;-deoxynucleoside. In certain embodiments, the 3&#x2032;-wing of a gapmer comprises at least one LNA nucleoside, at least one 2&#x2032;-substituted nucleoside, and at least one 2&#x2032;-deoxynucleoside.</p><p id="p-0194" num="0338">In certain embodiments, the 3&#x2032;-wing of a gapmer comprises at least one bicyclic nucleoside, at least one 2&#x2032;-MOE nucleoside, and at least one 2&#x2032;-deoxynucleoside. In certain embodiments, the 3&#x2032;-wing of a gapmer comprises at least one constrained ethyl nucleoside, at least one 2&#x2032;-MOE nucleoside, and at least one 2&#x2032;-deoxynucleoside. In certain embodiments, the 3&#x2032;-wing of a gapmer comprises at least one LNA nucleoside, at least one 2&#x2032;-MOE nucleoside, and at least one 2&#x2032;-deoxynucleoside.</p><p id="p-0195" num="0339">In certain embodiments, the 3&#x2032;-wing of a gapmer comprises at least one bicyclic nucleoside, at least one 2&#x2032;-OMe nucleoside, and at least one 2&#x2032;-deoxynucleoside. In certain embodiments, the 3&#x2032;-wing of a gapmer comprises at least one constrained ethyl nucleoside, at least one 2&#x2032;-OMe nucleoside, and at least one 2&#x2032;-deoxynucleoside. In certain embodiments, the 3&#x2032;-wing of a gapmer comprises at least one LNA nucleoside, at least one 2&#x2032;-OMe nucleoside, and at least one 2&#x2032;-deoxynucleoside.</p><p id="p-0196" num="0340">In certain embodiments, the 3&#x2032;-wing of a gapmer has a nucleoside motif selected from among the following: ABB, ABAA, AAABAA, AAAAABAA, AABAA, AAAABAA, AAABAA, ABAB, AAAAA, AAABB, AAAAAAAA, AAAAAAA, AAAAAA, AAAAB, AAAA, AAA, AA, AB, ABBB, ABAB, AABBB; wherein each A is a modified nucleoside of a first type, each B is a modified nucleoside of a second type. In certain embodiments, an oligonucleotide comprises any 3&#x2032;-wing motif provided herein. In certain such embodiments, the oligonucleotide is a 3&#x2032;-hemimer (does not comprise a 5&#x2032;-wing). In certain embodiments, such an oligonucleotide is a gapmer. In certain such embodiments, the 5&#x2032;-wing of the gapmer may comprise any nucleoside motif.</p><p id="p-0197" num="0341">In certain embodiments, the 3&#x2032;-wing of a gapmer has a nucleoside motif selected from among the following: BBA, AAB, AAA, BBB, BBAA, AABB, WBBA, WAAB, BBBA, BBBBA, BBBB, BBBBBA, ABBBBB, BBAAA, AABBB, BBBAA, BBBBA, BBBBB, BABA, AAAAA, BBAAAA, AABBBB, BAAAA, and ABBBB, wherein each A is a modified nucleoside of a first type, each B is a modified nucleoside of a second type, and each W is a modified nucleoside of either the first type, the second type or a third type.</p><p id="p-0198" num="0342">In certain embodiments, the 3&#x2032;-wing of a gapmer has a nucleoside motif selected from among the following: ABB; AAABAA; AABAA; AAAABAA; AAAAA; AAABB; AAAAAAAA; AAAAAAA; AAAAAA; AAAAB; AB; ABBB; and ABAB, wherein each A is a modified nucleoside of a first type, each B is a modified nucleoside of a second type, and each W is a modified nucleoside of either the first type, the second type or a third type.</p><p id="p-0199" num="0343">In certain embodiments, the 3&#x2032;-wing of a gapmer has a sugar motif selected from among those listed in the following non-limiting tables:</p><p id="p-0200" num="0000"><tables id="TABLE-US-00003" num="00003"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;3</entry></row><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Certain&#x2003;3&#x2032;-Wing&#x2003;Sugar&#x2003;Motifs</entry></row><row><entry>Certain&#x2003;3&#x2032;-Wing&#x2003;Sugar&#x2003;Motifs</entry></row><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="49pt" align="left"/><colspec colname="2" colwidth="42pt" align="left"/><colspec colname="3" colwidth="42pt" align="left"/><colspec colname="4" colwidth="42pt" align="left"/><colspec colname="5" colwidth="42pt" align="left"/><tbody valign="top"><row><entry>AAAAA</entry><entry>ABCBB</entry><entry>BABCC</entry><entry>BCBBA</entry><entry>CBACC</entry></row><row><entry> </entry></row><row><entry>AAAAB</entry><entry>ABCBC</entry><entry>BACAA</entry><entry>BCBBB</entry><entry>CBBAA</entry></row><row><entry> </entry></row><row><entry>AAAAC</entry><entry>ABCCA</entry><entry>BACAB</entry><entry>BCBBC</entry><entry>CBBAB</entry></row><row><entry> </entry></row><row><entry>AAABA</entry><entry>ABCCB</entry><entry>BACAC</entry><entry>BCBCA</entry><entry>CBBAC</entry></row><row><entry> </entry></row><row><entry>AAABB</entry><entry>ABCCC</entry><entry>BACBA</entry><entry>BCBCB</entry><entry>CBBBA</entry></row><row><entry> </entry></row><row><entry>AAABC</entry><entry>ACAAA</entry><entry>BACBB</entry><entry>BCBCC</entry><entry>CBBBB</entry></row><row><entry> </entry></row><row><entry>AAACA</entry><entry>ACAAB</entry><entry>BACBC</entry><entry>BCCAA</entry><entry>CBBBC</entry></row><row><entry> </entry></row><row><entry>AAACB</entry><entry>ACAAC</entry><entry>BACCA</entry><entry>BCCAB</entry><entry>CBBCA</entry></row><row><entry> </entry></row><row><entry>AAACC</entry><entry>ACABA</entry><entry>BACCB</entry><entry>BCCAC</entry><entry>CBBCB</entry></row><row><entry> </entry></row><row><entry>AABAA</entry><entry>ACABB</entry><entry>BACCC</entry><entry>BCCBA</entry><entry>CBBCC</entry></row><row><entry> </entry></row><row><entry>AABAB</entry><entry>ACABC</entry><entry>BBAAA</entry><entry>BCCBB</entry><entry>CBCAA</entry></row><row><entry> </entry></row><row><entry>AABAC</entry><entry>ACACA</entry><entry>BBAAB</entry><entry>BCCBC</entry><entry>CBCAB</entry></row><row><entry> </entry></row><row><entry>AABBA</entry><entry>ACACB</entry><entry>BBAAC</entry><entry>BCCCA</entry><entry>CBCAC</entry></row><row><entry> </entry></row><row><entry>AABBB</entry><entry>ACACC</entry><entry>BBABA</entry><entry>BCCCB</entry><entry>CBCBA</entry></row><row><entry> </entry></row><row><entry>AABBC</entry><entry>ACBAA</entry><entry>BBABB</entry><entry>BCCCC</entry><entry>CBCBB</entry></row><row><entry> </entry></row><row><entry>AABCA</entry><entry>ACBAB</entry><entry>BBABC</entry><entry>CAAAA</entry><entry>CBCBC</entry></row><row><entry> </entry></row><row><entry>AABCB</entry><entry>ACBAC</entry><entry>BBACA</entry><entry>CAAAB</entry><entry>CBCCA</entry></row><row><entry> </entry></row><row><entry>AABCC</entry><entry>ACBBA</entry><entry>BBACB</entry><entry>CAAAC</entry><entry>CBCCB</entry></row><row><entry> </entry></row><row><entry>AACAA</entry><entry>ACBBB</entry><entry>BBACC</entry><entry>CAABA</entry><entry>CBCCC</entry></row><row><entry> </entry></row><row><entry>AACAB</entry><entry>ACBBC</entry><entry>BBBAA</entry><entry>CAABB</entry><entry>CCAAA</entry></row><row><entry> </entry></row><row><entry>AACAC</entry><entry>ACBCA</entry><entry>BBBAB</entry><entry>CAABC</entry><entry>CCAAB</entry></row><row><entry> </entry></row><row><entry>AACBA</entry><entry>ACBCB</entry><entry>BBBAC</entry><entry>CAACA</entry><entry>CCAAC</entry></row><row><entry> </entry></row><row><entry>AACBB</entry><entry>ACBCC</entry><entry>BBBBA</entry><entry>CAACB</entry><entry>CCABA</entry></row><row><entry> </entry></row><row><entry>AACBC</entry><entry>ACCAA</entry><entry>BBBBB</entry><entry>CAACC</entry><entry>CCABB</entry></row><row><entry> </entry></row><row><entry>AACCA</entry><entry>ACCAB</entry><entry>BBBBC</entry><entry>CABAA</entry><entry>CCABC</entry></row><row><entry> </entry></row><row><entry>AACCB</entry><entry>ACCAC</entry><entry>BBBCA</entry><entry>CABAB</entry><entry>CCACA</entry></row><row><entry> </entry></row><row><entry>AACCC</entry><entry>ACCBA</entry><entry>BBBCB</entry><entry>CABAC</entry><entry>CCACB</entry></row><row><entry> </entry></row><row><entry>ABAAA</entry><entry>ACCBB</entry><entry>BBBCC</entry><entry>CABBA</entry><entry>CCACC</entry></row><row><entry> </entry></row><row><entry>ABAAB</entry><entry>ACCBC</entry><entry>BBCAA</entry><entry>CABBB</entry><entry>CCBAA</entry></row><row><entry> </entry></row><row><entry>ABAAC</entry><entry>ACCCA</entry><entry>BBCAB</entry><entry>CABBC</entry><entry>CCBAB</entry></row><row><entry> </entry></row><row><entry>ABABA</entry><entry>ACCCB</entry><entry>BBCAC</entry><entry>CABCA</entry><entry>CCBAC</entry></row><row><entry> </entry></row><row><entry>ABABB</entry><entry>ACCCC</entry><entry>BBCBA</entry><entry>CABCB</entry><entry>CCBBA</entry></row><row><entry> </entry></row><row><entry>ABABC</entry><entry>BAAAA</entry><entry>BBCBB</entry><entry>CABCC</entry><entry>CCBBB</entry></row><row><entry> </entry></row><row><entry>ABACA</entry><entry>BAAAB</entry><entry>BBCBC</entry><entry>CACAA</entry><entry>CCBBC</entry></row><row><entry> </entry></row><row><entry>ABACB</entry><entry>BAAAC</entry><entry>BBCCA</entry><entry>CACAB</entry><entry>CCBCA</entry></row><row><entry> </entry></row><row><entry>ABACC</entry><entry>BAABA</entry><entry>BBCCB</entry><entry>CACAC</entry><entry>CCBCB</entry></row><row><entry> </entry></row><row><entry>ABBAA</entry><entry>BAABB</entry><entry>BBCCC</entry><entry>CACBA</entry><entry>CCBCC</entry></row><row><entry> </entry></row><row><entry>ABBAB</entry><entry>BAABC</entry><entry>BCAAA</entry><entry>CACBB</entry><entry>CCCAA</entry></row><row><entry> </entry></row><row><entry>ABBAC</entry><entry>BAACA</entry><entry>BCAAB</entry><entry>CACBC</entry><entry>CCCAB</entry></row><row><entry> </entry></row><row><entry>ABBBA</entry><entry>BAACB</entry><entry>BCAAC</entry><entry>CACCA</entry><entry>CCCAC</entry></row><row><entry> </entry></row><row><entry>ABBBB</entry><entry>BAACC</entry><entry>BCABA</entry><entry>CACCB</entry><entry>CCCBA</entry></row><row><entry> </entry></row><row><entry>ABBBC</entry><entry>BABAA</entry><entry>BCABB</entry><entry>CACCC</entry><entry>CCCBB</entry></row><row><entry> </entry></row><row><entry>ABBCA</entry><entry>BABAB</entry><entry>BCABC</entry><entry>CBAAA</entry><entry>CCCBC</entry></row><row><entry> </entry></row><row><entry>ABBCB</entry><entry>BABAC</entry><entry>BCACA</entry><entry>CBAAB</entry><entry>CCCCA</entry></row><row><entry> </entry></row><row><entry>ABBCC</entry><entry>BABBA</entry><entry>BCACB</entry><entry>CBAAC</entry><entry>CCCCB</entry></row><row><entry> </entry></row><row><entry>ABCAA</entry><entry>BABBB</entry><entry>BCACC</entry><entry>CBABA</entry><entry>CCCCC</entry></row><row><entry> </entry></row><row><entry>ABCAB</entry><entry>BABBC</entry><entry>BCBAA</entry><entry>CBABB</entry><entry/></row><row><entry> </entry></row><row><entry>ABCAC</entry><entry>BABCA</entry><entry>BCBAB</entry><entry>CBABC</entry><entry/></row><row><entry> </entry></row><row><entry>ABCBA</entry><entry>BABCB</entry><entry>BCBAC</entry><entry>CBACA</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0201" num="0000"><tables id="TABLE-US-00004" num="00004"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;4</entry></row><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Certain&#x2003;3&#x2032;-Wing&#x2003;Sugar&#x2003;Motifs</entry></row><row><entry>Certain&#x2003;3&#x2032;-Wing&#x2003;Sugar&#x2003;Motifs</entry></row><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="56pt" align="left"/><colspec colname="2" colwidth="42pt" align="left"/><colspec colname="3" colwidth="42pt" align="left"/><colspec colname="4" colwidth="42pt" align="left"/><colspec colname="5" colwidth="35pt" align="left"/><tbody valign="top"><row><entry>AAAAA</entry><entry>BABC</entry><entry>CBAB</entry><entry>ABBB</entry><entry>BAA</entry></row><row><entry> </entry></row><row><entry>AAAAB</entry><entry>BACA</entry><entry>CBAC</entry><entry>BAAA</entry><entry>BAB</entry></row><row><entry> </entry></row><row><entry>AAABA</entry><entry>BACB</entry><entry>CBBA</entry><entry>BAAB</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>AAABB</entry><entry>BACC</entry><entry>CBBB</entry><entry>BABA</entry><entry>BBB</entry></row><row><entry> </entry></row><row><entry>AABAA</entry><entry>BBAA</entry><entry>CBBC</entry><entry>BABB</entry><entry>AA</entry></row><row><entry> </entry></row><row><entry>AABAB</entry><entry>BBAB</entry><entry>CBCA</entry><entry>BBAA</entry><entry>AB</entry></row><row><entry> </entry></row><row><entry>AABBA</entry><entry>BBAC</entry><entry>CBCB</entry><entry>BBAB</entry><entry>AC</entry></row><row><entry> </entry></row><row><entry>AABBB</entry><entry>BBBA</entry><entry>CBCC</entry><entry>BBBA</entry><entry>BA</entry></row><row><entry> </entry></row><row><entry>ABAAA</entry><entry>BBBB</entry><entry>CCAA</entry><entry>BBBB</entry><entry>BB</entry></row><row><entry> </entry></row><row><entry>ABAAB</entry><entry>BBBC</entry><entry>CCAB</entry><entry>AAA</entry><entry>BC</entry></row><row><entry> </entry></row><row><entry>ABABA</entry><entry>BBCA</entry><entry>CCAC</entry><entry>AAB</entry><entry>CA</entry></row><row><entry> </entry></row><row><entry>ABABB</entry><entry>BBCB</entry><entry>CCBA</entry><entry>AAC</entry><entry>CB</entry></row><row><entry> </entry></row><row><entry>ABBAA</entry><entry>BBCC</entry><entry>CCBB</entry><entry>ABA</entry><entry>CC</entry></row><row><entry> </entry></row><row><entry>ABBAB</entry><entry>BCAA</entry><entry>CCBC</entry><entry>ABB</entry><entry>AA</entry></row><row><entry> </entry></row><row><entry>ABBBA</entry><entry>BCAB</entry><entry>CCCA</entry><entry>ABC</entry><entry>AB</entry></row><row><entry> </entry></row><row><entry>ABBBB</entry><entry>BCAC</entry><entry>CCCB</entry><entry>ACA</entry><entry>BA</entry></row><row><entry> </entry></row><row><entry>BAAAA</entry><entry>ABCB</entry><entry>BCBA</entry><entry>ACB</entry><entry/></row><row><entry> </entry></row><row><entry>BAAAB</entry><entry>ABCC</entry><entry>BCBB</entry><entry>ACC</entry><entry/></row><row><entry> </entry></row><row><entry>BAABA</entry><entry>ACAA</entry><entry>BCBC</entry><entry>BAA</entry><entry/></row><row><entry> </entry></row><row><entry>BAABB</entry><entry>ACAB</entry><entry>BCCA</entry><entry>BAB</entry><entry/></row><row><entry> </entry></row><row><entry>BABAA</entry><entry>ACAC</entry><entry>BCCB</entry><entry>BAC</entry><entry/></row><row><entry> </entry></row><row><entry>BABAB</entry><entry>ACBA</entry><entry>BCCC</entry><entry>BBA</entry><entry/></row><row><entry> </entry></row><row><entry>BABBA</entry><entry>ACBB</entry><entry>CAAA</entry><entry>BBB</entry><entry/></row><row><entry> </entry></row><row><entry>BABBB</entry><entry>ACBC</entry><entry>CAAB</entry><entry>BBC</entry><entry/></row><row><entry> </entry></row><row><entry>BBAAA</entry><entry>ACCA</entry><entry>CAAC</entry><entry>BCA</entry><entry/></row><row><entry> </entry></row><row><entry>BBAAB</entry><entry>ACCB</entry><entry>CABA</entry><entry>BCB</entry><entry/></row><row><entry> </entry></row><row><entry>BBABA</entry><entry>ACCC</entry><entry>CABB</entry><entry>BCC</entry><entry/></row><row><entry> </entry></row><row><entry>BBABB</entry><entry>BAAA</entry><entry>CABC</entry><entry>CAA</entry><entry/></row><row><entry> </entry></row><row><entry>BBBAA</entry><entry>BAAB</entry><entry>CACA</entry><entry>CAB</entry><entry/></row><row><entry> </entry></row><row><entry>BBBAB</entry><entry>BAAC</entry><entry>CACB</entry><entry>CAC</entry><entry/></row><row><entry> </entry></row><row><entry>BBBBA</entry><entry>BABA</entry><entry>CACC</entry><entry>CBA</entry><entry/></row><row><entry> </entry></row><row><entry>BBBBB</entry><entry>BABB</entry><entry>CBAA</entry><entry>CBB</entry><entry/></row><row><entry> </entry></row><row><entry>AAAA</entry><entry>AACC</entry><entry>CCCC</entry><entry>CBC</entry><entry/></row><row><entry> </entry></row><row><entry>AAAB</entry><entry>ABAA</entry><entry>AAAA</entry><entry>CCA</entry><entry/></row><row><entry> </entry></row><row><entry>AAAC</entry><entry>ABAB</entry><entry>AAAB</entry><entry>CCB</entry><entry/></row><row><entry> </entry></row><row><entry>AABA</entry><entry>ABAC</entry><entry>AABA</entry><entry>CCC</entry><entry/></row><row><entry> </entry></row><row><entry>AABB</entry><entry>ABBA</entry><entry>AABB</entry><entry>AAA</entry><entry/></row><row><entry> </entry></row><row><entry>AABC</entry><entry>ABBB</entry><entry>ABAA</entry><entry>AAB</entry><entry/></row><row><entry> </entry></row><row><entry>AACA</entry><entry>ABBC</entry><entry>ABAB</entry><entry>ABA</entry><entry/></row><row><entry> </entry></row><row><entry>AACB</entry><entry>ABCA</entry><entry>ABBA</entry><entry>ABB</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0202" num="0344">In certain embodiments, each A, each B, and each C located at the 5&#x2032;-most 3&#x2032;-wing region nucleoside is a modified nucleoside. For example, in certain embodiments the 3&#x2032;-wing motif is selected from among ABB, BBB, and CBB, wherein the underlined nucleoside represents the the 5&#x2032;-most 3&#x2032;-wing region nucleoside and wherein the underlined nucleoside is a modified nucleoside.</p><p id="p-0203" num="0345">In certain embodiments, each A comprises an unmodified 2&#x2032;-deoxyfuranose sugar moiety. In certain embodiments, each A comprises a modified sugar moiety. In certain embodiments, each A comprises a 2&#x2032;-substituted sugar moiety. In certain embodiments, each A comprises a 2&#x2032;-substituted sugar moiety selected from among F, ara-F, OCH<sub>3 </sub>and O(CH<sub>2</sub>)<sub>2</sub>&#x2014;OCH<sub>3</sub>. In certain embodiments, each A comprises a bicyclic sugar moiety. In certain embodiments, each A comprises a bicyclic sugar moiety selected from among cEt, cMOE, LNA, &#x3b1;-L-LNA, ENA and 2&#x2032;-thio LNA. In certain embodiments, each A comprises a modified nucleobase. In certain embodiments, each A comprises a modified nucleobase selected from among 2-thio-thymidine nucleoside and 5-propyne uridine nucleoside. In certain embodiments, each A comprises a 5&#x2032;-substituted sugar moiety selected from among 5&#x2032;-Me DNA, and 5&#x2032;-(R)-Me DNA.</p><p id="p-0204" num="0346">In certain embodiments, each B comprises an unmodified 2&#x2032;-deoxyfuranose sugar moiety. In certain embodiments, each B comprises a modified sugar moiety. In certain embodiments, each B comprises a 2&#x2032;-substituted sugar moiety. In certain embodiments, each B comprises a 2&#x2032;-substituted sugar moiety selected from among F, (ara)-F, OCH<sub>3 </sub>and O(CH<sub>2</sub>)<sub>2</sub>&#x2014;OCH<sub>3</sub>. In certain embodiments, each B comprises a bicyclic sugar moiety. In certain embodiments, each B comprises a bicyclic sugar moiety selected from among cEt, cMOE, LNA, &#x3b1;-L-LNA, ENA and 2&#x2032;-thio LNA. In certain embodiments, each B comprises a modified nucleobase. In certain embodiments, each B comprises a modified nucleobase selected from among 2-thio-thymidine nucleoside and 5-propyne urindine nucleoside. In certain embodiments, each B comprises an HNA. In certain embodiments, each B comprises an F-HNA. In certain embodiments, each B comprises a 5&#x2032;-substituted sugar moiety selected from among 5&#x2032;-Me DNA, and 5&#x2032;-(R)-Me DNA.</p><p id="p-0205" num="0347">In certain embodiments, each A comprises a 2&#x2032;-substituted sugar moiety selected from among F, ara-F, OCH<sub>3 </sub>and O(CH<sub>2</sub>)<sub>2</sub>&#x2014;OCH<sub>3 </sub>and each B comprises a bicyclic sugar moiety selected from among cEt, cMOE, LNA, &#x3b1;-L-LNA, ENA and 2&#x2032;-thio LNA. In certain embodiments, each A comprises O(CH<sub>2</sub>)<sub>2</sub>&#x2014;OCH<sub>3 </sub>and each B comprises cEt.</p><p id="p-0206" num="0348">In certain embodiments, each C comprises an unmodified 2&#x2032;-deoxyfuranose sugar moiety. In certain embodiments, each C comprises a modified sugar moiety. In certain embodiments, each C comprises a 2&#x2032;-substituted sugar moiety. In certain embodiments, each C comprises a 2&#x2032;-substituted sugar moiety selected from among F, (ara)-F, OCH<sub>3 </sub>and O(CH<sub>2</sub>)<sub>2</sub>&#x2014;OCH<sub>3</sub>. In certain embodiments, each C comprises a 5&#x2032;-substituted sugar moiety. In certain embodiments, each C comprises a 5&#x2032;-substituted sugar moiety selected from among 5&#x2032;-Me, and 5&#x2032;-(R)-Me. In certain embodiments, each C comprises a bicyclic sugar moiety. In certain embodiments, each C comprises a bicyclic sugar moiety selected from among cEt, cMOE, LNA, &#x3b1;-L-LNA, ENA and 2&#x2032;-thio LNA. In certain embodiments, each C comprises a modified nucleobase. In certain embodiments, each C comprises a modified nucleobase selected from among 2-thio-thymidine and 5-propyne uridine. In certain embodiments, each C comprises a 2-thio-thymidine nucleoside. In certain embodiments, each C comprises an HNA. In certain embodiments, each C comprises an F-HNA.</p><p id="p-0207" num="0349">ix. Certain Central Regions (Gaps)</p><p id="p-0208" num="0350">In certain embodiments, the gap of a gapmer consists of 6 to 20 linked nucleosides. In certain embodiments, the gap of a gapmer consists of 6 to 15 linked nucleosides. In certain embodiments, the gap of a gapmer consists of 6 to 12 linked nucleosides. In certain embodiments, the gap of a gapmer consists of 6 to 10 linked nucleosides. In certain embodiments, the gap of a gapmer consists of 6 to 9 linked nucleosides. In certain embodiments, the gap of a gapmer consists of 6 to 8 linked nucleosides. In certain embodiments, the gap of a gapmer consists of 6 or 7 linked nucleosides. In certain embodiments, the gap of a gapmer consists of 7 to 10 linked nucleosides. In certain embodiments, the gap of a gapmer consists of 7 to 9 linked nucleosides. In certain embodiments, the gap of a gapmer consists of 7 or 8 linked nucleosides. In certain embodiments, the gap of a gapmer consists of 8 to 10 linked nucleosides. In certain embodiments, the gap of a gapmer consists of 8 or 9 linked nucleosides. In certain embodiments, the gap of a gapmer consists of 6 linked nucleosides. In certain embodiments, the gap of a gapmer consists of 7 linked nucleosides. In certain embodiments, the gap of a gapmer consists of 8 linked nucleosides. In certain embodiments, the gap of a gapmer consists of 9 linked nucleosides. In certain embodiments, the gap of a gapmer consists of 10 linked nucleosides. In certain embodiments, the gap of a gapmer consists of 11 linked nucleosides. In certain embodiments, the gap of a gapmer consists of 12 linked nucleosides.</p><p id="p-0209" num="0351">In certain embodiments, each nucleoside of the gap of a gapmer is a 2&#x2032;-deoxynucleoside. In certain embodiments, the gap comprises one or more modified nucleosides. In certain embodiments, each nucleoside of the gap of a gapmer is a 2&#x2032;-deoxynucleoside or is a modified nucleoside that is &#x201c;DNA-like.&#x201d; In such embodiments, &#x201c;DNA-like&#x201d; means that the nucleoside has similar characteristics to DNA, such that a duplex comprising the gapmer and an RNA molecule is capable of activating RNase H. For example, under certain conditions, 2&#x2032;-(ara)-F have been shown to support RNase H activation, and thus is DNA-like. In certain embodiments, one or more nucleosides of the gap of a gapmer is not a 2&#x2032;-deoxynucleoside and is not DNA-like. In certain such embodiments, the gapmer nonetheless supports RNase H activation (e.g., by virtue of the number or placement of the non-DNA nucleosides).</p><p id="p-0210" num="0352">In certain embodiments, gaps comprise a stretch of unmodified 2&#x2032;-deoxynucleoside interrupted by one or more modified nucleosides, thus resulting in three sub-regions (two stretches of one or more 2&#x2032;-deoxynucleosides and a stretch of one or more interrupting modified nucleosides). In certain embodiments, no stretch of unmodified 2&#x2032;-deoxynucleosides is longer than 5, 6, or 7 nucleosides. In certain embodiments, such short stretches is achieved by using short gap regions. In certain embodiments, short stretches are achieved by interrupting a longer gap region.</p><p id="p-0211" num="0353">In certain embodiments, the gap comprises one or more modified nucleosides. In certain embodiments, the gap comprises one or more modified nucleosides selected from among cEt, FHNA, LNA, and 2-thio-thymidine. In certain embodiments, the gap comprises one modified nucleoside. In certain embodiments, the gap comprises a 5&#x2032;-substituted sugar moiety selected from among 5&#x2032;-Me, and 5&#x2032;-(R)-Me. In certain embodiments, the gap comprises two modified nucleosides. In certain embodiments, the gap comprises three modified nucleosides. In certain embodiments, the gap comprises four modified nucleosides. In certain embodiments, the gap comprises two or more modified nucleosides and each modified nucleoside is the same. In certain embodiments, the gap comprises two or more modified nucleosides and each modified nucleoside is different.</p><p id="p-0212" num="0354">In certain embodiments, the gap comprises one or more modified linkages. In certain embodiments, the gap comprises one or more methyl phosphonate linkages. In certain embodiments the gap comprises two or more modified linkages. In certain embodiments, the gap comprises one or more modified linkages and one or more modified nucleosides. In certain embodiments, the gap comprises one modified linkage and one modified nucleoside. In certain embodiments, the gap comprises two modified linkages and two or more modified nucleosides.</p><p id="p-0213" num="0355">In certain embodiments, the gap comprises a nucleoside motif selected from among the following: DDDDXDDDDD; DDDDDXDDDDD; DDDXDDDDD; DDDDXDDDDDD; DDDDXDDDD; DDXDDDDDD; DDDXDDDDDD; DXDDDDDD; DDXDDDDDDD; DDXDDDDD; DDXDDDXDDD; DDDXDDDXDDD; DXDDDXDDD; DDXDDDXDD; DDXDDDDXDDD; DDXDDDDXDD; DXDDDDXDDD; DDDDXDDD; DDDXDDD; DXDDDDDDD; DDDDXXDDD; and DXXDXXDXX; wherein each D is an unmodified deoxynucleoside; and each X is a modified nucleoside or a substituted sugar moiety.</p><p id="p-0214" num="0356">In certain embodiments, the gap comprises a nucleoside motif selected from among the following: DDDDDDDDD; DXDDDDDDD; DDXDDDDDD; DDDXDDDDD; DDDDXDDDD; DDDDDXDDD; DDDDDDXDD; DDDDDDDXD; DXXDDDDDD; DDDDDDXXD; DDXXDDDDD; DDDXXDDDD; DDDDXXDDD; DDDDDXXDD; DXDDDDDXD; DXDDDDXDD; DXDDDXDDD; DXDDXDDDD; DXDXDDDDD; DDXDDDDXD; DDXDDDXDD; DDXDDXDDD; DDXDXDDDD; DDDXDDDXD; DDDXDDXDD; DDDXDXDDD; DDDDXDDXD; DDDDXDXDD; and DDDDDXDXD, wherein each D is an unmodified deoxynucleoside; and each X is a modified nucleoside or a substituted sugar moiety.</p><p id="p-0215" num="0357">In certain embodiments, the gap comprises a nucleoside motif selected from among the following: DDDDXDDDD, DXDDDDDDD, DXXDDDDDD, DDXDDDDDD, DDDXDDDDD, DDDDXDDDD, DDDDDXDDD, DDDDDDXDD, and DDDDDDDXD, wherein each D is an unmodified deoxynucleoside; and each X is a modified nucleoside or a substituted sugar moiety.</p><p id="p-0216" num="0358">In certain embodiments, the gap comprises a nucleoside motif selected from among the following: DDDDDDDD, DXDDDDDD, DDXDDDDD, DDDXDDDD, DDDDXDDD, DDDDDXDD, DDDDDDXD, DXDDDDXD, DXDDDXDD, DXDDXDDD, DXDXDDDD, DXXDDDDD, DDXXDDDD, DDXDXDDD, DDXDDXDD, DXDDDDXD, DDDXXDDD, DDDXDXDD, DDDXDDXD, DDDDXXDD, DDDDXDXD, and DDDDDXXD, wherein each D is an unmodified deoxynucleoside; and each X is a modified nucleoside or a substituted sugar moiety.</p><p id="p-0217" num="0359">In certain embodiments, the gap comprises a nucleoside motif selected from among the following: DXDDDDD, DDXDDDD, DDDXDDD, DDDDXDD, DDDDDXD, DXDDDXD, DXDDXDD, DXDXDDD, DXXDDDD, DDXXDDD, DDXDXDD, DDXDDXD, DDDXXDD, DDDXDXD, and DDDDXXD, wherein each D is an unmodified deoxynucleoside; and each X is a modified nucleoside or a substituted sugar moiety.</p><p id="p-0218" num="0360">In certain embodiments, the gap comprises a nucleoside motif selected from among the following: DXDDDD, DDXDDD, DDDXDD, DDDDXD, DXXDDD, DXDXDD, DXDDXD, DDXXDD, DDXDXD, and DDDXXD, wherein each D is an unmodified deoxynucleoside; and each X is a modified nucleoside or a substituted sugar moiety.</p><p id="p-0219" num="0361">In certain embodiments, the gap comprises a nucleoside motif selected from among the following: DXDDDD, DDXDDD, DDDXDD, DDDDXD, DXDDDDD, DDXDDDD, DDDXDDD, DDDDXDD, DDDDDXD, DXDDDDDD, DDXDDDDD, DDDXDDDD, DDDDXDDD, DDDDDXDD, DDDDDDXD, DXDDDDDDD; DDXDDDDDD, DDDXDDDDD, DDDDXDDDD, DDDDDXDDD, DDDDDDXDD, DDDDDDDXD, DXDDDDDDDD, DDXDDDDDDD, DDDXDDDDDD, DDDDXDDDDD, DDDDDXDDDD, DDDDDDXDDD, DDDDDDDXDD, and DDDDDDDDXD, wherein each D is an unmodified deoxynucleoside; and each X is a modified nucleoside or a substituted sugar moiety.</p><p id="p-0220" num="0362">In certain embodiments, each X comprises an unmodified 2&#x2032;-deoxyfuranose sugar moiety. In certain embodiments, each X comprises a modified sugar moiety. In certain embodiments, each X comprises a 2&#x2032;-substituted sugar moiety. In certain embodiments, each X comprises a 2&#x2032;-substituted sugar moiety selected from among F, (ara)-F, OCH<sub>3 </sub>and O(CH<sub>2</sub>)<sub>2</sub>&#x2014;OCH<sub>3</sub>. In certain embodiments, each X comprises a 5&#x2032;-substituted sugar moiety. In certain embodiments, each X comprises a 5&#x2032;-substituted sugar moiety selected from among 5&#x2032;-Me, and 5&#x2032;-(R)-Me. In certain embodiments, each X comprises a bicyclic sugar moiety. In certain embodiments, each X comprises a bicyclic sugar moiety selected from among cEt, cMOE, LNA, LNA, ENA and 2&#x2032;-thio LNA. In certain embodiments, each X comprises a modified nucleobase. In certain embodiments, each X comprises a modified nucleobase selected from among 2-thio-thymidine and 5-propyne uridine. In certain embodiments, each X comprises a 2-thio-thymidine nucleoside. In certain embodiments, each X comprises an HNA. In certain embodiments, each C comprises an F-HNA. In certain embodiments, X represents the location of a single differentiating nucleobase.</p><p id="p-0221" num="0363">x. Certain Gapmer Motifs</p><p id="p-0222" num="0364">In certain embodiments, a gapmer comprises a 5&#x2032;-wing, a gap, and a 3&#x2032; wing, wherein the 5&#x2032;-wing, gap, and 3&#x2032; wing are independently selected from among those discussed above. For example, in certain embodiments, a gapmer has a 5&#x2032;-wing, a gap, and a 3&#x2032;-wing having features selected from among any of those listed in the tables above and any 5&#x2032;-wing may be paired with any gap and any 3&#x2032;-wing. For example, in certain embodiments, a 5&#x2032;-wing may comprise AAABB, a 3&#x2032;-wing may comprise BBA, and the gap may comprise DDDDDDD. For example, in certain embodiments, a gapmer has a 5&#x2032;-wing, a gap, and a 3&#x2032;-wing having features selected from among those listed in the following non-limiting table, wherein each motif is represented as (5&#x2032;-wing)-(gap)-(3&#x2032;-wing), wherein each number represents the number of linked nucleosides in each portion of the motif, for example, a 5-10-5 motif would have a 5&#x2032;-wing comprising 5 nucleosides, a gap comprising 10 nucleosides, and a 3&#x2032;-wing comprising 5 nucleosides:</p><p id="p-0223" num="0000"><tables id="TABLE-US-00005" num="00005"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 5</entry></row><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Certain Gapmer Sugar Motifs</entry></row><row><entry>Certain Gapmer Sugar Motifs</entry></row><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="21pt" align="left"/><colspec colname="2" colwidth="28pt" align="center"/><colspec colname="3" colwidth="70pt" align="center"/><colspec colname="4" colwidth="28pt" align="center"/><colspec colname="5" colwidth="70pt" align="center"/><tbody valign="top"><row><entry/><entry>2-10-2</entry><entry>3-10-2</entry><entry>4-10-2</entry><entry>5-10-2</entry></row><row><entry/><entry>2-10-3</entry><entry>3-10-3</entry><entry>4-10-3</entry><entry>5-10-3</entry></row><row><entry/><entry>2-10-4</entry><entry>3-10-4</entry><entry>4-10-4</entry><entry>5-10-4</entry></row><row><entry/><entry>2-10-5</entry><entry>3-10-5</entry><entry>4-10-5</entry><entry>5-10-5</entry></row><row><entry/><entry>2-9-2</entry><entry>3-9-2</entry><entry>4-9-2</entry><entry>5-9-2</entry></row><row><entry/><entry>2-9-3</entry><entry>3-9-3</entry><entry>4-9-3</entry><entry>5-9-3</entry></row><row><entry/><entry>2-9-4</entry><entry>3-9-4</entry><entry>4-9-4</entry><entry>5-9-4</entry></row><row><entry/><entry>2-9-5</entry><entry>3-9-5</entry><entry>4-9-5</entry><entry>5-9-5</entry></row><row><entry/><entry>2-11-2</entry><entry>3-11-2</entry><entry>4-11-2</entry><entry>5-11-2</entry></row><row><entry/><entry>2-11-3</entry><entry>3-11-3</entry><entry>4-11-3</entry><entry>5-11-3</entry></row><row><entry/><entry>2-11-4</entry><entry>3-11-4</entry><entry>4-11-4</entry><entry>5-11-4</entry></row><row><entry/><entry>2-11-5</entry><entry>3-11-5</entry><entry>4-11-5</entry><entry>5-11-5</entry></row><row><entry/><entry>2-8-2</entry><entry>3-8-2</entry><entry>4-8-2</entry><entry>5-8-2</entry></row><row><entry/><entry>2-8-3</entry><entry>3-8-3</entry><entry>4-8-3</entry><entry>5-8-3</entry></row><row><entry/><entry>2-8-4</entry><entry>3-8-4</entry><entry>4-8-4</entry><entry>5-8-4</entry></row><row><entry/><entry>2-8-5</entry><entry>3-8-5</entry><entry>4-8-5</entry><entry>5-8-5</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0224" num="0365">In certain embodiments, a gapmer comprises a 5&#x2032;-wing, a gap, and a 3&#x2032; wing, wherein the 5&#x2032;-wing, gap, and 3&#x2032; wing are independently selected from among those discussed above. For example, in certain embodiments, a gapmer has a 5&#x2032;-wing, a gap, and a 3&#x2032;-wing having features selected from among those listed in the following non-limiting tables:</p><p id="p-0225" num="0000"><tables id="TABLE-US-00006" num="00006"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;6</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Certain&#x2003;Gapmer&#x2003;Nucleoside&#x2003;Motifs</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="14pt" align="left"/><colspec colname="2" colwidth="42pt" align="left"/><colspec colname="3" colwidth="119pt" align="left"/><colspec colname="4" colwidth="42pt" align="left"/><tbody valign="top"><row><entry/><entry>5&#x2032;-wing</entry><entry/><entry>3&#x2032;-wing</entry></row><row><entry/><entry>region</entry><entry>Central&#x2003;gap&#x2003;region</entry><entry>region</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row><row><entry/><entry>ADDA</entry><entry>DDDDDD</entry><entry>ABB</entry></row><row><entry> </entry></row><row><entry/><entry>ABBA</entry><entry>DDDADDDD</entry><entry>ABAA</entry></row><row><entry> </entry></row><row><entry/><entry>AAAAAAA</entry><entry>DDDDDDDDDDD</entry><entry>AAA</entry></row><row><entry> </entry></row><row><entry/><entry>AAAAABB</entry><entry>DDDDDDDD</entry><entry>BBAAAAA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DDDDADDDD</entry><entry>ABB</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DDDDBDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DDDDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>AABAA</entry><entry>DDDDDDDDD</entry><entry>AABAA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DDDDDD</entry><entry>AABAA</entry></row><row><entry> </entry></row><row><entry/><entry>AAABAA</entry><entry>DDDDDDDDD</entry><entry>AAABAA</entry></row><row><entry> </entry></row><row><entry/><entry>AAABAA</entry><entry>DDDDDDDDD</entry><entry>AAB</entry></row><row><entry> </entry></row><row><entry/><entry>ABAB</entry><entry>DDDDDDDDD</entry><entry>ABAB</entry></row><row><entry> </entry></row><row><entry/><entry>AAABB</entry><entry>DDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABADB</entry><entry>DDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABA</entry><entry>DBDDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABA</entry><entry>DADDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABAB</entry><entry>DDDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>AA</entry><entry>DDDDDDDD</entry><entry>BBBBBBBB</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DDDDDD</entry><entry>ABADB</entry></row><row><entry> </entry></row><row><entry/><entry>AAAAB</entry><entry>DDDDDDD</entry><entry>BAAAA</entry></row><row><entry> </entry></row><row><entry/><entry>ABBB</entry><entry>DDDDDDDDD</entry><entry>AB</entry></row><row><entry> </entry></row><row><entry/><entry>AB</entry><entry>DDDDDDDDD</entry><entry>BBBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABBB</entry><entry>DDDDDDDDD</entry><entry>BBBA</entry></row><row><entry> </entry></row><row><entry/><entry>AB</entry><entry>DDDDDDDD</entry><entry>ABA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DDDDWDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>AAABB</entry><entry>DDDWDDD</entry><entry>BBAAA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DDDDWWDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABADB</entry><entry>DDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABBDC</entry><entry>DDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABBDDC</entry><entry>DDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABBDCC</entry><entry>DDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DWWDWWDWW</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DWDDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DDWDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DWWDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>AAABB</entry><entry>DDWDDDDDD</entry><entry>AA</entry></row><row><entry> </entry></row><row><entry/><entry>BB</entry><entry>DDWDWDDDD</entry><entry>BBABBBB</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DDDD(<sup>N</sup>D)DDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>AAABB</entry><entry>DDD(<sup>N</sup>D)DDD</entry><entry>BBAAA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DDDD(<sup>N</sup>D)(<sup>N</sup>D)DDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>D(<sup>N</sup>D)(<sup>N</sup>D)D(<sup>N</sup>D)(<sup>N</sup>D)D(<sup>N</sup>D)(<sup>N</sup>D)</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>D(<sup>N</sup>D)DDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DD(<sup>N</sup>D)DDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>D(<sup>N</sup>D)(<sup>N</sup>D)DDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>AAABB</entry><entry>DD(<sup>N</sup>D)DDDDDD</entry><entry>AA</entry></row><row><entry> </entry></row><row><entry/><entry>BB</entry><entry>DD(<sup>N</sup>D)D(<sup>N</sup>D)DDDD</entry><entry>BBABBBB</entry></row><row><entry> </entry></row><row><entry/><entry>ABAB</entry><entry>DDDDDDDDD</entry><entry>BABA</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0226" num="0000"><tables id="TABLE-US-00007" num="00007"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;7</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Certain&#x2003;Gapmer&#x2003;Nucleoside&#x2003;Motifs</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="21pt" align="left"/><colspec colname="2" colwidth="49pt" align="left"/><colspec colname="3" colwidth="98pt" align="left"/><colspec colname="4" colwidth="49pt" align="left"/><tbody valign="top"><row><entry/><entry>5&#x2032;-wing</entry><entry/><entry>3&#x2032;-wing</entry></row><row><entry/><entry>region</entry><entry>Central&#x2003;gap&#x2003;region</entry><entry>region</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row><row><entry/><entry>ABBW</entry><entry>DDDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DWDDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DDWDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DDDWDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DDDDWDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DDDDDWDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DDDDDDWDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DDDDDDDWD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DDDDDDDD</entry><entry>WBBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABBWW</entry><entry>DDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DWWDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DDWWDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DDDWWDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DDDDWWDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DDDDDWWDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DDDDDDWWD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DDDDDDD</entry><entry>WWBBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABBW</entry><entry>DDDDDDD</entry><entry>WBBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABBW</entry><entry>DDDDDDWD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABBW</entry><entry>DDDDDWDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABBW</entry><entry>DDDDWDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABBW</entry><entry>DDDWDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABBW</entry><entry>DDWDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABBW</entry><entry>DWDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DWDDDDDD</entry><entry>WBBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DWDDDDDWD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DWDDDDWDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DWDDDWDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DWDDWDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DWDWDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DDWDDDDD</entry><entry>WBBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DDWDDDDWD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DDWDDDWDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DDWDDWDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DDWDWDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DDWWDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DDDWDDDD</entry><entry>WBBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DDDWDDDWD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DDDWDDWDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DDDWDWDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DDDWWDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DDDDWDDD</entry><entry>WBBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DDDDWDDWD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DDDDWDWDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DDDDWWDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DDDDDWDD</entry><entry>WBBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DDDDDWDWD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DDDDDWWDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry/><entry>ABB</entry><entry>DDDDDDWD</entry><entry>WBBA</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0227" num="0000"><tables id="TABLE-US-00008" num="00008"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;8</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Certain&#x2003;Gapmer&#x2003;Nucleoside&#x2003;Motifs</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="70pt" align="left"/><colspec colname="2" colwidth="77pt" align="left"/><colspec colname="3" colwidth="70pt" align="left"/><tbody valign="top"><row><entry>5&#x2032;-wing&#x2003;region</entry><entry>Central&#x2003;gap&#x2003;region</entry><entry>3&#x2032;-wing&#x2003;region</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row><row><entry>ABBB</entry><entry>DDDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DBDDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDBDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDBDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDBDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDDBDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDDDBDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDDDDBD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDDDDD</entry><entry>BBBA</entry></row><row><entry> </entry></row><row><entry>ABBBB</entry><entry>DDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DBBDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDBBDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDBBDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDBBDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDDBBDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDDDBBD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDDDD</entry><entry>BBBBA</entry></row><row><entry> </entry></row><row><entry>ABBB</entry><entry>DDDDDDD</entry><entry>BBBA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDDDBD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABBB</entry><entry>DDDDDBDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABBB</entry><entry>DDDDBDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABBB</entry><entry>DDDBDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABBB</entry><entry>DDBDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABBB</entry><entry>DBDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DBDDDDDD</entry><entry>BBBA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DBDDDDDBD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DBDDDDBDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DBDDDBDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DBDDBDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DBDBDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDBDDDDD</entry><entry>BBBA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDBDDDDBD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDBDDDBDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDBDDBDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDBDBDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDBBDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDBDDDD</entry><entry>BBBA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDBDDDBD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDBDDBDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDBDBDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDBBDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDBDDD</entry><entry>BBBA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDBDDBD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDBDBDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDBBDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDDBDD</entry><entry>BBBA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDDBDBD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDDBBDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDDDBD</entry><entry>BBBA</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0228" num="0000"><tables id="TABLE-US-00009" num="00009"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;9</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Certain&#x2003;Gapmer&#x2003;Nucleoside&#x2003;Motifs</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="70pt" align="left"/><colspec colname="2" colwidth="77pt" align="left"/><colspec colname="3" colwidth="70pt" align="left"/><tbody valign="top"><row><entry>5&#x2032;-wing&#x2003;region</entry><entry>Central&#x2003;gap&#x2003;region</entry><entry>3&#x2032;-wing&#x2003;region</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row><row><entry>ABB</entry><entry>DDDDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>AB</entry><entry>DBDDDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>AB</entry><entry>DDBDDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>AB</entry><entry>DDDBDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>AB</entry><entry>DDDDBDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>AB</entry><entry>DDDDDBDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>AB</entry><entry>DDDDDDBDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>AB</entry><entry>DDDDDDDBDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>AB</entry><entry>DDDDDDDDBD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>AB</entry><entry>DDDDDDDDD</entry><entry>BBBA</entry></row><row><entry> </entry></row><row><entry>ABBB</entry><entry>DDDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>AB</entry><entry>DBBDDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>AB</entry><entry>DDBBDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>AB</entry><entry>DDDBBDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>AB</entry><entry>DDDDBBDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>AB</entry><entry>DDDDDBBDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>AB</entry><entry>DDDDDDBBDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>AB</entry><entry>DDDDDDDBBD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>AB</entry><entry>DDDDDDDD</entry><entry>BBBBA</entry></row><row><entry> </entry></row><row><entry>ABBBB</entry><entry>DDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>AB</entry><entry>DBBBDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>AB</entry><entry>DDBBBDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>AB</entry><entry>DDDBBBDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>AB</entry><entry>DDDDBBBDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>AB</entry><entry>DDDDDBBBDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>AB</entry><entry>DDDDDDBBBD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>AB</entry><entry>DDDDDDD</entry><entry>BBBBBA</entry></row><row><entry> </entry></row><row><entry>AB</entry><entry>DDDDDDDDD</entry><entry>BBBA</entry></row><row><entry> </entry></row><row><entry>AB</entry><entry>DDDDDDDBD</entry><entry>BBBA</entry></row><row><entry> </entry></row><row><entry>AB</entry><entry>DDDDDBDD</entry><entry>BBBA</entry></row><row><entry> </entry></row><row><entry>AB</entry><entry>DDDDBDDD</entry><entry>BBBA</entry></row><row><entry> </entry></row><row><entry>AB</entry><entry>DDDBDDDD</entry><entry>BBBA</entry></row><row><entry> </entry></row><row><entry>AB</entry><entry>DDBDDDDD</entry><entry>BBBA</entry></row><row><entry> </entry></row><row><entry>AB</entry><entry>DBDDDDDD</entry><entry>BBBA</entry></row><row><entry> </entry></row><row><entry>AB</entry><entry>DDDDDBD</entry><entry>BBBBA</entry></row><row><entry> </entry></row><row><entry>AB</entry><entry>DDDDBDD</entry><entry>BBBBA</entry></row><row><entry> </entry></row><row><entry>AB</entry><entry>DDDBDDD</entry><entry>BBBBA</entry></row><row><entry> </entry></row><row><entry>AB</entry><entry>DDBDDDD</entry><entry>BBBBA</entry></row><row><entry> </entry></row><row><entry>AB</entry><entry>DBDDDDD</entry><entry>BBBBA</entry></row><row><entry> </entry></row><row><entry>AB</entry><entry>DDDDBD</entry><entry>BBBBBA</entry></row><row><entry> </entry></row><row><entry>AB</entry><entry>DDDBDD</entry><entry>BBBBBA</entry></row><row><entry> </entry></row><row><entry>AB</entry><entry>DDBDDD</entry><entry>BBBBBA</entry></row><row><entry> </entry></row><row><entry>AB</entry><entry>DBDDDD</entry><entry>BBBBBA</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0229" num="0000"><tables id="TABLE-US-00010" num="00010"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;10</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Certain&#x2003;Gapmer&#x2003;Nucleoside&#x2003;Motifs</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="70pt" align="left"/><colspec colname="2" colwidth="77pt" align="left"/><colspec colname="3" colwidth="70pt" align="left"/><tbody valign="top"><row><entry>5&#x2032;-wing&#x2003;region</entry><entry>Central&#x2003;gap&#x2003;region</entry><entry>3&#x2032;-wing&#x2003;region</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row><row><entry>AAAAAA</entry><entry>DDDDDDD</entry><entry>BABA</entry></row><row><entry> </entry></row><row><entry>AAAAAB</entry><entry>DDDDDDD</entry><entry>BABA</entry></row><row><entry> </entry></row><row><entry>AAAABA</entry><entry>DDDDDDD</entry><entry>BABA</entry></row><row><entry> </entry></row><row><entry>AAABAA</entry><entry>DDDDDDD</entry><entry>BABA</entry></row><row><entry> </entry></row><row><entry>AABAAA</entry><entry>DDDDDDD</entry><entry>BABA</entry></row><row><entry> </entry></row><row><entry>ABAAAA</entry><entry>DDDDDDD</entry><entry>BABA</entry></row><row><entry> </entry></row><row><entry>BAAAAA</entry><entry>DDDDDDD</entry><entry>BABA</entry></row><row><entry> </entry></row><row><entry>ABAAAB</entry><entry>DDDDDDD</entry><entry>BABA</entry></row><row><entry> </entry></row><row><entry>ABAABA</entry><entry>DDDDDDD</entry><entry>BABA</entry></row><row><entry> </entry></row><row><entry>ABABAA</entry><entry>DDDDDDD</entry><entry>BABA</entry></row><row><entry> </entry></row><row><entry>ABBAAA</entry><entry>DDDDDDD</entry><entry>BABA</entry></row><row><entry> </entry></row><row><entry>AABAAB</entry><entry>DDDDDDD</entry><entry>BABA</entry></row><row><entry> </entry></row><row><entry>AABABA</entry><entry>DDDDDDD</entry><entry>BABA</entry></row><row><entry> </entry></row><row><entry>AABBAA</entry><entry>DDDDDDD</entry><entry>BABA</entry></row><row><entry> </entry></row><row><entry>AAABAB</entry><entry>DDDDDDD</entry><entry>BABA</entry></row><row><entry> </entry></row><row><entry>AAABBA</entry><entry>DDDDDDD</entry><entry>BABA</entry></row><row><entry> </entry></row><row><entry>AAAABB</entry><entry>DDDDDDD</entry><entry>BABA</entry></row><row><entry> </entry></row><row><entry>BAAAAB</entry><entry>DDDDDDD</entry><entry>BABA</entry></row><row><entry> </entry></row><row><entry>BAAABA</entry><entry>DDDDDDD</entry><entry>BABA</entry></row><row><entry> </entry></row><row><entry>BAABAA</entry><entry>DDDDDDD</entry><entry>BABA</entry></row><row><entry> </entry></row><row><entry>BABAAA</entry><entry>DDDDDDD</entry><entry>BABA</entry></row><row><entry> </entry></row><row><entry>BBAAAA</entry><entry>DDDDDDD</entry><entry>BABA</entry></row><row><entry> </entry></row><row><entry>BBBAAA</entry><entry>DDDDDDD</entry><entry>BABA</entry></row><row><entry> </entry></row><row><entry>BBABAA</entry><entry>DDDDDDD</entry><entry>BABA</entry></row><row><entry> </entry></row><row><entry>BBAABA</entry><entry>DDDDDDD</entry><entry>BABA</entry></row><row><entry> </entry></row><row><entry>BBAAAB</entry><entry>DDDDDDD</entry><entry>BABA</entry></row><row><entry> </entry></row><row><entry>ABABAB</entry><entry>DDDDDDD</entry><entry>BABA</entry></row><row><entry> </entry></row><row><entry>BBBBAA</entry><entry>DDDDDDD</entry><entry>BABA</entry></row><row><entry> </entry></row><row><entry>BBBABA</entry><entry>DDDDDDD</entry><entry>BABA</entry></row><row><entry> </entry></row><row><entry>BBBAAB</entry><entry>DDDDDDD</entry><entry>BABA</entry></row><row><entry> </entry></row><row><entry>BBBBBA</entry><entry>DDDDDDD</entry><entry>BABA</entry></row><row><entry> </entry></row><row><entry>BBBBAB</entry><entry>DDDDDDD</entry><entry>BABA</entry></row><row><entry> </entry></row><row><entry>AAABBB</entry><entry>DDDDDDD</entry><entry>BABA</entry></row><row><entry> </entry></row><row><entry>AABABB</entry><entry>DDDDDDD</entry><entry>BABA</entry></row><row><entry> </entry></row><row><entry>ABAABB</entry><entry>DDDDDDD</entry><entry>BABA</entry></row><row><entry> </entry></row><row><entry>BAAABB</entry><entry>DDDDDDD</entry><entry>BABA</entry></row><row><entry> </entry></row><row><entry>AABBBB</entry><entry>DDDDDDD</entry><entry>BABA</entry></row><row><entry> </entry></row><row><entry>ABABBB</entry><entry>DDDDDDD</entry><entry>BABA</entry></row><row><entry> </entry></row><row><entry>BAABBB</entry><entry>DDDDDDD</entry><entry>BABA</entry></row><row><entry> </entry></row><row><entry>ABBBBB</entry><entry>DDDDDDD</entry><entry>BABA</entry></row><row><entry> </entry></row><row><entry>BABBBB</entry><entry>DDDDDDD</entry><entry>BABA</entry></row><row><entry> </entry></row><row><entry>BBBBBB</entry><entry>DDDDDDD</entry><entry>BABA</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0230" num="0000"><tables id="TABLE-US-00011" num="00011"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;11</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Certain&#x2003;Gapmer&#x2003;Nucleoside&#x2003;Motifs</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="70pt" align="left"/><colspec colname="2" colwidth="77pt" align="left"/><colspec colname="3" colwidth="70pt" align="left"/><tbody valign="top"><row><entry>5&#x2032;-wing&#x2003;region</entry><entry>Central&#x2003;gap&#x2003;region</entry><entry>3&#x2032;-wing&#x2003;region</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row><row><entry>AAAAA</entry><entry>DDDDDDD</entry><entry>AAAAA</entry></row><row><entry> </entry></row><row><entry>AAAAB</entry><entry>DDDDDDD</entry><entry>AAAAA</entry></row><row><entry> </entry></row><row><entry>AAABA</entry><entry>DDDDDDD</entry><entry>AAAAA</entry></row><row><entry> </entry></row><row><entry>AAABB</entry><entry>DDDDDDD</entry><entry>AAAAA</entry></row><row><entry> </entry></row><row><entry>AABAA</entry><entry>DDDDDDD</entry><entry>AAAAA</entry></row><row><entry> </entry></row><row><entry>AABAB</entry><entry>DDDDDDD</entry><entry>AAAAA</entry></row><row><entry> </entry></row><row><entry>AABBA</entry><entry>DDDDDDD</entry><entry>AAAAA</entry></row><row><entry> </entry></row><row><entry>AABBB</entry><entry>DDDDDDD</entry><entry>AAAAA</entry></row><row><entry> </entry></row><row><entry>ABAAA</entry><entry>DDDDDDD</entry><entry>AAAAA</entry></row><row><entry> </entry></row><row><entry>ABAAB</entry><entry>DDDDDDD</entry><entry>AAAAA</entry></row><row><entry> </entry></row><row><entry>ABABA</entry><entry>DDDDDDD</entry><entry>AAAAA</entry></row><row><entry> </entry></row><row><entry>ABABB</entry><entry>DDDDDDD</entry><entry>AAAAA</entry></row><row><entry> </entry></row><row><entry>ABBAA</entry><entry>DDDDDDD</entry><entry>AAAAA</entry></row><row><entry> </entry></row><row><entry>ABBAB</entry><entry>DDDDDDD</entry><entry>AAAAA</entry></row><row><entry> </entry></row><row><entry>ABBBA</entry><entry>DDDDDDD</entry><entry>AAAAA</entry></row><row><entry> </entry></row><row><entry>ABBBB</entry><entry>DDDDDDD</entry><entry>AAAAA</entry></row><row><entry> </entry></row><row><entry>BAAAA</entry><entry>DDDDDDD</entry><entry>AAAAA</entry></row><row><entry> </entry></row><row><entry>BAAAB</entry><entry>DDDDDDD</entry><entry>AAAAA</entry></row><row><entry> </entry></row><row><entry>BAABA</entry><entry>DDDDDDD</entry><entry>AAAAA</entry></row><row><entry> </entry></row><row><entry>BAABB</entry><entry>DDDDDDD</entry><entry>AAAAA</entry></row><row><entry> </entry></row><row><entry>BABAA</entry><entry>DDDDDDD</entry><entry>AAAAA</entry></row><row><entry> </entry></row><row><entry>BABAB</entry><entry>DDDDDDD</entry><entry>AAAAA</entry></row><row><entry> </entry></row><row><entry>BABBA</entry><entry>DDDDDDD</entry><entry>AAAAA</entry></row><row><entry> </entry></row><row><entry>BABBB</entry><entry>DDDDDDD</entry><entry>AAAAA</entry></row><row><entry> </entry></row><row><entry>BBAAA</entry><entry>DDDDDDD</entry><entry>AAAAA</entry></row><row><entry> </entry></row><row><entry>BBAAB</entry><entry>DDDDDDD</entry><entry>AAAAA</entry></row><row><entry> </entry></row><row><entry>BBABA</entry><entry>DDDDDDD</entry><entry>AAAAA</entry></row><row><entry> </entry></row><row><entry>BBABB</entry><entry>DDDDDDD</entry><entry>AAAAA</entry></row><row><entry> </entry></row><row><entry>BBBAA</entry><entry>DDDDDDD</entry><entry>AAAAA</entry></row><row><entry> </entry></row><row><entry>BBBAB</entry><entry>DDDDDDD</entry><entry>AAAAA</entry></row><row><entry> </entry></row><row><entry>BBBBA</entry><entry>DDDDDDD</entry><entry>AAAAA</entry></row><row><entry> </entry></row><row><entry>BBBBB</entry><entry>DDDDDDD</entry><entry>AAAAA</entry></row><row><entry> </entry></row><row><entry>AAAAA</entry><entry>DDDDDDD</entry><entry>BAAAA</entry></row><row><entry> </entry></row><row><entry>AAAAB</entry><entry>DDDDDDD</entry><entry>BAAAA</entry></row><row><entry> </entry></row><row><entry>AAABA</entry><entry>DDDDDDD</entry><entry>BAAAA</entry></row><row><entry> </entry></row><row><entry>AAABB</entry><entry>DDDDDDD</entry><entry>BAAAA</entry></row><row><entry> </entry></row><row><entry>AABAA</entry><entry>DDDDDDD</entry><entry>BAAAA</entry></row><row><entry> </entry></row><row><entry>AABAB</entry><entry>DDDDDDD</entry><entry>BAAAA</entry></row><row><entry> </entry></row><row><entry>AABBA</entry><entry>DDDDDDD</entry><entry>BAAAA</entry></row><row><entry> </entry></row><row><entry>AABBB</entry><entry>DDDDDDD</entry><entry>BAAAA</entry></row><row><entry> </entry></row><row><entry>ABAAA</entry><entry>DDDDDDD</entry><entry>BAAAA</entry></row><row><entry> </entry></row><row><entry>ABAAB</entry><entry>DDDDDDD</entry><entry>BAAAA</entry></row><row><entry> </entry></row><row><entry>ABABA</entry><entry>DDDDDDD</entry><entry>BAAAA</entry></row><row><entry> </entry></row><row><entry>ABABB</entry><entry>DDDDDDD</entry><entry>BAAAA</entry></row><row><entry> </entry></row><row><entry>ABBAA</entry><entry>DDDDDDD</entry><entry>BAAAA</entry></row><row><entry> </entry></row><row><entry>ABBAB</entry><entry>DDDDDDD</entry><entry>BAAAA</entry></row><row><entry> </entry></row><row><entry>ABBBA</entry><entry>DDDDDDD</entry><entry>BAAAA</entry></row><row><entry> </entry></row><row><entry>ABBBB</entry><entry>DDDDDDD</entry><entry>BAAAA</entry></row><row><entry> </entry></row><row><entry>BAAAA</entry><entry>DDDDDDD</entry><entry>BAAAA</entry></row><row><entry> </entry></row><row><entry>BAAAB</entry><entry>DDDDDDD</entry><entry>BAAAA</entry></row><row><entry> </entry></row><row><entry>BAABA</entry><entry>DDDDDDD</entry><entry>BAAAA</entry></row><row><entry> </entry></row><row><entry>BAABB</entry><entry>DDDDDDD</entry><entry>BAAAA</entry></row><row><entry> </entry></row><row><entry>BABAA</entry><entry>DDDDDDD</entry><entry>BAAAA</entry></row><row><entry> </entry></row><row><entry>BABAB</entry><entry>DDDDDDD</entry><entry>BAAAA</entry></row><row><entry> </entry></row><row><entry>BABBA</entry><entry>DDDDDDD</entry><entry>BAAAA</entry></row><row><entry> </entry></row><row><entry>BABBB</entry><entry>DDDDDDD</entry><entry>BAAAA</entry></row><row><entry> </entry></row><row><entry>BBAAA</entry><entry>DDDDDDD</entry><entry>BAAAA</entry></row><row><entry> </entry></row><row><entry>BBAAB</entry><entry>DDDDDDD</entry><entry>BAAAA</entry></row><row><entry> </entry></row><row><entry>BBABA</entry><entry>DDDDDDD</entry><entry>BAAAA</entry></row><row><entry> </entry></row><row><entry>BBABB</entry><entry>DDDDDDD</entry><entry>BAAAA</entry></row><row><entry> </entry></row><row><entry>BBBAA</entry><entry>DDDDDDD</entry><entry>BAAAA</entry></row><row><entry> </entry></row><row><entry>BBBAB</entry><entry>DDDDDDD</entry><entry>BAAAA</entry></row><row><entry> </entry></row><row><entry>BBBBA</entry><entry>DDDDDDD</entry><entry>BAAAA</entry></row><row><entry> </entry></row><row><entry>BBBBB</entry><entry>DDDDDDD</entry><entry>BAAAA</entry></row><row><entry> </entry></row><row><entry>AAAAA</entry><entry>DDDDDDD</entry><entry>BBAAA</entry></row><row><entry> </entry></row><row><entry>AAAAB</entry><entry>DDDDDDD</entry><entry>BBAAA</entry></row><row><entry> </entry></row><row><entry>AAABA</entry><entry>DDDDDDD</entry><entry>BBAAA</entry></row><row><entry> </entry></row><row><entry>AAABB</entry><entry>DDDDDDD</entry><entry>BBAAA</entry></row><row><entry> </entry></row><row><entry>AABAA</entry><entry>DDDDDDD</entry><entry>BBAAA</entry></row><row><entry> </entry></row><row><entry>AABAB</entry><entry>DDDDDDD</entry><entry>BBAAA</entry></row><row><entry> </entry></row><row><entry>AABBA</entry><entry>DDDDDDD</entry><entry>BBAAA</entry></row><row><entry> </entry></row><row><entry>AABBB</entry><entry>DDDDDDD</entry><entry>BBAAA</entry></row><row><entry> </entry></row><row><entry>ABAAA</entry><entry>DDDDDDD</entry><entry>BBAAA</entry></row><row><entry> </entry></row><row><entry>ABAAB</entry><entry>DDDDDDD</entry><entry>BBAAA</entry></row><row><entry> </entry></row><row><entry>ABABA</entry><entry>DDDDDDD</entry><entry>BBAAA</entry></row><row><entry> </entry></row><row><entry>ABABB</entry><entry>DDDDDDD</entry><entry>BBAAA</entry></row><row><entry> </entry></row><row><entry>ABBAA</entry><entry>DDDDDDD</entry><entry>BBAAA</entry></row><row><entry> </entry></row><row><entry>ABBAB</entry><entry>DDDDDDD</entry><entry>BBAAA</entry></row><row><entry> </entry></row><row><entry>ABBBA</entry><entry>DDDDDDD</entry><entry>BBAAA</entry></row><row><entry> </entry></row><row><entry>ABBBB</entry><entry>DDDDDDD</entry><entry>BBAAA</entry></row><row><entry> </entry></row><row><entry>BAAAA</entry><entry>DDDDDDD</entry><entry>BBAAA</entry></row><row><entry> </entry></row><row><entry>BAAAB</entry><entry>DDDDDDD</entry><entry>BBAAA</entry></row><row><entry> </entry></row><row><entry>BAABA</entry><entry>DDDDDDD</entry><entry>BBAAA</entry></row><row><entry> </entry></row><row><entry>BAABB</entry><entry>DDDDDDD</entry><entry>BBAAA</entry></row><row><entry> </entry></row><row><entry>BABAA</entry><entry>DDDDDDD</entry><entry>BBAAA</entry></row><row><entry> </entry></row><row><entry>BABAB</entry><entry>DDDDDDD</entry><entry>BBAAA</entry></row><row><entry> </entry></row><row><entry>BABBA</entry><entry>DDDDDDD</entry><entry>BBAAA</entry></row><row><entry> </entry></row><row><entry>BABBB</entry><entry>DDDDDDD</entry><entry>BBAAA</entry></row><row><entry> </entry></row><row><entry>BBAAA</entry><entry>DDDDDDD</entry><entry>BBAAA</entry></row><row><entry> </entry></row><row><entry>BBAAB</entry><entry>DDDDDDD</entry><entry>BBAAA</entry></row><row><entry> </entry></row><row><entry>BBABA</entry><entry>DDDDDDD</entry><entry>BBAAA</entry></row><row><entry> </entry></row><row><entry>BBABB</entry><entry>DDDDDDD</entry><entry>BBAAA</entry></row><row><entry> </entry></row><row><entry>BBBAA</entry><entry>DDDDDDD</entry><entry>BBAAA</entry></row><row><entry> </entry></row><row><entry>BBBAB</entry><entry>DDDDDDD</entry><entry>BBAAA</entry></row><row><entry> </entry></row><row><entry>BBBBA</entry><entry>DDDDDDD</entry><entry>BBAAA</entry></row><row><entry> </entry></row><row><entry>BBBBB</entry><entry>DDDDDDD</entry><entry>BBAAA</entry></row><row><entry> </entry></row><row><entry>AAAAA</entry><entry>DDDDDDD</entry><entry>BBBAA</entry></row><row><entry> </entry></row><row><entry>AAAAB</entry><entry>DDDDDDD</entry><entry>BBBAA</entry></row><row><entry> </entry></row><row><entry>AAABA</entry><entry>DDDDDDD</entry><entry>BBBAA</entry></row><row><entry> </entry></row><row><entry>AAABB</entry><entry>DDDDDDD</entry><entry>BBBAA</entry></row><row><entry> </entry></row><row><entry>AABAA</entry><entry>DDDDDDD</entry><entry>BBBAA</entry></row><row><entry> </entry></row><row><entry>AABAB</entry><entry>DDDDDDD</entry><entry>BBBAA</entry></row><row><entry> </entry></row><row><entry>AABBA</entry><entry>DDDDDDD</entry><entry>BBBAA</entry></row><row><entry> </entry></row><row><entry>AABBB</entry><entry>DDDDDDD</entry><entry>BBBAA</entry></row><row><entry> </entry></row><row><entry>ABAAA</entry><entry>DDDDDDD</entry><entry>BBBAA</entry></row><row><entry> </entry></row><row><entry>ABAAB</entry><entry>DDDDDDD</entry><entry>BBBAA</entry></row><row><entry> </entry></row><row><entry>ABABA</entry><entry>DDDDDDD</entry><entry>BBBAA</entry></row><row><entry> </entry></row><row><entry>ABABB</entry><entry>DDDDDDD</entry><entry>BBBAA</entry></row><row><entry> </entry></row><row><entry>ABBAA</entry><entry>DDDDDDD</entry><entry>BBBAA</entry></row><row><entry> </entry></row><row><entry>ABBAB</entry><entry>DDDDDDD</entry><entry>BBBAA</entry></row><row><entry> </entry></row><row><entry>ABBBA</entry><entry>DDDDDDD</entry><entry>BBBAA</entry></row><row><entry> </entry></row><row><entry>ABBBB</entry><entry>DDDDDDD</entry><entry>BBBAA</entry></row><row><entry> </entry></row><row><entry>BAAAA</entry><entry>DDDDDDD</entry><entry>BBBAA</entry></row><row><entry> </entry></row><row><entry>BAAAB</entry><entry>DDDDDDD</entry><entry>BBBAA</entry></row><row><entry> </entry></row><row><entry>BAABA</entry><entry>DDDDDDD</entry><entry>BBBAA</entry></row><row><entry> </entry></row><row><entry>BAABB</entry><entry>DDDDDDD</entry><entry>BBBAA</entry></row><row><entry> </entry></row><row><entry>BABAA</entry><entry>DDDDDDD</entry><entry>BBBAA</entry></row><row><entry> </entry></row><row><entry>BABAB</entry><entry>DDDDDDD</entry><entry>BBBAA</entry></row><row><entry> </entry></row><row><entry>BABBA</entry><entry>DDDDDDD</entry><entry>BBBAA</entry></row><row><entry> </entry></row><row><entry>BABBB</entry><entry>DDDDDDD</entry><entry>BBBAA</entry></row><row><entry> </entry></row><row><entry>BBAAA</entry><entry>DDDDDDD</entry><entry>BBBAA</entry></row><row><entry> </entry></row><row><entry>BBAAB</entry><entry>DDDDDDD</entry><entry>BBBAA</entry></row><row><entry> </entry></row><row><entry>BBABA</entry><entry>DDDDDDD</entry><entry>BBBAA</entry></row><row><entry> </entry></row><row><entry>BBABB</entry><entry>DDDDDDD</entry><entry>BBBAA</entry></row><row><entry> </entry></row><row><entry>BBBAA</entry><entry>DDDDDDD</entry><entry>BBBAA</entry></row><row><entry> </entry></row><row><entry>BBBAB</entry><entry>DDDDDDD</entry><entry>BBBAA</entry></row><row><entry> </entry></row><row><entry>BBBBA</entry><entry>DDDDDDD</entry><entry>BBBAA</entry></row><row><entry> </entry></row><row><entry>BBBBB</entry><entry>DDDDDDD</entry><entry>BBBAA</entry></row><row><entry> </entry></row><row><entry>AAAAA</entry><entry>DDDDDDD</entry><entry>BBBBA</entry></row><row><entry> </entry></row><row><entry>AAAAB</entry><entry>DDDDDDD</entry><entry>BBBBA</entry></row><row><entry> </entry></row><row><entry>AAABA</entry><entry>DDDDDDD</entry><entry>BBBBA</entry></row><row><entry> </entry></row><row><entry>AAABB</entry><entry>DDDDDDD</entry><entry>BBBBA</entry></row><row><entry> </entry></row><row><entry>AABAA</entry><entry>DDDDDDD</entry><entry>BBBBA</entry></row><row><entry> </entry></row><row><entry>AABAB</entry><entry>DDDDDDD</entry><entry>BBBBA</entry></row><row><entry> </entry></row><row><entry>AABBA</entry><entry>DDDDDDD</entry><entry>BBBBA</entry></row><row><entry> </entry></row><row><entry>AABBB</entry><entry>DDDDDDD</entry><entry>BBBBA</entry></row><row><entry> </entry></row><row><entry>ABAAA</entry><entry>DDDDDDD</entry><entry>BBBBA</entry></row><row><entry> </entry></row><row><entry>ABAAB</entry><entry>DDDDDDD</entry><entry>BBBBA</entry></row><row><entry> </entry></row><row><entry>ABABA</entry><entry>DDDDDDD</entry><entry>BBBBA</entry></row><row><entry> </entry></row><row><entry>ABABB</entry><entry>DDDDDDD</entry><entry>BBBBA</entry></row><row><entry> </entry></row><row><entry>ABBAA</entry><entry>DDDDDDD</entry><entry>BBBBA</entry></row><row><entry> </entry></row><row><entry>ABBAB</entry><entry>DDDDDDD</entry><entry>BBBBA</entry></row><row><entry> </entry></row><row><entry>ABBBA</entry><entry>DDDDDDD</entry><entry>BBBBA</entry></row><row><entry> </entry></row><row><entry>ABBBB</entry><entry>DDDDDDD</entry><entry>BBBBA</entry></row><row><entry> </entry></row><row><entry>BAAAA</entry><entry>DDDDDDD</entry><entry>BBBBA</entry></row><row><entry> </entry></row><row><entry>BAAAB</entry><entry>DDDDDDD</entry><entry>BBBBA</entry></row><row><entry> </entry></row><row><entry>BAABA</entry><entry>DDDDDDD</entry><entry>BBBBA</entry></row><row><entry> </entry></row><row><entry>BAABB</entry><entry>DDDDDDD</entry><entry>BBBBA</entry></row><row><entry> </entry></row><row><entry>BABAA</entry><entry>DDDDDDD</entry><entry>BBBBA</entry></row><row><entry> </entry></row><row><entry>BABAB</entry><entry>DDDDDDD</entry><entry>BBBBA</entry></row><row><entry> </entry></row><row><entry>BABBA</entry><entry>DDDDDDD</entry><entry>BBBBA</entry></row><row><entry> </entry></row><row><entry>BABBB</entry><entry>DDDDDDD</entry><entry>BBBBA</entry></row><row><entry> </entry></row><row><entry>BBAAA</entry><entry>DDDDDDD</entry><entry>BBBBA</entry></row><row><entry> </entry></row><row><entry>BBAAB</entry><entry>DDDDDDD</entry><entry>BBBBA</entry></row><row><entry> </entry></row><row><entry>BBABA</entry><entry>DDDDDDD</entry><entry>BBBBA</entry></row><row><entry> </entry></row><row><entry>BBABB</entry><entry>DDDDDDD</entry><entry>BBBBA</entry></row><row><entry> </entry></row><row><entry>BBBAA</entry><entry>DDDDDDD</entry><entry>BBBBA</entry></row><row><entry> </entry></row><row><entry>BBBAB</entry><entry>DDDDDDD</entry><entry>BBBBA</entry></row><row><entry> </entry></row><row><entry>BBBBA</entry><entry>DDDDDDD</entry><entry>BBBBA</entry></row><row><entry> </entry></row><row><entry>BBBBB</entry><entry>DDDDDDD</entry><entry>BBBBA</entry></row><row><entry> </entry></row><row><entry>AAAAA</entry><entry>DDDDDDD</entry><entry>BBBBB</entry></row><row><entry> </entry></row><row><entry>AAAAB</entry><entry>DDDDDDD</entry><entry>BBBBB</entry></row><row><entry> </entry></row><row><entry>AAABA</entry><entry>DDDDDDD</entry><entry>BBBBB</entry></row><row><entry> </entry></row><row><entry>AAABB</entry><entry>DDDDDDD</entry><entry>BBBBB</entry></row><row><entry> </entry></row><row><entry>AABAA</entry><entry>DDDDDDD</entry><entry>BBBBB</entry></row><row><entry> </entry></row><row><entry>AABAB</entry><entry>DDDDDDD</entry><entry>BBBBB</entry></row><row><entry> </entry></row><row><entry>AABBA</entry><entry>DDDDDDD</entry><entry>BBBBB</entry></row><row><entry> </entry></row><row><entry>AABBB</entry><entry>DDDDDDD</entry><entry>BBBBB</entry></row><row><entry> </entry></row><row><entry>ABAAA</entry><entry>DDDDDDD</entry><entry>BBBBB</entry></row><row><entry> </entry></row><row><entry>ABAAB</entry><entry>DDDDDDD</entry><entry>BBBBB</entry></row><row><entry> </entry></row><row><entry>ABABA</entry><entry>DDDDDDD</entry><entry>BBBBB</entry></row><row><entry> </entry></row><row><entry>ABABB</entry><entry>DDDDDDD</entry><entry>BBBBB</entry></row><row><entry> </entry></row><row><entry>ABBAA</entry><entry>DDDDDDD</entry><entry>BBBBB</entry></row><row><entry> </entry></row><row><entry>ABBAB</entry><entry>DDDDDDD</entry><entry>BBBBB</entry></row><row><entry> </entry></row><row><entry>ABBBA</entry><entry>DDDDDDD</entry><entry>BBBBB</entry></row><row><entry> </entry></row><row><entry>ABBBB</entry><entry>DDDDDDD</entry><entry>BBBBB</entry></row><row><entry> </entry></row><row><entry>BAAAA</entry><entry>DDDDDDD</entry><entry>BBBBB</entry></row><row><entry> </entry></row><row><entry>BAAAB</entry><entry>DDDDDDD</entry><entry>BBBBB</entry></row><row><entry> </entry></row><row><entry>BAABA</entry><entry>DDDDDDD</entry><entry>BBBBB</entry></row><row><entry> </entry></row><row><entry>BAABB</entry><entry>DDDDDDD</entry><entry>BBBBB</entry></row><row><entry> </entry></row><row><entry>BABAA</entry><entry>DDDDDDD</entry><entry>BBBBB</entry></row><row><entry> </entry></row><row><entry>BABAB</entry><entry>DDDDDDD</entry><entry>BBBBB</entry></row><row><entry> </entry></row><row><entry>BABBA</entry><entry>DDDDDDD</entry><entry>BBBBB</entry></row><row><entry> </entry></row><row><entry>BABBB</entry><entry>DDDDDDD</entry><entry>BBBBB</entry></row><row><entry> </entry></row><row><entry>BBAAA</entry><entry>DDDDDDD</entry><entry>BBBBB</entry></row><row><entry> </entry></row><row><entry>BBAAB</entry><entry>DDDDDDD</entry><entry>BBBBB</entry></row><row><entry> </entry></row><row><entry>BBABA</entry><entry>DDDDDDD</entry><entry>BBBBB</entry></row><row><entry> </entry></row><row><entry>BBABB</entry><entry>DDDDDDD</entry><entry>BBBBB</entry></row><row><entry> </entry></row><row><entry>BBBAA</entry><entry>DDDDDDD</entry><entry>BBBBB</entry></row><row><entry> </entry></row><row><entry>BBBAB</entry><entry>DDDDDDD</entry><entry>BBBBB</entry></row><row><entry> </entry></row><row><entry>BBBBA</entry><entry>DDDDDDD</entry><entry>BBBBB</entry></row><row><entry> </entry></row><row><entry>BBBBB</entry><entry>DDDDDDD</entry><entry>BBBBB</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0231" num="0000"><tables id="TABLE-US-00012" num="00012"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;12</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Certain&#x2003;Gapmer&#x2003;Nucleoside&#x2003;Motifs</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="70pt" align="left"/><colspec colname="2" colwidth="77pt" align="left"/><colspec colname="3" colwidth="70pt" align="left"/><tbody valign="top"><row><entry>5&#x2032;-wing&#x2003;region</entry><entry>Central&#x2003;gap&#x2003;region</entry><entry>3&#x2032;-wing&#x2003;region</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row><row><entry>AAAW</entry><entry>DDDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>AABW</entry><entry>DDDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABAW</entry><entry>DDDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABBW</entry><entry>DDDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>BAAW</entry><entry>DDDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>BABW</entry><entry>DDDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>BBAW</entry><entry>DDDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>BBBW</entry><entry>DDDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDDDDD</entry><entry>WAAA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDDDDD</entry><entry>WAAB</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDDDDD</entry><entry>WABA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDDDDD</entry><entry>WABB</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDDDDD</entry><entry>WBAA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDDDDD</entry><entry>WBAB</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDDDDD</entry><entry>WBBA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDDDDD</entry><entry>WBBB</entry></row><row><entry> </entry></row><row><entry>AAAWW</entry><entry>DDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>AABWW</entry><entry>DDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABAWW</entry><entry>DDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABBWW</entry><entry>DDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>BAAWW</entry><entry>DDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>BABWW</entry><entry>DDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>BBAWW</entry><entry>DDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>BBBWW</entry><entry>DDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDDDD</entry><entry>WWAAA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDDDD</entry><entry>WWAAB</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDDDD</entry><entry>WWABA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDDDD</entry><entry>WWABB</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDDDD</entry><entry>WWBAA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDDDD</entry><entry>WWBAB</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDDDD</entry><entry>WWBBA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDDDD</entry><entry>WWBBB</entry></row><row><entry> </entry></row><row><entry>AAAAW</entry><entry>DDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>AAABW</entry><entry>DDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>AABAW</entry><entry>DDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>AABBW</entry><entry>DDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABAAW</entry><entry>DDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABABW</entry><entry>DDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABBAW</entry><entry>DDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>ABBBW</entry><entry>DDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>BAAAW</entry><entry>DDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>BAABW</entry><entry>DDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>BABAW</entry><entry>DDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>BABBW</entry><entry>DDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>BBAAW</entry><entry>DDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>BBABW</entry><entry>DDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>BBBAW</entry><entry>DDDDDDD</entry><entry>BBA</entry></row><row><entry> </entry></row><row><entry>BBBBW</entry><entry>DDDDDDD</entry><entry>WAAAA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDDDD</entry><entry>WAAAB</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDDDD</entry><entry>WAABA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDDDD</entry><entry>WAABB</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDDDD</entry><entry>WABAA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDDDD</entry><entry>WABAB</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDDDD</entry><entry>WABBA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDDDD</entry><entry>WABBB</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDDDD</entry><entry>WBAAA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDDDD</entry><entry>WBAAB</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDDDD</entry><entry>WBABA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDDDD</entry><entry>WBABB</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDDDD</entry><entry>WBBAA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDDDD</entry><entry>WBBAB</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDDDD</entry><entry>WBBBA</entry></row><row><entry> </entry></row><row><entry>ABB</entry><entry>DDDDDDD</entry><entry>WBBBB</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables><br/>wherein each A is a modified nucleoside of a first type, each B is a modified nucleoside of a second type and each W is a modified nucleoside or nucleobase of either the first type, the second type or a third type, each D is a nucleoside comprising an unmodified 2&#x2032;deoxy sugar moiety and unmodified nucleobase, and <sup>N</sup>D is modified nucleoside comprising a modified nucleobase and an unmodified 2&#x2032;deoxy sugar moiety.</p><p id="p-0232" num="0366">In certain embodiments, each A comprises a modified sugar moiety. In certain embodiments, each A comprises a 2&#x2032;-substituted sugar moiety. In certain embodiments, each A comprises a 2&#x2032;-substituted sugar moiety selected from among F, ara-F, OCH<sub>3 </sub>and O(CH<sub>2</sub>)<sub>2</sub>&#x2014;OCH<sub>3</sub>. In certain embodiments, each A comprises a bicyclic sugar moiety. In certain embodiments, each A comprises a bicyclic sugar moiety selected from among cEt, cMOE, LNA, &#x3b1;-L-LNA, ENA and 2&#x2032;-thio LNA. In certain embodiments, each A comprises a modified nucleobase. In certain embodiments, each A comprises a modified nucleobase selected from among 2-thio-thymidine nucleoside and 5-propyne uridine nucleoside. In certain embodiments, each A comprises an HNA. In certain embodiments, each A comprises an F-HNA. In certain embodiments, each A comprises a 5&#x2032;-substituted sugar moiety selected from among 5&#x2032;-Me, and 5&#x2032;-(R)-Me.</p><p id="p-0233" num="0367">In certain embodiments, each B comprises a modified sugar moiety. In certain embodiments, each B comprises a 2&#x2032;-substituted sugar moiety. In certain embodiments, each B comprises a 2&#x2032;-substituted sugar moiety selected from among F, (ara)-F, OCH<sub>3 </sub>and O(CH<sub>2</sub>)<sub>2</sub>&#x2014;OCH<sub>3</sub>. In certain embodiments, each B comprises a bicyclic sugar moiety. In certain embodiments, each B comprises a bicyclic sugar moiety selected from among cEt, cMOE, LNA, &#x3b1;-L-LNA, ENA and 2&#x2032;-thio LNA. In certain embodiments, each B comprises a modified nucleobase. In certain embodiments, each B comprises a modified nucleobase selected from among 2-thio-thymidine nucleoside and 5-propyne urindine nucleoside. In certain embodiments, each B comprises an HNA. In certain embodiments, each B comprises an F-HNA. In certain embodiments, each B comprises a 5&#x2032;-substituted sugar moiety selected from among 5&#x2032;-Me, and 5&#x2032;-(R)-Me.</p><p id="p-0234" num="0368">In certain embodiments, each C comprises a modified sugar moiety. In certain embodiments, each C comprises a 2&#x2032;-substituted sugar moiety. In certain embodiments, each C comprises a 2&#x2032;-substituted sugar moiety selected from among F, (ara)-F, OCH<sub>3 </sub>and O(CH<sub>2</sub>)<sub>2</sub>&#x2014;OCH<sub>3</sub>. In certain embodiments, each C comprises a 5&#x2032;-substituted sugar moiety. In certain embodiments, each C comprises a 5&#x2032;-substituted sugar moiety selected from among 5&#x2032;-Me, and 5&#x2032;-(R)-Me. In certain embodiments, each C comprises a bicyclic sugar moiety. In certain embodiments, each C comprises a bicyclic sugar moiety selected from among cEt, cMOE, LNA, &#x3b1;-L-LNA, ENA and 2&#x2032;-thio LNA. In certain embodiments, each C comprises a modified nucleobase. In certain embodiments, each C comprises a modified nucleobase selected from among 2-thio-thymidine and 5-propyne uridine. In certain embodiments, each C comprises a 2-thio-thymidine nucleoside. In certain embodiments, each C comprises an HNA. In certain embodiments, each C comprises an F-HNA.</p><p id="p-0235" num="0369">In certain embodiments, each W comprises a modified sugar moiety. In certain embodiments, each W comprises a 2&#x2032;-substituted sugar moiety. In certain embodiments, each W comprises a 2&#x2032;-substituted sugar moiety selected from among F, (ara)-F, OCH<sub>3 </sub>and O(CH<sub>2</sub>)<sub>2</sub>&#x2014;OCH<sub>3</sub>. In certain embodiments, each W comprises a 5&#x2032;-substituted sugar moiety. In certain embodiments, each W comprises a 5&#x2032;-substituted sugar moiety selected from among 5&#x2032;-Me, and 5&#x2032;-(R)-Me. In certain embodiments, each W comprises a bicyclic sugar moiety. In certain embodiments, each W comprises a bicyclic sugar moiety selected from among cEt, cMOE, LNA, &#x3b1;-L-LNA, ENA and 2&#x2032;-thio LNA. In certain embodiments, each W comprises a sugar surrogate. In certain embodiments, each W comprises a sugar surrogate selected from among HNA and F-HNA. In certain embodiments, each W comprises a 2-thio-thymidine nucleoside.</p><p id="p-0236" num="0370">In certain embodiments, at least one of A or B comprises a bicyclic sugar moiety, and the other comprises a 2&#x2032;-substituted sugar moiety. In certain embodiments, one of A or B is an LNA nucleoside and the other of A or B comprises a 2&#x2032;-substituted sugar moiety. In certain embodiments, one of A or B is a cEt nucleoside and the other of A or B comprises a 2&#x2032;-substituted sugar moiety. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside and the other of A or B comprises a 2&#x2032;-substituted sugar moiety. In certain embodiments, one of A or B is an LNA nucleoside and the other of A or B comprises a 2&#x2032;-MOE sugar moiety. In certain embodiments, one of A or B is a cEt nucleoside and the other of A or B comprises a 2&#x2032;-MOE sugar moiety. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside and the other of A or B comprises a 2&#x2032;-MOE sugar moiety. In certain embodiments, one of A or B is an LNA nucleoside and the other of A or B comprises a 2&#x2032;-F sugar moiety. In certain embodiments, one of A or B is a cEt nucleoside and the other of A or B comprises a 2&#x2032;-F sugar moiety. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside and the other of A or B comprises a 2&#x2032;-F sugar moiety. In certain embodiments, one of A or B is an LNA nucleoside and the other of A or B comprises a 2&#x2032;-(ara)-F sugar moiety. In certain embodiments, one of A or B is a cEt nucleoside and the other of A or B comprises a 2&#x2032;-(ara)-F sugar moiety. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside and the other of A or B comprises a 2&#x2032;-(ara)-F sugar moiety.</p><p id="p-0237" num="0371">In certain embodiments, A comprises a bicyclic sugar moiety, and B comprises a 2&#x2032;-substituted sugar moiety. In certain embodiments, A is an LNA nucleoside and B comprises a 2&#x2032;-substituted sugar moiety. In certain embodiments, A is a cEt nucleoside and B comprises a 2&#x2032;-substituted sugar moiety. In certain embodiments, A is an &#x3b1;-L-LNA nucleoside and B comprises a 2&#x2032;-substituted sugar moiety.</p><p id="p-0238" num="0372">In certain embodiments, A comprises a bicyclic sugar moiety, and B comprises a 2&#x2032;-MOE sugar moiety. In certain embodiments, A is an LNA nucleoside and B comprises a 2&#x2032;-MOE sugar moiety. In certain embodiments, A is a cEt nucleoside and B comprises a 2&#x2032;-MOE sugar moiety. In certain embodiments, A is an &#x3b1;-L-LNA nucleoside and B comprises a 2&#x2032;-MOE sugar moiety.</p><p id="p-0239" num="0373">In certain embodiments, A comprises a bicyclic sugar moiety, and B comprises a 2&#x2032;-F sugar moiety. In certain embodiments, A is an LNA nucleoside and B comprises a 2&#x2032;-F sugar moiety. In certain embodiments, A is a cEt nucleoside and B comprises a 2&#x2032;-F sugar moiety. In certain embodiments, A is an &#x3b1;-L-LNA nucleoside and B comprises a 2&#x2032;-F sugar moiety.</p><p id="p-0240" num="0374">In certain embodiments, A comprises a bicyclic sugar moiety, and B comprises a 2&#x2032;-(ara)-F sugar moiety. In certain embodiments, A is an LNA nucleoside and B comprises a 2&#x2032;-(ara)-F sugar moiety. In certain embodiments, A is a cEt nucleoside and B comprises a 2&#x2032;-(ara)-F sugar moiety. In certain embodiments, A is an &#x3b1;-L-LNA nucleoside and B comprises a 2&#x2032;-(ara)-F sugar moiety.</p><p id="p-0241" num="0375">In certain embodiments, B comprises a bicyclic sugar moiety, and A comprises a 2&#x2032;-MOE sugar moiety. In certain embodiments, B is an LNA nucleoside and A comprises a 2&#x2032;-MOE sugar moiety. In certain embodiments, B is a cEt nucleoside and A comprises a 2&#x2032;-MOE sugar moiety. In certain embodiments, B is an &#x3b1;-L-LNA nucleoside and A comprises a 2&#x2032;-MOE sugar moiety.</p><p id="p-0242" num="0376">In certain embodiments, B comprises a bicyclic sugar moiety, and A comprises a 2&#x2032;-F sugar moiety. In certain embodiments, B is an LNA nucleoside and A comprises a 2&#x2032;-F sugar moiety. In certain embodiments, B is a cEt nucleoside and A comprises a 2&#x2032;-F sugar moiety. In certain embodiments, B is an &#x3b1;-L-LNA nucleoside and A comprises a 2&#x2032;-F sugar moiety.</p><p id="p-0243" num="0377">In certain embodiments, B comprises a bicyclic sugar moiety, and A comprises a 2&#x2032;-(ara)-F sugar moiety. In certain embodiments, B is an LNA nucleoside and A comprises a 2&#x2032;-(ara)-F sugar moiety. In certain embodiments, B is a cEt nucleoside and A comprises a 2&#x2032;-(ara)-F sugar moiety. In certain embodiments, B is an &#x3b1;-L-LNA nucleoside and A comprises a 2&#x2032;-(ara)-F sugar moiety.</p><p id="p-0244" num="0378">In certain embodiments, at least one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-substituted sugar moiety and W comprises a modified nucleobase. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-substituted sugar moiety, and W comprises a modified nucleobase. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-substituted sugar moiety, and C comprises a modified nucleobase. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-substituted sugar moiety, and W comprises a modified nucleobase.</p><p id="p-0245" num="0379">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a modified nucleobase. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a modified nucleobase. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a modified nucleobase. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a modified nucleobase.</p><p id="p-0246" num="0380">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a modified nucleobase. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a modified nucleobase. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a modified nucleobase. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a modified nucleobase.</p><p id="p-0247" num="0381">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a modified nucleobase. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a modified nucleobase. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a modified nucleobase. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a modified nucleobase.</p><p id="p-0248" num="0382">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-substituted sugar moiety, and W comprises a 2-thio-thymidine nucleobase. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-substituted sugar moiety, and W comprises a 2-thio-thymidine nucleobase. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-substituted sugar moiety, and W comprises a 2-thio-thymidine nucleobase. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-substituted sugar moiety, and W comprises a 2-thio-thymidine nucleobase.</p><p id="p-0249" num="0383">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a 2-thio-thymidine nucleobase. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a 2-thio-thymidine nucleobase. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a 2-thio-thymidine nucleobase. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a 2-thio-thymidine nucleobase.</p><p id="p-0250" num="0384">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a 2-thio-thymidine nucleobase. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a 2-thio-thymidine nucleobase. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a 2-thio-thymidine nucleobase. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a 2-thio-thymidine nucleobase.</p><p id="p-0251" num="0385">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a 2-thio-thymidine nucleobase. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a 2-thio-thymidine nucleobase. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a 2-thio-thymidine nucleobase. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises 2-thio-thymidine nucleobase.</p><p id="p-0252" num="0386">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a 5-propyne uridine nucleobase. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and C comprises a 5-propyne uridine nucleobase. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a 5-propyne uridine nucleobase. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and C comprises a 5-propyne uridine nucleobase.</p><p id="p-0253" num="0387">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a 5-propyne uridine nucleobase. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-F sugar moiety, and C comprises a 5-propyne uridine nucleobase. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a 5-propyne uridine nucleobase. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a 5-propyne uridine nucleobase.</p><p id="p-0254" num="0388">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a 5-propyne uridine nucleobase. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a 5-propyne uridine nucleobase. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a 5-propyne uridine nucleobase. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a 5-propyne uridine nucleobase.</p><p id="p-0255" num="0389">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a sugar surrogate. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a sugar surrogate. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a sugar surrogate. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a sugar surrogate.</p><p id="p-0256" num="0390">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a sugar surrogate. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a sugar surrogate. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a sugar surrogate. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a sugar surrogate.</p><p id="p-0257" num="0391">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a sugar surrogate. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a sugar surrogate. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a sugar surrogate. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises sugar surrogate.</p><p id="p-0258" num="0392">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a HNA sugar surrogate. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a HNA sugar surrogate. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a HNA sugar surrogate. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a HNA sugar surrogate.</p><p id="p-0259" num="0393">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a HNA sugar surrogate. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a HNA sugar surrogate. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a HNA sugar surrogate. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a sugar HNA surrogate.</p><p id="p-0260" num="0394">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a HNA sugar surrogate. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a HNA sugar surrogate. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a HNA sugar surrogate. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a HNA sugar surrogate.</p><p id="p-0261" num="0395">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a F-HNA sugar surrogate. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a F-HNA sugar surrogate. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a F-HNA sugar surrogate. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a F-HNA sugar surrogate.</p><p id="p-0262" num="0396">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a F-HNA sugar surrogate. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a F-HNA sugar surrogate. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a F-HNA sugar surrogate. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a F-HNA sugar surrogate.</p><p id="p-0263" num="0397">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a F-HNA sugar surrogate. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a F-HNA sugar surrogate. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a F-HNA sugar surrogate. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a F-HNA sugar surrogate.</p><p id="p-0264" num="0398">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a 5&#x2032;-Me DNA sugar moiety. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a 5&#x2032;-Me DNA sugar moiety. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a 5&#x2032;-Me DNA sugar moiety. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a 5&#x2032;-Me DNA sugar moiety.</p><p id="p-0265" num="0399">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a 5&#x2032;-Me DNA sugar moiety. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a 5&#x2032;-Me DNA sugar moiety. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a 5&#x2032;-Me DNA sugar moiety. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a 5&#x2032;-Me DNA sugar moiety.</p><p id="p-0266" num="0400">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a 5&#x2032;-Me DNA sugar moiety. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a 5&#x2032;-Me DNA sugar moiety. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a 5&#x2032;-Me DNA sugar moiety. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a 5&#x2032;-Me DNA sugar moiety.</p><p id="p-0267" num="0401">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a 5&#x2032;-(R)-Me DNA sugar moiety. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a 5&#x2032;-(R)-Me DNA sugar moiety. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a 5&#x2032;-(R)-Me DNA sugar moiety. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a 5&#x2032;-(R)-Me DNA sugar moiety.</p><p id="p-0268" num="0402">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a 5&#x2032;-(R)-Me DNA sugar moiety. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a 5&#x2032;-(R)-Me DNA sugar moiety. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a 5&#x2032;-(R)-Me DNA sugar moiety. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a 5&#x2032;-(R)-Me DNA sugar moiety.</p><p id="p-0269" num="0403">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a 5&#x2032;-(R)-Me DNA sugar moiety. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a 5&#x2032;-(R)-Me DNA sugar moiety. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a 5&#x2032;-(R)-Me DNA sugar moiety. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a 5&#x2032;-(R)-Me DNA sugar moiety.</p><p id="p-0270" num="0404">In certain embodiments, at least two of A, B or W comprises a 2&#x2032;-substituted sugar moiety, and the other comprises a bicyclic sugar moiety. In certain embodiments, at least two of A, B or W comprises a bicyclic sugar moiety, and the other comprises a 2&#x2032;-substituted sugar moiety. In certain embodiments, a gapmer has a sugar motif other than: E-K-K-(D)<sub>9</sub>-K-K-E; E-E-E-E-K-(D)<sub>9</sub>-E-E-E-E-E; E-K-K-K-(D)<sub>9</sub>-K-K-K-E; K-E-E-K-(D)<sub>9</sub>-K-E-E-K; K-D-D-K-(D)<sub>9</sub>-K-D-D-K; K-E-K-E-K-(D)<sub>9</sub>-K-E-K-E-K; K-D-K-D-K-(D)<sub>9</sub>-K-D-K-D-K; E-K-E-K-(D)<sub>9</sub>-K-E-K-E; E-E-E-E-E-K-(D)<sub>9</sub>-E-E-E-E-E; or E-K-E-K-E-(D)<sub>9</sub>-E-K-E-K-E, E-E-E-K-K-(D)<sub>7</sub>-E-E-K, E-K-E-K-K-K-(D)<sub>7</sub>-K-E-K-E, E-K-E-K-E-K-(D)<sub>7</sub>-K-E-K-E, wherein K is a nucleoside comprising a cEt sugar moiety and E is a nucleoside comprising a 2&#x2032;-MOE sugar moiety.</p><p id="p-0271" num="0405">In certain embodiments a gapmer comprises a A-(D)<sub>4</sub>-A-(D)<sub>4</sub>-A-(D)<sub>4</sub>-AA motif. In certain embodiments a gapmer comprises a B-(D)<sub>4</sub>-A-(D)<sub>4</sub>-A-(D)<sub>4</sub>-AA motif. In certain embodiments a gapmer comprises a A-(D)<sub>4</sub>-B-(D)<sub>4</sub>-A-(D)<sub>4</sub>-AA motif. In certain embodiments a gapmer comprises a A-(D)<sub>4</sub>-A-(D)<sub>4</sub>-B-(D)<sub>4</sub>-AA motif. In certain embodiments a gapmer comprises a A-(D)<sub>4</sub>-A-(D)<sub>4</sub>-A-(D)<sub>4</sub>-BA motif. In certain embodiments a gapmer comprises a A-(D)<sub>4</sub>-A-(D)<sub>4</sub>-A-(D)<sub>4</sub>-BB motif. In certain embodiments a gapmer comprises a K-(D)<sub>4</sub>-K-(D)<sub>4</sub>-K-(D)<sub>4</sub>-K-E motif</p><p id="p-0272" num="0406">xi. Certain Internucleoside Linkage Motifs</p><p id="p-0273" num="0407">In certain embodiments, oligonucleotides comprise modified internucleoside linkages arranged along the oligonucleotide or region thereof in a defined pattern or modified internucleoside linkage motif. In certain embodiments, internucleoside linkages are arranged in a gapped motif, as described above for nucleoside motif. In such embodiments, the internucleoside linkages in each of two wing regions are different from the internucleoside linkages in the gap region. In certain embodiments the internucleoside linkages in the wings are phosphodiester and the internucleoside linkages in the gap are phosphorothioate. The nucleoside motif is independently selected, so such oligonucleotides having a gapped internucleoside linkage motif may or may not have a gapped nucleoside motif and if it does have a gapped nucleoside motif, the wing and gap lengths may or may not be the same.</p><p id="p-0274" num="0408">In certain embodiments, oligonucleotides comprise a region having an alternating internucleoside linkage motif. In certain embodiments, oligonucleotides of the present invention comprise a region of uniformly modified internucleoside linkages. In certain such embodiments, the oligonucleotide comprises a region that is uniformly linked by phosphorothioate internucleoside linkages. In certain embodiments, the oligonucleotide is uniformly linked by phosphorothioate. In certain embodiments, each internucleoside linkage of the oligonucleotide is selected from phosphodiester and phosphorothioate. In certain embodiments, each internucleoside linkage of the oligonucleotide is selected from phosphodiester and phosphorothioate and at least one internucleoside linkage is phosphorothioate.</p><p id="p-0275" num="0409">In certain embodiments, the oligonucleotide comprises at least 6 phosphorothioate internucleoside linkages. In certain embodiments, the oligonucleotide comprises at least 8 phosphorothioate internucleoside linkages. In certain embodiments, the oligonucleotide comprises at least 10 phosphorothioate internucleoside linkages. In certain embodiments, the oligonucleotide comprises at least one block of at least 6 consecutive phosphorothioate internucleoside linkages. In certain embodiments, the oligonucleotide comprises at least one block of at least 8 consecutive phosphorothioate internucleoside linkages. In certain embodiments, the oligonucleotide comprises at least one block of at least 10 consecutive phosphorothioate internucleoside linkages. In certain embodiments, the oligonucleotide comprises at least block of at least one 12 consecutive phosphorothioate internucleoside linkages. In certain such embodiments, at least one such block is located at the 3&#x2032; end of the oligonucleotide. In certain such embodiments, at least one such block is located within 3 nucleosides of the 3&#x2032; end of the oligonucleotide.</p><p id="p-0276" num="0410">In certain embodiments, oligonucleotides comprise one or more methylphosponate linkages. In certain embodiments, oligonucleotides having a gapmer nucleoside motif comprise a linkage motif comprising all phosphorothioate linkages except for one or two methylphosponate linkages. In certain embodiments, one methylphosponate linkage is in the central gap of an oligonucleotide having a gapmer nucleoside motif.</p><p id="p-0277" num="0411">xii. Certain Modification Motifs</p><p id="p-0278" num="0412">Modification motifs define oligonucleotides by nucleoside motif (sugar motif and nucleobase motif) and linkage motif. For example, certain oligonucleotides have the following modification motif:<ul id="ul0003" list-style="none">    <li id="ul0003-0001" num="0000">    <ul id="ul0004" list-style="none">        <li id="ul0004-0001" num="0413">A<sub>s</sub>A<sub>s</sub>A<sub>s</sub>D<sub>s</sub>D<sub>s</sub>D<sub>s</sub>D<sub>s</sub>(<sup>N</sup>D)<sub>s</sub>D<sub>s</sub>D<sub>s</sub>D<sub>s</sub>D<sub>s</sub>B<sub>s</sub>B<sub>s</sub>B;<br/>wherein each A is a modified nucleoside comprising a 2&#x2032;-substituted sugar moiety; each D is an unmodified 2&#x2032;-deoxynucleoside; each B is a modified nucleoside comprising a bicyclic sugar moiety; <sup>N</sup>D is a modified nucleoside comprising a modified nucleobase; and s is a phosphorothioate internucleoside linkage. Thus, the sugar motif is a gapmer motif. The nucleobase modification motif is a single modified nucleobase at 8<sup>th </sup>nucleoside from the 5&#x2032;-end. Combining the sugar motif and the nucleobase modification motif, the nucleoside motif is an interrupted gapmer where the gap of the sugar modified gapmer is interrupted by a nucleoside comprising a modified nucleobase. The linkage motif is uniform phosphorothioate. The following non-limiting Table further illustrates certain modification motifs:</li>    </ul>    </li></ul></p><p id="p-0279" num="0000"><tables id="TABLE-US-00013" num="00013"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;13</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Certain&#x2003;Modification&#x2003;Motifs</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="56pt" align="left"/><colspec colname="2" colwidth="91pt" align="left"/><colspec colname="3" colwidth="70pt" align="left"/><tbody valign="top"><row><entry>5&#x2032;-wing</entry><entry/><entry/></row><row><entry>region</entry><entry>Central&#x2003;gap&#x2003;region</entry><entry>3&#x2032;-wing&#x2003;region</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row><row><entry>B<sub>s</sub>B<sub>s</sub></entry><entry><sub>s</sub>D<sub>s</sub>D<sub>s</sub>D<sub>s</sub>D<sub>s</sub>D<sub>s</sub>D<sub>s</sub>D<sub>s</sub>D<sub>s</sub>D<sub>s</sub></entry><entry>A<sub>s</sub>A<sub>s</sub>A<sub>s</sub>A<sub>s</sub>A<sub>s</sub>A<sub>s</sub>A<sub>s</sub>A</entry></row><row><entry> </entry></row><row><entry>AsBsBs</entry><entry>DsDsDsDsDsDsDsDsDs</entry><entry>BsBsA</entry></row><row><entry> </entry></row><row><entry>AsBsBs</entry><entry>DsDsDsDs(<sup>N</sup>D)sDsDsDs</entry><entry>BsBsA</entry></row><row><entry/><entry>Ds</entry><entry/></row><row><entry> </entry></row><row><entry>AsBsBs</entry><entry>DsDsDsDsAsDsDsDsDs</entry><entry>BsBsA</entry></row><row><entry> </entry></row><row><entry>AsBsBs</entry><entry>DsDsDsDsBsDsDsDsDs</entry><entry>BsBsA</entry></row><row><entry> </entry></row><row><entry>AsBsBs</entry><entry>DsDsDsDsWsDsDsDsDs</entry><entry>BsBsA</entry></row><row><entry> </entry></row><row><entry>AsBsBsBs</entry><entry>DsDsDsDsDsDsDsDsDs</entry><entry>BsBsAsBsB</entry></row><row><entry> </entry></row><row><entry>AsBsBs</entry><entry>DsDsDsDsDsDsDsDsDs</entry><entry>BsBsAsBsB</entry></row><row><entry> </entry></row><row><entry>BsBsAsBsBs</entry><entry>DsDsDsDsDsDsDsDsDs</entry><entry>BsBsA</entry></row><row><entry> </entry></row><row><entry>AsBsBs</entry><entry>DsDsDsDsDsDsDsDsDs</entry><entry>BsBsAsBsBsBsB</entry></row><row><entry> </entry></row><row><entry>AsAsBsAsAs</entry><entry>DsDsDsDsDsDsDsDsDs</entry><entry>BsBsA</entry></row><row><entry> </entry></row><row><entry>AsAsAsBsAsAs</entry><entry>DsDsDsDsDsDsDsDsDs</entry><entry>BsBsA</entry></row><row><entry> </entry></row><row><entry>AsAsBsAsAs</entry><entry>DsDsDsDsDsDsDsDsDs</entry><entry>AsAsBsAsA</entry></row><row><entry> </entry></row><row><entry>AsAsAsBsAsAs</entry><entry>DsDsDsDsDsDsDsDsDs</entry><entry>AsAsBsAsAsA</entry></row><row><entry> </entry></row><row><entry>AsAsAsAsBsAs</entry><entry>DsDsDsDsDsDsDsDsDs</entry><entry>BsBsA</entry></row><row><entry>As</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>AsBsAsBs</entry><entry>DsDsDsDsDsDsDsDsDs</entry><entry>BsAsBsA</entry></row><row><entry> </entry></row><row><entry>AsBsAsBs</entry><entry>DsDsDsDsDsDsDsDsDs</entry><entry>AsAsBsAsAs</entry></row><row><entry> </entry></row><row><entry>AsBsBs</entry><entry>DsDsDsDsDsDsDsDsDs</entry><entry>BsAsBsA</entry></row><row><entry> </entry></row><row><entry>BsBsAsBsBsBs</entry><entry>DsDsDsDsDsDsDsDsDs</entry><entry>BsAsBsA</entry></row><row><entry>B</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>AsAsAsAsAs</entry><entry>DsDsDsDsDsDsDsDsDs</entry><entry>AsAsAsAsA</entry></row><row><entry> </entry></row><row><entry>AsAsAsAsAs</entry><entry>DsDsDsDsDsDsDs</entry><entry>AsAsAsAsA</entry></row><row><entry> </entry></row><row><entry>AsAsAsAsAs</entry><entry>DsDsDsDsDsDsDsDsDs</entry><entry>BsBsAsBsBsBsB</entry></row><row><entry> </entry></row><row><entry>AsAsAsBsBs</entry><entry>DsDsDsDsDsDsDs</entry><entry>BsBsA</entry></row><row><entry> </entry></row><row><entry>AsBsAsBs</entry><entry>DsDsDsDsDsDsDsDs</entry><entry>BsBsA</entry></row><row><entry> </entry></row><row><entry>AsBsAsBs</entry><entry>DsDsDsDsDsDsDs</entry><entry>AsAsAsBsBs</entry></row><row><entry> </entry></row><row><entry>AsAsAsAsBs</entry><entry>DsDsDsDsDsDsDs</entry><entry>BsAsAsAsA</entry></row><row><entry> </entry></row><row><entry>BsBs</entry><entry>DsDsDsDsDsDsDsDs</entry><entry>AsA</entry></row><row><entry> </entry></row><row><entry>AsAs</entry><entry>DsDsDsDsDsDsDs</entry><entry>AsAsAsAsAsAsAsA</entry></row><row><entry> </entry></row><row><entry>AsAsAs</entry><entry>DsDsDsDsDsDsDs</entry><entry>AsAsAsAsAsAsA</entry></row><row><entry> </entry></row><row><entry>AsAsAs</entry><entry>DsDsDsDsDsDsDs</entry><entry>AsAsAsAsAsA</entry></row><row><entry> </entry></row><row><entry>AsBs</entry><entry>DsDsDsDsDsDsDs</entry><entry>BsBsBsA</entry></row><row><entry> </entry></row><row><entry>AsBsBsBs</entry><entry>DsDsDsDsDsDsDsDsDs</entry><entry>BsA</entry></row><row><entry> </entry></row><row><entry>AsBs</entry><entry>DsDsDsDsDsDsDsDsDs</entry><entry>BsBsBsA</entry></row><row><entry> </entry></row><row><entry>AsAsAsBsBs</entry><entry>DsDsDs(<sup>N</sup>D)sDsDsDs</entry><entry>BsBsAsAsA</entry></row><row><entry> </entry></row><row><entry>AsAsAsBsBs</entry><entry>DsDsDsAsDsDsDs</entry><entry>BsBsAsAsA</entry></row><row><entry> </entry></row><row><entry>AsAsAsBsBs</entry><entry>DsDsDsBsDsDsDs</entry><entry>BsBsAsAsA</entry></row><row><entry> </entry></row><row><entry>AsAsAsAsBs</entry><entry>DsDsDsDsDsDsDs</entry><entry>BsAsAsAsA</entry></row><row><entry> </entry></row><row><entry>AsAsBsBsBs</entry><entry>DsDsDsDsDsDsDs</entry><entry>BsBsBsAsA</entry></row><row><entry> </entry></row><row><entry>AsAsAsAsBs</entry><entry>DsDsDsDsDsDsDs</entry><entry>AsAsAsAsAs</entry></row><row><entry> </entry></row><row><entry>AsAsAsBsBs</entry><entry>DsDsDsDsDsDsDs</entry><entry>AsAsAsAsAs</entry></row><row><entry> </entry></row><row><entry>AsAsBsBsBs</entry><entry>DsDsDsDsDsDsDs</entry><entry>AsAsAsAsAs</entry></row><row><entry> </entry></row><row><entry>AsAsAsAsAs</entry><entry>DsDsDsDsDsDsDs</entry><entry>BsAsAsAsAs</entry></row><row><entry> </entry></row><row><entry>AsAsAsAsAs</entry><entry>DsDsDsDsDsDsDs</entry><entry>BsBsAsAsAs</entry></row><row><entry> </entry></row><row><entry>AsAsAsAsAs</entry><entry>DsDsDsDsDsDsDs</entry><entry>BsBsBsAsAs</entry></row><row><entry> </entry></row><row><entry>AsBsBs</entry><entry>DsDsDsDs(<sup>N</sup>)s(<sup>N</sup>)sDsDs</entry><entry>BsBsA</entry></row><row><entry/><entry>Ds</entry><entry/></row><row><entry> </entry></row><row><entry>AsBsBs</entry><entry>Ds(<sup>N</sup>D)s(<sup>N</sup>D)sDs(<sup>N</sup>D)s</entry><entry>BsBsA</entry></row><row><entry/><entry>(<sup>N</sup>D)sDs(<sup>N</sup>D)s(<sup>N</sup>D)s</entry><entry/></row><row><entry> </entry></row><row><entry>AsBsBs</entry><entry>Ds(<sup>N</sup>D)sDsDsDsDsDsDs</entry><entry>BsBsA</entry></row><row><entry/><entry>Ds</entry><entry/></row><row><entry> </entry></row><row><entry>AsBsBs</entry><entry>DsDs(<sup>N</sup>D)sDsDsDsDsDs</entry><entry>BsBsA</entry></row><row><entry/><entry>Ds</entry><entry/></row><row><entry> </entry></row><row><entry>AsBsBs</entry><entry>Ds(<sup>N</sup>D)s(<sup>N</sup>D)sDsDsDsDs</entry><entry>BsBsA</entry></row><row><entry/><entry>DsDs</entry><entry/></row><row><entry> </entry></row><row><entry>AsBsBs</entry><entry>DsDs(D)zDsDsDsDsDsDs</entry><entry>BsBsA</entry></row><row><entry> </entry></row><row><entry>AsBsBs</entry><entry>Ds(D)zDsDsDsDsDsDsDs</entry><entry>BsBsA</entry></row><row><entry> </entry></row><row><entry>AsBsBs</entry><entry>(D)zDsDsDsDsDsDsDsDs</entry><entry>BsBsA</entry></row><row><entry> </entry></row><row><entry>AsBsBs</entry><entry>DsDsAsDsDsDsDsDsDs</entry><entry>BsBsA</entry></row><row><entry> </entry></row><row><entry>AsBsBs</entry><entry>DsDsBsDsDsDsDsDsDs</entry><entry>BsBsA</entry></row><row><entry> </entry></row><row><entry>AsBsBs</entry><entry>AsDsDsDsDsDsDsDsDs</entry><entry>BsBsA</entry></row><row><entry> </entry></row><row><entry>AsBsBs</entry><entry>BsDsDsDsDsDsDsDsDs</entry><entry>BsBsA</entry></row><row><entry> </entry></row><row><entry>AsBsAsBs</entry><entry>DsDs(D)zDsDsDsDsDsDs</entry><entry>BsBsBsAsAs</entry></row><row><entry> </entry></row><row><entry>AsAsAsBsBs</entry><entry>DsDs(<sup>N</sup>D)sDsDsDsDsDs</entry><entry>AsA</entry></row><row><entry/><entry>Ds</entry><entry/></row><row><entry> </entry></row><row><entry>AsBsBsBs</entry><entry>Ds(D)zDsDsDsDsDsDsDs</entry><entry>AsAsAsBsBs</entry></row><row><entry> </entry></row><row><entry>AsBsBs</entry><entry>DsDsDsDsDsDsDsDs(D)z</entry><entry>BsBsA</entry></row><row><entry> </entry></row><row><entry>AsAsBsBsBs</entry><entry>DsDsDsAsDsDsDs</entry><entry>BsBsBsAsA</entry></row><row><entry> </entry></row><row><entry>AsAsBsBsBs</entry><entry>DsDsDsBsDsDsDs</entry><entry>BsBsBsAsA</entry></row><row><entry> </entry></row><row><entry>AsBsAsBs</entry><entry>DsDsDsAsDsDsDs</entry><entry>BsBsAsBsBsBsB</entry></row><row><entry> </entry></row><row><entry>AsBsBsBs</entry><entry>DsDsDsDs(D)zDsDsDsDs</entry><entry>BsA</entry></row><row><entry> </entry></row><row><entry>AsAsBsBsBs</entry><entry>DsDsAsAsDsDsDs</entry><entry>BsBsA</entry></row><row><entry> </entry></row><row><entry>AsBsBs</entry><entry>DsDsDsDs(D)zDsDsDsDs</entry><entry>BsBsBsA</entry></row><row><entry> </entry></row><row><entry>BsBs</entry><entry>DsDs(<sup>N</sup>D)sDs(<sup>N</sup>D)sDsDs</entry><entry>BsBsAsBsBsBsB</entry></row><row><entry/><entry>DsDs</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables><br/>wherein each A and B are nucleosides comprising differently modified sugar moieties, each D is a nucleoside comprising an unmodified 2&#x2032;deoxy sugar moiety, each W is a modified nucleoside of either the first type, the second type or a third type, each <sup>N</sup>D is a modified nucleoside comprising a modified nucleobase, s is a phosphorothioate internucleoside linkage, and z is a non-phosphorothioate internucleoside linkage.</p><p id="p-0280" num="0414">In certain embodiments, each A comprises a modified sugar moiety. In certain embodiments, each A comprises a 2&#x2032;-substituted sugar moiety. In certain embodiments, each A comprises a 2&#x2032;-substituted sugar moiety selected from among F, (ara)-F, OCH<sub>3 </sub>and O(CH<sub>2</sub>)<sub>2</sub>&#x2014;OCH<sub>3</sub>. In certain embodiments, each A comprises a bicyclic sugar moiety. In certain embodiments, each A comprises a bicyclic sugar moiety selected from among cEt, cMOE, LNA, &#x3b1;-L-LNA, ENA and 2&#x2032;-thio LNA. In certain embodiments, each A comprises a modified nucleobase. In certain embodiments, each A comprises a modified nucleobase selected from among 2-thio-thymidine nucleoside and 5-propyne uridine nucleoside. In certain embodiments, each B comprises a modified sugar moiety. In certain embodiments, each B comprises a 2&#x2032;-substituted sugar moiety. In certain embodiments, each B comprises a 2&#x2032;-substituted sugar moiety selected from among F, (ara)-F, OCH<sub>3 </sub>and O(CH<sub>2</sub>)<sub>2</sub>&#x2014;OCH<sub>3</sub>. In certain embodiments, each B comprises a bicyclic sugar moiety. In certain embodiments, each B comprises a bicyclic sugar moiety selected from among cEt, cMOE, LNA, &#x3b1;-L-LNA, ENA and 2&#x2032;-thio LNA. In certain embodiments, each B comprises a modified nucleobase. In certain embodiments, each B comprises a modified nucleobase selected from among 2-thio-thymidine nucleoside and 5-propyne urindine nucleoside. In certain embodiments, each A comprises an HNA. In certain embodiments, each A comprises an F-HNA.</p><p id="p-0281" num="0415">In certain embodiments, each W comprises a modified sugar moiety. In certain embodiments, each W comprises a 2&#x2032;-substituted sugar moiety. In certain embodiments, each W comprises a 2&#x2032;-substituted sugar moiety selected from among F, (ara)-F, OCH<sub>3 </sub>and O(CH<sub>2</sub>)<sub>2</sub>&#x2014;OCH<sub>3</sub>. In certain embodiments, each W comprises a 5&#x2032;-substituted sugar moiety. In certain embodiments, each W comprises a 5&#x2032;-substituted sugar moiety selected from among 5&#x2032;-Me, and 5&#x2032;-(R)-Me. In certain embodiments, each W comprises a bicyclic sugar moiety. In certain embodiments, each W comprises a bicyclic sugar moiety selected from among cEt, cMOE, LNA, &#x3b1;-L-LNA, ENA and 2&#x2032;-thio LNA. In certain embodiments, each W comprises a sugar surrogate. In certain embodiments, each W comprises a sugar surrogate selected from among HNA and F-HNA.</p><p id="p-0282" num="0416">In certain embodiments, at least one of A or B comprises a bicyclic sugar moiety, and the other comprises a 2&#x2032;-substituted sugar moiety. In certain embodiments, one of A or B is an LNA nucleoside and the other of A or B comprises a 2&#x2032;-substituted sugar moiety. In certain embodiments, one of A or B is a cEt nucleoside and the other of A or B comprises a 2&#x2032;-substituted sugar moiety. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside and the other of A or B comprises a 2&#x2032;-substituted sugar moiety. In certain embodiments, one of A or B is an LNA nucleoside and the other of A or B comprises a 2&#x2032;-MOE sugar moiety. In certain embodiments, one of A or B is a cEt nucleoside and the other of A or B comprises a 2&#x2032;-MOE sugar moiety. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside and the other of A or B comprises a 2&#x2032;-MOE sugar moiety. In certain embodiments, one of A or B is an LNA nucleoside and the other of A or B comprises a 2&#x2032;-F sugar moiety. In certain embodiments, one of A or B is a cEt nucleoside and the other of A or B comprises a 2&#x2032;-F sugar moiety. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside and the other of A or B comprises a 2&#x2032;-F sugar moiety. In certain embodiments, one of A or B is an LNA nucleoside and the other of A or B comprises a 2&#x2032;-(ara)-F sugar moiety. In certain embodiments, one of A or B is a cEt nucleoside and the other of A or B comprises a 2&#x2032;-(ara)-F sugar moiety. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside and the other of A or B comprises a 2&#x2032;-(ara)-F sugar moiety.</p><p id="p-0283" num="0417">In certain embodiments, A comprises a bicyclic sugar moiety, and B comprises a 2&#x2032;-substituted sugar moiety. In certain embodiments, A is an LNA nucleoside and B comprises a 2&#x2032;-substituted sugar moiety. In certain embodiments, A is a cEt nucleoside and B comprises a 2&#x2032;-substituted sugar moiety. In certain embodiments, A is an &#x3b1;-L-LNA nucleoside and B comprises a 2&#x2032;-substituted sugar moiety.</p><p id="p-0284" num="0418">In certain embodiments, A comprises a bicyclic sugar moiety, and B comprises a 2&#x2032;-MOE sugar moiety. In certain embodiments, A is an LNA nucleoside and B comprises a 2&#x2032;-MOE sugar moiety. In certain embodiments, A is a cEt nucleoside and B comprises a 2&#x2032;-MOE sugar moiety. In certain embodiments, A is an &#x3b1;-L-LNA nucleoside and B comprises a 2&#x2032;-MOE sugar moiety.</p><p id="p-0285" num="0419">In certain embodiments, A comprises a bicyclic sugar moiety, and B comprises a 2&#x2032;-F sugar moiety. In certain embodiments, A is an LNA nucleoside and B comprises a 2&#x2032;-F sugar moiety. In certain embodiments, A is a cEt nucleoside and B comprises a 2&#x2032;-F sugar moiety. In certain embodiments, A is an &#x3b1;-L-LNA nucleoside and B comprises a 2&#x2032;-F sugar moiety.</p><p id="p-0286" num="0420">In certain embodiments, A comprises a bicyclic sugar moiety, and B comprises a 2&#x2032;-(ara)-F sugar moiety. In certain embodiments, A is an LNA nucleoside and B comprises a 2&#x2032;-(ara)-F sugar moiety. In certain embodiments, A is a cEt nucleoside and B comprises a 2&#x2032;-(ara)-F sugar moiety. In certain embodiments, A is an &#x3b1;-L-LNA nucleoside and B comprises a 2&#x2032;-(ara)-F sugar moiety.</p><p id="p-0287" num="0421">In certain embodiments, B comprises a bicyclic sugar moiety, and A comprises a 2&#x2032;-MOE sugar moiety. In certain embodiments, B is an LNA nucleoside and A comprises a 2&#x2032;-MOE sugar moiety. In certain embodiments, B is a cEt nucleoside and A comprises a 2&#x2032;-MOE sugar moiety. In certain embodiments, B is an &#x3b1;-L-LNA nucleoside and A comprises a 2&#x2032;-MOE sugar moiety.</p><p id="p-0288" num="0422">In certain embodiments, B comprises a bicyclic sugar moiety, and A comprises a 2&#x2032;-F sugar moiety. In certain embodiments, B is an LNA nucleoside and A comprises a 2&#x2032;-F sugar moiety. In certain embodiments, B is a cEt nucleoside and A comprises a 2&#x2032;-F sugar moiety. In certain embodiments, B is an &#x3b1;-L-LNA nucleoside and A comprises a 2&#x2032;-F sugar moiety.</p><p id="p-0289" num="0423">In certain embodiments, B comprises a bicyclic sugar moiety, and A comprises a 2&#x2032;-(ara)-F sugar moiety. In certain embodiments, B is an LNA nucleoside and A comprises a 2&#x2032;-(ara)-F sugar moiety. In certain embodiments, B is a cEt nucleoside and A comprises a 2&#x2032;-(ara)-F sugar moiety. In certain embodiments, B is an &#x3b1;-L-LNA nucleoside and A comprises a 2&#x2032;-(ara)-F sugar moiety.</p><p id="p-0290" num="0424">In certain embodiments, at least one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-substituted sugar moiety and W comprises a modified nucleobase. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-substituted sugar moiety, and W comprises a modified nucleobase. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-substituted sugar moiety, and C comprises a modified nucleobase. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-substituted sugar moiety, and W comprises a modified nucleobase.</p><p id="p-0291" num="0425">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a modified nucleobase. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a modified nucleobase. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a modified nucleobase. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a modified nucleobase.</p><p id="p-0292" num="0426">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a modified nucleobase. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a modified nucleobase. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a modified nucleobase. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a modified nucleobase.</p><p id="p-0293" num="0427">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a modified nucleobase. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a modified nucleobase. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a modified nucleobase. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a modified nucleobase.</p><p id="p-0294" num="0428">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-substituted sugar moiety, and W comprises a 2-thio-thymidine nucleobase. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-substituted sugar moiety, and W comprises a 2-thio-thymidine nucleobase. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-substituted sugar moiety, and W comprises a 2-thio-thymidine nucleobase. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-substituted sugar moiety, and W comprises a 2-thio-thymidine nucleobase.</p><p id="p-0295" num="0429">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a 2-thio-thymidine nucleobase. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a 2-thio-thymidine nucleobase. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a 2-thio-thymidine nucleobase. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a 2-thio-thymidine nucleobase.</p><p id="p-0296" num="0430">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a 2-thio-thymidine nucleobase. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a 2-thio-thymidine nucleobase. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a 2-thio-thymidine nucleobase. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a 2-thio-thymidine nucleobase.</p><p id="p-0297" num="0431">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a 2-thio-thymidine nucleobase. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a 2-thio-thymidine nucleobase. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a 2-thio-thymidine nucleobase. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises 2-thio-thymidine nucleobase.</p><p id="p-0298" num="0432">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a 5-propyne uridine nucleobase. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and C comprises a 5-propyne uridine nucleobase. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a 5-propyne uridine nucleobase. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and C comprises a 5-propyne uridine nucleobase.</p><p id="p-0299" num="0433">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a 5-propyne uridine nucleobase. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-F sugar moiety, and C comprises a 5-propyne uridine nucleobase. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a 5-propyne uridine nucleobase. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a 5-propyne uridine nucleobase.</p><p id="p-0300" num="0434">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a 5-propyne uridine nucleobase. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a 5-propyne uridine nucleobase. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a 5-propyne uridine nucleobase. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a 5-propyne uridine nucleobase.</p><p id="p-0301" num="0435">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a sugar surrogate. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a sugar surrogate. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a sugar surrogate. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a sugar surrogate.</p><p id="p-0302" num="0436">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a sugar surrogate. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a sugar surrogate. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a sugar surrogate. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a sugar surrogate.</p><p id="p-0303" num="0437">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a sugar surrogate. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a sugar surrogate. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a sugar surrogate. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises sugar surrogate.</p><p id="p-0304" num="0438">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a HNA sugar surrogate. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a HNA sugar surrogate. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a HNA sugar surrogate. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a HNA sugar surrogate.</p><p id="p-0305" num="0439">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a HNA sugar surrogate. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a HNA sugar surrogate. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a HNA sugar surrogate. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a sugar HNA surrogate.</p><p id="p-0306" num="0440">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a HNA sugar surrogate. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a HNA sugar surrogate. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a HNA sugar surrogate. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a HNA sugar surrogate.</p><p id="p-0307" num="0441">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a F-HNA sugar surrogate. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a F-HNA sugar surrogate. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a F-HNA sugar surrogate. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a F-HNA sugar surrogate.</p><p id="p-0308" num="0442">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a F-HNA sugar surrogate. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a F-HNA sugar surrogate. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a F-HNA sugar surrogate. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a F-HNA sugar surrogate.</p><p id="p-0309" num="0443">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a F-HNA sugar surrogate. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a F-HNA sugar surrogate. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a F-HNA sugar surrogate. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a F-HNA sugar surrogate.</p><p id="p-0310" num="0444">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a 5 &#x2018;-Me DNA sugar moiety. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2019;-MOE sugar moiety, and W comprises a 5&#x2032;-Me DNA sugar moiety. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a 5 &#x2018;-Me DNA sugar moiety. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2019;-MOE sugar moiety, and W comprises a 5&#x2032;-Me DNA sugar moiety.</p><p id="p-0311" num="0445">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a 5&#x2032;-Me DNA sugar moiety. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a 5&#x2032;-Me DNA sugar moiety. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a 5&#x2032;-Me DNA sugar moiety. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a 5&#x2032;-Me DNA sugar moiety.</p><p id="p-0312" num="0446">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a 5&#x2032;-Me DNA sugar moiety. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a 5&#x2032;-Me DNA sugar moiety. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a 5&#x2032;-Me DNA sugar moiety. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a 5&#x2032;-Me DNA sugar moiety.</p><p id="p-0313" num="0447">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a 5&#x2032;-(R)-Me DNA sugar moiety. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a 5&#x2032;-(R)-Me DNA sugar moiety. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a 5&#x2032;-(R)-Me DNA sugar moiety. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-MOE sugar moiety, and W comprises a 5&#x2032;-(R)-Me DNA sugar moiety.</p><p id="p-0314" num="0448">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a 5&#x2032;-(R)-Me DNA sugar moiety. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a 5&#x2032;-(R)-Me DNA sugar moiety. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a 5&#x2032;-(R)-Me DNA sugar moiety. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-F sugar moiety, and W comprises a 5&#x2032;-(R)-Me DNA sugar moiety.</p><p id="p-0315" num="0449">In certain embodiments, one of A or B comprises a bicyclic sugar moiety, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a 5&#x2032;-(R)-Me DNA sugar moiety. In certain embodiments, one of A or B is an LNA nucleoside, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a 5&#x2032;-(R)-Me DNA sugar moiety. In certain embodiments, one of A or B is a cEt nucleoside, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a 5&#x2032;-(R)-Me DNA sugar moiety. In certain embodiments, one of A or B is an &#x3b1;-L-LNA nucleoside, another of A or B comprises a 2&#x2032;-(ara)-F sugar moiety, and W comprises a 5&#x2032;-(R)-Me DNA sugar moiety.</p><p id="p-0316" num="0450">In certain embodiments, at least two of A, B or W comprises a 2&#x2032;-substituted sugar moiety, and the other comprises a bicyclic sugar moiety. In certain embodiments, at least two of A, B or W comprises a bicyclic sugar moiety, and the other comprises a 2&#x2032;-substituted sugar moiety.</p><p id="p-0317" num="0451">c. Certain Overall Lengths</p><p id="p-0318" num="0452">In certain embodiments, the present invention provides oligomeric compounds including oligonucleotides of any of a variety of ranges of lengths. In certain embodiments, the invention provides oligomeric compounds or oligonucleotides consisting of X to Y linked nucleosides, where X represents the fewest number of nucleosides in the range and Y represents the largest number of nucleosides in the range. In certain such embodiments, X and Y are each independently selected from 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, and 50; provided that X&#x2264;Y. For example, in certain embodiments, the invention provides oligomeric compounds which comprise oligonucleotides consisting of 8 to 9, 8 to 10, 8 to 11, 8 to 12, 8 to 13, 8 to 14, 8 to 15, 8 to 16, 8 to 17, 8 to 18, 8 to 19, 8 to 20, 8 to 21, 8 to 22, 8 to 23, 8 to 24, 8 to 25, 8 to 26, 8 to 27, 8 to 28, 8 to 29, 8 to 30, 9 to 10, 9 to 11, 9 to 12, 9 to 13, 9 to 14, 9 to 15, 9 to 16, 9 to 17, 9 to 18, 9 to 19, 9 to 20, 9 to 21, 9 to 22, 9 to 23, 9 to 24, 9 to 25, 9 to 26, 9 to 27, 9 to 28, 9 to 29, 9 to 30, 10 to 11, 10 to 12, 10 to 13, 10 to 14, 10 to 15, 10 to 16, 10 to 17, 10 to 18, 10 to 19, 10 to 20, 10 to 21, 10 to 22, 10 to 23, 10 to 24, 10 to 25, 10 to 26, 10 to 27, 10 to 28, 10 to 29, 10 to 30, 11 to 12, 11 to 13, 11 to 14, 11 to 15, 11 to 16, 11 to 17, 11 to 18, 11 to 19, 11 to 20, 11 to 21, 11 to 22, 11 to 23, 11 to 24, 11 to 25, 11 to 26, 11 to 27, 11 to 28, 11 to 29, 11 to 30, 12 to 13, 12 to 14, 12 to 15, 12 to 16, 12 to 17, 12 to 18, 12 to 19, 12 to 20, 12 to 21, 12 to 22, 12 to 23, 12 to 24, 12 to 25, 12 to 26, 12 to 27, 12 to 28, 12 to 29, 12 to 30, 13 to 14, 13 to 15, 13 to 16, 13 to 17, 13 to 18, 13 to 19, 13 to 20, 13 to 21, 13 to 22, 13 to 23, 13 to 24, 13 to 25, 13 to 26, 13 to 27, 13 to 28, 13 to 29, 13 to 30, 14 to 15, 14 to 16, 14 to 17, 14 to 18, 14 to 19, 14 to 20, 14 to 21, 14 to 22, 14 to 23, 14 to 24, 14 to 25, 14 to 26, 14 to 27, 14 to 28, 14 to 29, 14 to 30, 15 to 16, 15 to 17, 15 to 18, 15 to 19, 15 to 20, 15 to 21, 15 to 22, 15 to 23, 15 to 24, 15 to 25, 15 to 26, 15 to 27, 15 to 28, 15 to 29, 15 to 30, 16 to 17, 16 to 18, 16 to 19, 16 to 20, 16 to 21, 16 to 22, 16 to 23, 16 to 24, 16 to 25, 16 to 26, 16 to 27, 16 to 28, 16 to 29, 16 to 30, 17 to 18, 17 to 19, 17 to 20, 17 to 21, 17 to 22, 17 to 23, 17 to 24, 17 to 25, 17 to 26, 17 to 27, 17 to 28, 17 to 29, 17 to 30, 18 to 19, 18 to 20, 18 to 21, 18 to 22, 18 to 23, 18 to 24, 18 to 25, 18 to 26, 18 to 27, 18 to 28, 18 to 29, 18 to 30, 19 to 20, 19 to 21, 19 to 22, 19 to 23, 19 to 24, 19 to 25, 19 to 26, 19 to 29, 19 to 28, 19 to 29, 19 to 30, 20 to 21, 20 to 22, 20 to 23, 20 to 24, 20 to 25, 20 to 26, 20 to 27, 20 to 28, 20 to 29, 20 to 30, 21 to 22, 21 to 23, 21 to 24, 21 to 25, 21 to 26, 21 to 27, 21 to 28, 21 to 29, 21 to 30, 22 to 23, 22 to 24, 22 to 25, 22 to 26, 22 to 27, 22 to 28, 22 to 29, 22 to 30, 23 to 24, 23 to 25, 23 to 26, 23 to 27, 23 to 28, 23 to 29, 23 to 30, 24 to 25, 24 to 26, 24 to 27, 24 to 28, 24 to 29, 24 to 30, 25 to 26, 25 to 27, 25 to 28, 25 to 29, 25 to 30, 26 to 27, 26 to 28, 26 to 29, 26 to 30, 27 to 28, 27 to 29, 27 to 30, 28 to 29, 28 to 30, or 29 to 30 linked nucleosides. In embodiments where the number of nucleosides of an oligomeric compound or oligonucleotide is limited, whether to a range or to a specific number, the oligomeric compound or oligonucleotide may, nonetheless further comprise additional other substituents. For example, an oligonucleotide comprising 8-30 nucleosides excludes oligonucleotides having 31 nucleosides, but, unless otherwise indicated, such an oligonucleotide may further comprise, for example one or more conjugates, terminal groups, or other substituents. In certain embodiments, a gapmer oligonucleotide has any of the above lengths.</p><p id="p-0319" num="0453">Further, where an oligonucleotide is described by an overall length range and by regions having specified lengths, and where the sum of specified lengths of the regions is less than the upper limit of the overall length range, the oligonucleotide may have additional nucleosides, beyond those of the specified regions, provided that the total number of nucleosides does not exceed the upper limit of the overall length range.</p><p id="p-0320" num="0454">d. Certain Oligonucleotides</p><p id="p-0321" num="0455">In certain embodiments, oligonucleotides of the present invention are characterized by their modification motif and overall length. In certain embodiments, such parameters are each independent of one another. Thus, unless otherwise indicated, each internucleoside linkage of an oligonucleotide having a gapmer sugar motif may be modified or unmodified and may or may not follow the gapmer modification pattern of the sugar modifications. For example, the internucleoside linkages within the wing regions of a sugar-gapmer may be the same or different from one another and may be the same or different from the internucleoside linkages of the gap region. Likewise, such sugar-gapmer oligonucleotides may comprise one or more modified nucleobase independent of the gapmer pattern of the sugar modifications. One of skill in the art will appreciate that such motifs may be combined to create a variety of oligonucleotides. Herein if a description of an oligonucleotide or oligomeric compound is silent with respect to one or more parameter, such parameter is not limited. Thus, an oligomeric compound described only as having a gapmer sugar motif without further description may have any length, internucleoside linkage motif, and nucleobase modification motif. Unless otherwise indicated, all chemical modifications are independent of nucleobase sequence.</p><p id="p-0322" num="0456">e. Certain Conjugate Groups</p><p id="p-0323" num="0457">In certain embodiments, oligomeric compounds are modified by attachment of one or more conjugate groups. In general, conjugate groups modify one or more properties of the attached oligomeric compound including but not limited to pharmacodynamics, pharmacokinetics, stability, binding, absorption, cellular distribution, cellular uptake, charge and clearance. Conjugate groups are routinely used in the chemical arts and are linked directly or via an optional conjugate linking moiety or conjugate linking group to a parent compound such as an oligomeric compound, such as an oligonucleotide. Conjugate groups includes without limitation, intercalators, reporter molecules, polyamines, polyamides, polyethylene glycols, thioethers, polyethers, cholesterols, thiocholesterols, cholic acid moieties, folate, lipids, phospholipids, biotin, phenazine, phenanthridine, anthraquinone, adamantane, acridine, fluoresceins, rhodamines, coumarins and dyes. Certain conjugate groups have been described previously, for example: cholesterol moiety (Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989, 86, 6553-6556), cholic acid (Manoharan et al., Bioorg. Med. Chem. Let., 1994, 4, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., Ann. N.Y. Acad. Sci., 1992, 660, 306-309; Manoharan et al., Bioorg. Med. Chem. Let., 1993, 3, 2765-2770), a thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20, 533-538), an aliphatic chain, e.g., do-decan-diol or undecyl residues (Saison-Behmoaras et al., EMBO J., 1991, 10, 1111-1118; Kabanov et al., FEBS Lett., 1990, 259, 327-330; Svinarchuk et al., Biochimie, 1993, 75, 49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethyl-ammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654; Shea et al., Nucl. Acids Res., 1990, 18, 3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al., Nucleosides &#x26; Nucleotides, 1995, 14, 969-973), or adamantane acetic acid (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654), a palmityl moiety (Mishra et al., Biochim. Biophys. Acta, 1995, 1264, 229-237), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., J. Pharmacol. Exp. Ther., 1996, 277, 923-937).</p><p id="p-0324" num="0458">In certain embodiments, a conjugate group comprises an active drug substance, for example, aspirin, warfarin, phenylbutazone, ibuprofen, suprofen, fen-bufen, ketoprofen, (S)-(+)-pranoprofen, carprofen, dansylsarcosine, 2,3,5-triiodobenzoic acid, flufenamic acid, folinic acid, a benzothiadiazide, chlorothiazide, a diazepine, indo-methicin, a barbiturate, a cephalosporin, a sulfa drug, an antidiabetic, an antibacterial or an antibiotic.</p><p id="p-0325" num="0459">In certain embodiments, conjugate groups are directly attached to oligonucleotides in oligomeric compounds. In certain embodiments, conjugate groups are attached to oligonucleotides by a conjugate linking group. In certain such embodiments, conjugate linking groups, including, but not limited to, bifunctional linking moieties such as those known in the art are amenable to the compounds provided herein. Conjugate linking groups are useful for attachment of conjugate groups, such as chemical stabilizing groups, functional groups, reporter groups and other groups to selective sites in a parent compound such as for example an oligomeric compound. In general a bifunctional linking moiety comprises a hydrocarbyl moiety having two functional groups. One of the functional groups is selected to bind to a parent molecule or compound of interest and the other is selected to bind essentially any selected group such as chemical functional group or a conjugate group. In some embodiments, the conjugate linker comprises a chain structure or an oligomer of repeating units such as ethylene glycol or amino acid units. Examples of functional groups that are routinely used in a bifunctional linking moiety include, but are not limited to, electrophiles for reacting with nucleophilic groups and nucleophiles for reacting with electrophilic groups. In some embodiments, bifunctional linking moieties include amino, hydroxyl, carboxylic acid, thiol, unsaturations (e.g., double or triple bonds), and the like.</p><p id="p-0326" num="0460">Some nonlimiting examples of conjugate linking moieties include pyrrolidine, 8-amino-3,6-dioxaoctanoic acid (ADO), succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) and 6-aminohexanoic acid (AHEX or AHA). Other linking groups include, but are not limited to, substituted C<sub>1</sub>-C<sub>10 </sub>alkyl, substituted or unsubstituted C<sub>2</sub>-C<sub>10 </sub>alkenyl or substituted or unsubstituted C<sub>2</sub>-C<sub>10 </sub>alkynyl, wherein a nonlimiting list of preferred substituent groups includes hydroxyl, amino, alkoxy, carboxy, benzyl, phenyl, nitro, thiol, thioalkoxy, halogen, alkyl, aryl, alkenyl and alkynyl.</p><p id="p-0327" num="0461">Conjugate groups may be attached to either or both ends of an oligonucleotide (terminal conjugate groups) and/or at any internal position.</p><p id="p-0328" num="0462">In certain embodiments, conjugate groups are at the 3&#x2032;-end of an oligonucleotide of an oligomeric compound. In certain embodiments, conjugate groups are near the 3&#x2032;-end. In certain embodiments, conjugates are attached at the 3&#x2032;end of an oligomeric compound, but before one or more terminal group nucleosides. In certain embodiments, conjugate groups are placed within a terminal group. In certain embodiments, the present invention provides oligomeric compounds. In certain embodiments, oligomeric compounds comprise an oligonucleotide. In certain embodiments, an oligomeric compound comprises an oligonucleotide and one or more conjugate and/or terminal groups. Such conjugate and/or terminal groups may be added to oligonucleotides having any of the motifs discussed above. Thus, for example, an oligomeric compound comprising an oligonucleotide having region of alternating nucleosides may comprise a terminal group.</p><heading id="h-0007" level="1">C. Antisense Compounds</heading><p id="p-0329" num="0463">In certain embodiments, oligomeric compounds provided herein are antisense compounds. Such antisense compounds are capable of hybridizing to a target nucleic acid, resulting in at least one antisense activity. In certain embodiments, antisense compounds specifically hybridize to one or more target nucleic acid. In certain embodiments, a specifically hybridizing antisense compound has a nucleobase sequence comprising a region having sufficient complementarity to a target nucleic acid to allow hybridization and result in antisense activity and insufficient complementarity to any non-target so as to avoid non-specific hybridization to any non-target nucleic acid sequences under conditions in which specific hybridization is desired (e.g., under physiological conditions for in vivo or therapeutic uses, and under conditions in which assays are performed in the case of in vitro assays).</p><p id="p-0330" num="0464">In certain embodiments, the present invention provides antisense compounds comprising oligonucleotides that are fully complementary to the target nucleic acid over the entire length of the oligonucleotide. In certain embodiments, oligonucleotides are 99% complementary to the target nucleic acid. In certain embodiments, oligonucleotides are 95% complementary to the target nucleic acid. In certain embodiments, such oligonucleotides are 90% complementary to the target nucleic acid.</p><p id="p-0331" num="0465">In certain embodiments, such oligonucleotides are 85% complementary to the target nucleic acid. In certain embodiments, such oligonucleotides are 80% complementary to the target nucleic acid. In certain embodiments, an antisense compound comprises a region that is fully complementary to a target nucleic acid and is at least 80% complementary to the target nucleic acid over the entire length of the oligonucleotide. In certain such embodiments, the region of full complementarity is from 6 to 14 nucleobases in length.</p><p id="p-0332" num="0466">a. Certain Antisense Activities and Mechanisms</p><p id="p-0333" num="0467">In certain antisense activities, hybridization of an antisense compound results in recruitment of a protein that cleaves of the target nucleic acid. For example, certain antisense compounds result in RNase H mediated cleavage of target nucleic acid. RNase H is a cellular endonuclease that cleaves the RNA strand of an RNA:DNA duplex. The &#x201c;DNA&#x201d; in such an RNA:DNA duplex, need not be unmodified DNA. In certain embodiments, the invention provides antisense compounds that are sufficiently &#x201c;DNA-like&#x201d; to elicit RNase H activity. Such DNA-like antisense compounds include, but are not limited to gapmers having unmodified deoxyfuronose sugar moieties in the nucleosides of the gap and modified sugar moieties in the nucleosides of the wings.</p><p id="p-0334" num="0468">Antisense activities may be observed directly or indirectly. In certain embodiments, observation or detection of an antisense activity involves observation or detection of a change in an amount of a target nucleic acid or protein encoded by such target nucleic acid; a change in the ratio of splice variants of a nucleic acid or protein; and/or a phenotypic change in a cell or animal.</p><p id="p-0335" num="0469">In certain embodiments, compounds comprising oligonucleotides having a gapmer nucleoside motif described herein have desirable properties compared to non-gapmer oligonucleotides or to gapmers having other motifs. In certain circumstances, it is desirable to identify motifs resulting in a favorable combination of potent antisense activity and relatively low toxicity. In certain embodiments, compounds of the present invention have a favorable therapeutic index (measure of activity divided by measure of toxicity).</p><p id="p-0336" num="0470">b. Certain Selective Antisense Compounds</p><p id="p-0337" num="0471">In certain embodiments, antisense compounds provided are selective for a target relative to a non-target nucleic acid. In certain embodiments, the nucleobase sequences of the target and non-target nucleic acids differ by no more than 4 differentiating nucleobases in the targeted region. In certain embodiments, the nucleobase sequences of the target and non-target nucleic acids differ by no more than 3 differentiating nucleobases in the targeted region. In certain embodiments, the nucleobase sequences of the target and non-target nucleic acids differ by no more than 2 differentiating nucleobases in the targeted region. In certain embodiments, the nucleobase sequences of the target and non-target nucleic acids differ by a single differentiating nucleobase in the targeted region. In certain embodiments, the target and non-target nucleic acids are transcripts from different genes. In certain embodiments, the target and non-target nucleic acids are different alleles for the same gene. In certain embodiments, the introduction of a mismatch between an antisense compound and a non-target nucleic acid may alter the RNase H cleavage site of a target nucleic acid compared to a non-target nucleic acid. In certain embodiments, the target and non-target nucleic acids are not functionally related to one another (e.g., are transcripts from different genes). In certain embodiments, the target and not-target nucleic acids are allelic variants of one another. In certain embodiments, the allelic variant contains a single nucleotide polymorphism (SNP). In certain embodiments, a SNP is associated with a mutant allele. In certain embodiments, a mutant SNP is associated with a disease. In certain embodiments a mutant SNP is associated with a disease, but is not causative of the disease. In certain embodiments, mRNA and protein expression of a mutant allele is associated with disease.</p><p id="p-0338" num="0472">Selectivity of antisense compounds is achieved, principally, by nucleobase complementarity. For example, if an antisense compound has no mismatches for a target nucleic acid and one or more mismatches for a non-target nucleic acid, some amount of selectivity for the target nucleic acid will result. In certain embodiments, provided herein are antisense compounds with enhanced selectivity (i.e. the ratio of activity for the target to the activity for non-target is greater). For example, in certain embodiments, a selective nucleoside comprises a particular feature or combination of features (e.g., chemical modification, motif, placement of selective nucleoside, and/or self-complementary region) that increases selectivity of an antisense compound compared to an antisense compound not having that feature or combination of features. In certain embodiments, such feature or combination of features increases antisense activity for the target. In certain embodiments, such feature or combination of features decreases activity for the target, but decreases activity for the non-target by a greater amount, thus resulting in an increase in selectivity.</p><p id="p-0339" num="0473">Without being limited by mechanism, enhanced selectivity may result from a larger difference in the affinity of an antisense compound for its target compared to its affinity for the non-target and/or a larger difference in RNase H activity for the resulting duplexes. For example, in certain embodiments, a selective antisense compound comprises a modified nucleoside at that same position as a differentiating nucleobase (i.e., the selective nucleoside is modified). That modification may increase the difference in binding affinity of the antisense compound for the target relative to the non-target. In addition or in the alternative, the chemical modification may increase the difference in RNAse H activity for the duplex formed by the antisense compound and its target compared to the RNase activity for the duplex formed by the antisense compound and the non-target. For example, the modification may exaggerate a structure that is less compatible for RNase H to bind, cleave and/or release the non-target.</p><p id="p-0340" num="0474">In certain embodiments, an antisense compound binds its intended target to form a target duplex. In certain embodiments, RNase H cleaves the target nucleic acid of the target duplex. In certain such embodiments, there is a primary cleavage site between two particular nucleosides of the target nucleic acid (the primary target cleavage site), which accounts for the largest amount of cleavage of the target nucleic acid. In certain embodiments, there are one or more secondary target cleavage sites. In certain embodiments, the same antisense compound hybridizes to a non-target to form a non-target duplex. In certain such embodiments, the non-target differs from the target by a single nucleobase within the target region, and so the antisense compound hybridizes with a single mismatch. Because of the mismatch, in certain embodiments, RNase H cleavage of the non-target may be reduced compared to cleavage of the target, but still occurs. In certain embodiments, though, the primary site of that cleavage of the non-target nucleic acid (primary non-target cleavage site) is different from that of the target. That is; the primary site is shifted due to the mismatch. In such a circumstance, one may use a modification placed in the antisense compound to disrupt RNase H cleavage at the primary non-target cleavage site. Such modification will result in reduced cleavage of the non-target, but will result little or no decrease in cleavage of the target. In certain embodiments, the modification is a modified sugar, nucleobase and/or linkage.</p><p id="p-0341" num="0475">In certain embodiments, the primary non-target cleavage site is towards the 5&#x2032;-end of the antisense compound, and the 5&#x2032;-end of an antisense compound may be modified to prevent RNaseH cleavage. In this manner, it is thought that one having skill in the art may modify the 5&#x2032;-end of an antisense compound, or modify the nucleosides in the gap region of the 5&#x2032;-end of the antisense compound, or modify the the 3&#x2032;-most 5&#x2032;-region nucleosides of the antisense compound to selectively inhibit RNaseH cleavage of the non-target nucleic acid duplex while retaining RNase H cleavage of the target nucleic acid duplex. In certain embodiments, 1-3 of the 3&#x2032;-most 5&#x2032;-region nucleosides of the antisense compound comprises a bicyclic sugar moiety.</p><p id="p-0342" num="0476">For example, in certain embodiments the target nucleic acid may have an allelic variant, e.g. a non-target nucleic acid, containing a single nucleotide polymorphism. An antisense compound may be designed having a single nucleobase mismatch from the non-target nucleic acid, but which has full complementarity to the target nucleic acid. The mismatch between the antisense compound and the non-target nucleic acid may destabilize the antisense compound non-target nucleic acid duplex, and consequently the cleavage site of RNaseH may shift upstream towards the 5&#x2032;-end of the antisense compound. Modification of the 5&#x2032;-end of the antisense compound or the gap region near the 5&#x2032;-end of the antisense compound, or one or more of the 3&#x2032;-most nucleosides of the 5&#x2032;-wing region, will then prevent RNaseH cleavage of the non-target nucleic acid. Since the target nucleic acid is fully complementary to the antisense compound, the antisense compound and the target nucleic acid will form a more stabilized antisense compound-target nucleic acid duplex and the cleavage site of RnaseH will be more downstream, towards the 3&#x2032; end of the antisense compound. Accordingly, modifications at the 5&#x2032;-end of the antisense compound will prevent RNaseH cleavage of the non-target nucleic acid, but will not substantially effect RNaseH cleavage of the target nucleic acid, and selectivity between a target nucleic acid and its allelic variant may be achieved. In certain embodiments, one or more of the 3&#x2032;-most nucleosides of the 5&#x2032;-wing region comprises a bicyclic sugar moiety. In certain embodiments, one or more of the 3&#x2032;-most nucleosides of the 5&#x2032;-wing region comprises a bicyclic sugar moiety selected from cEt and LNA. In certain embodiments, one or more of the 3&#x2032;-most nucleosides of the 5&#x2032;-wing region comprises cEt. In certain embodiments, one or more of the 3&#x2032;-most nucleosides of the 5&#x2032;-wing region comprises LNA.</p><p id="p-0343" num="0477">In certain embodiments, the introduction of a mismatch between an antisense compound and a target nucleic acid may alter the RNase H cleavage site of a target nucleic acid compared to a non-target nucleic acid by shifting the RNaseH cleavage site downstream from the mismatch site and towards the 3&#x2032;-end of the antisense compound. In certain embodiments where the cleavage site of a target nucleic acid compared to a non-target nucleic acid has shifted downstream towards the 3&#x2032;-end of the antisense compound, the 3&#x2032;-end of an antisense compound may be modified to prevent RNaseH cleavage. In this manner, it is thought that one having skill in the art may modify the 3&#x2032;-end of an antisense compound, or modify the nucleosides in the gap region near the 3&#x2032;-end of antisense compound, to selectively inhibit RNaseH cleavage of the non-target nucleic acid while retaining RNase H cleavage of the target nucleic acid.</p><p id="p-0344" num="0478">For example, in certain embodiments the target nucleic acid may have an allelic variant, e.g. a non-target nucleic acid, containing a single nucleotide polymorphism. An antisense compound may be designed having a single nucleobase mismatch from the non-target nucleic acid, but which has full complementarity to target nucleic acid. The mismatch between the antisense compound and the non-target nucleic acid may destabilize the antisense compound-non-target nucleic acid duplex, and consequently the cleavage site of RNaseH may shift downstream towards the 3&#x2032;-end of the antisense compound. Modification of the 3&#x2032;-end of the antisense compound, or one or more of the the 5&#x2032;-most nucleosides of the 3&#x2032;-wing region, or the gap region of the antisense compound near the 3&#x2032;-end will then prevent RNaseH cleavage of the non-target nucleic acid. Since the target nucleic acid is fully complementary to the antisense compound, the antisense compound and the target nucleic acid will form a more stabilized antisense compound-target nucleic acid duplex and the cleavage site of RnaseH will be more upstream, towards the 5&#x2032; end of the antisense compound. Accordingly, modifications at the 3&#x2032;-end of the antisense compound will prevent RNaseH cleavage of the non-target nucleic acid, but will not substantially effect RNaseH cleavage of the target nucleic acid, and selectivity between a target nucleic acid and its allelic variant may be achieved. In certain embodiments, one or more of the 5&#x2032;-most nucleosides of the 3&#x2032;-wing region comprises a bicyclic sugar moiety. In certain embodiments, one or more of the 5&#x2032;-most nucleosides of the 3&#x2032;-wing region comprises a bicyclic sugar moiety selected from cEt and LNA. In certain embodiments, one or more of the 5&#x2032;-most nucleosides of the 3&#x2032;-wing region comprises cEt. In certain embodiments, one or more of the 5&#x2032;-most nucleosides of the 3&#x2032;-wing region comprises LNA.</p><p id="p-0345" num="0479">In certain embodiments, the selectivity of antisense compounds having certain gaps, e.g. gaps of 7 nucleosides or longer, may be improved by the addition of one or more bicyclic nucleosides at the 3&#x2032;-most 5&#x2032;-wing nucleoside. In certain embodiments, the selectivity of antisense compounds having certain gaps, e.g. gaps of 7 nucleosides or longer, may be improved by the addition of two or more bicyclic nucleosides at the 3&#x2032;-most 5&#x2032;-wing nucleoside. In certain embodiments, the selectivity of antisense compounds having certain gaps, e.g. gaps of 7 nucleosides or longer, may be improved by the addition of one bicyclic nucleoside at the 3&#x2032;-most 5&#x2032;-wing nucleoside. In certain embodiments, the selectivity of antisense compounds having certain gaps, e.g. gaps of 7 nucleosides or longer, may be improved by the addition of two bicyclic nucleosides at the 3&#x2032;-most 5&#x2032;-wing nucleoside. In certain embodiments, the selectivity of antisense compounds having certain gaps, e.g. gaps of 7 nucleosides or longer, may be improved by the addition of three bicyclic nucleosides at the 3&#x2032;-most 5&#x2032;-wing nucleoside. In certain embodiments, the selectivity of antisense compounds having certain gaps, e.g. gaps of 7 nucleosides or longer, may be improved by the addition of four bicyclic nucleosides at the 3&#x2032;-most 5&#x2032;-wing nucleoside. In certain embodiments, the selectivity of antisense compounds having certain gaps, e.g. gaps of 7 nucleosides or longer, may be improved by the addition of five bicyclic nucleosides at the 3&#x2032;-most 5&#x2032;-wing nucleoside. In certain embodiments discussed above, the bicyclic nucleosides at the 3&#x2032;-most 5&#x2032;-wing nucleoside are selected from among cEt, cMOE, LNA, &#x3b1;-LNA, ENA and 2&#x2032;-thio LNA. In certain embodiments discussed above, the bicyclic nucleosides at the 3&#x2032;-most 5&#x2032;-wing nucleoside comprise cEt. In certain embodiments discussed above, the bicyclic nucleosides at the 3&#x2032;-most 5&#x2032;-wing nucleoside comprise LNA.</p><p id="p-0346" num="0480">In certain embodiments, the selectivity of antisense compounds having certain gaps, e.g. gaps of 7 nucleosides or longer, may be improved by the addition of one or more bicyclic nucleosides at the 3&#x2032;-most 5&#x2032;-wing nucleoside and the addition of one or more bicyclic nucleosides at the 5&#x2032;-most 3&#x2032;-wing nucleoside. In certain embodiments, the selectivity of antisense compounds having certain gaps, e.g. gaps of 7 nucleosides or longer, may be improved by the addition of two or more bicyclic nucleosides at the 3&#x2032;-most 5&#x2032;-wing nucleoside and the addition of one or more bicyclic nucleosides at the 5&#x2032;-most 3&#x2032;-wing nucleoside. In certain embodiments, the selectivity of antisense compounds having certain gaps, e.g. gaps of 7 nucleosides or longer, may be improved by the addition of one bicyclic nucleoside at the 3&#x2032;-most 5&#x2032;-wing nucleoside and the addition of one or more bicyclic nucleosides at the 5&#x2032;-most 3&#x2032;-wing nucleoside. In certain embodiments, the selectivity of antisense compounds having certain gaps, e.g. gaps of 7 nucleosides or longer, may be improved by the addition of two bicyclic nucleosides at the 3&#x2032;-most 5&#x2032;-wing nucleoside and the addition of one or more bicyclic nucleosides at the 5&#x2032;-most 3&#x2032;-wing nucleoside. In certain embodiments, the selectivity of antisense compounds having certain gaps, e.g. gaps of 7 nucleosides or longer, may be improved by the addition of three bicyclic nucleosides at the 3&#x2032;-most 5&#x2032;-wing nucleoside and the addition of one or more bicyclic nucleosides at the 5&#x2032;-most 3&#x2032;-wing nucleoside. In certain embodiments, the selectivity of antisense compounds having certain gaps, e.g. gaps of 7 nucleosides or longer, may be improved by the addition of four bicyclic nucleosides at the 3&#x2032;-most 5&#x2032;-wing nucleoside and the addition of one or more bicyclic nucleosides at the 5&#x2032;-most 3&#x2032;-wing nucleoside. In certain embodiments, the selectivity of antisense compounds having certain gaps, e.g. gaps of 7 nucleosides or longer, may be improved by the addition of four bicyclic nucleosides at the 3&#x2032;-most 5&#x2032;-wing nucleoside and the addition of one or more bicyclic nucleosides at the 5&#x2032;-most 3&#x2032;-wing nucleoside.</p><p id="p-0347" num="0481">In certain embodiments, the selectivity of antisense compounds having certain gaps, e.g. gaps of 7 nucleosides or shorter, may be improved by the addition of one or more bicyclic nucleosides at the 3&#x2032;-most 5&#x2032;-wing nucleoside. In certain embodiments, the selectivity of antisense compounds having certain gaps, e.g. gaps of 7 nucleosides or shorter, may be improved by the addition of two or more bicyclic nucleosides at the 3&#x2032;-most 5&#x2032;-wing nucleoside. In certain embodiments, the selectivity of antisense compounds having certain gaps, e.g. gaps of 7 nucleosides or shorter, may be improved by the addition of one bicyclic nucleoside at the 3&#x2032;-most 5&#x2032;-wing nucleoside. In certain embodiments, the selectivity of antisense compounds having certain gaps, e.g. gaps of 7 nucleosides or shorter, may be improved by the addition of two bicyclic nucleosides at the 3&#x2032;-most 5&#x2032;-wing nucleoside. In certain embodiments, the selectivity of antisense compounds having certain gaps, e.g. gaps of 7 nucleosides or shorter, may be improved by the addition of three bicyclic nucleosides at the 3&#x2032;-most 5&#x2032;-wing nucleoside. In certain embodiments, the selectivity of antisense compounds having certain gaps, e.g. gaps of 7 nucleosides or shorter, may be improved by the addition of four bicyclic nucleosides at the 3&#x2032;-most 5&#x2032;-wing nucleoside. In certain embodiments, the selectivity of antisense compounds having certain gaps, e.g. gaps of 7 nucleosides or shorter, may be improved by the addition of five bicyclic nucleosides at the 3&#x2032;-most 5&#x2032;-wing nucleoside. In certain embodiments discussed above, the bicyclic nucleosides at the 3&#x2032;-most 5&#x2032;-wing nucleoside are selected from among cEt, cMOE, LNA, &#x3b1;-LNA, ENA and 2&#x2032;-thio LNA. In certain embodiments discussed above, the bicyclic nucleosides at the 3&#x2032;-most 5&#x2032;-wing nucleoside comprise cEt. In certain embodiments discussed above, the bicyclic nucleosides at the 3&#x2032;-most 5&#x2032;-wing nucleoside comprise LNA.</p><p id="p-0348" num="0482">Antisense compounds having certain specified motifs have enhanced selectivity, including, but not limited to motifs described above. In certain embodiments, enhanced selectivity is achieved by oligonucleotides comprising any one or more of:</p><p id="p-0349" num="0483">a modification motif comprising a long 5&#x2032;-wing (longer than 5, 6, or 7 nucleosides);</p><p id="p-0350" num="0484">a modification motif comprising a long 3&#x2032;-wing (longer than 5, 6, or 7 nucleosides);</p><p id="p-0351" num="0485">a modification motif comprising a short gap region (shorter than 8, 7, or 6 nucleosides); and</p><p id="p-0352" num="0486">a modification motif comprising an interrupted gap region (having no uninterrupted stretch of unmodified 2&#x2032;-deoxynucleosides longer than 7, 6 or 5).</p><p id="p-0353" num="0487">i. Certain Selective Nucleobase Sequence Elements</p><p id="p-0354" num="0488">In certain embodiments, selective antisense compounds comprise nucleobase sequence elements. Such nucleobase sequence elements are independent of modification motifs. Accordingly, oligonucleotides having any of the motifs (modification motifs, nucleoside motifs, sugar motifs, nucleobase modification motifs, and/or linkage motifs) may also comprise one or more of the following nucleobase sequence elements.</p><p id="p-0355" num="0489">ii. Alignment of Differentiating Nucleobase/Target-Selective Nucleoside</p><p id="p-0356" num="0490">In certain embodiments, a target region and a region of a non-target nucleic acid differ by 1-4 differentiating nucleobase. In such embodiments, selective antisense compounds have a nucleobase sequence that aligns with the non-target nucleic acid with 1-4 mismatches. A nucleoside of the antisense compound that corresponds to a differentiating nucleobase of the target nucleic acid is referred to herein as a target-selective nucleoside. In certain embodiments, selective antisense compounds having a gapmer motif align with a non-target nucleic acid, such that a target-selective nucleoside is positioned in the gap. In certain embodiments, a target-selective nucleoside is the 1<sup>st </sup>nucleoside of the gap from the 5&#x2032; end. In certain embodiments, a target-selective nucleoside is the 2<sup>nd </sup>nucleoside of the gap from the 5&#x2032; end. In certain embodiments, a target-selective nucleoside is the 3<sup>rd </sup>nucleoside of the gap from the 5&#x2032;-end. In certain embodiments, a target-selective nucleoside is the 4<sup>th </sup>nucleoside of the gap from the 5&#x2032;-end. In certain embodiments, a target-selective nucleoside is the 5<sup>th </sup>nucleoside of the gap from the 5&#x2032;-end. In certain embodiments, a target-selective nucleoside is the 6<sup>rd </sup>nucleoside of the gap from the 5&#x2032;-end. In certain embodiments, a target-selective nucleoside is the 8<sup>th </sup>nucleoside of the gap from the 3&#x2032;-end. In certain embodiments, a target-selective nucleoside is the 7<sup>th </sup>nucleoside of the gap from the 3&#x2032;-end. In certain embodiments, a target-selective nucleoside is the 6<sup>th </sup>nucleoside of the gap from the 3&#x2032;-end. In certain embodiments, a target-selective nucleoside is the 5<sup>th </sup>nucleoside of the gap from the 3&#x2032;-end. In certain embodiments, a target-selective nucleoside is the 4<sup>th </sup>nucleoside of the gap from the 3&#x2032;-end. In certain embodiments, a target-selective nucleoside is the 3<sup>rd </sup>nucleoside of the gap from the 3&#x2032;-end. In certain embodiments, a target-selective nucleoside is the 2<sup>nd </sup>nucleoside of the gap from the 3&#x2032;-end.</p><p id="p-0357" num="0491">In certain embodiments, a target-selective nucleoside comprises a modified nucleoside. In certain embodiments, a target-selective nucleoside comprises a modified sugar. In certain embodiments, a target-selective nucleoside comprises a sugar surrogate. In certain embodiments, a target-selective nucleoside comprises a sugar surrogate selected from among HNA and F-HNA. In certain embodiments, a target-selective nucleoside comprises a sugar surrogate selected from among F-CeNA, FRNA, and FANA. In certain embodiments, a target-selective nucleoside comprises a 2&#x2032;-substituted sugar moiety. In certain embodiments, a target-selective nucleoside comprises a 2&#x2032;-substituted sugar moiety selected from among MOE, F and (ara)-F. In certain embodiments, a target-selective nucleoside comprises a 5&#x2032;-substituted sugar moiety. In certain embodiments, a target-selective nucleoside comprises a 5&#x2032;-substituted sugar moiety selected from 5&#x2032;-(R)-Me DNA. In certain embodiments, a target-selective nucleoside comprises a 5&#x2032;-substituted sugar moiety selected from 5&#x2032;-(S)-Me DNA. In certain embodiments, a target-selective nucleoside comprises a bicyclic sugar moiety. In certain embodiments, a target-selective nucleoside comprises a bicyclic sugar moiety selected from among cEt, and &#x3b1;-L-LNA. In certain embodiments, a target-selective nucleoside comprises a modified nucleobase. In certain embodiments, a target-selective nucleoside comprises a modified nucleobase selected from among 2-thio-thymidine and 5-propyne uridine.</p><p id="p-0358" num="0492">In certain embodiments, a modification at position 4 from the 5&#x2032;-end increases selectivity. In certain embodiments, a modification at position 5 from the 5&#x2032;-end increases selectivity. In certain embodiments, a modification at position 7 from the 5&#x2032;-end increases selectivity. In certain embodiments, a modification at position 8 from the 5&#x2032;-end increases potency and selectivity. In certain embodiments, a modification at position 9 from the 5&#x2032;-end increases potency. In certain embodiments, a modification at position 10 from the 5&#x2032;-end increases selectivity. In certain embodiments, a modification at position 11 from the 5&#x2032;-end increases selectivity. In certain embodiments, a modification at position 12 from the 5&#x2032;-end increases potency. In certain embodiments, an S-5&#x2032;-Me-DNA modification increases allele selectivity.</p><p id="p-0359" num="0493">iii. Mismatches to the Target Nucleic Acid</p><p id="p-0360" num="0494">In certain embodiments, selective antisense compounds comprise one or more mismatched nucleobases relative to the target nucleic acid. In certain such embodiments, antisense activity against the target is reduced by such mismatch, but activity against the non-target is reduced by a greater amount. Thus, in certain embodiments selectivity is improved. Any nucleobase other than the differentiating nucleobase is suitable for a mismatch. In certain embodiments, however, the mismatch is specifically positioned within the gap of an oligonucleotide having a gapmer motif. In certain embodiments, a mismatch relative to the target nucleic acid is at positions 1, 2, 3, 4, 5, 6, 7, or 8 from the 5&#x2032;-end of the gap region. In certain embodiments, a mismatch relative to the target nucleic acid is at positions 9, 8, 7, 6, 5, 4, 3, 2, 1 of the antisense compounds from the 3&#x2032;-end of the gap region. In certain embodiments, a mismatch relative to the target nucleic acid is at positions 1, 2, 3, or 4 of the antisense compounds from the 5&#x2032;-end of the wing region. In certain embodiments, a mismatch relative to the target nucleic acid is at positions 4, 3, 2, or 1 of the antisense compounds from the 3&#x2032;-end of the wing region.</p><p id="p-0361" num="0495">iv. Self Complementary Regions</p><p id="p-0362" num="0496">In certain embodiments, selective antisense compounds comprise a region that is not complementary to the target. In certain embodiments, such region is complementary to another region of the antisense compound. Such regions are referred to herein as self-complementary regions. For example, in certain embodiments, an antisense compound has a first region at one end that is complementary to a second region at the other end. In certain embodiments, one of the first and second regions is complementary to the target nucleic acid. Unless the target nucleic acid also includes a self-complementary region, the other of the first and second region of the antisense compound will not be complementary to the target nucleic acid. For illustrative purposes, certain antisense compounds have the following nucleobase motif:<ul id="ul0005" list-style="none">    <li id="ul0005-0001" num="0000">    <ul id="ul0006" list-style="none">        <li id="ul0006-0001" num="0497">ABCXXXXXXXXXC&#x2032;B&#x2032;A&#x2032;;</li>        <li id="ul0006-0002" num="0498">ABCXXXXXXX(X/C&#x2032;)(X/B&#x2032;)(X/A&#x2032;);</li>        <li id="ul0006-0003" num="0499">(X/A)(X/B)(X/C)XXXXXXXXXC&#x2032;B&#x2032;A&#x2032;<br/>where each of A, B, and C are any nucleobase; A&#x2032;, B&#x2032;, and C&#x2032; are the complementary bases to A, B, and C, respectively; each X is a nucleobase complementary to the target nucleic acid; and two letters in parentheses (e.g., (X/C&#x2032;)) indicates that the nucleobase is complementary to the target nucleic acid and to the designated nucleoside within the antisense oligonucleotide.</li>    </ul>    </li></ul></p><p id="p-0363" num="0500">Without being bound to any mechanism, in certain embodiments, such antisense compounds are expected to form self-structure, which is disrupted upon contact with a target nucleic acid. Contact with a non-target nucleic acid is expected to disrupt the self-structure to a lesser degree, thus increasing selectivity compared to the same antisense compound lacking the self-complementary regions.</p><p id="p-0364" num="0501">v. Combinations of Features</p><p id="p-0365" num="0502">Though it is clear to one of skill in the art, the above motifs and other elements for increasing selectivity may be used alone or in combination. For example, a single antisense compound may include any one, two, three, or more of: self-complementary regions, a mismatch relative to the target nucleic acid, a short nucleoside gap, an interrupted gap, and specific placement of the selective nucleoside.</p><heading id="h-0008" level="1">D. Certain Target Nucleic Acids</heading><p id="p-0366" num="0503">In certain embodiments, antisense compounds comprise or consist of an oligonucleotide comprising a region that is complementary to a target nucleic acid. In certain embodiments, the target nucleic acid is an endogenous RNA molecule. In certain embodiments, the target nucleic acid is a non-coding RNA. In certain such embodiments, the target non-coding RNA is selected from: a long-non-coding RNA, a short non-coding RNA, an intronic RNA molecule, a snoRNA, a scaRNA, a microRNA (including pre-microRNA and mature microRNA), a ribosomal RNA, and promoter directed RNA. In certain embodiments, the target nucleic acid encodes a protein. In certain such embodiments, the target nucleic acid is selected from: an mRNA and a pre-mRNA, including intronic, exonic and untranslated regions. In certain embodiments, oligomeric compounds are at least partially complementary to more than one target nucleic acid. For example, antisense compounds of the present invention may mimic microRNAs, which typically bind to multiple targets.</p><p id="p-0367" num="0504">In certain embodiments, the target nucleic acid is a nucleic acid other than a mature mRNA. In certain embodiments, the target nucleic acid is a nucleic acid other than a mature mRNA or a microRNA. In certain embodiments, the target nucleic acid is a non-coding RNA other than a microRNA. In certain embodiments, the target nucleic acid is a non-coding RNA other than a microRNA or an intronic region of a pre-mRNA. In certain embodiments, the target nucleic acid is a long non-coding RNA. In certain embodiments, the target RNA is an mRNA. In certain embodiments, the target nucleic acid is a pre-mRNA. In certain such embodiments, the target region is entirely within an intron. In certain embodiments, the target region spans an intron/exon junction. In certain embodiments, the target region is at least 50% within an intron. In certain embodiments, the target nucleic acid is selected from among non-coding RNA, including exonic regions of pre-mRNA. In certain embodiments, the target nucleic acid is a ribosomal RNA (rRNA). In certain embodiments, the target nucleic acid is a non-coding RNA associated with splicing of other pre-mRNAs. In certain embodiments, the target nucleic acid is a nuclear-retained non-coding RNA.</p><p id="p-0368" num="0505">In certain embodiments, antisense compounds described herein are complementary to a target nucleic acid comprising a single-nucleotide polymorphism. In certain such embodiments, the antisense compound is capable of modulating expression of one allele of the single-nucleotide polymorphism-containing-target nucleic acid to a greater or lesser extent than it modulates another allele. In certain embodiments an antisense compound hybridizes to a single-nucleotide polymorphism-containing-target nucleic acid at the single-nucleotide polymorphism site. In certain embodiments, the target nucleic acid is a Huntingtin gene transcript. In certain embodiments, the target nucleic acid is a single-nucleotide polymorphism-containing-target nucleic acid of a Huntingtin gene transcript. In certain embodiments, the target nucleic acid is not a Huntingtin gene transcript. In certain embodiments, the target nucleic acid is a single-nucleotide polymorphism-containing-target nucleic acid of a gene transcript other than Huntingtin. In certain embodiments, the target nucleic acid is any nucleic acid other than a Huntingtin gene transcript.</p><p id="p-0369" num="0506">a. Single-Nucleotide Polymorphism</p><p id="p-0370" num="0507">In certain embodiments, the invention provides selective antisense compounds that have greater activity for a target nucleic acid than for a homologous or partially homologous non-target nucleic acid. In certain such embodiments, the target and non-target nucleic acids are not functionally related to one another (e.g., are transcripts from different genes). In certain embodiments, the target and not-target nucleic acids are allelic variants of one another. Certain embodiments of the present invention provide methods, compounds, and compositions for selectively inhibiting mRNA and protein expression of an allelic variant of a particular gene or DNA sequence. In certain embodiments, the allelic variant contains a single nucleotide polymorphism (SNP). In certain embodiments, a SNP is associated with a mutant allele. In certain embodiments, a mutant SNP is associated with a disease. In certain embodiments a mutant SNP is associated with a disease, but is not causative of the disease. In certain embodiments, mRNA and protein expression of a mutant allele is associated with disease.</p><p id="p-0371" num="0508">In certain embodiments, the expressed gene product of a mutant allele results in aggregation of the mutant proteins causing disease. In certain embodiments, the expressed gene product of a mutant allele results in gain of function causing disease. In certain embodiments, genes with an autosomal dominant mutation resulting in a toxic gain of function of the protein are the APP gene encoding amyloid precursor protein involved in Alzheimer's disease (Gene, 371: 68, 2006); the PrP gene encoding prion protein involved in Creutzfeldt-Jakob disease and in fatal familial insomnia (Nat. Med. 1997, 3: 1009); GFAP gene encoding glial fibrillary acidic protein involved in Alexander disease (J. Neurosci. 2006, 26:111623); alpha-synuclein gene encoding alpha-synuclein protein involved in Parkinson's disease (J. Clin. Invest. 2003, 111: 145); SOD-1 gene encoding the SOD-1 protein involved in amyotrophic lateral sclerosis (Science 1998, 281: 1851); atrophin-1 gene encoding atrophin-1 protein involved in dentato-rubral and pallido-luysian atrophy (DRPA) (Trends Mol. Med. 2001, 7: 479); SCA1 gene encoding ataxin-1 protein involved in spino-cerebellar ataxia-1 (SCA1) (Protein Sci. 2003, 12: 953); PLP gene encoding proteolipid protein involved in Pelizaeus-Merzbacher disease (NeuroMol Med. 2007, 4: 73); DYT1 gene encoding torsinA protein involved in Torsion dystonia (Brain Res. 2000, 877: 379); and alpha-B crystalline gene encoding alpha-B crystalline protein involved in protein aggregation diseases, including cardiomyopathy (Cell 2007, 130: 427); alpha1-antitrypsin gene encoding alpha1-antitrypsin protein involved in chronic obstructive pulmonary disease (COPD), liver disease and hepatocellular carcinoma (New Engl J Med. 2002, 346: 45); Ltk gene encoding leukocyte tyrosine kinase protein involved in systemic lupus erythematosus (Hum. Mol. Gen. 2004, 13: 171); PCSK9 gene encoding PCSK9 protein involved in hypercholesterolemia (Hum Mutat. 2009, 30: 520); prolactin receptor gene encoding prolactin receptor protein involved in breast tumors (Proc. Natl. Assoc. Sci. 2008, 105: 4533); CCLS gene encoding the chemokine CCLS involved in COPD and asthma (Eur. Respir. J. 2008, 32: 327); PTPN22 gene encoding PTPN22 protein involved in Type 1 diabetes, Rheumatoid arthritis, Graves disease, and SLE (Proc. Natl. Assoc. Sci. 2007, 104: 19767); androgen receptor gene encoding the androgen receptor protein involved in spinal and bulbar muscular atrophy or Kennedy's disease (J Steroid Biochem. Mol. Biol. 2008, 108: 245); CHMP4B gene encoding chromatin modifying protein-4B involved in progressive childhood posterior subcapsular cataracts (Am. J. Hum. Genet 2007, 81: 596); FXR/NR1H4 gene encoding Farnesoid X receptor protein involved in cholesterol gallstone disease, arthrosclerosis and diabetes (Mol. Endocrinol. 2007, 21: 1769); ABCA1 gene encoding ABCA1 protein involved in cardiovascular disease (Transl. Res. 2007, 149: 205); CaSR gene encoding the calcium sensing receptor protein involved in primary hypercalciuria (Kidney Int. 2007, 71: 1155); alpha-globin gene encoding alpha-globin protein involved in alpha-thallasemia (Science 2006, 312: 1215); httlpr gene encoding HTTLPR protein involved in obsessive compulsive disorder (Am. J. Hum. Genet. 2006, 78: 815); AVP gene encoding arginine vasopressin protein in stress-related disorders such as anxiety disorders and comorbid depression (CNS Neurol. Disord. Drug Targets 2006, 5: 167); GNAS gene encoding G proteins involved in congenital visual defects, hypertension, metabolic syndrome (Trends Pharmacol. Sci. 2006, 27: 260); APAF1 gene encoding APAF1 protein involved in a predisposition to major depression (Mol. Psychiatry 2006, 11: 76); TGF-beta1 gene encoding TGF-beta1 protein involved in breast cancer and prostate cancer (Cancer Epidemiol. Biomarkers Prev. 2004, 13: 759); AChR gene encoding acetylcholine receptor involved in congential myasthenic syndrome (Neurology 2004, 62: 1090); P2Y12 gene encoding adenosine diphosphate (ADP) receptor protein involved in risk of peripheral arterial disease (Circulation 2003, 108: 2971); LQT1 gene encoding LQT1 protein involved in atrial fibrillation (Cardiology 2003, 100: 109); RET protooncogene encoding RET protein involved in sporadic pheochromocytoma (J. Clin. Endocrinol. Metab. 2003, 88: 4911); filamin A gene encoding filamin A protein involved in various congenital malformations (Nat. Genet. 2003, 33: 487); TARDBP gene encoding TDP-43 protein involved in amyotrophic lateral sclerosis (Hum. Mol. Gene.t 2010, 19: 671); SCA3 gene encoding ataxin-3 protein involved in Machado-Joseph disease (PLoS One 2008, 3: e3341); SCAT gene encoding ataxin-7 protein involved in spino-cerebellar ataxia-7 (PLoS One 2009, 4: e7232); and HTT gene encoding huntingtin protein involved in Huntington's disease (Neurobiol Dis. 1996, 3:183); and the CA4 gene encoding carbonic anhydrase 4 protein, CRX gene encoding cone-rod homeobox transcription factor protein, FSCN2 gene encoding retinal fascin homolog 2 protein, IMPDH1 gene encoding inosine monophosphate dehydrogenase 1 protein, NR2E3 gene encoding nuclear receptor subfamily 2 group E3 protein, NRL gene encoding neural retina leucine zipper protein, PRPF3 (RP18) gene encoding pre-mRNA splicing factor 3 protein, PRPF8 (RP13) gene encoding pre-mRNA splicing factor 8 protein, PRPF31 (RP11) gene encoding pre-mRNA splicing factor 31 protein, RDS gene encoding peripherin 2 protein, ROM1 gene encoding rod outer membrane protein 1 protein, RHO gene encoding rhodopsin protein, RP1 gene encoding RP1 protein, RPGR gene encoding retinitis pigmentosa GTPase regulator protein, all of which are involved in Autosomal Dominant Retinitis Pigmentosa disease (Adv Exp Med Biol. 2008, 613:203)</p><p id="p-0372" num="0509">In certain embodiments, the mutant allele is associated with any disease from the group consisting of Alzheimer's disease, Creutzfeldt-Jakob disease, fatal familial insomnia, Alexander disease, Parkinson's disease, amyotrophic lateral sclerosis, dentato-rubral and pallido-luysian atrophy DRPA, spino-cerebellar ataxia, Torsion dystonia, cardiomyopathy, chronic obstructive pulmonary disease (COPD), liver disease, hepatocellular carcinoma, systemic lupus erythematosus, hypercholesterolemia, breast cancer, asthma, Type 1 diabetes, Rheumatoid arthritis, Graves disease, SLE, spinal and bulbar muscular atrophy, Kennedy's disease, progressive childhood posterior subcapsular cataracts, cholesterol gallstone disease, arthrosclerosis, cardiovascular disease, primary hypercalciuria, alpha-thallasemia, obsessive compulsive disorder, Anxiety, comorbid depression, congenital visual defects, hypertension, metabolic syndrome, prostate cancer, congential myasthenic syndrome, peripheral arterial disease, atrial fibrillation, sporadic pheochromocytoma, congenital malformations, Machado-Joseph disease, Huntington's disease, and Autosomal Dominant Retinitis Pigmentosa disease.</p><p id="p-0373" num="0510">i. Certain Huntingtin Targets</p><p id="p-0374" num="0511">In certain embodiments, an allelic variant of huntingtin is selectively reduced. Nucleotide sequences that encode huntingtin include, without limitation, the following: GENBANK Accession No. NT_006081.18, truncated from nucleotides 1566000 to 1768000 (replaced by GENBANK Accession No. NT_006051), incorporated herein as SEQ ID NO: 1, and NM_002111.6, incorporated herein as SEQ ID NO: 574.</p><p id="p-0375" num="0512">Table 14 provides SNPs found in the GM04022, GM04281, GM02171, and GM02173B cell lines. Also provided are the allelic variants found at each SNP position, the genotype for each of the cell lines, and the percentage of HD patients having a particular allelic variant. For example, the two allelic variants for SNP rs6446723 are T and C. The GM04022 cell line is heterozygous TC, the GM02171 cell line is homozygous CC, the GM02173 cell line is heterozygous TC, and the GM04281 cell line is homozygous TT. Fifty percent of HD patients have a Tat SNP position rs6446723.</p><p id="p-0376" num="0000"><tables id="TABLE-US-00014" num="00014"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="280pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 14</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Allelic Variations for SNPs Associated with HD</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="8"><colspec colname="1" colwidth="42pt" align="left"/><colspec colname="2" colwidth="35pt" align="center"/><colspec colname="3" colwidth="35pt" align="center"/><colspec colname="4" colwidth="35pt" align="center"/><colspec colname="5" colwidth="35pt" align="center"/><colspec colname="6" colwidth="35pt" align="center"/><colspec colname="7" colwidth="42pt" align="center"/><colspec colname="8" colwidth="21pt" align="center"/><tbody valign="top"><row><entry>SNP</entry><entry>Variation</entry><entry>GM04022</entry><entry>GM02171</entry><entry>GM02173</entry><entry>GM04281</entry><entry>TargetPOP</entry><entry>allele</entry></row><row><entry namest="1" nameend="8" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="8"><colspec colname="1" colwidth="42pt" align="left"/><colspec colname="2" colwidth="35pt" align="center"/><colspec colname="3" colwidth="35pt" align="center"/><colspec colname="4" colwidth="35pt" align="center"/><colspec colname="5" colwidth="35pt" align="center"/><colspec colname="6" colwidth="35pt" align="center"/><colspec colname="7" colwidth="42pt" align="char" char="."/><colspec colname="8" colwidth="21pt" align="center"/><tbody valign="top"><row><entry>rs6446723</entry><entry>T/C</entry><entry>TC</entry><entry>CC</entry><entry>TC</entry><entry>TT</entry><entry>0.50</entry><entry>T</entry></row><row><entry>rs3856973</entry><entry>A/G</entry><entry>AG</entry><entry>AA</entry><entry>AG</entry><entry>GG</entry><entry>0.50</entry><entry>G</entry></row><row><entry>rs2285086</entry><entry>A/G</entry><entry>AG</entry><entry>GG</entry><entry>AG</entry><entry>AA</entry><entry>0.50</entry><entry>A</entry></row><row><entry>rs363092</entry><entry>A/C</entry><entry>AC</entry><entry>AA</entry><entry>AC</entry><entry>CC</entry><entry>0.49</entry><entry>C</entry></row><row><entry>rs916171</entry><entry>C/G</entry><entry>GC</entry><entry>GG</entry><entry>GC</entry><entry>CC</entry><entry>0.49</entry><entry>C</entry></row><row><entry>rs6844859</entry><entry>T/C</entry><entry>TC</entry><entry>CC</entry><entry>TC</entry><entry>TT</entry><entry>0.49</entry><entry>T</entry></row><row><entry>rs7691627</entry><entry>A/G</entry><entry>AG</entry><entry>AA</entry><entry>AG</entry><entry>GG</entry><entry>0.49</entry><entry>G</entry></row><row><entry>rs4690073</entry><entry>A/G</entry><entry>AG</entry><entry>AA</entry><entry>AG</entry><entry>GG</entry><entry>0.49</entry><entry>G</entry></row><row><entry>rs2024115</entry><entry>A/G</entry><entry>AG</entry><entry>GG</entry><entry>AG</entry><entry>AA</entry><entry>0.48</entry><entry>A</entry></row><row><entry>rs11731237</entry><entry>T/C</entry><entry>CC</entry><entry>CC</entry><entry>TC</entry><entry>TT</entry><entry>0.43</entry><entry>T</entry></row><row><entry>rs362296</entry><entry>A/C</entry><entry>CC</entry><entry>AC</entry><entry>AC</entry><entry>AC</entry><entry>0.42</entry><entry>C</entry></row><row><entry>rs10015979</entry><entry>A/G</entry><entry>AA</entry><entry>AA</entry><entry>AG</entry><entry>GG</entry><entry>0.42</entry><entry>G</entry></row><row><entry>rs7659144</entry><entry>C/G</entry><entry>CG</entry><entry>CG</entry><entry>CG</entry><entry>CC</entry><entry>0.41</entry><entry>C</entry></row><row><entry>rs363096</entry><entry>T/C</entry><entry>CC</entry><entry>CC</entry><entry>TC</entry><entry>TT</entry><entry>0.40</entry><entry>T</entry></row><row><entry>rs362273</entry><entry>A/G</entry><entry>AA</entry><entry>AG</entry><entry>AG</entry><entry>AA</entry><entry>0.39</entry><entry>A</entry></row><row><entry>rs16843804</entry><entry>T/C</entry><entry>CC</entry><entry>TC</entry><entry>TC</entry><entry>CC</entry><entry>0.38</entry><entry>C</entry></row><row><entry>rs362271</entry><entry>A/G</entry><entry>GG</entry><entry>AG</entry><entry>AG</entry><entry>GG</entry><entry>0.38</entry><entry>G</entry></row><row><entry>rs362275</entry><entry>T/C</entry><entry>CC</entry><entry>TC</entry><entry>TC</entry><entry>CC</entry><entry>0.38</entry><entry>C</entry></row><row><entry>rs3121419</entry><entry>T/C</entry><entry>CC</entry><entry>TC</entry><entry>TC</entry><entry>CC</entry><entry>0.38</entry><entry>C</entry></row><row><entry>rs362272</entry><entry>A/G</entry><entry>GG</entry><entry>&#x2014;</entry><entry>AG</entry><entry>GG</entry><entry>0.38</entry><entry>G</entry></row><row><entry>rs3775061</entry><entry>A/G</entry><entry>AA</entry><entry>AG</entry><entry>AG</entry><entry>AA</entry><entry>0.38</entry><entry>A</entry></row><row><entry>rs34315806</entry><entry>T/C</entry><entry>CC</entry><entry>TC</entry><entry>TC</entry><entry>CC</entry><entry>0.38</entry><entry>C</entry></row><row><entry>rs363099</entry><entry>T/C</entry><entry>CC</entry><entry>TC</entry><entry>TC</entry><entry>CC</entry><entry>0.38</entry><entry>C</entry></row><row><entry>rs2298967</entry><entry>T/C</entry><entry>TT</entry><entry>TC</entry><entry>TC</entry><entry>TT</entry><entry>0.38</entry><entry>T</entry></row><row><entry>rs363088</entry><entry>A/T</entry><entry>AA</entry><entry>TA</entry><entry>TA</entry><entry>AA</entry><entry>0.38</entry><entry>A</entry></row><row><entry>rs363064</entry><entry>T/C</entry><entry>CC</entry><entry>TC</entry><entry>TC</entry><entry>CC</entry><entry>0.35</entry><entry>C</entry></row><row><entry>rs363102</entry><entry>A/G</entry><entry>AG</entry><entry>AA</entry><entry>AA</entry><entry>AA</entry><entry>0.23</entry><entry>G</entry></row><row><entry>rs2798235</entry><entry>A/G</entry><entry>AG</entry><entry>GG</entry><entry>GG</entry><entry>GG</entry><entry>0.21</entry><entry>A</entry></row><row><entry>rs363080</entry><entry>T/C</entry><entry>TC</entry><entry>CC</entry><entry>CC</entry><entry>CC</entry><entry>0.21</entry><entry>T</entry></row><row><entry>rs363072</entry><entry>A/T</entry><entry>TA</entry><entry>TA</entry><entry>AA</entry><entry>AA</entry><entry>0.13</entry><entry>A</entry></row><row><entry>rs363125</entry><entry>A/C</entry><entry>AC</entry><entry>AC</entry><entry>CC</entry><entry>CC</entry><entry>0.12</entry><entry>C</entry></row><row><entry>rs362303</entry><entry>T/C</entry><entry>TC</entry><entry>TC</entry><entry>CC</entry><entry>CC</entry><entry>0.12</entry><entry>C</entry></row><row><entry>rs362310</entry><entry>T/C</entry><entry>TC</entry><entry>TC</entry><entry>CC</entry><entry>CC</entry><entry>0.12</entry><entry>C</entry></row><row><entry>rs10488840</entry><entry>A/G</entry><entry>AG</entry><entry>AG</entry><entry>GG</entry><entry>GG</entry><entry>0.12</entry><entry>G</entry></row><row><entry>rs362325</entry><entry>T/C</entry><entry>TC</entry><entry>TC</entry><entry>TT</entry><entry>TT</entry><entry>0.11</entry><entry>T</entry></row><row><entry>rs35892913</entry><entry>A/G</entry><entry>GG</entry><entry>GG</entry><entry>GG</entry><entry>GG</entry><entry>0.10</entry><entry>A</entry></row><row><entry>rs363102</entry><entry>A/G</entry><entry>AG</entry><entry>AA</entry><entry>AA</entry><entry>AA</entry><entry>0.09</entry><entry>A</entry></row><row><entry>rs363096</entry><entry>T/C</entry><entry>CC</entry><entry>CC</entry><entry>TC</entry><entry>TT</entry><entry>0.09</entry><entry>C</entry></row><row><entry>rs11731237</entry><entry>T/C</entry><entry>CC</entry><entry>CC</entry><entry>TC</entry><entry>TT</entry><entry>0.09</entry><entry>C</entry></row><row><entry>rs10015979</entry><entry>A/G</entry><entry>AA</entry><entry>AA</entry><entry>AG</entry><entry>GG</entry><entry>0.08</entry><entry>A</entry></row><row><entry>rs363080</entry><entry>T/C</entry><entry>TC</entry><entry>CC</entry><entry>CC</entry><entry>CC</entry><entry>0.07</entry><entry>C</entry></row><row><entry>rs2798235</entry><entry>A/G</entry><entry>AG</entry><entry>GG</entry><entry>GG</entry><entry>GG</entry><entry>0.07</entry><entry>G</entry></row><row><entry>rs1936032</entry><entry>C/G</entry><entry>GC</entry><entry>CC</entry><entry>CC</entry><entry>CC</entry><entry>0.06</entry><entry>C</entry></row><row><entry>rs2276881</entry><entry>A/G</entry><entry>GG</entry><entry>GG</entry><entry>GG</entry><entry>GG</entry><entry>0.06</entry><entry>G</entry></row><row><entry>rs363070</entry><entry>A/G</entry><entry>AA</entry><entry>AA</entry><entry>AA</entry><entry>AA</entry><entry>0.06</entry><entry>A</entry></row><row><entry>rs35892913</entry><entry>A/G</entry><entry>GG</entry><entry>GG</entry><entry>GG</entry><entry>GG</entry><entry>0.04</entry><entry>G</entry></row><row><entry>rs12502045</entry><entry>T/C</entry><entry>CC</entry><entry>CC</entry><entry>CC</entry><entry>CC</entry><entry>0.04</entry><entry>C</entry></row><row><entry>rs6446723</entry><entry>T/C</entry><entry>TC</entry><entry>CC</entry><entry>TC</entry><entry>TT</entry><entry>0.04</entry><entry>C</entry></row><row><entry>rs7685686</entry><entry>A/G</entry><entry>AG</entry><entry>GG</entry><entry>AG</entry><entry>AA</entry><entry>0.04</entry><entry>G</entry></row><row><entry>rs3733217</entry><entry>T/C</entry><entry>CC</entry><entry>CC</entry><entry>CC</entry><entry>CC</entry><entry>0.03</entry><entry>C</entry></row><row><entry>rs6844859</entry><entry>T/C</entry><entry>TC</entry><entry>CC</entry><entry>TC</entry><entry>TT</entry><entry>0.03</entry><entry>C</entry></row><row><entry>rs362331</entry><entry>T/C</entry><entry>TC</entry><entry>CC</entry><entry>TC</entry><entry>TT</entry><entry>0.03</entry><entry>C</entry></row><row><entry namest="1" nameend="8" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0009" level="1">E. Certain Indications</heading><p id="p-0377" num="0513">In certain embodiments, provided herein are methods of treating an animal or individual comprising administering one or more pharmaceutical compositions as described herein. In certain embodiments, the individual or animal has Huntington's disease.</p><p id="p-0378" num="0514">In certain embodiments, compounds targeted to huntingtin as described herein may be administered to reduce the severity of physiological symptoms of Huntington's disease. In certain embodiments, compounds targeted to huntingtin as described herein may be administered to reduce the rate of degeneration in an individual or an animal having Huntington's disease. In certain embodiments, compounds targeted to huntingtin as described herein may be administered regeneration function in an individual or an animal having Huntington's disease. In certain embodiments, symptoms of Huntingtin's disease may be reversed by treatment with a compound as described herein.</p><p id="p-0379" num="0515">In certain embodiments, compounds targeted to huntingtin as described herein may be administered to ameliorate one or more symptoms of Huntington's disease. In certain embodiments administration of compounds targeted to huntingtin as described herein may improve the symptoms of Huntington's disease as measured by any metric known to those having skill in the art. In certain embodiments, administration of compounds targeted to huntingtin as described herein may improve a rodent's rotarod assay performance. In certain embodiments, administration of compounds targeted to huntingtin as described herein may improve a rodent's plus maze assay. In certain embodiments, administration of compounds targeted to huntingtin as described herein may improve a rodent's open field assay performance.</p><p id="p-0380" num="0516">Accordingly, provided herein are methods for ameliorating a symptom associated with Huntington's disease in a subject in need thereof. In certain embodiments, provided is a method for reducing the rate of onset of a symptom associated with Huntington's disease. In certain embodiments, provided is a method for reducing the severity of a symptom associated with Huntington's disease. In certain embodiments, provided is a method for regenerating neurological function as shown by an improvement of a symptom associated with Huntington's disease. In such embodiments, the methods comprise administering to an individual or animal in need thereof a therapeutically effective amount of a compound targeted to a huntingtin nucleic acid.</p><p id="p-0381" num="0517">Huntington's disease is characterized by numerous physical, neurological, psychiatric, and/or peripheral symptoms. Any symptom known to one of skill in the art to be associated with Huntington's disease can be ameliorated or otherwise modulated as set forth above in the methods described above. In certain embodiments, the symptom is a physical symptom selected from the group consisting of restlessness, lack of coordination, unintentionally initiated motions, unintentionally uncompleted motions, unsteady gait, chorea, rigidity, writhing motions, abnormal posturing, instability, abnormal facial expressions, difficulty chewing, difficulty swallowing, difficulty speaking, seizure, and sleep disturbances. In certain embodiments, the symptom is a cognitive symptom selected from the group consisting of impaired planning, impaired flexibility, impaired abstract thinking, impaired rule acquisition, impaired initiation of appropriate actions, impaired inhibition of inappropriate actions, impaired short-term memory, impaired long-term memory, paranoia, disorientation, confusion, hallucination and dementia. In certain embodiments, the symptom is a psychiatric symptom selected from the group consisting of anxiety, depression, blunted affect, egocentrisms, aggression, compulsive behavior, irritability and suicidal ideation. In certain embodiments, the symptom is a peripheral symptom selected from the group consisting of reduced brain mass, muscle atrophy, cardiac failure, impaired glucose tolerance, weight loss, osteoporosis, and testicular atrophy.</p><p id="p-0382" num="0518">In certain embodiments, the symptom is restlessness. In certain embodiments, the symptom is lack of coordination. In certain embodiments, the symptom is unintentionally initiated motions. In certain embodiments, the symptom is unintentionally uncompleted motions. In certain embodiments, the symptom is unsteady gait. In certain embodiments, the symptom is chorea. In certain embodiments, the symptom is rigidity. In certain embodiments, the symptom is writhing motions. In certain embodiments, the symptom is abnormal posturing. In certain embodiments, the symptom is instability. In certain embodiments, the symptom is abnormal facial expressions. In certain embodiments, the symptom is difficulty chewing. In certain embodiments, the symptom is difficulty swallowing. In certain embodiments, the symptom is difficulty speaking. In certain embodiments, the symptom is seizures. In certain embodiments, the symptom is sleep disturbances.</p><p id="p-0383" num="0519">In certain embodiments, the symptom is impaired planning. In certain embodiments, the symptom is impaired flexibility. In certain embodiments, the symptom is impaired abstract thinking. In certain embodiments, the symptom is impaired rule acquisition. In certain embodiments, the symptom is impaired initiation of appropriate actions. In certain embodiments, the symptom is impaired inhibition of inappropriate actions. In certain embodiments, the symptom is impaired short-term memory. In certain embodiments, the symptom is impaired long-term memory. In certain embodiments, the symptom is paranoia. In certain embodiments, the symptom is disorientation. In certain embodiments, the symptom is confusion. In certain embodiments, the symptom is hallucination. In certain embodiments, the symptom is dementia.</p><p id="p-0384" num="0520">In certain embodiments, the symptom is anxiety. In certain embodiments, the symptom is depression. In certain embodiments, the symptom is blunted affect. In certain embodiments, the symptom is egocentrism. In certain embodiments, the symptom is aggression. In certain embodiments, the symptom is compulsive behavior. In certain embodiments, the symptom is irritability. In certain embodiments, the symptom is suicidal ideation.</p><p id="p-0385" num="0521">In certain embodiments, the symptom is reduced brain mass. In certain embodiments, the symptom is muscle atrophy. In certain embodiments, the symptom is cardiac failure. In certain embodiments, the symptom is impaired glucose tolerance. In certain embodiments, the symptom is weight loss. In certain embodiments, the symptom is osteoporosis. In certain embodiments, the symptom is testicular atrophy.</p><p id="p-0386" num="0522">In certain embodiments, symptoms of Huntington's disease may be quantifiable. For example, osteoporosis may be measured and quantified by, for example, bone density scans. For such symptoms, in certain embodiments, the symptom may be reduced by about 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 99%, or a range defined by any two of these values.</p><p id="p-0387" num="0523">In certain embodiments, provided are methods of treating an individual comprising administering one or more pharmaceutical compositions as described herein. In certain embodiments, the individual has Huntington's disease.</p><p id="p-0388" num="0524">In certain embodiments, administration of an antisense compound targeted to a huntingtin nucleic acid results in reduction of huntingtin expression by at least about 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 99%, or a range defined by any two of these values.</p><p id="p-0389" num="0525">In certain embodiments, pharmaceutical compositions comprising an antisense compound targeted to huntingtin are used for the preparation of a medicament for treating a patient suffering or susceptible to Huntington's disease.</p><heading id="h-0010" level="1">F. Certain Pharmaceutical Compositions</heading><p id="p-0390" num="0526">In certain embodiments, the present invention provides pharmaceutical compositions comprising one or more antisense compound. In certain embodiments, such pharmaceutical composition comprises a suitable pharmaceutically acceptable diluent or carrier. In certain embodiments, a pharmaceutical composition comprises a sterile saline solution and one or more antisense compound. In certain embodiments, such pharmaceutical composition consists of a sterile saline solution and one or more antisense compound. In certain embodiments, the sterile saline is pharmaceutical grade saline. In certain embodiments, a pharmaceutical composition comprises one or more antisense compound and sterile water. In certain embodiments, a pharmaceutical composition consists of one or more antisense compound and sterile water. In certain embodiments, the sterile saline is pharmaceutical grade water. In certain embodiments, a pharmaceutical composition comprises one or more antisense compound and phosphate-buffered saline (PBS). In certain embodiments, a pharmaceutical composition consists of one or more antisense compound and sterile phosphate-buffered saline (PBS). In certain embodiments, the sterile saline is pharmaceutical grade PBS.</p><p id="p-0391" num="0527">In certain embodiments, antisense compounds may be admixed with pharmaceutically acceptable active and/or inert substances for the preparation of pharmaceutical compositions or formulations. Compositions and methods for the formulation of pharmaceutical compositions depend on a number of criteria, including, but not limited to, route of administration, extent of disease, or dose to be administered.</p><p id="p-0392" num="0528">Pharmaceutical compositions comprising antisense compounds encompass any pharmaceutically acceptable salts, esters, or salts of such esters. In certain embodiments, pharmaceutical compositions comprising antisense compounds comprise one or more oligonucleotide which, upon administration to an animal, including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof. Accordingly, for example, the disclosure is also drawn to pharmaceutically acceptable salts of antisense compounds, prodrugs, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents. Suitable pharmaceutically acceptable salts include, but are not limited to, sodium and potassium salts.</p><p id="p-0393" num="0529">A prodrug can include the incorporation of additional nucleosides at one or both ends of an oligomeric compound which are cleaved by endogenous nucleases within the body, to form the active antisense oligomeric compound.</p><p id="p-0394" num="0530">Lipid moieties have been used in nucleic acid therapies in a variety of methods. In certain such methods, the nucleic acid is introduced into preformed liposomes or lipoplexes made of mixtures of cationic lipids and neutral lipids. In certain methods, DNA complexes with mono- or poly-cationic lipids are formed without the presence of a neutral lipid. In certain embodiments, a lipid moiety is selected to increase distribution of a pharmaceutical agent to a particular cell or tissue. In certain embodiments, a lipid moiety is selected to increase distribution of a pharmaceutical agent to fat tissue. In certain embodiments, a lipid moiety is selected to increase distribution of a pharmaceutical agent to muscle tissue.</p><p id="p-0395" num="0531">In certain embodiments, pharmaceutical compositions provided herein comprise one or more modified oligonucleotides and one or more excipients. In certain such embodiments, excipients are selected from water, salt solutions, alcohol, polyethylene glycols, gelatin, lactose, amylase, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose and polyvinylpyrrolidone.</p><p id="p-0396" num="0532">In certain embodiments, a pharmaceutical composition provided herein comprises a delivery system. Examples of delivery systems include, but are not limited to, liposomes and emulsions. Certain delivery systems are useful for preparing certain pharmaceutical compositions including those comprising hydrophobic compounds. In certain embodiments, certain organic solvents such as dimethylsulfoxide are used.</p><p id="p-0397" num="0533">In certain embodiments, a pharmaceutical composition provided herein comprises one or more tissue-specific delivery molecules designed to deliver the one or more pharmaceutical agents of the present invention to specific tissues or cell types. For example, in certain embodiments, pharmaceutical compositions include liposomes coated with a tissue-specific antibody.</p><p id="p-0398" num="0534">In certain embodiments, a pharmaceutical composition provided herein comprises a co-solvent system. Certain of such co-solvent systems comprise, for example, benzyl alcohol, a nonpolar surfactant, a water-miscible organic polymer, and an aqueous phase. In certain embodiments, such co-solvent systems are used for hydrophobic compounds. A non-limiting example of such a co-solvent system is the VPD co-solvent system, which is a solution of absolute ethanol comprising 3% w/v benzyl alcohol, 8% w/v of the nonpolar surfactant Polysorbate 80&#x2122; and 65% w/v polyethylene glycol 300. The proportions of such co-solvent systems may be varied considerably without significantly altering their solubility and toxicity characteristics. Furthermore, the identity of co-solvent components may be varied: for example, other surfactants may be used instead of Polysorbate 80&#x2122;; the fraction size of polyethylene glycol may be varied; other biocompatible polymers may replace polyethylene glycol, e.g., polyvinyl pyrrolidone; and other sugars or polysaccharides may substitute for dextrose.</p><p id="p-0399" num="0535">In certain embodiments, a pharmaceutical composition provided herein is prepared for oral administration. In certain embodiments, pharmaceutical compositions are prepared for buccal administration.</p><p id="p-0400" num="0536">In certain embodiments, a pharmaceutical composition is prepared for administration by injection (e.g., intravenous, subcutaneous, intramuscular, etc.). In certain of such embodiments, a pharmaceutical composition comprises a carrier and is formulated in aqueous solution, such as water or physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer. In certain embodiments, other ingredients are included (e.g., ingredients that aid in solubility or serve as preservatives). In certain embodiments, injectable suspensions are prepared using appropriate liquid carriers, suspending agents and the like. Certain pharmaceutical compositions for injection are presented in unit dosage form, e.g., in ampoules or in multi-dose containers. Certain pharmaceutical compositions for injection are suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Certain solvents suitable for use in pharmaceutical compositions for injection include, but are not limited to, lipophilic solvents and fatty oils, such as sesame oil, synthetic fatty acid esters, such as ethyl oleate or triglycerides, and liposomes. Aqueous injection suspensions may contain.</p><heading id="h-0011" level="1">G. Administration</heading><p id="p-0401" num="0537">In certain embodiments, the compounds and compositions as described herein are administered parenterally.</p><p id="p-0402" num="0538">In certain embodiments, parenteral administration is by infusion. Infusion can be chronic or continuous or short or intermittent. In certain embodiments, infused pharmaceutical agents are delivered with a pump. In certain embodiments, parenteral administration is by injection.</p><p id="p-0403" num="0539">In certain embodiments, compounds and compositions are delivered to the CNS. In certain embodiments, compounds and compositions are delivered to the cerebrospinal fluid. In certain embodiments, compounds and compositions are administered to the brain parenchyma. In certain embodiments, compounds and compositions are delivered to an animal by intrathecal administration, or intracerebroventricular administration. Broad distribution of compounds and compositions, described herein, within the central nervous system may be achieved with intraparenchymal administration, intrathecal administration, or intracerebroventricular administration.</p><p id="p-0404" num="0540">In certain embodiments, parenteral administration is by injection. The injection may be delivered with a syringe or a pump. In certain embodiments, the injection is a bolus injection. In certain embodiments, the injection is administered directly to a tissue, such as striatum, caudate, cortex, hippocampus and cerebellum.</p><p id="p-0405" num="0541">Therefore, in certain embodiments, delivery of a compound or composition described herein can affect the pharmacokinetic profile of the compound or composition. In certain embodiments, injection of a compound or composition described herein, to a targeted tissue improves the pharmacokinetic profile of the compound or composition as compared to infusion of the compound or composition. In a certain embodiment, the injection of a compound or composition improves potency compared to broad diffusion, requiring less of the compound or composition to achieve similar pharmacology. In certain embodiments, similar pharmacology refers to the amount of time that a target mRNA and/or target protein is down-regulated (e.g. duration of action). In certain embodiments, methods of specifically localizing a pharmaceutical agent, such as by bolus injection, decreases median effective concentration (EC50) by a factor of about 50 (e.g. 50 fold less concentration in tissue is required to achieve the same or similar pharmacodynamic effect). In certain embodiments, methods of specifically localizing a pharmaceutical agent, such as by bolus injection, decreases median effective concentration (EC50) by a factor of 20, 25, 30, 35, 40, 45 or 50. In certain embodiments the pharmaceutical agent in an antisense compound as further described herein. In certain embodiments, the targeted tissue is brain tissue. In certain embodiments the targeted tissue is striatal tissue. In certain embodiments, decreasing EC50 is desirable because it reduces the dose required to achieve a pharmacological result in a patient in need thereof.</p><p id="p-0406" num="0542">In certain embodiments, an antisense oligonucleotide is delivered by injection or infusion once every month, every two months, every 90 days, every 3 months, every 6 months, twice a year or once a year.</p><heading id="h-0012" level="1">H. Certain Combination Therapies</heading><p id="p-0407" num="0543">In certain embodiments, one or more pharmaceutical compositions are co-administered with one or more other pharmaceutical agents. In certain embodiments, such one or more other pharmaceutical agents are designed to treat the same disease, disorder, or condition as the one or more pharmaceutical compositions described herein. In certain embodiments, such one or more other pharmaceutical agents are designed to treat a different disease, disorder, or condition as the one or more pharmaceutical compositions described herein. In certain embodiments, such one or more other pharmaceutical agents are designed to treat an undesired side effect of one or more pharmaceutical compositions as described herein. In certain embodiments, one or more pharmaceutical compositions are co-administered with another pharmaceutical agent to treat an undesired effect of that other pharmaceutical agent. In certain embodiments, one or more pharmaceutical compositions are co-administered with another pharmaceutical agent to produce a combinational effect. In certain embodiments, one or more pharmaceutical compositions are co-administered with another pharmaceutical agent to produce a synergistic effect.</p><p id="p-0408" num="0544">In certain embodiments, one or more pharmaceutical compositions and one or more other pharmaceutical agents are administered at the same time. In certain embodiments, one or more pharmaceutical compositions and one or more other pharmaceutical agents are administered at different times. In certain embodiments, one or more pharmaceutical compositions and one or more other pharmaceutical agents are prepared together in a single formulation. In certain embodiments, one or more pharmaceutical compositions and one or more other pharmaceutical agents are prepared separately.</p><p id="p-0409" num="0545">In certain embodiments, pharmaceutical agents that may be co-administered with a pharmaceutical composition of include antipsychotic agents, such as, e.g., haloperidol, chlorpromazine, clozapine, quetapine, and olanzapine; antidepressant agents, such as, e.g., fluoxetine, sertraline hydrochloride, venlafaxine and nortriptyline; tranquilizing agents such as, e.g., benzodiazepines, clonazepam, paroxetine, venlafaxin, and beta-blockers; mood-stabilizing agents such as, e.g., lithium, valproate, lamotrigine, and carbamazepine; paralytic agents such as, e.g., Botulinum toxin; and/or other experimental agents including, but not limited to, tetrabenazine (Xenazine), creatine, conezyme Q10, trehalose, docosahexanoic acids, ACR16, ethyl-EPA, atomoxetine, citalopram, dimebon, memantine, sodium phenylbutyrate, ramelteon, ursodiol, zyprexa, xenasine, tiapride, riluzole, amantadine, [123I]MNI-420, atomoxetine, tetrabenazine, digoxin, detromethorphan, warfarin, alprozam, ketoconazole, omeprazole, and minocycline.</p><heading id="h-0013" level="2">Nonlimiting Disclosure and Incorporation by Reference</heading><p id="p-0410" num="0546">While certain compounds, compositions and methods described herein have been described with specificity in accordance with certain embodiments, the following examples serve only to illustrate the compounds described herein and are not intended to limit the same. Each of the references, GenBank accession numbers, and the like recited in the present application is incorporated herein by reference in its entirety.</p><p id="p-0411" num="0547">Although the sequence listing accompanying this filing identifies each sequence as either &#x201c;RNA&#x201d; or &#x201c;DNA&#x201d; as required, in reality, those sequences may be modified with any combination of chemical modifications. One of skill in the art will readily appreciate that such designation as &#x201c;RNA&#x201d; or &#x201c;DNA&#x201d; to describe modified oligonucleotides is, in certain instances, arbitrary. For example, an oligonucleotide comprising a nucleoside comprising a 2&#x2032;-OH sugar moiety and a thymine base could be described as a DNA having a modified sugar (2&#x2032;-OH for the natural 2&#x2032;-H of DNA) or as an RNA having a modified base (thymine (methylated uracil) for natural uracil of RNA).</p><p id="p-0412" num="0548">Accordingly, nucleic acid sequences provided herein, including, but not limited to those in the sequence listing, are intended to encompass nucleic acids containing any combination of natural or modified RNA and/or DNA, including, but not limited to such nucleic acids having modified nucleobases. By way of further example and without limitation, an oligomeric compound having the nucleobase sequence &#x201c;ATCGATCG&#x201d; encompasses any oligomeric compounds having such nucleobase sequence, whether modified or unmodified, including, but not limited to, such compounds comprising RNA bases, such as those having sequence &#x201c;AUCGAUCG&#x201d; and those having some DNA bases and some RNA bases such as &#x201c;AUCGATCG&#x201d; and oligomeric compounds having other modified or naturally occurring bases, such as &#x201c;AT<sup>me</sup>CGAUCG,&#x201d; wherein <sup>me</sup>C indicates a cytosine base comprising a methyl group at the 5-position.</p><heading id="h-0014" level="1">EXAMPLES</heading><p id="p-0413" num="0549">The following examples illustrate certain embodiments of the present invention and are not limiting. Moreover, where specific embodiments are provided, the inventors have contemplated generic application of those specific embodiments. For example, disclosure of an oligonucleotide having a particular motif provides reasonable support for additional oligonucleotides having the same or similar motif. And, for example, where a particular high-affinity modification appears at a particular position, other high-affinity modifications at the same position are considered suitable, unless otherwise indicated.</p><heading id="h-0015" level="1">Example 1</heading><heading id="h-0016" level="2">Single Nucleotide Polymorphisms (SNPs) in the Huntingtin (HTT) Gene Sequence</heading><p id="p-0414" num="0550">SNP positions (identified by Hayden et al, WO/2009/135322) associated with the HTT gene were mapped to the HTT genomic sequence, designated herein as SEQ ID NO: 1 (NT_006081.18 truncated from nucleotides 1566000 to 1768000). Table 15 provides SNP positions associated with the HTT gene. Table 15 provides a reference SNP ID number from the Entrez SNP database at the National Center for Biotechnology Information (NCBI, http://www.ncbi.nlm.nih.gov/sites/entrez?db=snp), incorporated herein by reference. Table 15 furnishes further details on each SNP. The &#x2018;Reference SNP ID number&#x2019; or &#x2018;RS number&#x2019; is the number designated to each SNP from the Entrez SNP database at NCBI, incorporated herein by reference. &#x2018;SNP position&#x2019; refers to the nucleotide position of the SNP on SEQ ID NO: 1. &#x2018;Polymorphism&#x2019; indicates the nucleotide variants at that SNP position. &#x2018;Major allele&#x2019; indicates the nucleotide associated with the major allele, or the nucleotide present in a statistically significant proportion of individuals in the human population. &#x2018;Minor allele&#x2019; indicates the nucleotide associated with the minor allele, or the nucleotide present in a relatively small proportion of individuals in the human population.</p><p id="p-0415" num="0000"><tables id="TABLE-US-00015" num="00015"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 15</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Single Nuclear Polymorphisms (SNPs)</entry></row><row><entry>and their positions on SEQ ID NO: 1</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="42pt" align="left"/><colspec colname="2" colwidth="42pt" align="center"/><colspec colname="3" colwidth="49pt" align="center"/><colspec colname="4" colwidth="42pt" align="center"/><colspec colname="5" colwidth="42pt" align="center"/><tbody valign="top"><row><entry>RS No.</entry><entry>SNP position</entry><entry>Polymorphism</entry><entry>Major allele</entry><entry>Minor allele</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="42pt" align="left"/><colspec colname="2" colwidth="42pt" align="char" char="."/><colspec colname="3" colwidth="49pt" align="center"/><colspec colname="4" colwidth="42pt" align="center"/><colspec colname="5" colwidth="42pt" align="center"/><tbody valign="top"><row><entry>rs2857936</entry><entry>1963</entry><entry>C/T</entry><entry>C</entry><entry>T</entry></row><row><entry>rs12506200</entry><entry>3707</entry><entry>A/G</entry><entry>G</entry><entry>A</entry></row><row><entry>rs762855</entry><entry>14449</entry><entry>A/G</entry><entry>G</entry><entry>A</entry></row><row><entry>rs3856973</entry><entry>19826</entry><entry>G/A</entry><entry>G</entry><entry>A</entry></row><row><entry>rs2285086</entry><entry>28912</entry><entry>G/A</entry><entry>A</entry><entry>G</entry></row><row><entry>rs7659144</entry><entry>37974</entry><entry>C/G</entry><entry>C</entry><entry>G</entry></row><row><entry>rs16843804</entry><entry>44043</entry><entry>C/T</entry><entry>C</entry><entry>T</entry></row><row><entry>rs2024115</entry><entry>44221</entry><entry>G/A</entry><entry>A</entry><entry>G</entry></row><row><entry>rs10015979</entry><entry>49095</entry><entry>A/G</entry><entry>A</entry><entry>G</entry></row><row><entry>rs7691627</entry><entry>51063</entry><entry>A/G</entry><entry>G</entry><entry>A</entry></row><row><entry>rs2798235</entry><entry>54485</entry><entry>G/A</entry><entry>G</entry><entry>A</entry></row><row><entry>rs4690072</entry><entry>62160</entry><entry>G/T</entry><entry>T</entry><entry>G</entry></row><row><entry>rs6446723</entry><entry>66466</entry><entry>C/T</entry><entry>T</entry><entry>C</entry></row><row><entry>rs363081</entry><entry>73280</entry><entry>G/A</entry><entry>G</entry><entry>A</entry></row><row><entry>rs363080</entry><entry>73564</entry><entry>T/C</entry><entry>C</entry><entry>T</entry></row><row><entry>rs363075</entry><entry>77327</entry><entry>G/A</entry><entry>G</entry><entry>A</entry></row><row><entry>rs363064</entry><entry>81063</entry><entry>T/C</entry><entry>C</entry><entry>T</entry></row><row><entry>rs3025849</entry><entry>83420</entry><entry>A/G</entry><entry>A</entry><entry>G</entry></row><row><entry>rs6855981</entry><entry>87929</entry><entry>A/G</entry><entry>G</entry><entry>A</entry></row><row><entry>rs363102</entry><entry>88669</entry><entry>G/A</entry><entry>A</entry><entry>G</entry></row><row><entry>rs11731237</entry><entry>91466</entry><entry>C/T</entry><entry>C</entry><entry>T</entry></row><row><entry>rs4690073</entry><entry>99803</entry><entry>A/G</entry><entry>G</entry><entry>A</entry></row><row><entry>rs363144</entry><entry>100948</entry><entry>T/G</entry><entry>T</entry><entry>G</entry></row><row><entry>rs3025838</entry><entry>101099</entry><entry>C/T</entry><entry>C</entry><entry>T</entry></row><row><entry>rs34315806</entry><entry>101687</entry><entry>A/G</entry><entry>G</entry><entry>A</entry></row><row><entry>rs363099</entry><entry>101709</entry><entry>T/C</entry><entry>C</entry><entry>T</entry></row><row><entry>rs363096</entry><entry>119674</entry><entry>T/C</entry><entry>T</entry><entry>c</entry></row><row><entry>rs2298967</entry><entry>125400</entry><entry>C/T</entry><entry>T</entry><entry>c</entry></row><row><entry>rs2298969</entry><entry>125897</entry><entry>A/G</entry><entry>G</entry><entry>A</entry></row><row><entry>rs6844859</entry><entry>130139</entry><entry>C/T</entry><entry>T</entry><entry>c</entry></row><row><entry>rs363092</entry><entry>135682</entry><entry>C/A</entry><entry>C</entry><entry>A</entry></row><row><entry>rs7685686</entry><entry>146795</entry><entry>A/G</entry><entry>A</entry><entry>G</entry></row><row><entry>rs363088</entry><entry>149983</entry><entry>A/T</entry><entry>A</entry><entry>T</entry></row><row><entry>rs362331</entry><entry>155488</entry><entry>C/T</entry><entry>T</entry><entry>C</entry></row><row><entry>rs916171</entry><entry>156468</entry><entry>G/C</entry><entry>C</entry><entry>G</entry></row><row><entry>rs362322</entry><entry>161018</entry><entry>A/G</entry><entry>A</entry><entry>G</entry></row><row><entry>rs362275</entry><entry>164255</entry><entry>T/C</entry><entry>C</entry><entry>T</entry></row><row><entry>rs362273</entry><entry>167080</entry><entry>A/G</entry><entry>A</entry><entry>G</entry></row><row><entry>rs2276881</entry><entry>171314</entry><entry>G/A</entry><entry>G</entry><entry>A</entry></row><row><entry>rs3121419</entry><entry>171910</entry><entry>T/C</entry><entry>C</entry><entry>T</entry></row><row><entry>rs362272</entry><entry>174633</entry><entry>G/A</entry><entry>G</entry><entry>A</entry></row><row><entry>rs362271</entry><entry>175171</entry><entry>G/A</entry><entry>G</entry><entry>A</entry></row><row><entry>rs3775061</entry><entry>178407</entry><entry>C/T</entry><entry>C</entry><entry>T</entry></row><row><entry>rs362310</entry><entry>179429</entry><entry>A/G</entry><entry>G</entry><entry>A</entry></row><row><entry>rs362307</entry><entry>181498</entry><entry>T/C</entry><entry>C</entry><entry>T</entry></row><row><entry>rs362306</entry><entry>181753</entry><entry>G/A</entry><entry>G</entry><entry>A</entry></row><row><entry>rs362303</entry><entry>181960</entry><entry>T/C</entry><entry>C</entry><entry>T</entry></row><row><entry>rs362296</entry><entry>186660</entry><entry>C/A</entry><entry>C</entry><entry>A</entry></row><row><entry>rs1006798</entry><entry>198026</entry><entry>A/G</entry><entry>A</entry><entry>G</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0017" level="1">Example 2</heading><heading id="h-0018" level="2">Modified Oligonucleotides Targeting Huntingtin (HTT) Single Nucleotide Polymorphisms (SNP)</heading><p id="p-0416" num="0551">A series of modified oligonucleotides were designed. These modified oligonucleotides were designed to target SNP positions associated with the HTT gene. In the tables, the 1&#x2032; subscript indicates an (S)-cEt modification; &#x2018;e&#x2019; subscript indicates MOE modification; &#x2018;g&#x2019; subscript indicates a 3&#x2032;-fluoro-HNA modification; &#x2018;f&#x2019; subscript indicates 2&#x2032;-alpha-fluoro-2&#x2032;-deoxyribose; &#x2018;m&#x2019; before the cytosine residue indicates a 5-methylcytosine; &#x2018;x&#x2019; before the thymine residue indicates a 2-thiothymine; number along with &#x2018;d&#x2019; indicates a the number of deoxyribose nucleosides; the &#x2018;o&#x2019; subscript after the sugar modification subscripts indicates a phosphate ester linkage; &#x2018;mp&#x2019; subscript after the nucleoside indicates a methylphosphonate full linker; &#x2018;s&#x2019; subscript after the nucleoside indicates a phosphorothioate internucleoside linkages. The underlined nucleoside indicates the position on the modified oligonucleotide opposite to the SNP position.</p><p id="p-0417" num="0000"><tables id="TABLE-US-00016" num="00016"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="371pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;16</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Modified&#x2003;oligonucleotides&#x2003;targeting&#x2003;Huntingtin&#x2003;(HTT)&#x2003;SNP&#x2003;rs2024115</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="42pt" align="left"/><colspec colname="2" colwidth="189pt" align="left"/><colspec colname="3" colwidth="42pt" align="left"/><colspec colname="4" colwidth="63pt" align="left"/><colspec colname="5" colwidth="35pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry/><entry/><entry>SEQ</entry></row><row><entry>Isis&#x2003;No.</entry><entry>SEQUENCE</entry><entry>SNP</entry><entry>Motif</entry><entry>ID.&#x2003;NO.</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="42pt" align="center"/><colspec colname="2" colwidth="189pt" align="left"/><colspec colname="3" colwidth="42pt" align="left"/><colspec colname="4" colwidth="63pt" align="left"/><colspec colname="5" colwidth="35pt" align="center"/><tbody valign="top"><row><entry>589567</entry><entry>T<sub>es</sub>&#x2003;mC<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;G<sub>ds</sub>&#x2003;mC<sub>ds</sub><u style="single">&#x2003;T<sub>ds</sub></u>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;mC<sub>ks</sub></entry><entry>rs2024115</entry><entry>eekk-d8-kkeee</entry><entry>&#x2003;37</entry></row><row><entry/><entry>G<sub>ks</sub>&#x2003;A<sub>es</sub>&#x2003;T<sub>es</sub>&#x2003;G<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>607448</entry><entry>mC<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;G<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;mC<sub>ks</sub>&#x2003;G<sub>ks</sub></entry><entry>rs2024115</entry><entry>ekk-d8-kkeee</entry><entry>102</entry></row><row><entry/><entry>A<sub>es</sub>&#x2003;T<sub>es</sub>&#x2003;G<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>607441</entry><entry>T<sub>es</sub>&#x2003;mC<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;G<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;mC<sub>ks</sub></entry><entry>rs2024115</entry><entry>eekk-d8-kkee</entry><entry>103</entry></row><row><entry/><entry>G<sub>ks</sub>&#x2003;A<sub>es</sub>T<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>607455</entry><entry>A<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;G<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;mC<sub>ks</sub>&#x2003;G<sub>ks</sub>&#x2003;A<sub>es</sub></entry><entry>rs2024115</entry><entry>ek-d8-kkeee</entry><entry>104</entry></row><row><entry/><entry>T<sub>es</sub>G<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>607462</entry><entry>mC<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;G<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;mC<sub>ks</sub>&#x2003;G<sub>ks</sub></entry><entry>rs2024115</entry><entry>eek-d8-kkee</entry><entry>105</entry></row><row><entry/><entry>A<sub>es</sub>T<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>607469</entry><entry>T<sub>es</sub>&#x2003;mC<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;G<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;mC<sub>ks</sub></entry><entry>rs2024115</entry><entry>eeek-d8-kee</entry><entry>106</entry></row><row><entry/><entry>G<sub>es</sub>&#x2003;A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0418" num="0000"><tables id="TABLE-US-00017" num="00017"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="371pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;17</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Modified&#x2003;oligonucleotides&#x2003;targeting&#x2003;Huntingtin&#x2003;(HTT)&#x2003;SNP&#x2003;rs6446723</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="42pt" align="left"/><colspec colname="2" colwidth="189pt" align="left"/><colspec colname="3" colwidth="42pt" align="left"/><colspec colname="4" colwidth="63pt" align="left"/><colspec colname="5" colwidth="35pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry/><entry/><entry>SEQ</entry></row><row><entry>Isis&#x2003;No.</entry><entry>SEQUENCE</entry><entry>SNP</entry><entry>Motif</entry><entry>ID.&#x2003;NO.</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="42pt" align="center"/><colspec colname="2" colwidth="189pt" align="left"/><colspec colname="3" colwidth="42pt" align="left"/><colspec colname="4" colwidth="63pt" align="left"/><colspec colname="5" colwidth="35pt" align="center"/><tbody valign="top"><row><entry>589450</entry><entry>T<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;<u style="single">A</u><sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;mC<sub>ks</sub></entry><entry>rs6446723</entry><entry>eeekk-d7-kkeee</entry><entry>&#x2003;32</entry></row><row><entry/><entry>T<sub>ks</sub>&#x2003;T<sub>es</sub>&#x2003;T<sub>es</sub>&#x2003;A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>589546</entry><entry>T<sub>e</sub>s&#x2003;A<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;<u style="single">A</u><sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;mC<sub>ks</sub></entry><entry>rs6446723</entry><entry>eekk-d8-kkeee</entry><entry>&#x2003;35</entry></row><row><entry/><entry>T<sub>ks</sub>&#x2003;T<sub>es</sub>&#x2003;T<sub>es</sub>&#x2003;A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>589547</entry><entry>A<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;<u style="single">A</u><sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ks</sub></entry><entry>rs6446723</entry><entry>eekk-d8-kkeee</entry><entry>&#x2003;36</entry></row><row><entry/><entry>T<sub>ks</sub>&#x2003;T<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;T<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>589718</entry><entry>T<sub>e</sub>s&#x2003;A<sub>ks</sub>&#x2003;A<sub>es</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;<u style="single">A</u><sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;mC<sub>ks</sub></entry><entry>rs6446723</entry><entry>ekek-d8-kekee</entry><entry>&#x2003;44</entry></row><row><entry/><entry>T<sub>es</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>es</sub>&#x2003;A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>617104</entry><entry>T<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;A<sub>eo</sub>&#x2003;T<sub>ko</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;mC<sub>ko</sub></entry><entry>rs6446723</entry><entry>eeekk-d7-kkeee</entry><entry>&#x2003;84</entry></row><row><entry/><entry>T<sub>ko</sub>&#x2003;T<sub>es</sub>&#x2003;T<sub>es</sub>&#x2003;A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>617106</entry><entry>T<sub>e</sub>s&#x2003;A<sub>eo</sub>&#x2003;A<sub>ko</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;A<sub>ds</sub></entry><entry>rs6446723</entry><entry>eekk-d8-kkeee</entry><entry>&#x2003;85</entry></row><row><entry/><entry>mC<sub>ko</sub>&#x2003;T<sub>ko</sub>&#x2003;T<sub>es</sub>&#x2003;T<sub>es</sub>&#x2003;A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>617108</entry><entry>T<sub>es</sub>&#x2003;A<sub>ko</sub>&#x2003;A<sub>eo</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;A<sub>ds</sub></entry><entry>rs6446723</entry><entry>ekek-d8-kekee</entry><entry>&#x2003;86</entry></row><row><entry/><entry>mC<sub>ko</sub>&#x2003;T<sub>eo</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>es</sub>&#x2003;A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>617109</entry><entry>A<sub>es</sub>&#x2003;A<sub>eo</sub>&#x2003;T<sub>ko</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;A<sub>ds</sub></entry><entry>rs6446723</entry><entry>eekk-d8-kkeee</entry><entry>&#x2003;87</entry></row><row><entry/><entry>T<sub>ko</sub>&#x2003;T<sub>ko</sub>&#x2003;T<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;T<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>607446</entry><entry>A<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;mC<sub>ks</sub>&#x2003;T<sub>ks</sub></entry><entry>rs6446723</entry><entry>ekk-d8-kkeee</entry><entry>&#x2003;92</entry></row><row><entry/><entry>T<sub>es</sub>&#x2003;T<sub>es</sub>&#x2003;A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>607439</entry><entry>TesA<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;mC<sub>ks</sub></entry><entry>rs6446723</entry><entry>eekk-d8-kkee</entry><entry>&#x2003;93</entry></row><row><entry/><entry>T<sub>ks</sub>&#x2003;T<sub>es</sub>&#x2003;T<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>607453</entry><entry>A<sub>es</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;mC<sub>ks</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>es</sub></entry><entry>rs6446723</entry><entry>ek-d8-kkeee</entry><entry>&#x2003;94</entry></row><row><entry/><entry>T<sub>es</sub>&#x2003;A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>607460</entry><entry>A<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;mC<sub>ks</sub>&#x2003;T<sub>ks</sub></entry><entry>rs6446723</entry><entry>ekk-d8-kkee</entry><entry>&#x2003;95</entry></row><row><entry/><entry>T<sub>es</sub>&#x2003;T<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>607467</entry><entry>T<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;mC<sub>ks</sub></entry><entry>rs6446723</entry><entry>eekk-d8-kee</entry><entry>&#x2003;96</entry></row><row><entry/><entry>T<sub>es</sub>&#x2003;T<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>607447</entry><entry>A<sub>es</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ks</sub></entry><entry>rs6446723</entry><entry>ekk-d8-kkeee</entry><entry>&#x2003;97</entry></row><row><entry/><entry>T<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;T<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>607440</entry><entry>A<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ks</sub></entry><entry>rs6446723</entry><entry>eekk-d8-kkee</entry><entry>&#x2003;98</entry></row><row><entry/><entry>T<sub>ks</sub>&#x2003;T<sub>es</sub>&#x2003;A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>607454</entry><entry>Tes&#x2003;T<sub>ks</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>es</sub></entry><entry>rs6446723</entry><entry>ek-d8-kkeee</entry><entry>&#x2003;99</entry></row><row><entry/><entry>A<sub>es</sub>&#x2003;T<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>607461</entry><entry>A<sub>es</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ks</sub></entry><entry>rs6446723</entry><entry>ekk-d8-kkee</entry><entry>100</entry></row><row><entry/><entry>T<sub>es</sub>&#x2003;A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>607468</entry><entry>A<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;T<sub>es</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ks</sub></entry><entry>rs6446723</entry><entry>eeek-d8-kee</entry><entry>101</entry></row><row><entry/><entry>T<sub>es</sub>&#x2003;T<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>607474</entry><entry>A<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;T<sub>es</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;mC<sub>ks</sub>&#x2003;T<sub>ks</sub></entry><entry>rs6446723</entry><entry>eeek-d7-kkeee</entry><entry>127</entry></row><row><entry/><entry>T<sub>es</sub>&#x2003;T<sub>es</sub>&#x2003;A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>607475</entry><entry>T<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>ks</sub></entry><entry>rs6446723</entry><entry>eeek-d7-kkeee</entry><entry>128</entry></row><row><entry/><entry>T<sub>es</sub>&#x2003;T<sub>es</sub>&#x2003;T<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>607476</entry><entry>A<sub>es</sub>&#x2003;T<sub>es</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;mC<sub>ks</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>es</sub></entry><entry>rs6446723</entry><entry>eek-d7-kkeee</entry><entry>129</entry></row><row><entry/><entry>T<sub>es</sub>&#x2003;A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>607477</entry><entry>A<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;T<sub>es</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;mC<sub>ks</sub>&#x2003;T<sub>ks</sub></entry><entry>rs6446723</entry><entry>eeek-d7-kkee</entry><entry>130</entry></row><row><entry/><entry>T<sub>es</sub>&#x2003;T<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>607478</entry><entry>T<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;T<sub>es</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;mC<sub>ks</sub></entry><entry>rs6446723</entry><entry>eeeek-d7-kke</entry><entry>131</entry></row><row><entry/><entry>T<sub>ks</sub>&#x2003;T<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0419" num="0000"><tables id="TABLE-US-00018" num="00018"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="350pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;18</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Modified&#x2003;oligonucleotides&#x2003;targeting&#x2003;Huntingtin&#x2003;(HTT)&#x2003;SNP&#x2003;rs363080</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="42pt" align="left"/><colspec colname="2" colwidth="182pt" align="left"/><colspec colname="3" colwidth="35pt" align="left"/><colspec colname="4" colwidth="56pt" align="left"/><colspec colname="5" colwidth="35pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry/><entry/><entry>SEQ</entry></row><row><entry>Isis&#x2003;No.</entry><entry>SEQUENCE</entry><entry>SNP</entry><entry>Motif</entry><entry>ID.&#x2003;NO.</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="42pt" align="center"/><colspec colname="2" colwidth="182pt" align="left"/><colspec colname="3" colwidth="35pt" align="left"/><colspec colname="4" colwidth="56pt" align="left"/><colspec colname="5" colwidth="35pt" align="center"/><tbody valign="top"><row><entry>609234</entry><entry>A<sub>es</sub>&#x2003;G<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;G<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;G<sub>ks</sub></entry><entry>rs363080</entry><entry>ekk-d8-kkee</entry><entry>156</entry></row><row><entry/><entry>G<sub>es</sub>&#x2003;mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>609235</entry><entry>G<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;G<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ks</sub>&#x2003;G<sub>ks</sub></entry><entry>rs363080</entry><entry>ekk-d8-kkee</entry><entry>157</entry></row><row><entry/><entry>mC<sub>es</sub>&#x2003;T<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>609236</entry><entry>A<sub>es</sub>&#x2003;G<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;G<sub>ks</sub></entry><entry>rs363080</entry><entry>ekk-d8-kkee</entry><entry>158</entry></row><row><entry/><entry>mC<sub>ks</sub>&#x2003;T<sub>es</sub>&#x2003;mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>609237</entry><entry>G<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;mC<sub>ks</sub></entry><entry>rs363080</entry><entry>ekk-d8-kkee</entry><entry>159</entry></row><row><entry/><entry>T<sub>ks</sub>&#x2003;mC<sub>es</sub>&#x2003;mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>609238</entry><entry>A<sub>es</sub>&#x2003;G<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;G<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;A<sub>ks</sub></entry><entry>rs363080</entry><entry>ekk-d8-kkeee</entry><entry>160</entry></row><row><entry/><entry>G<sub>ks</sub>&#x2003;G<sub>es</sub>&#x2003;mC<sub>es</sub>&#x2003;T<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>609239</entry><entry>G<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;G<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ks</sub>&#x2003;G<sub>ks</sub></entry><entry>rs363080</entry><entry>ekk-d8-kkeee</entry><entry>161</entry></row><row><entry/><entry>mC<sub>es</sub>&#x2003;T<sub>es</sub>&#x2003;mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>609240</entry><entry>A<sub>es</sub>&#x2003;G<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;G<sub>ks</sub></entry><entry>rs363080</entry><entry>ekk-d8-kkeee</entry><entry>162</entry></row><row><entry/><entry>mC<sub>ks</sub>&#x2003;T<sub>es</sub>&#x2003;mC<sub>es</sub>&#x2003;mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>609241</entry><entry>G<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;mC<sub>ks</sub></entry><entry>rs363080</entry><entry>ekk-d8-kkeee</entry><entry>163</entry></row><row><entry/><entry>T<sub>ks</sub>&#x2003;mC<sub>es</sub>&#x2003;mC<sub>es</sub>&#x2003;A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0420" num="0000"><tables id="TABLE-US-00019" num="00019"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="350pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;19</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Modified&#x2003;oligonucleotid<sub>es&#x2003;</sub>targeting&#x2003;Huntingtin&#x2003;(HTT)&#x2003;SNP&#x2003;rs363064</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="42pt" align="left"/><colspec colname="2" colwidth="175pt" align="left"/><colspec colname="3" colwidth="35pt" align="left"/><colspec colname="4" colwidth="63pt" align="left"/><colspec colname="5" colwidth="35pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry/><entry/><entry>SEQ</entry></row><row><entry>Isis&#x2003;No.</entry><entry>SEQUENCE</entry><entry>SNP</entry><entry>Motif</entry><entry>ID.&#x2003;NO.</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row><row><entry>589532</entry><entry>G<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>T<sub>ks&#x2003;</sub>Ak<sub>S</sub>&#x2003;mC<sub>ds&#x2003;</sub><u style="single">G</u><sub>ds</sub>&#x2003;G<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>mC<sub>ks</sub></entry><entry>rs363064</entry><entry>eeekk-d7-kkeee</entry><entry>&#x2003;33</entry></row><row><entry/><entry>A<sub>ks&#x2003;</sub>T<sub>es&#x2003;</sub>T<sub>es&#x2003;</sub>T<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>589645</entry><entry>G<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>ks&#x2003;</sub>T<sub>ks&#x2003;</sub>A<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub><u style="single">G</u><sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>mC<sub>ks</sub></entry><entry>rs363064</entry><entry>eekk-d8-kkeee</entry><entry>&#x2003;42</entry></row><row><entry/><entry>A<sub>ks&#x2003;</sub>T<sub>es&#x2003;</sub>T<sub>es&#x2003;</sub>T<sub>e</sub></entry><entry/><entry>&#x2003;</entry><entry/></row><row><entry> </entry></row><row><entry>589646</entry><entry>A<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>T<sub>ks&#x2003;</sub>A<sub>ks&#x2003;</sub>mC<sub>ds</sub>&#x2003;<u style="single">G</u><sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ks</sub></entry><entry>rs363064</entry><entry>eekk-d8-kkeee</entry><entry>&#x2003;43</entry></row><row><entry/><entry>T<sub>ks&#x2003;</sub>T<sub>es</sub>&#x2003;T<sub>es</sub>&#x2003;T<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>617107</entry><entry>A<sub>es</sub>&#x2003;A<sub>eo</sub>&#x2003;T<sub>ko</sub>&#x2003;A<sub>ks&#x2003;</sub>mC<sub>ds&#x2003;</sub><u style="single">G</u><sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ko</sub></entry><entry>rs363064</entry><entry>eekk-d8-kkeee</entry><entry>&#x2003;88</entry></row><row><entry/><entry>T<sub>ko</sub>&#x2003;T<sub>es&#x2003;</sub>T<sub>es&#x2003;</sub>T<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>617110</entry><entry>G<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>eo</sub>&#x2003;T<sub>ko</sub>&#x2003;A<sub>ks&#x2003;</sub>mC<sub>ds&#x2003;</sub><u style="single">G</u><sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>mC<sub>ko</sub></entry><entry>rs363064</entry><entry>eeekk-d7-kkeee</entry><entry>&#x2003;89</entry></row><row><entry/><entry>T<sub>ko</sub>&#x2003;T<sub>es</sub>&#x2003;T<sub>es</sub>&#x2003;T<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>607449</entry><entry>A<sub>es</sub>&#x2003;T<sub>ks&#x2003;</sub>A<sub>ks&#x2003;</sub>mC<sub>ds&#x2003;</sub><u style="single">G</u><sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ks&#x2003;</sub>T<sub>ks</sub></entry><entry>rs363064</entry><entry>ekk-d8-kkeee</entry><entry>107</entry></row><row><entry/><entry>T<sub>es&#x2003;</sub>T<sub>es&#x2003;</sub>T<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>607442</entry><entry>A<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>T<sub>ks&#x2003;</sub>A<sub>ks&#x2003;</sub>mC<sub>ds&#x2003;</sub><u style="single">G</u><sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ks</sub></entry><entry>rs363064</entry><entry>eekk-d8-kkee</entry><entry>108</entry></row><row><entry/><entry>T<sub>ks&#x2003;</sub>T<sub>es</sub>&#x2003;T<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>607456</entry><entry>T<sub>es</sub>&#x2003;A<sub>ks&#x2003;</sub>mC<sub>ds&#x2003;</sub><u style="single">G</u><sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ks&#x2003;</sub>T<sub>ks&#x2003;</sub>T<sub>es</sub></entry><entry>rs363064</entry><entry>ek-d8-kkeee</entry><entry>109</entry></row><row><entry/><entry>T<sub>es</sub>&#x2003;T<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>607463</entry><entry>A<sub>es&#x2003;</sub>T<sub>es&#x2003;</sub>A<sub>ks&#x2003;</sub>mC<sub>ds&#x2003;</sub><u style="single">G</u><sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ks&#x2003;</sub>T<sub>ks</sub></entry><entry>rs363064</entry><entry>eek-d8-kkee</entry><entry>110</entry></row><row><entry/><entry>T<sub>es</sub>&#x2003;T<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>607470</entry><entry>A<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;T<sub>es</sub>&#x2003;A<sub>ks&#x2003;</sub>mC<sub>ds&#x2003;</sub><u style="single">G</u><sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ks</sub></entry><entry>rs363064</entry><entry>eeek-d8-kee</entry><entry>111</entry></row><row><entry/><entry>T<sub>es</sub>&#x2003;T<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>607450</entry><entry>A<sub>es&#x2003;</sub>A<sub>ks&#x2003;</sub>T<sub>ks&#x2003;</sub>A<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub><u style="single">G</u><sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>mC<sub>ks&#x2003;</sub>A<sub>ks</sub></entry><entry>rs363064</entry><entry>ekk-d8-kkeee</entry><entry>112</entry></row><row><entry/><entry>T<sub>es&#x2003;</sub>T<sub>es</sub>&#x2003;T<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>607443</entry><entry>G<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>ks&#x2003;</sub>T<sub>ks&#x2003;</sub>A<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub><u style="single">G</u><sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>mC<sub>ks</sub></entry><entry>rs363064</entry><entry>eekk-d8-kkee</entry><entry>113</entry></row><row><entry/><entry>A<sub>ks&#x2003;</sub>T<sub>es&#x2003;</sub>T<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>607457</entry><entry>A<sub>es&#x2003;</sub>T<sub>ks&#x2003;</sub>A<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub><u style="single">G</u><sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>mC<sub>ks&#x2003;</sub>A<sub>ks&#x2003;</sub>T<sub>es</sub></entry><entry>rs363064</entry><entry>ek-d8-kkeee</entry><entry>114</entry></row><row><entry/><entry>T<sub>es</sub>&#x2003;T<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>607464</entry><entry>A<sub>es</sub>&#x2003;A<sub>ks&#x2003;</sub>T<sub>ks&#x2003;</sub>A<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub><u style="single">G</u><sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>mC<sub>ks&#x2003;</sub>A<sub>ks</sub></entry><entry>rs363064</entry><entry>ekk-d8-kkee</entry><entry>115</entry></row><row><entry/><entry>T<sub>es</sub>&#x2003;T<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>607471</entry><entry>G<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>T<sub>ks&#x2003;</sub>A<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub><u style="single">G</u><sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>mC<sub>ks</sub></entry><entry>rs363064</entry><entry>eeek-d8-kee</entry><entry>116</entry></row><row><entry/><entry>A<sub>es</sub>&#x2003;T<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0421" num="0000"><tables id="TABLE-US-00020" num="00020"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="392pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;20</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Modified&#x2003;oligonucleotides&#x2003;targeting&#x2003;Huntingtin&#x2003;(HTT)&#x2003;SNP&#x2003;rs7685686</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="42pt" align="left"/><colspec colname="2" colwidth="189pt" align="left"/><colspec colname="3" colwidth="42pt" align="left"/><colspec colname="4" colwidth="84pt" align="left"/><colspec colname="5" colwidth="35pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry/><entry/><entry>SEQ</entry></row><row><entry>Isis&#x2003;No.</entry><entry>SEQUENCE</entry><entry>SNP</entry><entry>Motif</entry><entry>ID.&#x2003;NO.</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="42pt" align="center"/><colspec colname="2" colwidth="189pt" align="left"/><colspec colname="3" colwidth="42pt" align="left"/><colspec colname="4" colwidth="84pt" align="left"/><colspec colname="5" colwidth="35pt" align="center"/><tbody valign="top"><row><entry>460209</entry><entry>T<sub>es&#x2003;</sub>A<sub>ks&#x2003;</sub>A<sub>ks&#x2003;</sub>A<sub>ds</sub>&#x2003;T<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub><u style="single">T</u><sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ks&#x2003;</sub>mC<sub>ks</sub></entry><entry>rs7685686</entry><entry>ekk-d9-kke</entry><entry>&#x2003;3</entry></row><row><entry/><entry>mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>476333</entry><entry>A<sub>es&#x2003;</sub>T<sub>ks&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>ks&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub><u style="single">T</u><sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ks</sub></entry><entry>rs7685686</entry><entry>ekek-d9-keke</entry><entry>&#x2003;4</entry></row><row><entry/><entry>mC<sub>es&#x2003;</sub>mC<sub>ks&#x2003;</sub>A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>540083</entry><entry>A<sub>es&#x2003;</sub>A<sub>ks&#x2003;</sub>T<sub>ks&#x2003;</sub>T<sub>ks&#x2003;</sub>G<sub>ds&#x2003;</sub><u style="single">T</u><sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>mC<sub>ds</sub></entry><entry>rs7685686</entry><entry>ekkk-d9-ke</entry><entry>&#x2003;7</entry></row><row><entry/><entry>A<sub>ks&#x2003;</sub>G<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>540094</entry><entry>T<sub>es&#x2003;</sub>T<sub>ks&#x2003;</sub>G<sub>ds&#x2003;</sub><u style="single">T</u><sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ks&#x2003;</sub>G<sub>ks</sub></entry><entry>rs7685686</entry><entry>ek-d9-kkke</entry><entry>&#x2003;8</entry></row><row><entry/><entry>A<sub>ks&#x2003;</sub>A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>540095</entry><entry>A<sub>es&#x2003;</sub>T<sub>ks&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub><u style="single">T</u><sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>mC<sub>ks&#x2003;</sub>A<sub>ks</sub></entry><entry>rs7685686</entry><entry>ek-d9-kkke</entry><entry>&#x2003;9</entry></row><row><entry/><entry>G<sub>ks&#x2003;</sub>A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>540096</entry><entry>A<sub>es&#x2003;</sub>A<sub>ks&#x2003;</sub>T<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub><u style="single">T</u><sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>mC<sub>ks&#x2003;</sub>mC<sub>ks</sub></entry><entry>rs7685686</entry><entry>ek-d9-kkke</entry><entry>10</entry></row><row><entry/><entry>A<sub>ks&#x2003;</sub>G<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>540108</entry><entry>A<sub>es&#x2003;</sub>T<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>ks&#x2003;</sub>A<sub>ks&#x2003;</sub>T<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub><u style="single">T</u><sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ks&#x2003;</sub>A<sub>ks</sub></entry><entry>rs7685686</entry><entry>eeekk-d7-kkeee</entry><entry>11</entry></row><row><entry/><entry>mC<sub>es&#x2003;</sub>mC<sub>es&#x2003;</sub>A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>550913</entry><entry>A<sub>ks&#x2003;</sub>A<sub>ks&#x2003;</sub>T<sub>es&#x2003;</sub>A<sub>ks&#x2003;</sub>A<sub>ks&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub><u style="single">T</u><sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds</sub></entry><entry>rs7685686</entry><entry>kkekk-d9-kkekk</entry><entry>12</entry></row><row><entry/><entry>A<sub>ks&#x2003;</sub>mC<sub>ks&#x2003;</sub>mC<sub>es&#x2003;</sub>T<sub>ks&#x2003;</sub>T<sub>k</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>551429</entry><entry>T<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>ks&#x2003;</sub>T<sub>ks&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub><u style="single">T</u><sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ks</sub></entry><entry>rs7685686</entry><entry>eeekk-d7-kke</entry><entry>13</entry></row><row><entry/><entry>mC<sub>ks&#x2003;</sub>mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>556845</entry><entry>T<sub>es&#x2003;</sub>A<sub>ks&#x2003;</sub>A<sub>ks&#x2003;</sub>A<sub>ds&#x2003;</sub>xT<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ks</sub></entry><entry>rs7685686</entry><entry>ekk-d9-kke</entry><entry>14</entry></row><row><entry/><entry>mC<sub>ks&#x2003;</sub>mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>558257</entry><entry>T<sub>es&#x2003;</sub>A<sub>ks&#x2003;</sub>A<sub>ks&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>T<sub>dmp</sub>&#x2003;G<sub>ds&#x2003;</sub><u style="single">T</u><sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ks</sub></entry><entry>rs7685686</entry><entry>ekk-d9-kke</entry><entry>15</entry></row><row><entry/><entry>mC<sub>ks&#x2003;</sub>mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>566267</entry><entry>T<sub>es&#x2003;</sub>A<sub>ks&#x2003;</sub>A<sub>ks&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>gs</sub>&#x2003;T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub><u style="single">T</u><sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ks</sub></entry><entry>rs7685686</entry><entry>ekkdk-d7-kke</entry><entry>16</entry></row><row><entry/><entry>mC<sub>ks&#x2003;</sub>mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>568876</entry><entry>A<sub>ks&#x2003;</sub>T<sub>ks&#x2003;</sub>A<sub>ks&#x2003;</sub>A<sub>ks&#x2003;</sub>A<sub>ks&#x2003;</sub>T<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub><u style="single">T</u><sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ks&#x2003;</sub>A<sub>ks</sub></entry><entry>rs7685686</entry><entry>kkkkk-d7-kkkkk</entry><entry>17</entry></row><row><entry/><entry>mC<sub>ks&#x2003;</sub>mC<sub>ks&#x2003;</sub>A<sub>k</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>571036</entry><entry>A<sub>es&#x2003;</sub>T<sub>ks&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>ks&#x2003;</sub>A<sub>es&#x2003;</sub>T<sub>ks&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub><u style="single">T</u><sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ks</sub></entry><entry>rs7685686</entry><entry>ekekek-d7-keke</entry><entry>18</entry></row><row><entry/><entry>mC<sub>es&#x2003;</sub>mC<sub>ks&#x2003;</sub>A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>571037</entry><entry>A<sub>es&#x2003;</sub>T<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>ks&#x2003;</sub>T<sub>ks&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub><u style="single">T</u><sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ks</sub></entry><entry>rs7685686</entry><entry>eeeekk-d7-keke</entry><entry>19</entry></row><row><entry/><entry>mC<sub>es&#x2003;</sub>mC<sub>ks&#x2003;</sub>A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>571039</entry><entry>A<sub>es&#x2003;</sub>T<sub>ks&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>ks&#x2003;</sub>A<sub>ds&#x2003;</sub>xT<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub><u style="single">T</u><sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ks</sub></entry><entry>rs7685686</entry><entry>ekek-d9-keke</entry><entry>20</entry></row><row><entry/><entry>mC<sub>es&#x2003;</sub>mC<sub>ks&#x2003;</sub>A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>571069</entry><entry>A<sub>es&#x2003;</sub>T<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>ks&#x2003;</sub>T<sub>ks&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub><u style="single">T</u><sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ks</sub></entry><entry>rs7685686</entry><entry>eeeekk-d7-kkee</entry><entry>21</entry></row><row><entry/><entry>mC<sub>ks&#x2003;</sub>mC<sub>es&#x2003;</sub>A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>571171</entry><entry>A<sub>es&#x2003;</sub>T<sub>ks&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>ks&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>T<sub>dmp</sub>&#x2003;G<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ks</sub></entry><entry>rs7685686</entry><entry>ekek-d9-keke</entry><entry>22</entry></row><row><entry/><entry>mC<sub>es&#x2003;</sub>mC<sub>ks&#x2003;</sub>A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>572771</entry><entry>T<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>ks&#x2003;</sub>T<sub>ks&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub><u style="single">T</u><sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ks</sub></entry><entry>rs7685686</entry><entry>eeekk-d7-kkee</entry><entry>23</entry></row><row><entry/><entry>mC<sub>ks&#x2003;</sub>mC<sub>es&#x2003;</sub>A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>572772</entry><entry>A<sub>es&#x2003;</sub>T<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>ks&#x2003;</sub>T<sub>ks&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub><u style="single">T</u><sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ks</sub></entry><entry>rs7685686</entry><entry>eeeekk-d7-kke</entry><entry>24</entry></row><row><entry/><entry>mC<sub>ks&#x2003;</sub>mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>575007</entry><entry>T<sub>es&#x2003;</sub>A<sub>ks&#x2003;</sub>A<sub>ks&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ks&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub><u style="single">T</u><sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ks</sub></entry><entry>rs7685686</entry><entry>ekkdk-d7-kke</entry><entry>25</entry></row><row><entry/><entry>mC<sub>ks&#x2003;</sub>mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>575008</entry><entry>T<sub>es&#x2003;</sub>A<sub>ks&#x2003;</sub>A<sub>ks&#x2003;</sub>A<sub>ks&#x2003;</sub>T<sub>ks&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub><u style="single">T</u><sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ks</sub></entry><entry>rs7685686</entry><entry>ekkkk-d7-kke</entry><entry>26</entry></row><row><entry/><entry>mC<sub>ks&#x2003;</sub>mCe</entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>585246</entry><entry>T<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>ks&#x2003;</sub>T<sub>ks&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ks</sub></entry><entry>rs7685686</entry><entry>eeekk-d7-kkeee</entry><entry>31</entry></row><row><entry/><entry>mC<sub>ks&#x2003;</sub>mC<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>G<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>589537</entry><entry>A<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;A<sub>ks&#x2003;</sub>T<sub>ks&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>mC<sub>ks</sub></entry><entry>rs7685686</entry><entry>eekk-d8-kkeee</entry><entry>34</entry></row><row><entry/><entry>mC<sub>ks&#x2003;</sub>A<sub>es&#x2003;</sub>G<sub>es&#x2003;</sub>A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>593199</entry><entry>T<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>eo</sub>&#x2003;A<sub>ko</sub>&#x2003;T<sub>ks&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ko</sub>&#x2003;C<sub>ks</sub></entry><entry>rs7685686</entry><entry>eeekk-d7-kke</entry><entry>47</entry></row><row><entry/><entry>C<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>593200</entry><entry>A<sub>e</sub>s&#x2003;T<sub>ks&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mCA<sub>ds&#x2003;</sub><u style="single">T</u><sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>mC<sub>ko</sub>&#x2003;A<sub>ko</sub></entry><entry>rs7685686</entry><entry>ek-d9-kkke</entry><entry>48</entry></row><row><entry/><entry>G<sub>ks&#x2003;</sub>A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>593201</entry><entry>A<sub>es&#x2003;</sub>T<sub>ko</sub>&#x2003;A<sub>es&#x2003;</sub>A<sub>ko</sub>&#x2003;A<sub>es&#x2003;</sub>T<sub>ks&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub><u style="single">T</u><sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ko</sub></entry><entry>rs7685686</entry><entry>ekekek-d7-keke</entry><entry>49</entry></row><row><entry/><entry>mC<sub>es&#x2003;</sub>mC<sub>ks&#x2003;</sub>A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>593202</entry><entry>A<sub>e</sub>s&#x2003;T<sub>ko</sub>&#x2003;A<sub>ko</sub>&#x2003;A<sub>ko</sub>&#x2003;A<sub>ks&#x2003;</sub>T<sub>ks&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub><u style="single">T</u><sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ko</sub></entry><entry>rs7685686</entry><entry>ekkkk-d7-kkke</entry><entry>50</entry></row><row><entry/><entry>mC<sub>ko</sub>&#x2003;mC<sub>ks&#x2003;</sub>A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>593203</entry><entry>T<sub>ks&#x2003;</sub>A<sub>ko</sub>&#x2003;A<sub>ko</sub>&#x2003;A<sub>ko</sub>&#x2003;T<sub>ks&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub><u style="single">T</u><sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ko</sub></entry><entry>rs7685686</entry><entry>kkkkk-d7-kkkkk</entry><entry>51</entry></row><row><entry/><entry>mC<sub>ko</sub>&#x2003;mC<sub>ko</sub>&#x2003;A<sub>ks&#x2003;</sub>G<sub>k</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>593204</entry><entry>A<sub>ks&#x2003;</sub>T<sub>ko</sub>&#x2003;A<sub>ko</sub>&#x2003;A<sub>ko</sub>&#x2003;A<sub>ko</sub>&#x2003;T<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub><u style="single">T</u><sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ko</sub>&#x2003;A<sub>ko</sub></entry><entry>rs7685686</entry><entry>kkkkk-d7-kkkkk</entry><entry>52</entry></row><row><entry/><entry>mC<sub>ko</sub>&#x2003;mC<sub>ko</sub>&#x2003;A<sub>k</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>598229</entry><entry>A<sub>es&#x2003;</sub>T<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>ks&#x2003;</sub>T<sub>ks&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub><u style="single">T</u><sub>ds&#x2003;</sub>mC<sub>ks&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ks</sub></entry><entry>rs7685686</entry><entry>eeeekk-d3-k-d3-keke</entry><entry>53</entry></row><row><entry/><entry>mC<sub>es&#x2003;</sub>mC<sub>ks&#x2003;</sub>A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>598299</entry><entry>T<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>ks&#x2003;</sub>T<sub>ks&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub><u style="single">T</u><sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ks&#x2003;</sub>mC<sub>es</sub></entry><entry>rs7685686</entry><entry>eeekk-d7-keee</entry><entry>54</entry></row><row><entry/><entry>mC<sub>es&#x2003;</sub>A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>598300</entry><entry>T<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>ks&#x2003;</sub>T<sub>ks&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub><u style="single">T</u><sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>es&#x2003;</sub>mC<sub>es</sub></entry><entry>rs7685686</entry><entry>eeekk-d7-eeee</entry><entry>55</entry></row><row><entry/><entry>mC<sub>es&#x2003;</sub>A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>598301</entry><entry>T<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>T<sub>ks&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub><u style="single">T</u><sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ks&#x2003;</sub>mC<sub>ks</sub></entry><entry>rs7685686</entry><entry>eeeek-d7-kkee</entry><entry>56</entry></row><row><entry/><entry>mC<sub>es&#x2003;</sub>A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>598302</entry><entry>T<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>T<sub>ks&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub><u style="single">T</u><sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ks&#x2003;</sub>mC<sub>es</sub></entry><entry>rs7685686</entry><entry>eeeek-d7-keee</entry><entry>57</entry></row><row><entry/><entry>mC<sub>es&#x2003;</sub>A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>598303</entry><entry>T<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>T<sub>ks&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub><u style="single">T</u><sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>es&#x2003;</sub>mC<sub>es</sub></entry><entry>rs7685686</entry><entry>eeeek-d7-eeee</entry><entry>58</entry></row><row><entry/><entry>mC<sub>es&#x2003;</sub>A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>598304</entry><entry>T<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ks&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub><u style="single">T</u><sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ks&#x2003;</sub>mC<sub>es</sub></entry><entry>rs7685686</entry><entry>eeedk-d7-keee</entry><entry>59</entry></row><row><entry/><entry>mC<sub>es&#x2003;</sub>A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>598305</entry><entry>A<sub>es&#x2003;</sub>T<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ks&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub><u style="single">T</u><sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ks</sub></entry><entry>rs7685686</entry><entry>eeeedk-d7-kkee</entry><entry>60</entry></row><row><entry/><entry>mC<sub>ks&#x2003;</sub>mC<sub>es&#x2003;</sub>A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>598306</entry><entry>A<sub>es&#x2003;</sub>T<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ks&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub><u style="single">T</u><sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ks</sub></entry><entry>rs7685686</entry><entry>eeeedk-d7-keee</entry><entry>61</entry></row><row><entry/><entry>mC<sub>es&#x2003;</sub>mC<sub>es&#x2003;</sub>A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>598307</entry><entry>A<sub>es&#x2003;</sub>T<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ks&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub><u style="single">T</u><sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>es</sub></entry><entry>rs7685686</entry><entry>eeeedk-d7-eeee</entry><entry>62</entry></row><row><entry/><entry>mC<sub>es&#x2003;</sub>mC<sub>es&#x2003;</sub>A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>598308</entry><entry>T<sub>es&#x2003;</sub>A<sub>eo</sub>&#x2003;A<sub>eo</sub>&#x2003;A<sub>es&#x2003;</sub>T<sub>ks&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub><u style="single">T</u><sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ks</sub></entry><entry>rs7685686</entry><entry>eeeek-d7-keeee</entry><entry>63</entry></row><row><entry/><entry>mC<sub>eo</sub>&#x2003;mC<sub>eo</sub>&#x2003;A<sub>es&#x2003;</sub>G<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>598309</entry><entry>A<sub>es&#x2003;</sub>A<sub>eo</sub>&#x2003;A<sub>eo</sub>&#x2003;T<sub>ks&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub><u style="single">T</u><sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ks&#x2003;</sub>mC<sub>es</sub></entry><entry>rs7685686</entry><entry>eeek-d7-keeeee</entry><entry>64</entry></row><row><entry/><entry>mC<sub>eo</sub>&#x2003;A<sub>eo</sub>&#x2003;G<sub>es</sub>&#x2003;A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>598310</entry><entry>A<sub>es&#x2003;</sub>A<sub>eo</sub>&#x2003;T<sub>ks&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub><u style="single">T</u><sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ks&#x2003;</sub>mC<sub>es&#x2003;</sub>mC<sub>es</sub></entry><entry>rs7685686</entry><entry>eek-d7-keeeeee</entry><entry>65</entry></row><row><entry/><entry>A<sub>eo</sub>&#x2003;G<sub>eo</sub>&#x2003;A<sub>es&#x2003;</sub>A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>606560</entry><entry>A<sub>es&#x2003;</sub>T<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>ks&#x2003;</sub>A<sub>ds&#x2003;</sub>xT<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub><u style="single">T</u><sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ks</sub></entry><entry>rs7685686</entry><entry>eeek-d9-keke</entry><entry>66</entry></row><row><entry/><entry>mC<sub>es&#x2003;</sub>mC<sub>ks&#x2003;</sub>A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>606561</entry><entry>A<sub>es&#x2003;</sub>T<sub>ks&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>ks&#x2003;</sub>A<sub>ds&#x2003;</sub>xT<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ks</sub></entry><entry>rs7685686</entry><entry>ekek-d9-keee</entry><entry>67</entry></row><row><entry/><entry>mC<sub>es&#x2003;</sub>mC<sub>es&#x2003;</sub>A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>606562</entry><entry>A<sub>es&#x2003;</sub>T<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>ks&#x2003;</sub>A<sub>ds&#x2003;</sub>xT<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ks</sub></entry><entry>rs7685686</entry><entry>eeek-d9-keee</entry><entry>68</entry></row><row><entry/><entry>mC<sub>es&#x2003;</sub>mC<sub>es&#x2003;</sub>A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>606578</entry><entry>A<sub>es&#x2003;</sub>T<sub>ks&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>ks&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub><u style="single">T</u><sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>Afs&#x2003;T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ks</sub></entry><entry>rs7685686</entry><entry>ekek-d6-k-dd-keke</entry><entry>69</entry></row><row><entry/><entry>mC<sub>es&#x2003;</sub>mC<sub>ks&#x2003;</sub>A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>617115</entry><entry>A<sub>es&#x2003;</sub>T<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>T<sub>ks&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub><u style="single">T</u><sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ks</sub></entry><entry>rs7685686</entry><entry>eeeeek-d7-kke</entry><entry>70</entry></row><row><entry/><entry>mC<sub>ks&#x2003;</sub>mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>617116</entry><entry>A<sub>es&#x2003;</sub>T<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>ks&#x2003;</sub>T<sub>ks&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub><u style="single">T</u><sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ks</sub></entry><entry>rs7685686</entry><entry>eeeekk-d7-kee</entry><entry>71</entry></row><row><entry/><entry>mC<sub>es&#x2003;</sub>mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>617117</entry><entry>A<sub>es</sub>&#x2003;T<sub>e</sub>s&#x2003;A<sub>es</sub>&#x2003;A<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>T<sub>ks&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub><u style="single">T</u><sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ks</sub></entry><entry>rs7685686</entry><entry>eeeeek-d7-kee</entry><entry>72</entry></row><row><entry/><entry>mC<sub>es&#x2003;</sub>mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>617118</entry><entry>A<sub>es&#x2003;</sub>T<sub>eo</sub>&#x2003;A<sub>eo</sub>&#x2003;A<sub>eo</sub>&#x2003;A<sub>eo</sub>&#x2003;T<sub>ks&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub><u style="single">T</u><sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ks</sub></entry><entry>rs7685686</entry><entry>eeeeek-d7-kee</entry><entry>73</entry></row><row><entry/><entry>mC<sub>es&#x2003;</sub>mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>617119</entry><entry>A<sub>es</sub>&#x2003;T<sub>eo</sub>&#x2003;A<sub>eo</sub>&#x2003;A<sub>eo</sub>&#x2003;A<sub>eo</sub>&#x2003;T<sub>ks&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub><u style="single">T</u><sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>es</sub></entry><entry>rs7685686</entry><entry>eeeeek-d7-eee</entry><entry>74</entry></row><row><entry/><entry>mC<sub>es&#x2003;</sub>mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>617425</entry><entry>A<sub>es&#x2003;</sub>T<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>T<sub>ks&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub><u style="single">T</u><sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>es</sub></entry><entry>rs7685686</entry><entry>eeeeek-d7-eee</entry><entry>75</entry></row><row><entry/><entry>mC<sub>es&#x2003;</sub>mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>613581</entry><entry>A<sub>e</sub>s&#x2003;A<sub>eo</sub>&#x2003;T<sub>eo</sub>&#x2003;A<sub>eo</sub>&#x2003;A<sub>es&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ks&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds</sub></entry><entry>rs7685686</entry><entry>eeeeedk-d7-eeeee</entry><entry>76</entry></row><row><entry/><entry>mC<sub>ds&#x2003;</sub>A<sub>eo</sub>&#x2003;mC<sub>eo</sub>&#x2003;mC<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>G<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>613582</entry><entry>A<sub>es&#x2003;</sub>T<sub>es&#x2003;</sub>A<sub>eo</sub>&#x2003;A<sub>eo</sub>&#x2003;A<sub>es&#x2003;</sub>T<sub>ks&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds</sub></entry><entry>rs7685686</entry><entry>eeeeek-d7-eeeeee</entry><entry>77</entry></row><row><entry/><entry>A<sub>eo</sub>&#x2003;mC<sub>eo</sub>&#x2003;mC<sub>eo</sub>&#x2003;A<sub>es&#x2003;</sub>G<sub>es&#x2003;</sub>A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>613583</entry><entry>T<sub>e</sub>s&#x2003;A<sub>eo</sub>&#x2003;A<sub>e</sub>o&#x2003;A<sub>es&#x2003;</sub>T<sub>ks&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>es</sub></entry><entry>rs7685686</entry><entry>eeeek-d7-eeeeeee</entry><entry>78</entry></row><row><entry/><entry>mC<sub>eo</sub>&#x2003;mC<sub>eo</sub>&#x2003;A<sub>eo</sub>&#x2003;G<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>613584</entry><entry>A<sub>es&#x2003;</sub>A<sub>eo</sub>&#x2003;A<sub>es&#x2003;</sub>T<sub>ks&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>es&#x2003;</sub>mC<sub>eo</sub></entry><entry>rs7685686</entry><entry>eeek-d7-eeeeeeee</entry><entry>79</entry></row><row><entry/><entry>mC<sub>eo</sub>&#x2003;A<sub>eo</sub>&#x2003;G<sub>eo</sub>&#x2003;A<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>613585</entry><entry>A<sub>es&#x2003;</sub>A<sub>eo</sub>&#x2003;T<sub>ks&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>es&#x2003;</sub>mC<sub>es</sub></entry><entry>rs7685686</entry><entry>eek-d7-eeeeeeeee</entry><entry>80</entry></row><row><entry/><entry>mC<sub>eo</sub>&#x2003;A<sub>eo</sub>&#x2003;G<sub>eo</sub>&#x2003;A<sub>eo</sub>&#x2003;A<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>613586</entry><entry>A<sub>es&#x2003;</sub>T<sub>ks&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>es&#x2003;</sub>mC<sub>es&#x2003;</sub>mC<sub>eo</sub></entry><entry>rs7685686</entry><entry>ek-d7-eeeeeeeeee</entry><entry>81</entry></row><row><entry/><entry>A<sub>eo</sub>&#x2003;G<sub>eo</sub>&#x2003;A<sub>eo</sub>&#x2003;A<sub>eo</sub>&#x2003;A<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>613588</entry><entry>T<sub>es&#x2003;</sub>A<sub>es&#x2003;</sub>A<sub>eo</sub>&#x2003;T<sub>eo</sub>&#x2003;A<sub>eo</sub>&#x2003;A<sub>eo</sub>&#x2003;A<sub>es&#x2003;</sub>T<sub>ks&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds</sub></entry><entry>rs7685686</entry><entry>eeeeeeek-d7-eeee</entry><entry>82</entry></row><row><entry/><entry>mC<sub>ds</sub>&#x2003;A<sub>eo</sub>&#x2003;mC<sub>es&#x2003;</sub>mC<sub>es&#x2003;</sub>A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>613589</entry><entry>T<sub>es&#x2003;</sub>T<sub>es&#x2003;</sub>A<sub>eo</sub>&#x2003;A<sub>eo</sub>&#x2003;T<sub>eo</sub>&#x2003;A<sub>eo</sub>&#x2003;A<sub>eo</sub>&#x2003;A<sub>es&#x2003;</sub>T<sub>ks&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds</sub></entry><entry>rs7685686</entry><entry>eeeeeeeek-d7-eee</entry><entry>83</entry></row><row><entry/><entry>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>es&#x2003;</sub>mC<sub>es&#x2003;</sub>mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>617105</entry><entry>A<sub>es&#x2003;</sub>A<sub>eo</sub>&#x2003;A<sub>ko</sub>&#x2003;T<sub>ks&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>mC<sub>ko</sub></entry><entry>rs7685686</entry><entry>eekk-d8-kkeee</entry><entry>90</entry></row><row><entry/><entry>mC<sub>ko</sub>&#x2003;A<sub>es&#x2003;</sub>G<sub>es</sub>&#x2003;A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>617111</entry><entry>A<sub>es&#x2003;</sub>T<sub>ko</sub>&#x2003;A<sub>eo</sub>&#x2003;A<sub>ks&#x2003;</sub>A<sub>ds&#x2003;</sub>xT<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>G<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ds&#x2003;</sub>T<sub>ds&#x2003;</sub>mC<sub>ds&#x2003;</sub>A<sub>ko</sub></entry><entry>rs7685686</entry><entry>ekek-d9-keke</entry><entry>91</entry></row><row><entry/><entry>mC<sub>es&#x2003;</sub>mC<sub>ks&#x2003;</sub>A<sub>e</sub></entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0422" num="0000"><tables id="TABLE-US-00021" num="00021"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="329pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;21</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Modified&#x2003;oligonucleotides&#x2003;targeting&#x2003;Huntingtin&#x2003;(HTT)&#x2003;SNP&#x2003;rs363088</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="42pt" align="center"/><colspec colname="2" colwidth="140pt" align="left"/><colspec colname="3" colwidth="35pt" align="left"/><colspec colname="4" colwidth="63pt" align="left"/><colspec colname="5" colwidth="49pt" align="center"/><tbody valign="top"><row><entry>Isis&#x2003;No.</entry><entry>SEQUENCE</entry><entry>SNP</entry><entry>Motif</entry><entry>SEQ&#x2003;ID.&#x2003;NO.</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row><row><entry>435871</entry><entry>T<sub>es</sub>&#x2003;mC<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;mC<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;G<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub></entry><entry>rs363088</entry><entry>eeeee-d9-eeeee</entry><entry>&#x2003;2</entry></row><row><entry/><entry><u style="single">T<sub>ds</sub></u>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>es</sub>&#x2003;mC<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;T<sub>es</sub></entry><entry/><entry/><entry/></row><row><entry/><entry>mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>525366</entry><entry>mC<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;G<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;<u style="single">T<sub>ds</sub></u></entry><entry>rs363088</entry><entry>ekek-d9-keke</entry><entry>&#x2003;5</entry></row><row><entry/><entry>mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ks</sub>&#x2003;mC<sub>es</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>525368</entry><entry>A<sub>ks</sub>&#x2003;mC<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;G<sub>ks</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;<u style="single">T<sub>ds</sub></u>&#x2003;mC<sub>ds</sub></entry><entry>rs363088</entry><entry>kekk-d8-keke</entry><entry>&#x2003;6</entry></row><row><entry/><entry>T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ks</sub>&#x2003;mC<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;T<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>575172</entry><entry>A<sub>es</sub>&#x2003;mC<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;G<sub>ks</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;<u style="single">T<sub>ds</sub></u>&#x2003;mC<sub>ds</sub></entry><entry>rs363088</entry><entry>ekkk-d8-kke</entry><entry>27</entry></row><row><entry/><entry>T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>575175</entry><entry>A<sub>es</sub>&#x2003;mC<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;G<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;<u style="single">T<sub>ds</sub></u>&#x2003;mC<sub>ds</sub></entry><entry>rs363088</entry><entry>ekk-d8-kkke</entry><entry>28</entry></row><row><entry/><entry>T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ks</sub>&#x2003;T<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>582658</entry><entry>mC<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;G<sub>ks</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;<u style="single">T<sub>ds</sub></u></entry><entry>rs363088</entry><entry>ekekk-d8-keke</entry><entry>29</entry></row><row><entry/><entry>mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ks</sub>&#x2003;mC<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;T<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>582661</entry><entry>C<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;G<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;<u style="single">T<sub>ds</sub></u></entry><entry>rs363088</entry><entry>ekek-d8-kkeke</entry><entry>30</entry></row><row><entry/><entry>mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ks</sub>&#x2003;T<sub>ks</sub>&#x2003;mC<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;T<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>589595</entry><entry>mC<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;mC<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;G<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;<u style="single">T<sub>ds</sub></u></entry><entry>rs363088</entry><entry>eekk-d8-kkeee</entry><entry>38</entry></row><row><entry/><entry>mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ks</sub>&#x2003;T<sub>ks</sub>&#x2003;mC<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;T<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>589596</entry><entry>A<sub>es</sub>&#x2003;mC<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;G<sub>ks</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;<u style="single">T<sub>ds</sub></u>&#x2003;mC<sub>ds</sub></entry><entry>rs363088</entry><entry>eekk-d8-kkeee</entry><entry>39</entry></row><row><entry/><entry>T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;A<sub>es</sub>&#x2003;T<sub>es</sub>&#x2003;mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>591416</entry><entry>mC<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;mC<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;G<sub>ks</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;<u style="single">T<sub>ds</sub></u></entry><entry>rs363088</entry><entry>eeekk-d8-kkee</entry><entry>46</entry></row><row><entry/><entry>mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;A<sub>es</sub>&#x2003;T<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0423" num="0000"><tables id="TABLE-US-00022" num="00022"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="329pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;22</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Modified&#x2003;oligonucleotides&#x2003;targeting&#x2003;Huntingtin&#x2003;(HTT)&#x2003;SNP&#x2003;rs362307</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="42pt" align="center"/><colspec colname="2" colwidth="140pt" align="left"/><colspec colname="3" colwidth="35pt" align="left"/><colspec colname="4" colwidth="56pt" align="left"/><colspec colname="5" colwidth="56pt" align="center"/><tbody valign="top"><row><entry>Isis&#x2003;No.</entry><entry>SEQUENCE</entry><entry>SNP</entry><entry>Motif</entry><entry>SEQ&#x2003;ID.&#x2003;NO.</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row><row><entry>609230</entry><entry>G<sub>es</sub>&#x2003;G<sub>ks</sub>&#x2003;G<sub>ks</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;A<sub>ds</sub></entry><entry>rs362307</entry><entry>ekk-d8-kkee</entry><entry>148</entry></row><row><entry/><entry>mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;mC<sub>es</sub>&#x2003;A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>609231</entry><entry>A<sub>es</sub>&#x2003;G<sub>ks</sub>&#x2003;G<sub>ks</sub>&#x2003;G<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub></entry><entry>rs362307</entry><entry>ekk-d8-kkee</entry><entry>149</entry></row><row><entry/><entry>A<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ks</sub>&#x2003;mC<sub>es</sub>&#x2003;mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>609232</entry><entry>A<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;G<sub>ks</sub>&#x2003;G<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ds</sub></entry><entry>rs362307</entry><entry>ekk-d8-kkee</entry><entry>150</entry></row><row><entry/><entry>G<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;mC<sub>ks</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>es</sub>&#x2003;mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>609233</entry><entry>mC<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;G<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;mC<sub>ds</sub></entry><entry>rs362307</entry><entry>ekk-d8-kkee</entry><entry>151</entry></row><row><entry/><entry>A<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;T<sub>es</sub>&#x2003;T<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>609242</entry><entry>G<sub>es</sub>&#x2003;G<sub>ks</sub>&#x2003;G<sub>ks</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;A<sub>ds</sub></entry><entry>rs362307</entry><entry>ekk-d8-kkeee</entry><entry>152</entry></row><row><entry/><entry>mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;mC<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>609243</entry><entry>A<sub>es</sub>&#x2003;G<sub>ks</sub>&#x2003;G<sub>ks</sub>&#x2003;G<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub></entry><entry>rs362307</entry><entry>ekk-d8-kkeee</entry><entry>153</entry></row><row><entry/><entry>A<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ks</sub>&#x2003;mC<sub>es</sub>&#x2003;mC<sub>es</sub>&#x2003;A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>609244</entry><entry>A<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;G<sub>ks</sub>&#x2003;G<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ds</sub></entry><entry>rs362307</entry><entry>ekk-d8-kkeee</entry><entry>154</entry></row><row><entry/><entry>G<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;mC<sub>ks</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>es</sub>&#x2003;mC<sub>es</sub>&#x2003;mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>609245</entry><entry>mC<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;G<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;mC<sub>ds</sub></entry><entry>rs362307</entry><entry>ekk-d8-kkeee</entry><entry>155</entry></row><row><entry/><entry>A<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;T<sub>es</sub>&#x2003;T<sub>es</sub>&#x2003;mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0424" num="0000"><tables id="TABLE-US-00023" num="00023"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="378pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;22</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Modified&#x2003;oligonucleotides&#x2003;targeting&#x2003;Huntingtin&#x2003;(HTT)&#x2003;SNP&#x2003;rs7685686&#x2003;(G)</entry></row><row><entry>As&#x2003;described&#x2003;above&#x2003;in&#x2003;Example&#x2003;1,&#x2003;certain&#x2003;SNPs&#x2003;may&#x2003;have&#x2003;two&#x2003;or&#x2003;more&#x2003;allelic</entry></row><row><entry>variants.&#x2003;For&#x2003;example,&#x2003;the&#x2003;two&#x2003;allelic&#x2003;variants&#x2003;for&#x2003;SNP&#x2003;rs7685686&#x2003;are&#x2003;A&#x2003;and</entry></row><row><entry>G.&#x2003;In&#x2003;certain&#x2003;embodiments,&#x2003;antisense&#x2003;oligonucleotides&#x2003;can&#x2003;be&#x2003;designed</entry></row><row><entry>that&#x2003;target&#x2003;either&#x2003;allelic&#x2003;variant.&#x2003;In&#x2003;certain&#x2003;embodiments,&#x2003;a&#x2003;higher&#x2003;percentage</entry></row><row><entry>of&#x2003;the&#x2003;population&#x2003;may&#x2003;have&#x2003;a&#x2003;particular&#x2003;allelic&#x2003;variant.&#x2003;Modified&#x2003;oligonucleotides</entry></row><row><entry>were&#x2003;designed&#x2003;to&#x2003;target&#x2003;the&#x2003;G&#x2003;allelic&#x2003;variant&#x2003;of&#x2003;rs7685686.&#x2003;These&#x2003;modified</entry></row><row><entry>oligonucleotides&#x2003;are&#x2003;described&#x2003;further&#x2003;in&#x2003;Table&#x2003;22&#x2003;below.</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="42pt" align="center"/><colspec colname="2" colwidth="168pt" align="left"/><colspec colname="3" colwidth="49pt" align="left"/><colspec colname="4" colwidth="70pt" align="left"/><colspec colname="5" colwidth="49pt" align="center"/><tbody valign="top"><row><entry>Isis&#x2003;No.</entry><entry>SEQUENCE</entry><entry>SNP</entry><entry>Motif</entry><entry>SEQ&#x2003;ID.&#x2003;NO.</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row><row><entry>609274</entry><entry>T<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;m<u style="single">C</u><sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ks</sub></entry><entry>rs7685686</entry><entry>ekk-d7-kkeee</entry><entry>132</entry></row><row><entry/><entry>mC<sub>ks</sub>&#x2003;A<sub>es</sub>&#x2003;mC<sub>es</sub>&#x2003;mC<sub>e</sub></entry><entry>(G)</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>609226</entry><entry>T<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;m<u style="single">C</u><sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub></entry><entry>rs7685686</entry><entry>ekk-d8-kkee</entry><entry>136</entry></row><row><entry/><entry>mC<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>es</sub>&#x2003;mC<sub>es</sub></entry><entry>(G)</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>609266</entry><entry>T<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;m<u style="single">C</u><sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ds&#x2003;Tks</sub></entry><entry>rs7685686</entry><entry>ekk-d7-kkeeeee</entry><entry>140</entry></row><row><entry/><entry>mC<sub>ks</sub>&#x2003;A<sub>es</sub>&#x2003;mC<sub>es</sub>&#x2003;mC<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;G<sub>e</sub></entry><entry>(G)</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>609270</entry><entry>T<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;m<u style="single">C</u><sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ds&#x2003;Tds</sub></entry><entry>rs7685686</entry><entry>ekk-d8-kkeeee</entry><entry>144</entry></row><row><entry/><entry>mC<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>es</sub>&#x2003;mC<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;G<sub>e</sub></entry><entry>(G)</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>611714</entry><entry>T<sub>es</sub>A<sub>es</sub>A<sub>es</sub>A<sub>ks</sub>T<sub>ks</sub>T<sub>ds</sub>G<sub>ds</sub>mC<sub>ds</sub>mC<sub>ds</sub>A<sub>ds</sub>T<sub>ds</sub>m<u style="single">C</u><sub>ds</sub>A<sub>ks</sub>mC<sub>ks</sub>mC<sub>e</sub></entry><entry>rs7685686</entry><entry>eeekk-d7-kke</entry><entry>164</entry></row><row><entry/><entry/><entry>(G)</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>611715</entry><entry>A<sub>e</sub>s&#x2003;Tks&#x2003;A<sub>e</sub>s&#x2003;A<sub>ks</sub>A<sub>ds</sub>&#x2003;xT<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;m<u style="single">C</u><sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ds</sub></entry><entry>rs7685686</entry><entry>ekek-d9-keke</entry><entry>165</entry></row><row><entry/><entry>T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>es</sub>&#x2003;mC<sub>ks</sub>&#x2003;A<sub>e</sub></entry><entry>(G)</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>611716</entry><entry>A<sub>es</sub>&#x2003;T<sub>ks</sub>&#x2003;A<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>dx</sub>&#x2003;G<sub>ds</sub>&#x2003;m<u style="single">C</u><sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ds</sub></entry><entry>rs7685686</entry><entry>ekek-d9-keke</entry><entry>166</entry></row><row><entry/><entry>T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub>mC<sub>es</sub>&#x2003;mC<sub>ks</sub>A<sub>e</sub></entry><entry>(G)</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>611717</entry><entry>A<sub>e</sub>s&#x2003;T<sub>es</sub>A<sub>es</sub>A<sub>es</sub>A<sub>ks</sub>T<sub>ks</sub>T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;m<u style="single">C</u><sub>ds</sub>&#x2003;mC<sub>ds</sub>A<sub>ds</sub>&#x2003;T<sub>ds</sub></entry><entry>rs7685686</entry><entry>eeeekk-d7-kke</entry><entry>167</entry></row><row><entry/><entry>mC<sub>ds</sub>A<sub>ks</sub>mC<sub>ks</sub>&#x2003;mC<sub>e</sub></entry><entry>(G)</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>611718</entry><entry>T<sub>e</sub>A<sub>ks</sub>A<sub>ks</sub>A<sub>ds</sub>&#x2003;T<sub>ks</sub>T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;m<u style="single">C</u><sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>A<sub>ks</sub></entry><entry>rs7685686</entry><entry>ekk-d-k-d7-kke</entry><entry>168</entry></row><row><entry/><entry>mCksmC<sub>e</sub></entry><entry>(G)</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>611719</entry><entry>T<sub>e</sub>A<sub>ks</sub>A<sub>ks</sub>A<sub>ks</sub>T<sub>ks</sub>T<sub>ds</sub>G<sub>ds</sub>m<u style="single">C</u><sub>ds</sub>mC<sub>ds</sub>A<sub>ds</sub>T<sub>ds</sub>&#x2003;m<sub>Cds</sub>A<sub>ks</sub>mC<sub>ks</sub>mC<sub>e</sub></entry><entry>rs7685686</entry><entry>ekkkk-d7-kke</entry><entry>169</entry></row><row><entry/><entry/><entry>(G)</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>611720</entry><entry>AeT<sub>ks</sub>T<sub>ds</sub>G<sub>ds</sub>mC<sub>ds</sub>m<u style="single">C</u><sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>mC<sub>ds</sub>A<sub>ds</sub>&#x2003;mC<sub>ds</sub></entry><entry>rs7685686</entry><entry>ek-d9-kkke</entry><entry>170</entry></row><row><entry/><entry>mC<sub>ko</sub>A<sub>ko</sub>G<sub>ks</sub>A<sub>e</sub></entry><entry>(G)</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>611721</entry><entry>T<sub>es</sub>A<sub>es</sub>A<sub>es</sub>A<sub>es</sub>T<sub>ks</sub>T<sub>ks</sub>dG<sub>ds</sub>mC<sub>ds</sub>m<u style="single">C</u><sub>ds</sub>A<sub>ds</sub>T<sub>ds</sub>&#x2003;mC<sub>ds</sub>A<sub>ks</sub>mC<sub>es</sub></entry><entry>rs7685686</entry><entry>eeeek-d7-keee</entry><entry>171</entry></row><row><entry/><entry>mC<sub>es</sub>A<sub>es</sub></entry><entry>(G)</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>611722</entry><entry>A<sub>es</sub>&#x2003;T<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ds</sub></entry><entry>rs7685686</entry><entry>eeee-d-k-d7-keee</entry><entry>172</entry></row><row><entry/><entry>T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>es</sub>mC<sub>es</sub>&#x2003;A<sub>e</sub></entry><entry>(G)</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>611723</entry><entry>T<sub>e</sub>s&#x2003;A<sub>eo</sub>&#x2003;A<sub>eo</sub>&#x2003;A<sub>es</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>m<u style="single">C</u><sub>ds</sub>mC<sub>ds</sub>A<sub>ds</sub>T<sub>ds</sub>&#x2003;mC<sub>ds</sub></entry><entry>rs7685686</entry><entry>eeeek-d7-keeee</entry><entry>173</entry></row><row><entry/><entry>A<sub>ks</sub>mC<sub>eo</sub>mC<sub>eo</sub>A<sub>es</sub>G<sub>e</sub></entry><entry>(G)</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>609275</entry><entry>A<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;m<u style="single">C</u><sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ks</sub></entry><entry>rs7685686</entry><entry>ekk-d7-kkeee</entry><entry>133</entry></row><row><entry/><entry>A<sub>ks</sub>&#x2003;mC<sub>es</sub>&#x2003;mC<sub>es</sub>&#x2003;A<sub>e</sub></entry><entry>(G)</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>609227</entry><entry>A<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;Aks&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;m<u style="single">C</u><sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub></entry><entry>rs7685686</entry><entry>ekk-d8-kkee</entry><entry>137</entry></row><row><entry/><entry>A<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;mC<sub>es</sub>&#x2003;A<sub>e</sub></entry><entry>(G)</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>609267</entry><entry>A<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;m<u style="single">C</u><sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ks</sub></entry><entry>rs7685686</entry><entry>ekk-d7-kkeeeee</entry><entry>141</entry></row><row><entry/><entry>A<sub>ks</sub>&#x2003;mC<sub>es</sub>&#x2003;mC<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;G<sub>es</sub>&#x2003;A<sub>e</sub></entry><entry>(G)</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>609271</entry><entry>A<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;m<u style="single">C</u><sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mCds</entry><entry>rs7685686</entry><entry>ekk-d8-kkeeee</entry><entry>145</entry></row><row><entry/><entry>A<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;mC<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;G<sub>es</sub>&#x2003;A<sub>e</sub></entry><entry>(G)</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>609276</entry><entry>A<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;m<u style="single">C</u><sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub></entry><entry>rs7685686</entry><entry>ekk-d7-kkeee</entry><entry>134</entry></row><row><entry/><entry>mC<sub>ks</sub>&#x2003;mC<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;G<sub>e</sub></entry><entry>(G)</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>609228</entry><entry>A<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;m<u style="single">C</u><sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ds</sub></entry><entry>rs7685686</entry><entry>ekk-d8-kkee</entry><entry>138</entry></row><row><entry/><entry>mC<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;A<sub>es</sub>&#x2003;G<sub>e</sub></entry><entry>(G)</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>609268</entry><entry>A<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;m<u style="single">C</u><sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub></entry><entry>rs7685686</entry><entry>ekk-d7-kkeeeee</entry><entry>142</entry></row><row><entry/><entry>mC<sub>ks</sub>&#x2003;mC<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;G<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;A<sub>e</sub></entry><entry>(G)</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>609272</entry><entry>A<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;m<u style="single">C</u><sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ds</sub></entry><entry>rs7685686</entry><entry>ekk-d8-kkeeee</entry><entry>146</entry></row><row><entry/><entry>mC<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;A<sub>es</sub>&#x2003;G<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;A<sub>e</sub></entry><entry>(G)</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>609277</entry><entry>A<sub>es</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ks</sub>&#x2003;G<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;m<u style="single">C</u><sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;mC<sub>ks</sub></entry><entry>rs7685686</entry><entry>ekk-d7-kkeee</entry><entry>135</entry></row><row><entry/><entry>mC<sub>ks</sub>&#x2003;A<sub>es</sub>&#x2003;G<sub>es</sub>&#x2003;A<sub>e</sub></entry><entry>(G)</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>609229</entry><entry>A<sub>es</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ks</sub>&#x2003;G<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;m<u style="single">C</u><sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;mC<sub>ds</sub></entry><entry>rs7685686</entry><entry>ekk-d8-kkee</entry><entry>139</entry></row><row><entry/><entry>mC<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;G<sub>es</sub>&#x2003;A<sub>e</sub></entry><entry>(G)</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>609269</entry><entry>A<sub>es</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ks</sub>&#x2003;G<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;m<u style="single">C</u><sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;mC<sub>ds</sub></entry><entry>rs7685686</entry><entry>ekk-d7-kkeeeee</entry><entry>143</entry></row><row><entry/><entry>m<sub>ks</sub>s&#x2003;A<sub>es</sub>&#x2003;G<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;A<sub>e</sub></entry><entry>(G)</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>609273</entry><entry>A<sub>es</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ks</sub>&#x2003;G<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;m<u style="single">C</u><sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;mC<sub>ds</sub></entry><entry>rs7685686</entry><entry>ekk-d8-kkeeee</entry><entry>147</entry></row><row><entry/><entry>mC<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;G<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;A<sub>e</sub></entry><entry>(G)</entry><entry/><entry/></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0425" num="0000"><tables id="TABLE-US-00024" num="00024"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="336pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;23</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Modified&#x2003;oligonucleotides&#x2003;targeting&#x2003;Huntingtin&#x2003;(HTT)&#x2003;SNP&#x2003;rs362273</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="42pt" align="center"/><colspec colname="2" colwidth="140pt" align="left"/><colspec colname="3" colwidth="42pt" align="left"/><colspec colname="4" colwidth="63pt" align="left"/><colspec colname="5" colwidth="49pt" align="center"/><tbody valign="top"><row><entry>Isis&#x2003;No.</entry><entry>SEQUENCE</entry><entry>SNP</entry><entry>Motif</entry><entry>SEQ&#x2003;ID.&#x2003;NO.</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row><row><entry>589601</entry><entry>T<sub>es</sub>&#x2003;T<sub>es</sub>&#x2003;G<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub></entry><entry>rs362273</entry><entry>eekk-d8-kkeee</entry><entry>40</entry></row><row><entry/><entry>G<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;G<sub>ks</sub>&#x2003;mC<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;G<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>589602</entry><entry>T<sub>es</sub>&#x2003;G<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;T<sub>ks</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub></entry><entry>rs362273</entry><entry>eekk-d8-kkeee</entry><entry>41</entry></row><row><entry/><entry>mC<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;A<sub>es</sub>&#x2003;G<sub>es</sub>&#x2003;mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>589737</entry><entry>T<sub>es</sub>&#x2003;T<sub>ks</sub>&#x2003;G<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub></entry><entry>rs362273</entry><entry>ekek-d8-kekee</entry><entry>45</entry></row><row><entry/><entry>G<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;G<sub>es</sub>&#x2003;mC<sub>ks</sub>&#x2003;A<sub>es</sub>&#x2003;G<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>607451</entry><entry>G<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;T<sub>ks</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub></entry><entry>rs362273</entry><entry>ekk-d8-kkeee</entry><entry>117</entry></row><row><entry/><entry>mC<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;A<sub>es</sub>&#x2003;G<sub>es</sub>&#x2003;mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>607452</entry><entry>T<sub>es</sub>&#x2003;G<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub></entry><entry>rs362273</entry><entry>ekk-d8-kkeee</entry><entry>122</entry></row><row><entry/><entry>mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;G<sub>ks</sub>&#x2003;mC<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;G<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0426" num="0000"><tables id="TABLE-US-00025" num="00025"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="322pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;24</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Modified&#x2003;oligonucleotides&#x2003;targeting&#x2003;Huntingtin&#x2003;(HTT)&#x2003;SNP&#x2003;rs362274</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="42pt" align="center"/><colspec colname="2" colwidth="140pt" align="left"/><colspec colname="3" colwidth="35pt" align="left"/><colspec colname="4" colwidth="56pt" align="left"/><colspec colname="5" colwidth="49pt" align="center"/><tbody valign="top"><row><entry>Isis&#x2003;No.</entry><entry>SEQUENCE</entry><entry>SNP</entry><entry>Motif</entry><entry>SEQ&#x2003;ID.&#x2003;NO.</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row><row><entry>607444</entry><entry>T<sub>es</sub>&#x2003;G<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;T<sub>ks</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub></entry><entry>rs362274</entry><entry>eekk-d8-kkee</entry><entry>118</entry></row><row><entry/><entry>mC<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;A<sub>es</sub>&#x2003;G<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>607445</entry><entry>T<sub>es</sub>&#x2003;T<sub>es</sub>&#x2003;G<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub></entry><entry>rs362274</entry><entry>eekk-d8-kkee</entry><entry>123</entry></row><row><entry/><entry>G<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;G<sub>ks</sub>&#x2003;mC<sub>es</sub>&#x2003;A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0427" num="0000"><tables id="TABLE-US-00026" num="00026"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="308pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;25</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Modified&#x2003;oligonucleotides&#x2003;targeting&#x2003;Huntingtin&#x2003;(HTT)&#x2003;SNP&#x2003;rs362275</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="42pt" align="center"/><colspec colname="2" colwidth="133pt" align="left"/><colspec colname="3" colwidth="35pt" align="left"/><colspec colname="4" colwidth="49pt" align="left"/><colspec colname="5" colwidth="49pt" align="center"/><tbody valign="top"><row><entry>Isis&#x2003;No.</entry><entry>SEQUENCE</entry><entry>SNP</entry><entry>Motif</entry><entry>SEQ&#x2003;ID.&#x2003;NO.</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row><row><entry>607458</entry><entry>A<sub>es</sub>&#x2003;T<sub>ks</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;mC<sub>ds</sub></entry><entry>rs362275</entry><entry>ek-d8-kkeee</entry><entry>119</entry></row><row><entry/><entry>A<sub>ds</sub>&#x2003;G<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;A<sub>es</sub>&#x2003;G<sub>es</sub>&#x2003;mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>607459</entry><entry>G<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub></entry><entry>rs362275</entry><entry>ek-d8-kkeee</entry><entry>124</entry></row><row><entry/><entry>mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;G<sub>ks</sub>&#x2003;mC<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;G<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0428" num="0000"><tables id="TABLE-US-00027" num="00027"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="308pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;25</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Modified&#x2003;oligonucleotides&#x2003;targeting&#x2003;Huntingtin&#x2003;(HTT)&#x2003;SNP&#x2003;rs362276</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="42pt" align="center"/><colspec colname="2" colwidth="126pt" align="left"/><colspec colname="3" colwidth="42pt" align="left"/><colspec colname="4" colwidth="49pt" align="left"/><colspec colname="5" colwidth="49pt" align="center"/><tbody valign="top"><row><entry>Isis&#x2003;No.</entry><entry>SEQUENCE</entry><entry>SNP</entry><entry>Motif</entry><entry>SEQ&#x2003;ID.&#x2003;NO.</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row><row><entry>607465</entry><entry>G<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;T<sub>ks</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub></entry><entry>rs362276</entry><entry>eek-d8-kkee</entry><entry>120</entry></row><row><entry/><entry>mC<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;A<sub>es</sub>&#x2003;G<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>607466</entry><entry>T<sub>es</sub>&#x2003;G<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub></entry><entry>rs362276</entry><entry>eek-d8-kkee</entry><entry>125</entry></row><row><entry/><entry>G<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;G<sub>ks</sub>&#x2003;mC<sub>es</sub>&#x2003;A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0429" num="0000"><tables id="TABLE-US-00028" num="00028"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="308pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;26</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Modified&#x2003;oligonucleotides&#x2003;targeting&#x2003;Huntingtin&#x2003;(HTT)&#x2003;SNP&#x2003;rs362277</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="35pt" align="center"/><colspec colname="2" colwidth="140pt" align="left"/><colspec colname="3" colwidth="35pt" align="left"/><colspec colname="4" colwidth="49pt" align="left"/><colspec colname="5" colwidth="49pt" align="center"/><tbody valign="top"><row><entry>Isis&#x2003;No.</entry><entry>SEQUENCE</entry><entry>SNP</entry><entry>Motif</entry><entry>SEQ&#x2003;ID.&#x2003;NO.</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row><row><entry>607472</entry><entry>T<sub>es</sub>&#x2003;G<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;T<sub>ks</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ds</sub></entry><entry>rs362276</entry><entry>eeek-d8-kee</entry><entry>121</entry></row><row><entry/><entry>mC<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;G<sub>ks</sub>&#x2003;mC<sub>es</sub>&#x2003;A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>607473</entry><entry>T<sub>es</sub>&#x2003;T<sub>es</sub>&#x2003;G<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub></entry><entry>rs362276</entry><entry>eeek-d8-kee</entry><entry>126</entry></row><row><entry/><entry>G<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;G<sub>es</sub>&#x2003;mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0019" level="1">Example 3: Modified Oligonucleotides Targeting Huntingtin (HTT) Single Nucleotide Polymorphisms (SNP)</heading><p id="p-0430" num="0552">A series of modified oligonucleotides targeting Huntingtin (HTT) were designed. These modified oligonucleotides were designed to target SNP positions associated with the HTT gene. The table below provides the sequence and motif for each modified oligonucleotide. The motifs indicate certain 2&#x2032;-modifications to the nucleobases in the nucleobase sequences. In the table below, &#x2018;k&#x2019; indicates an (S)-cEt modification; &#x2018;e&#x2019; indicates a MOE modification; a number along with &#x2018;d&#x2019; indicates the number of deoxyribose nucleosides. For example, a compound having an ekk-d9-kke motif would have the following structure: N<sub>e</sub>N<sub>k</sub>N<sub>k</sub>N<sub>d</sub>N<sub>d</sub>N<sub>d</sub>N<sub>d</sub>N<sub>d</sub>N<sub>d</sub>N<sub>d</sub>N<sub>d</sub>N<sub>d</sub>N<sub>k</sub>N<sub>k</sub>N<sub>e</sub>, wherein each N represents a nucleobase and wherein each subscript represents a nucleobase modification according to the examples described above. All internucleoside linkages are phosphorothioate unless otherwise indicated.</p><p id="p-0431" num="0000"><tables id="TABLE-US-00029" num="00029"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="35pt" align="left"/><colspec colname="2" colwidth="49pt" align="left"/><colspec colname="3" colwidth="91pt" align="left"/><colspec colname="4" colwidth="84pt" align="left"/><colspec colname="5" colwidth="49pt" align="center"/><thead><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row><row><entry>Isis&#x2003;No.</entry><entry>SNP</entry><entry>SEQUENCE&#x2003;(5&#x2032;&#x2003;to&#x2003;3&#x2032;)</entry><entry>MOTIF&#x2003;(5&#x2032;to&#x2003;3&#x2032;)</entry><entry>SEQ&#x2003;ID&#x2003;NO.</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry>460207</entry><entry>rs362332</entry><entry>ACACAGTAGATGAGG</entry><entry>ekk-d9-kke</entry><entry>174</entry></row><row><entry> </entry></row><row><entry>460218</entry><entry>rs362332</entry><entry>GCACACAGTAGATGAGGGA</entry><entry>eeeee-d3-k-d5-eeeee</entry><entry>175</entry></row><row><entry> </entry></row><row><entry>460026</entry><entry>rs2298969</entry><entry>AAGGGATGCTGACTTGGGC</entry><entry>eeee-d9-eeeee</entry><entry>176</entry></row><row><entry> </entry></row><row><entry>460208</entry><entry>rs4690072</entry><entry>CAGTGCTACCCAACC</entry><entry>ekk-d9-kke</entry><entry>177</entry></row><row><entry> </entry></row><row><entry>525364</entry><entry>rs4690072</entry><entry>ACAGTGCTACCCAACCT</entry><entry>ekek-d9-keke</entry><entry>178</entry></row><row><entry> </entry></row><row><entry>435331</entry><entry>rs2024115</entry><entry>TTCAAGCTAGTAACGATGC</entry><entry>eeeee-d9-eeeee</entry><entry>179</entry></row><row><entry> </entry></row><row><entry>525365</entry><entry>rs2024115</entry><entry>CTTCAAGCTAGTAACGA</entry><entry>ekek-d9-keke</entry><entry>180</entry></row><row><entry> </entry></row><row><entry>525368</entry><entry>rs363088</entry><entry>ACAGCTATCTTCTCA</entry><entry>ekk-d9-kke</entry><entry>181</entry></row><row><entry> </entry></row><row><entry>460065</entry><entry>rs7685686</entry><entry>ATAAATTGTCATCACCAG</entry><entry>eeee-d9-eeeee</entry><entry>182</entry></row><row><entry> </entry></row><row><entry>435879</entry><entry>rs7685686</entry><entry>AATAAATTGTCATCACCAG</entry><entry>eeeee-d9-eeeee</entry><entry>183</entry></row><row><entry> </entry></row><row><entry>460085</entry><entry>rs7685686</entry><entry>ATAAATTGTCATCACCA</entry><entry>eeeee-d7-eeeee</entry><entry>184</entry></row><row><entry> </entry></row><row><entry>435870</entry><entry>rs362331</entry><entry>GCACACAGTAGATGAGGGA</entry><entry>eeeee-d9-eeeee</entry><entry>185</entry></row><row><entry> </entry></row><row><entry>460071</entry><entry>rs362331</entry><entry>GCACACAGTAGATGAGGGA</entry><entry>eeeee-d10-eeee</entry><entry>186</entry></row><row><entry> </entry></row><row><entry>460212</entry><entry>rs362331</entry><entry>GCACACAGTAGATGAGGGA</entry><entry>eeeee-d4-k-d4-eeeee</entry><entry>187</entry></row><row><entry> </entry></row><row><entry>460231</entry><entry>rs362331</entry><entry>ACAGTAGATGAGGGAGCAG</entry><entry>eeeee-k-d8-eeeee</entry><entry>188</entry></row><row><entry> </entry></row><row><entry>474892</entry><entry>rs362331</entry><entry>CACACAGTAGATGAGGG</entry><entry>kekk-d9-kkek</entry><entry>189</entry></row><row><entry> </entry></row><row><entry>435890</entry><entry>rs2298969</entry><entry>AAGGGATGCTGACTTGGGC</entry><entry>eeeee-d9-eeeee</entry><entry>190</entry></row><row><entry> </entry></row><row><entry>460210</entry><entry>rs2298969</entry><entry>GGGATGCTGACTTGG</entry><entry>ekk-d9-kke</entry><entry>191</entry></row><row><entry> </entry></row><row><entry>474871</entry><entry>rs7685686</entry><entry>ATAAATTGTCATCACCA</entry><entry>ekkk-d9-kkke</entry><entry>192</entry></row><row><entry> </entry></row><row><entry>474891</entry><entry>rs7685686</entry><entry>ATAAATTGTCATCACCA</entry><entry>kekk-d9-kkek</entry><entry>193</entry></row><row><entry> </entry></row><row><entry>474919</entry><entry>rs7685686</entry><entry>AATAAATTGTCATCACCAG</entry><entry>kekek-d9-kekek</entry><entry>194</entry></row><row><entry> </entry></row><row><entry>474923</entry><entry>rs7685686</entry><entry>AATAAATTGTCATCACCAG</entry><entry>kdkdk-d9-kdkdk</entry><entry>195</entry></row><row><entry> </entry></row><row><entry>476337</entry><entry>rs7685686</entry><entry>AATAAATTGTCATCACCAG</entry><entry>ekeke-d9-ekeke</entry><entry>196</entry></row><row><entry> </entry></row><row><entry>460012</entry><entry>rs4690072</entry><entry>ACAGTGCTACCCAACCT</entry><entry>eee-d9-eeeee</entry><entry>197</entry></row><row><entry> </entry></row><row><entry>525367</entry><entry>rs2024115</entry><entry>TTCAAGCTAGTAACG</entry><entry>ekk-d9-kke</entry><entry>198</entry></row><row><entry> </entry></row><row><entry>435869</entry><entry>rs362306</entry><entry>GAGCAGCTGCAACCTGGCA</entry><entry>eeeee-d9-eeeee</entry><entry>199</entry></row><row><entry> </entry></row><row><entry>460069</entry><entry>rs362306</entry><entry>GAGCAGCTGCAACCTGGCA</entry><entry>eeeee-d10-eeee</entry><entry>200</entry></row><row><entry> </entry></row><row><entry>460206</entry><entry>rs362306</entry><entry>GCAGCTGCAACCTGG</entry><entry>ekk-d9-kke</entry><entry>201</entry></row><row><entry> </entry></row><row><entry>463571</entry><entry>rs362273</entry><entry>TTGATCTGTAGCAGCAGCT</entry><entry>eeeee-d9-eeeee</entry><entry>202</entry></row><row><entry> </entry></row><row><entry>476444</entry><entry>rs6844859</entry><entry>CCTTCCTCACTGAGGATGA</entry><entry>eeeee-d9-eeeee</entry><entry>203</entry></row><row><entry> </entry></row><row><entry>435330</entry><entry>rs3856973</entry><entry>TAACACTCGATTAACCCTG</entry><entry>eeeee-d9-eeeee</entry><entry>204</entry></row><row><entry> </entry></row><row><entry>435868</entry><entry>rs362275</entry><entry>AAGAAGCCTGATAAAATCT</entry><entry>eeeee-d9-eeeee</entry><entry>205</entry></row><row><entry> </entry></row><row><entry>491416</entry><entry>rs7685686</entry><entry>TGCTTCAGAGCTGAGCAGAA</entry><entry>eeeee-d10-eeeee</entry><entry>206</entry></row><row><entry> </entry></row><row><entry>553748</entry><entry/><entry>ACCACAACGGCGATT</entry><entry>ekk-d9-kke</entry><entry>207</entry></row><row><entry> </entry></row><row><entry>553751</entry><entry/><entry>TACCTAAGAGCACAT</entry><entry>ekk-d9-kke</entry><entry>208</entry></row><row><entry> </entry></row><row><entry>553752</entry><entry>rs2285086</entry><entry>TAGTTCATCCCAGTG</entry><entry>ekk-d9-kke</entry><entry>209</entry></row><row><entry> </entry></row><row><entry>553754</entry><entry>rs2798235</entry><entry>GAGGAGGTATACTGT</entry><entry>ekk-d9-kke</entry><entry>210</entry></row><row><entry> </entry></row><row><entry>553762</entry><entry>rs362303</entry><entry>TGGTGCCGGGTGTCT</entry><entry>ekk-d9-kke</entry><entry>211</entry></row><row><entry> </entry></row><row><entry>553764</entry><entry>rs362310</entry><entry>AAACGGCGCAGCGGG</entry><entry>ekk-d9-kke</entry><entry>212</entry></row><row><entry> </entry></row><row><entry>553765</entry><entry/><entry>CGCCTATACCATACA</entry><entry>ekk-d9-kke</entry><entry>213</entry></row><row><entry> </entry></row><row><entry>553767</entry><entry/><entry>GATAATATCCTATCA</entry><entry>ekk-d9-kke</entry><entry>214</entry></row><row><entry> </entry></row><row><entry>553768</entry><entry>rs363080</entry><entry>AGAGAACAAGAAGGC</entry><entry>ekk-d9-kke</entry><entry>215</entry></row><row><entry> </entry></row><row><entry>553769</entry><entry>rs363092</entry><entry>AACCACTGTGGGATG</entry><entry>ekk-d9-kke</entry><entry>216</entry></row><row><entry> </entry></row><row><entry>553772</entry><entry>rs363102</entry><entry>CTAAAACTAACTTGA</entry><entry>ekk-d9-kke</entry><entry>217</entry></row><row><entry> </entry></row><row><entry>553773</entry><entry/><entry>CGTTGAAGTACTGTC</entry><entry>ekk-d9-kke</entry><entry>218</entry></row><row><entry> </entry></row><row><entry>553775</entry><entry>rs3856973</entry><entry>TAACACTCGATTAAC</entry><entry>ekk-d9-kke</entry><entry>219</entry></row><row><entry> </entry></row><row><entry>553776</entry><entry>rs4690073</entry><entry>CCTAAATCAATCTAC</entry><entry>ekk-d9-kke</entry><entry>220</entry></row><row><entry> </entry></row><row><entry>553777</entry><entry>rs6446723</entry><entry>ATTTTCTAGACTTTA</entry><entry>ekk-d9-kke</entry><entry>221</entry></row><row><entry> </entry></row><row><entry>553778</entry><entry>rs6844859</entry><entry>CTTCCTCACTGAGGA</entry><entry>ekk-d9-kke</entry><entry>222</entry></row><row><entry> </entry></row><row><entry>553779</entry><entry>rs7659144</entry><entry>GAAATGGGTTTTTCC</entry><entry>ekk-d9-kke</entry><entry>223</entry></row><row><entry> </entry></row><row><entry>553780</entry><entry>rs7691627</entry><entry>TAAGAAACACAATCA</entry><entry>ekk-d9-kke</entry><entry>224</entry></row><row><entry> </entry></row><row><entry>553781</entry><entry>rs916171</entry><entry>GAACAAACAGAAGAA</entry><entry>ekk-d9-kke</entry><entry>225</entry></row><row><entry> </entry></row><row><entry>553782</entry><entry>rs362303</entry><entry>TGGTGCCAGGTGTCT</entry><entry>ekk-d9-kke</entry><entry>226</entry></row><row><entry> </entry></row><row><entry>553784</entry><entry>rs362310</entry><entry>AAACGGCACAGCGGG</entry><entry>ekk-d9-kke</entry><entry>227</entry></row><row><entry> </entry></row><row><entry>435295</entry><entry>rs2024115</entry><entry>ACTTCAAGCTAGTAACGAT</entry><entry>eeeee-d9-eeeee</entry><entry>228</entry></row><row><entry> </entry></row><row><entry>553742</entry><entry/><entry>ACACCACAACGGCGATTTG</entry><entry>eeeee-d9-eeeee</entry><entry>229</entry></row><row><entry> </entry></row><row><entry>553743</entry><entry/><entry>CTTACCTAAGAGCACATTT</entry><entry>eeeee-d9-eeeee</entry><entry>230</entry></row><row><entry> </entry></row><row><entry>435864</entry><entry>rs2285086</entry><entry>GCTAGTTCATCCCAGTGAG</entry><entry>eeeee-d9-eeeee</entry><entry>231</entry></row><row><entry> </entry></row><row><entry>435910</entry><entry>rs2798235</entry><entry>CAGAGGAGGTATACTGTAT</entry><entry>eeeee-d9-eeeee</entry><entry>232</entry></row><row><entry> </entry></row><row><entry>435311</entry><entry>rs362303</entry><entry>AATGGTGCCGGGTGTCTAG</entry><entry>eeeee-d9-eeeee</entry><entry>233</entry></row><row><entry> </entry></row><row><entry>435309</entry><entry>rs362310</entry><entry>AGAAACGGCGCAGCGGGAA</entry><entry>eeeee-d9-eeeee</entry><entry>234</entry></row><row><entry> </entry></row><row><entry>553744</entry><entry/><entry>TCCGCCTATACCATACAAT</entry><entry>eeeee-d9-eeeee</entry><entry>235</entry></row><row><entry> </entry></row><row><entry>553745</entry><entry/><entry>ATGATAATATCCTATCAAA</entry><entry>eeeee-d9-eeeee</entry><entry>236</entry></row><row><entry> </entry></row><row><entry>435911</entry><entry>rs363080</entry><entry>AGAGAGAACAAGAAGGCTC</entry><entry>eeeee-d9-eeeee</entry><entry>237</entry></row><row><entry> </entry></row><row><entry>435872</entry><entry>rs363092</entry><entry>CAAACCACTGTGGGATGAA</entry><entry>eeeee-d9-eeeee</entry><entry>238</entry></row><row><entry> </entry></row><row><entry>435300</entry><entry>rs363102</entry><entry>ATCTAAAACTAACTTGAGA</entry><entry>eeeee-d9-eeeee</entry><entry>239</entry></row><row><entry> </entry></row><row><entry>553746</entry><entry/><entry>AGCGTTGAAGTACTGTCCC</entry><entry>eeeee-d9-eeeee</entry><entry>240</entry></row><row><entry> </entry></row><row><entry>435294</entry><entry>rs3856973</entry><entry>GTTAACACTCGATTAACCC</entry><entry>eeeee-d9-eeeee</entry><entry>241</entry></row><row><entry> </entry></row><row><entry>435301</entry><entry>rs4690073</entry><entry>TCCCTAAATCAATCTACAA</entry><entry>eeeee-d9-eeeee</entry><entry>242</entry></row><row><entry> </entry></row><row><entry>435875</entry><entry>rs6446723</entry><entry>TAATTTTCTAGACTTTATG</entry><entry>eeeee-d9-eeeee</entry><entry>243</entry></row><row><entry> </entry></row><row><entry>435876</entry><entry>rs6844859</entry><entry>ACCTTCCTCACTGAGGATG</entry><entry>eeeee-d9-eeeee</entry><entry>244</entry></row><row><entry> </entry></row><row><entry>435878</entry><entry>rs7659144</entry><entry>TGGAAATGGGTTTTTCCAC</entry><entry>eeeee-d9-eeeee</entry><entry>245</entry></row><row><entry> </entry></row><row><entry>435880</entry><entry>rs7691627</entry><entry>AATAAGAAACACAATCAAA</entry><entry>eeeee-d9-eeeee</entry><entry>246</entry></row><row><entry> </entry></row><row><entry>435906</entry><entry>rs916171</entry><entry>CAGAACAAACAGAAGAATT</entry><entry>eeeee-d9-eeeee</entry><entry>247</entry></row><row><entry> </entry></row><row><entry>435329</entry><entry>rs362303</entry><entry>AATGGTGCCAGGTGTCTAG</entry><entry>eeeee-d9-eeeee</entry><entry>248</entry></row><row><entry> </entry></row><row><entry>435327</entry><entry>rs362310</entry><entry>AGAAACGGCACAGCGGGAA</entry><entry>eeeee-d9-eeeee</entry><entry>249</entry></row><row><entry> </entry></row><row><entry>553766</entry><entry>rs363064</entry><entry>AGAATACGGGTAACA</entry><entry>ekk-d9-kke</entry><entry>250</entry></row><row><entry> </entry></row><row><entry>553771</entry><entry>rs363099</entry><entry>CTGAGCGGAGAAACC</entry><entry>ekk-d9-kke</entry><entry>251</entry></row><row><entry> </entry></row><row><entry>553770</entry><entry>rs363096</entry><entry>TTCCCTAAAAACAAA</entry><entry>ekk-d9-kke</entry><entry>252</entry></row><row><entry> </entry></row><row><entry>553753</entry><entry>rs2298967</entry><entry>CTTTTCTATTGTCTG</entry><entry>ekk-d9-kke</entry><entry>253</entry></row><row><entry> </entry></row><row><entry>553758</entry><entry>rs362272</entry><entry>TAGAGGACGCCGTGC</entry><entry>ekk-d9-kke</entry><entry>254</entry></row><row><entry> </entry></row><row><entry>553783</entry><entry>rs363096</entry><entry>TTCCCTAGAAACAAA</entry><entry>ekk-d9-kke</entry><entry>255</entry></row><row><entry> </entry></row><row><entry>553763</entry><entry>rs362307</entry><entry>CAAGGGCACAGACTT</entry><entry>ekk-d9-kke</entry><entry>256</entry></row><row><entry> </entry></row><row><entry>553750</entry><entry>rs16843804</entry><entry>TAACCGTGGCATGGG</entry><entry>ekk-d9-kke</entry><entry>257</entry></row><row><entry> </entry></row><row><entry>553755</entry><entry>rs3121419</entry><entry>GACTATAGCACCCAG</entry><entry>ekk-d9-kke</entry><entry>258</entry></row><row><entry> </entry></row><row><entry>553757</entry><entry>rs362271</entry><entry>GTGTGTACAGAACCT</entry><entry>ekk-d9-kke</entry><entry>259</entry></row><row><entry> </entry></row><row><entry>553760</entry><entry>rs362275</entry><entry>GAAGCCTGATAAAAT</entry><entry>ekk-d9-kke</entry><entry>260</entry></row><row><entry> </entry></row><row><entry>553774</entry><entry>rs3775061</entry><entry>TTCAGAATGCCTCAT</entry><entry>ekk-d9-kke</entry><entry>261</entry></row><row><entry> </entry></row><row><entry>553761</entry><entry>rs362296</entry><entry>GGACAGGGTGTGCTC</entry><entry>ekk-d9-kke</entry><entry>262</entry></row><row><entry> </entry></row><row><entry>553747</entry><entry>rs10015979</entry><entry>AGCTAGGCTAAAGAG</entry><entry>ekk-d9-kke</entry><entry>263</entry></row><row><entry> </entry></row><row><entry>553749</entry><entry>rs11731237</entry><entry>TGGGCAGAAAGGACT</entry><entry>ekk-d9-kke</entry><entry>264</entry></row><row><entry> </entry></row><row><entry>553759</entry><entry>rs362273</entry><entry>TGATCTGTAGCAGCA</entry><entry>ekk-d9-kke</entry><entry>265</entry></row><row><entry> </entry></row><row><entry>553756</entry><entry>rs34315806</entry><entry>CTTTTCCGTGCTGTT</entry><entry>ekk-d9-kke</entry><entry>266</entry></row><row><entry> </entry></row><row><entry>435298</entry><entry>rs363064</entry><entry>GGAGAATACGGGTAACATT</entry><entry>eeeee-d9-eeeee</entry><entry>267</entry></row><row><entry> </entry></row><row><entry>435303</entry><entry>rs363099</entry><entry>GGCTGAGCGGAGAAACCCT</entry><entry>eeeee-d9-eeeee</entry><entry>268</entry></row><row><entry> </entry></row><row><entry>435304</entry><entry>rs363096</entry><entry>GATTCCCTAAAAACAAAAA</entry><entry>eeeee-d9-eeeee</entry><entry>269</entry></row><row><entry> </entry></row><row><entry>435305</entry><entry>rs2298967</entry><entry>TGCTTTTCTATTGTCTGTC</entry><entry>eeeee-d9-eeeee</entry><entry>270</entry></row><row><entry> </entry></row><row><entry>435308</entry><entry>rs362272</entry><entry>CATAGAGGACGCCGTGCAG</entry><entry>eeeee-d9-eeeee</entry><entry>271</entry></row><row><entry> </entry></row><row><entry>435322</entry><entry>rs363096</entry><entry>GATTCCCTAGAAACAAAAA</entry><entry>eeeee-d9-eeeee</entry><entry>272</entry></row><row><entry> </entry></row><row><entry>435328</entry><entry>rs362307</entry><entry>CACAAGGGCACAGACTTCC</entry><entry>eeeee-d9-eeeee</entry><entry>273</entry></row><row><entry> </entry></row><row><entry>435863</entry><entry>rs16843804</entry><entry>TTTAACCGTGGCATGGGCA</entry><entry>eeeee-d9-eeeee</entry><entry>274</entry></row><row><entry> </entry></row><row><entry>435866</entry><entry>rs3121419</entry><entry>GAGACTATAGCACCCAGAT</entry><entry>eeeee-d9-eeeee</entry><entry>275</entry></row><row><entry> </entry></row><row><entry>435867</entry><entry>rs362271</entry><entry>ACGTGTGTACAGAACCTGC</entry><entry>eeeee-d9-eeeee</entry><entry>276</entry></row><row><entry> </entry></row><row><entry>435873</entry><entry>rs3775061</entry><entry>TGTTCAGAATGCCTCATCT</entry><entry>eeeee-d9-eeeee</entry><entry>277</entry></row><row><entry> </entry></row><row><entry>435882</entry><entry>rs362296</entry><entry>GGGGACAGGGTGTGCTCTC</entry><entry>eeeee-d9-eeeee</entry><entry>278</entry></row><row><entry> </entry></row><row><entry>435887</entry><entry>rs10015979</entry><entry>GCAGCTAGGCTAAAGAGTC</entry><entry>eeeee-d9-eeeee</entry><entry>279</entry></row><row><entry> </entry></row><row><entry>435909</entry><entry>rs11731237</entry><entry>GGTGGGCAGAAAGGACTGA</entry><entry>eeeee-d9-eeeee</entry><entry>280</entry></row><row><entry> </entry></row><row><entry>463566</entry><entry>rs362273</entry><entry>GTTGATCTGTAGCAGCAGC</entry><entry>eeeee-d9-eeeee</entry><entry>281</entry></row><row><entry> </entry></row><row><entry>463567</entry><entry>rs34315806</entry><entry>AACTTTTCCGTGCTGTTCT</entry><entry>eeeee-d9-eeeee</entry><entry>282</entry></row><row><entry> </entry></row><row><entry>589448</entry><entry>rs3856973</entry><entry>AACACTCGATTAACCCT</entry><entry>eeekk-d7-kkeee</entry><entry>283</entry></row><row><entry> </entry></row><row><entry>589447</entry><entry>rs3856973</entry><entry>TAACACTCGATTAACCC</entry><entry>eeekk-d7-kkeee</entry><entry>284</entry></row><row><entry> </entry></row><row><entry>589163</entry><entry>rs3856973</entry><entry>TTAACACTCGATTAACC</entry><entry>eeekk-d7-kkeee</entry><entry>285</entry></row><row><entry> </entry></row><row><entry>589446</entry><entry>rs3856973</entry><entry>GTTAACACTCGATTAAC</entry><entry>eeekk-d7-kkeee</entry><entry>286</entry></row><row><entry> </entry></row><row><entry>589445</entry><entry>rs3856973</entry><entry>AGTTAACACTCGATTAA</entry><entry>eeekk-d7-kkeee</entry><entry>287</entry></row><row><entry> </entry></row><row><entry>589669</entry><entry>rs3856973</entry><entry>AACACTCGATTAACCCT</entry><entry>eekek-d7-kekee</entry><entry>288</entry></row><row><entry> </entry></row><row><entry>589668</entry><entry>rs3856973</entry><entry>TAACACTCGATTAACCC</entry><entry>eekek-d7-kekee</entry><entry>289</entry></row><row><entry> </entry></row><row><entry>589667</entry><entry>rs3856973</entry><entry>TTAACACTCGATTAACC</entry><entry>eekek-d7-kekee</entry><entry>290</entry></row><row><entry> </entry></row><row><entry>589666</entry><entry>rs3856973</entry><entry>GTTAACACTCGATTAAC</entry><entry>eekek-d7-kekee</entry><entry>291</entry></row><row><entry> </entry></row><row><entry>589665</entry><entry>rs3856973</entry><entry>AGTTAACACTCGATTAA</entry><entry>eekek-d7-kekee</entry><entry>292</entry></row><row><entry> </entry></row><row><entry>589544</entry><entry>rs3856973</entry><entry>ACACTCGATTAACCCTG</entry><entry>eekk-d8-kkeee</entry><entry>293</entry></row><row><entry> </entry></row><row><entry>589543</entry><entry>rs3856973</entry><entry>AACACTCGATTAACCCT</entry><entry>eekk-d8-kkeee</entry><entry>294</entry></row><row><entry> </entry></row><row><entry>589542</entry><entry>rs3856973</entry><entry>TAACACTCGATTAACCC</entry><entry>eekk-d8-kkeee</entry><entry>295</entry></row><row><entry> </entry></row><row><entry>589541</entry><entry>rs3856973</entry><entry>TTAACACTCGATTAACC</entry><entry>eekk-d8-kkeee</entry><entry>296</entry></row><row><entry> </entry></row><row><entry>589540</entry><entry>rs3856973</entry><entry>GTTAACACTCGATTAAC</entry><entry>eekk-d8-kkeee</entry><entry>297</entry></row><row><entry> </entry></row><row><entry>589539</entry><entry>rs3856973</entry><entry>AGTTAACACTCGATTAA</entry><entry>eekk-d8-kkeee</entry><entry>298</entry></row><row><entry> </entry></row><row><entry>589716</entry><entry>rs3856973</entry><entry>ACACTCGATTAACCCTG</entry><entry>ekek-d8-kekee</entry><entry>299</entry></row><row><entry> </entry></row><row><entry>589715</entry><entry>rs3856973</entry><entry>AACACTCGATTAACCCT</entry><entry>ekek-d8-kekee</entry><entry>300</entry></row><row><entry> </entry></row><row><entry>589714</entry><entry>rs3856973</entry><entry>TAACACTCGATTAACCC</entry><entry>ekek-d8-kekee</entry><entry>301</entry></row><row><entry> </entry></row><row><entry>589713</entry><entry>rs3856973</entry><entry>TTAACACTCGATTAACC</entry><entry>ekek-d8-kekee</entry><entry>302</entry></row><row><entry> </entry></row><row><entry>589712</entry><entry>rs3856973</entry><entry>GTTAACACTCGATTAAC</entry><entry>ekek-d8-kekee</entry><entry>303</entry></row><row><entry> </entry></row><row><entry>589711</entry><entry>rs3856973</entry><entry>AGTTAACACTCGATTAA</entry><entry>ekek-d8-kekee</entry><entry>304</entry></row><row><entry> </entry></row><row><entry>589444</entry><entry>rs7685686</entry><entry>AAATTGTCATCACCAGA</entry><entry>eeekk-d7-kkeee</entry><entry>305</entry></row><row><entry> </entry></row><row><entry>589443</entry><entry>rs7685686</entry><entry>AATAAATTGTCATCACC</entry><entry>eeekk-d7-kkeee</entry><entry>306</entry></row><row><entry> </entry></row><row><entry>589442</entry><entry>rs7685686</entry><entry>TAATAAATTGTCATCAC</entry><entry>eeekk-d7-kkeee</entry><entry>307</entry></row><row><entry> </entry></row><row><entry>589664</entry><entry>rs7685686</entry><entry>AAATTGTCATCACCAGA</entry><entry>eekek-d7-kekee</entry><entry>308</entry></row><row><entry> </entry></row><row><entry>589663</entry><entry>rs7685686</entry><entry>TAAATTGTCATCACCAG</entry><entry>eekek-d7-kekee</entry><entry>309</entry></row><row><entry> </entry></row><row><entry>589662</entry><entry>rs7685686</entry><entry>ATAAATTGTCATCACCA</entry><entry>eekek-d7-kekee</entry><entry>310</entry></row><row><entry> </entry></row><row><entry>589661</entry><entry>rs7685686</entry><entry>AATAAATTGTCATCACC</entry><entry>eekek-d7-kekee</entry><entry>311</entry></row><row><entry> </entry></row><row><entry>589660</entry><entry>rs7685686</entry><entry>TAATAAATTGTCATCAC</entry><entry>eekek-d7-kekee</entry><entry>312</entry></row><row><entry> </entry></row><row><entry>589538</entry><entry>rs7685686</entry><entry>AATTGTCATCACCAGAA</entry><entry>eekk-d8-kkeee</entry><entry>313</entry></row><row><entry> </entry></row><row><entry>589536</entry><entry>rs7685686</entry><entry>TAAATTGTCATCACCAG</entry><entry>eekk-d8-kkeee</entry><entry>314</entry></row><row><entry> </entry></row><row><entry>589535</entry><entry>rs7685686</entry><entry>ATAAATTGTCATCACCA</entry><entry>eekk-d8-kkeee</entry><entry>315</entry></row><row><entry> </entry></row><row><entry>589534</entry><entry>rs7685686</entry><entry>AATAAATTGTCATCACC</entry><entry>eekk-d8-kkeee</entry><entry>316</entry></row><row><entry> </entry></row><row><entry>589533</entry><entry>rs7685686</entry><entry>TAATAAATTGTCATCAC</entry><entry>eekk-d8-kkeee</entry><entry>317</entry></row><row><entry> </entry></row><row><entry>589710</entry><entry>rs7685686</entry><entry>AATTGTCATCACCAGAA</entry><entry>ekek-d8-kekee</entry><entry>318</entry></row><row><entry> </entry></row><row><entry>589709</entry><entry>rs7685686</entry><entry>AAATTGTCATCACCAGA</entry><entry>ekek-d8-kekee</entry><entry>319</entry></row><row><entry> </entry></row><row><entry>589708</entry><entry>rs7685686</entry><entry>TAAATTGTCATCACCAG</entry><entry>ekek-d8-kekee</entry><entry>320</entry></row><row><entry> </entry></row><row><entry>589707</entry><entry>rs7685686</entry><entry>ATAAATTGTCATCACCA</entry><entry>ekek-d8-kekee</entry><entry>321</entry></row><row><entry> </entry></row><row><entry>589706</entry><entry>rs7685686</entry><entry>AATAAATTGTCATCACC</entry><entry>ekek-d8-kekee</entry><entry>322</entry></row><row><entry> </entry></row><row><entry>589705</entry><entry>rs7685686</entry><entry>TAATAAATTGTCATCAC</entry><entry>ekek-d8-kekee</entry><entry>323</entry></row><row><entry> </entry></row><row><entry>589468</entry><entry>rs2024115</entry><entry>TCAAGCTAGTAACGATG</entry><entry>eeekk-d7-kkeee</entry><entry>324</entry></row><row><entry> </entry></row><row><entry>589467</entry><entry>rs2024115</entry><entry>TTCAAGCTAGTAACGAT</entry><entry>eeekk-d7-kkeee</entry><entry>325</entry></row><row><entry> </entry></row><row><entry>589466</entry><entry>rs2024115</entry><entry>CTTCAAGCTAGTAACGA</entry><entry>eeekk-d7-kkeee</entry><entry>326</entry></row><row><entry> </entry></row><row><entry>589465</entry><entry>rs2024115</entry><entry>ACTTCAAGCTAGTAACG</entry><entry>eeekk-d7-kkeee</entry><entry>327</entry></row><row><entry> </entry></row><row><entry>589464</entry><entry>rs2024115</entry><entry>AACTTCAAGCTAGTAAC</entry><entry>eeekk-d7-kkeee</entry><entry>328</entry></row><row><entry> </entry></row><row><entry>589568</entry><entry>rs2024115</entry><entry>CAAGCTAGTAACGATGC</entry><entry>eekk-d8-kkeee</entry><entry>329</entry></row><row><entry> </entry></row><row><entry>589566</entry><entry>rs2024115</entry><entry>TTCAAGCTAGTAACGAT</entry><entry>eekk-d8-kkeee</entry><entry>330</entry></row><row><entry> </entry></row><row><entry>589565</entry><entry>rs2024115</entry><entry>CTTCAAGCTAGTAACGA</entry><entry>eekk-d8-kkeee</entry><entry>331</entry></row><row><entry> </entry></row><row><entry>589564</entry><entry>rs2024115</entry><entry>ACTTCAAGCTAGTAACG</entry><entry>eekk-d8-kkeee</entry><entry>332</entry></row><row><entry> </entry></row><row><entry>589563</entry><entry>rs2024115</entry><entry>AACTTCAAGCTAGTAAC</entry><entry>eekk-d8-kkeee</entry><entry>333</entry></row><row><entry> </entry></row><row><entry>589453</entry><entry>rs6446723</entry><entry>TTTTCTAGACTTTATGA</entry><entry>eeekk-d7-kkeee</entry><entry>334</entry></row><row><entry> </entry></row><row><entry>589452</entry><entry>rs6446723</entry><entry>ATTTTCTAGACTTTATG</entry><entry>eeekk-d7-kkeee</entry><entry>335</entry></row><row><entry> </entry></row><row><entry>589451</entry><entry>rs6446723</entry><entry>AATTTTCTAGACTTTAT</entry><entry>eeekk-d7-kkeee</entry><entry>336</entry></row><row><entry> </entry></row><row><entry>589449</entry><entry>rs6446723</entry><entry>TTAATTTTCTAGACTTT</entry><entry>eeekk-d7-kkeee</entry><entry>337</entry></row><row><entry> </entry></row><row><entry>589674</entry><entry>rs6446723</entry><entry>TTTTCTAGACTTTATGA</entry><entry>eekek-d7-kekee</entry><entry>338</entry></row><row><entry> </entry></row><row><entry>589673</entry><entry>rs6446723</entry><entry>ATTTTCTAGACTTTATG</entry><entry>eekek-d7-kekee</entry><entry>339</entry></row><row><entry> </entry></row><row><entry>589672</entry><entry>rs6446723</entry><entry>AATTTTCTAGACTTTAT</entry><entry>eekek-d7-kekee</entry><entry>340</entry></row><row><entry> </entry></row><row><entry>589671</entry><entry>rs6446723</entry><entry>TAATTTTCTAGACTTTA</entry><entry>eekek-d7-kekee</entry><entry>341</entry></row><row><entry> </entry></row><row><entry>589670</entry><entry>rs6446723</entry><entry>TTAATTTTCTAGACTTT</entry><entry>eekek-d7-kekee</entry><entry>342</entry></row><row><entry> </entry></row><row><entry>589550</entry><entry>rs6446723</entry><entry>TTTCTAGACTTTATGAT</entry><entry>eekk-d8-kkeee</entry><entry>343</entry></row><row><entry> </entry></row><row><entry>589549</entry><entry>rs6446723</entry><entry>TTTTCTAGACTTTATGA</entry><entry>eekk-d8-kkeee</entry><entry>344</entry></row><row><entry> </entry></row><row><entry>589548</entry><entry>rs6446723</entry><entry>ATTTTCTAGACTTTATG</entry><entry>eekk-d8-kkeee</entry><entry>345</entry></row><row><entry> </entry></row><row><entry>589545</entry><entry>rs6446723</entry><entry>TTAATTTTCTAGACTTT</entry><entry>eekk-d8-kkeee</entry><entry>346</entry></row><row><entry> </entry></row><row><entry>589722</entry><entry>rs6446723</entry><entry>TTTCTAGACTTTATGAT</entry><entry>ekek-d8-kekee</entry><entry>347</entry></row><row><entry> </entry></row><row><entry>589721</entry><entry>rs6446723</entry><entry>TTTTCTAGACTTTATGA</entry><entry>ekek-d8-kekee</entry><entry>348</entry></row><row><entry> </entry></row><row><entry>589720</entry><entry>rs6446723</entry><entry>ATTTTCTAGACTTTATG</entry><entry>ekek-d8-kekee</entry><entry>349</entry></row><row><entry> </entry></row><row><entry>589719</entry><entry>rs6446723</entry><entry>AATTTTCTAGACTTTAT</entry><entry>ekek-d8-kekee</entry><entry>350</entry></row><row><entry> </entry></row><row><entry>589717</entry><entry>rs6446723</entry><entry>TTAATTTTCTAGACTTT</entry><entry>ekek-d8-kekee</entry><entry>351</entry></row><row><entry> </entry></row><row><entry>589463</entry><entry>rs6844859</entry><entry>TTCCTCACTGAGGATGA</entry><entry>eeekk-d7-kkeee</entry><entry>352</entry></row><row><entry> </entry></row><row><entry>589462</entry><entry>rs6844859</entry><entry>CTTCCTCACTGAGGATG</entry><entry>eeekk-d7-kkeee</entry><entry>353</entry></row><row><entry> </entry></row><row><entry>589461</entry><entry>rs6844859</entry><entry>CCTTCCTCACTGAGGAT</entry><entry>eeekk-d7-kkeee</entry><entry>354</entry></row><row><entry> </entry></row><row><entry>589460</entry><entry>rs6844859</entry><entry>ACCTTCCTCACTGAGGA</entry><entry>eeekk-d7-kkeee</entry><entry>355</entry></row><row><entry> </entry></row><row><entry>589459</entry><entry>rs6844859</entry><entry>CACCTTCCTCACTGAGG</entry><entry>eeekk-d7-kkeee</entry><entry>356</entry></row><row><entry> </entry></row><row><entry>590761</entry><entry>rs6844859</entry><entry>TTCCTCACTGAGGATGA</entry><entry>eekek-d7-kekee</entry><entry>357</entry></row><row><entry> </entry></row><row><entry>590760</entry><entry>rs6844859</entry><entry>CTTCCTCACTGAGGATG</entry><entry>eekek-d7-kekee</entry><entry>358</entry></row><row><entry> </entry></row><row><entry>590759</entry><entry>rs6844859</entry><entry>CCTTCCTCACTGAGGAT</entry><entry>eekek-d7-kekee</entry><entry>359</entry></row><row><entry> </entry></row><row><entry>590758</entry><entry>rs6844859</entry><entry>ACCTTCCTCACTGAGGA</entry><entry>eekek-d7-kekee</entry><entry>360</entry></row><row><entry> </entry></row><row><entry>590757</entry><entry>rs6844859</entry><entry>CACCTTCCTCACTGAGG</entry><entry>eekek-d7-kekee</entry><entry>361</entry></row><row><entry> </entry></row><row><entry>589562</entry><entry>rs6844859</entry><entry>TCCTCACTGAGGATGAA</entry><entry>eekk-d8-kkeee</entry><entry>362</entry></row><row><entry> </entry></row><row><entry>589561</entry><entry>rs6844859</entry><entry>TTCCTCACTGAGGATGA</entry><entry>eekk-d8-kkeee</entry><entry>363</entry></row><row><entry> </entry></row><row><entry>589560</entry><entry>rs6844859</entry><entry>CTTCCTCACTGAGGATG</entry><entry>eekk-d8-kkeee</entry><entry>364</entry></row><row><entry> </entry></row><row><entry>589559</entry><entry>rs6844859</entry><entry>CCTTCCTCACTGAGGAT</entry><entry>eekk-d8-kkeee</entry><entry>365</entry></row><row><entry> </entry></row><row><entry>589558</entry><entry>rs6844859</entry><entry>ACCTTCCTCACTGAGGA</entry><entry>eekk-d8-kkeee</entry><entry>366</entry></row><row><entry> </entry></row><row><entry>589557</entry><entry>rs6844859</entry><entry>CACCTTCCTCACTGAGG</entry><entry>eekk-d8-kkeee</entry><entry>367</entry></row><row><entry> </entry></row><row><entry>590767</entry><entry>rs6844859</entry><entry>TCCTCACTGAGGATGAA</entry><entry>ekek-d8-kekee</entry><entry>368</entry></row><row><entry> </entry></row><row><entry>590766</entry><entry>rs6844859</entry><entry>TTCCTCACTGAGGATGA</entry><entry>ekek-d8-kekee</entry><entry>369</entry></row><row><entry> </entry></row><row><entry>590765</entry><entry>rs6844859</entry><entry>CTTCCTCACTGAGGATG</entry><entry>ekek-d8-kekee</entry><entry>370</entry></row><row><entry> </entry></row><row><entry>590764</entry><entry>rs6844859</entry><entry>CCTTCCTCACTGAGGAT</entry><entry>ekek-d8-kekee</entry><entry>371</entry></row><row><entry> </entry></row><row><entry>590763</entry><entry>rs6844859</entry><entry>ACCTTCCTCACTGAGGA</entry><entry>ekek-d8-kekee</entry><entry>372</entry></row><row><entry> </entry></row><row><entry>590762</entry><entry>rs6844859</entry><entry>CACCTTCCTCACTGAGG</entry><entry>ekek-d8-kekee</entry><entry>373</entry></row><row><entry> </entry></row><row><entry>589483</entry><entry>rs363092</entry><entry>ACCACTTTGGGATGAAT</entry><entry>eeekk-d7-kkeee</entry><entry>374</entry></row><row><entry> </entry></row><row><entry>589482</entry><entry>rs363092</entry><entry>AACCACTTTGGGATGAA</entry><entry>eeekk-d7-kkeee</entry><entry>375</entry></row><row><entry> </entry></row><row><entry>589481</entry><entry>rs363092</entry><entry>AAACCACTTTGGGATGA</entry><entry>eeekk-d7-kkeee</entry><entry>376</entry></row><row><entry> </entry></row><row><entry>589480</entry><entry>rs363092</entry><entry>CAAACCACTTTGGGATG</entry><entry>eeekk-d7-kkeee</entry><entry>377</entry></row><row><entry> </entry></row><row><entry>589479</entry><entry>rs363092</entry><entry>GCAAACCACTTTGGGAT</entry><entry>eeekk-d7-kkeee</entry><entry>378</entry></row><row><entry> </entry></row><row><entry>589586</entry><entry>rs363092</entry><entry>CCACTTTGGGATGAATA</entry><entry>eekk-d8-kkeee</entry><entry>379</entry></row><row><entry> </entry></row><row><entry>589585</entry><entry>rs363092</entry><entry>ACCACTTTGGGATGAAT</entry><entry>eekk-d8-kkeee</entry><entry>380</entry></row><row><entry> </entry></row><row><entry>589584</entry><entry>rs363092</entry><entry>AACCACTTTGGGATGAA</entry><entry>eekk-d8-kkeee</entry><entry>381</entry></row><row><entry> </entry></row><row><entry>589583</entry><entry>rs363092</entry><entry>AAACCACTTTGGGATGA</entry><entry>eekk-d8-kkeee</entry><entry>382</entry></row><row><entry> </entry></row><row><entry>589582</entry><entry>rs363092</entry><entry>CAAACCACTTTGGGATG</entry><entry>eekk-d8-kkeee</entry><entry>383</entry></row><row><entry> </entry></row><row><entry>589581</entry><entry>rs363092</entry><entry>GCAAACCACTTTGGGAT</entry><entry>eekk-d8-kkeee</entry><entry>384</entry></row><row><entry> </entry></row><row><entry>589458</entry><entry>rs2285086</entry><entry>AGTTCATCCCAGTGAGA</entry><entry>eeekk-d7-kkeee</entry><entry>385</entry></row><row><entry> </entry></row><row><entry>589457</entry><entry>rs2285086</entry><entry>TAGTTCATCCCAGTGAG</entry><entry>eeekk-d7-kkeee</entry><entry>386</entry></row><row><entry> </entry></row><row><entry>589456</entry><entry>rs2285086</entry><entry>CTAGTTCATCCCAGTGA</entry><entry>eeekk-d7-kkeee</entry><entry>387</entry></row><row><entry> </entry></row><row><entry>589455</entry><entry>rs2285086</entry><entry>GCTAGTTCATCCCAGTG</entry><entry>eeekk-d7-kkeee</entry><entry>388</entry></row><row><entry> </entry></row><row><entry>589454</entry><entry>rs2285086</entry><entry>TGCTAGTTCATCCCAGT</entry><entry>eeekk-d7-kkeee</entry><entry>389</entry></row><row><entry> </entry></row><row><entry>589679</entry><entry>rs2285086</entry><entry>AGTTCATCCCAGTGAGA</entry><entry>eekek-d7-kekee</entry><entry>390</entry></row><row><entry> </entry></row><row><entry>589678</entry><entry>rs2285086</entry><entry>TAGTTCATCCCAGTGAG</entry><entry>eekek-d7-kekee</entry><entry>391</entry></row><row><entry> </entry></row><row><entry>589677</entry><entry>rs2285086</entry><entry>CTAGTTCATCCCAGTGA</entry><entry>eekek-d7-kekee</entry><entry>392</entry></row><row><entry> </entry></row><row><entry>589676</entry><entry>rs2285086</entry><entry>GCTAGTTCATCCCAGTG</entry><entry>eekek-d7-kekee</entry><entry>393</entry></row><row><entry> </entry></row><row><entry>589675</entry><entry>rs2285086</entry><entry>TGCTAGTTCATCCCAGT</entry><entry>eekek-d7-kekee</entry><entry>394</entry></row><row><entry> </entry></row><row><entry>589556</entry><entry>rs2285086</entry><entry>GTTCATCCCAGTGAGAA</entry><entry>eekk-d8-kkeee</entry><entry>395</entry></row><row><entry> </entry></row><row><entry>589555</entry><entry>rs2285086</entry><entry>AGTTCATCCCAGTGAGA</entry><entry>eekk-d8-kkeee</entry><entry>396</entry></row><row><entry> </entry></row><row><entry>589554</entry><entry>rs2285086</entry><entry>TAGTTCATCCCAGTGAG</entry><entry>eekk-d8-kkeee</entry><entry>397</entry></row><row><entry> </entry></row><row><entry>589553</entry><entry>rs2285086</entry><entry>CTAGTTCATCCCAGTGA</entry><entry>eekk-d8-kkeee</entry><entry>398</entry></row><row><entry> </entry></row><row><entry>589552</entry><entry>rs2285086</entry><entry>GCTAGTTCATCCCAGTG</entry><entry>eekk-d8-kkeee</entry><entry>399</entry></row><row><entry> </entry></row><row><entry>589551</entry><entry>rs2285086</entry><entry>TGCTAGTTCATCCCAGT</entry><entry>eekk-d8-kkeee</entry><entry>400</entry></row><row><entry> </entry></row><row><entry>589728</entry><entry>rs2285086</entry><entry>GTTCATCCCAGTGAGAA</entry><entry>ekek-d8-kekee</entry><entry>401</entry></row><row><entry> </entry></row><row><entry>589727</entry><entry>rs2285086</entry><entry>AGTTCATCCCAGTGAGA</entry><entry>ekek-d8-kekee</entry><entry>402</entry></row><row><entry> </entry></row><row><entry>589726</entry><entry>rs2285086</entry><entry>TAGTTCATCCCAGTGAG</entry><entry>ekek-d8-kekee</entry><entry>403</entry></row><row><entry> </entry></row><row><entry>589725</entry><entry>rs2285086</entry><entry>CTAGTTCATCCCAGTGA</entry><entry>ekek-d8-kekee</entry><entry>404</entry></row><row><entry> </entry></row><row><entry>589724</entry><entry>rs2285086</entry><entry>GCTAGTTCATCCCAGTG</entry><entry>ekek-d8-kekee</entry><entry>405</entry></row><row><entry> </entry></row><row><entry>589723</entry><entry>rs2285086</entry><entry>TGCTAGTTCATCCCAGT</entry><entry>ekek-d8-kekee</entry><entry>406</entry></row><row><entry> </entry></row><row><entry>589473</entry><entry>rs2798235</entry><entry>AGGAGGCATACTGTATT</entry><entry>eeekk-d7-kkeee</entry><entry>407</entry></row><row><entry> </entry></row><row><entry>589472</entry><entry>rs2798235</entry><entry>GAGGAGGCATACTGTAT</entry><entry>eeekk-d7-kkeee</entry><entry>408</entry></row><row><entry> </entry></row><row><entry>589471</entry><entry>rs2798235</entry><entry>AGAGGAGGCATACTGTA</entry><entry>eeekk-d7-kkeee</entry><entry>409</entry></row><row><entry> </entry></row><row><entry>589470</entry><entry>rs2798235</entry><entry>CAGAGGAGGCATACTGT</entry><entry>eeekk-d7-kkeee</entry><entry>410</entry></row><row><entry> </entry></row><row><entry>589469</entry><entry>rs2798235</entry><entry>ACAGAGGAGGCATACTG</entry><entry>eeekk-d7-kkeee</entry><entry>411</entry></row><row><entry> </entry></row><row><entry>589574</entry><entry>rs2798235</entry><entry>GGAGGCATACTGTATTT</entry><entry>eekk-d8-kkeee</entry><entry>412</entry></row><row><entry> </entry></row><row><entry>589573</entry><entry>rs2798235</entry><entry>AGGAGGCATACTGTATT</entry><entry>eekk-d8-kkeee</entry><entry>413</entry></row><row><entry> </entry></row><row><entry>589572</entry><entry>rs2798235</entry><entry>GAGGAGGCATACTGTAT</entry><entry>eekk-d8-kkeee</entry><entry>414</entry></row><row><entry> </entry></row><row><entry>589571</entry><entry>rs2798235</entry><entry>AGAGGAGGCATACTGTA</entry><entry>eekk-d8-kkeee</entry><entry>415</entry></row><row><entry> </entry></row><row><entry>589570</entry><entry>rs2798235</entry><entry>CAGAGGAGGCATACTGT</entry><entry>eekk-d8-kkeee</entry><entry>416</entry></row><row><entry> </entry></row><row><entry>589569</entry><entry>rs2798235</entry><entry>ACAGAGGAGGCATACTG</entry><entry>eekk-d8-kkeee</entry><entry>417</entry></row><row><entry> </entry></row><row><entry>589478</entry><entry>rs363080</entry><entry>GAGAACGAGAAGGCTCC</entry><entry>eeekk-d7-kkeee</entry><entry>418</entry></row><row><entry> </entry></row><row><entry>589477</entry><entry>rs363080</entry><entry>AGAGAACGAGAAGGCTC</entry><entry>eeekk-d7-kkeee</entry><entry>419</entry></row><row><entry> </entry></row><row><entry>589476</entry><entry>rs363080</entry><entry>GAGAGAACGAGAAGGCT</entry><entry>eeekk-d7-kkeee</entry><entry>420</entry></row><row><entry> </entry></row><row><entry>589475</entry><entry>rs363080</entry><entry>AGAGAGAACGAGAAGGC</entry><entry>eeekk-d7-kkeee</entry><entry>421</entry></row><row><entry> </entry></row><row><entry>589474</entry><entry>rs363080</entry><entry>AAGAGAGAACGAGAAGG</entry><entry>eeekk-d7-kkeee</entry><entry>422</entry></row><row><entry> </entry></row><row><entry>589580</entry><entry>rs363080</entry><entry>AGAACGAGAAGGCTCCA</entry><entry>eekk-d8-kkeee</entry><entry>423</entry></row><row><entry> </entry></row><row><entry>589579</entry><entry>rs363080</entry><entry>GAGAACGAGAAGGCTCC</entry><entry>eekk-d8-kkeee</entry><entry>424</entry></row><row><entry> </entry></row><row><entry>589578</entry><entry>rs363080</entry><entry>AGAGAACGAGAAGGCTC</entry><entry>eekk-d8-kkeee</entry><entry>425</entry></row><row><entry> </entry></row><row><entry>589577</entry><entry>rs363080</entry><entry>GAGAGAACGAGAAGGCT</entry><entry>eekk-d8-kkeee</entry><entry>426</entry></row><row><entry> </entry></row><row><entry>589576</entry><entry>rs363080</entry><entry>AGAGAGAACGAGAAGGC</entry><entry>eekk-d8-kkeee</entry><entry>427</entry></row><row><entry> </entry></row><row><entry>589575</entry><entry>rs363080</entry><entry>AAGAGAGAACGAGAAGG</entry><entry>eekk-d8-kkeee</entry><entry>428</entry></row><row><entry> </entry></row><row><entry>589497</entry><entry>rs362273</entry><entry>GATCTGTAGCAGCAGCT</entry><entry>eeekk-d7-kkeee</entry><entry>429</entry></row><row><entry> </entry></row><row><entry>589496</entry><entry>rs362273</entry><entry>TGATCTGTAGCAGCAGC</entry><entry>eeekk-d7-kkeee</entry><entry>430</entry></row><row><entry> </entry></row><row><entry>589495</entry><entry>rs362273</entry><entry>TTGATCTGTAGCAGCAG</entry><entry>eeekk-d7-kkeee</entry><entry>431</entry></row><row><entry> </entry></row><row><entry>589494</entry><entry>rs362273</entry><entry>GTTGATCTGTAGCAGCA</entry><entry>eeekk-d7-kkeee</entry><entry>432</entry></row><row><entry> </entry></row><row><entry>589493</entry><entry>rs362273</entry><entry>GGTTGATCTGTAGCAGC</entry><entry>eeekk-d7-kkeee</entry><entry>433</entry></row><row><entry> </entry></row><row><entry>589689</entry><entry>rs362273</entry><entry>GATCTGTAGCAGCAGCT</entry><entry>eekek-d7-kekee</entry><entry>434</entry></row><row><entry> </entry></row><row><entry>589688</entry><entry>rs362273</entry><entry>TGATCTGTAGCAGCAGC</entry><entry>eekek-d7-kekee</entry><entry>435</entry></row><row><entry> </entry></row><row><entry>589687</entry><entry>rs362273</entry><entry>TTGATCTGTAGCAGCAG</entry><entry>eekek-d7-kekee</entry><entry>436</entry></row><row><entry> </entry></row><row><entry>589686</entry><entry>rs362273</entry><entry>GTTGATCTGTAGCAGCA</entry><entry>eekek-d7-kekee</entry><entry>437</entry></row><row><entry> </entry></row><row><entry>589685</entry><entry>rs362273</entry><entry>GGTTGATCTGTAGCAGC</entry><entry>eekek-d7-kekee</entry><entry>438</entry></row><row><entry> </entry></row><row><entry>589604</entry><entry>rs362273</entry><entry>ATCTGTAGCAGCAGCTT</entry><entry>eekk-d8-kkeee</entry><entry>439</entry></row><row><entry> </entry></row><row><entry>589603</entry><entry>rs362273</entry><entry>GATCTGTAGCAGCAGCT</entry><entry>eekk-d8-kkeee</entry><entry>440</entry></row><row><entry> </entry></row><row><entry>589600</entry><entry>rs362273</entry><entry>GTTGATCTGTAGCAGCA</entry><entry>eekk-d8-kkeee</entry><entry>441</entry></row><row><entry> </entry></row><row><entry>589599</entry><entry>rs362273</entry><entry>GGTTGATCTGTAGCAGC</entry><entry>eekk-d8-kkeee</entry><entry>442</entry></row><row><entry> </entry></row><row><entry>589740</entry><entry>rs362273</entry><entry>ATCTGTAGCAGCAGCTT</entry><entry>ekek-d8-kekee</entry><entry>443</entry></row><row><entry> </entry></row><row><entry>589739</entry><entry>rs362273</entry><entry>GATCTGTAGCAGCAGCT</entry><entry>ekek-d8-kekee</entry><entry>444</entry></row><row><entry> </entry></row><row><entry>589738</entry><entry>rs362273</entry><entry>TGATCTGTAGCAGCAGC</entry><entry>ekek-d8-kekee</entry><entry>445</entry></row><row><entry> </entry></row><row><entry>589736</entry><entry>rs362273</entry><entry>GTTGATCTGTAGCAGCA</entry><entry>ekek-d8-kekee</entry><entry>446</entry></row><row><entry> </entry></row><row><entry>589735</entry><entry>rs362273</entry><entry>GGTTGATCTGTAGCAGC</entry><entry>ekek-d8-kekee</entry><entry>447</entry></row><row><entry> </entry></row><row><entry>589492</entry><entry>rs363088</entry><entry>CAGCTATCTTCTCATCA</entry><entry>eeekk-d7-kkeee</entry><entry>448</entry></row><row><entry> </entry></row><row><entry>589491</entry><entry>rs363088</entry><entry>ACAGCTATCTTCTCATC</entry><entry>eeekk-d7-kkeee</entry><entry>449</entry></row><row><entry> </entry></row><row><entry>575481</entry><entry>rs363088</entry><entry>CACAGCTATCTTCTCAT</entry><entry>eeekk-d7-kkeee</entry><entry>450</entry></row><row><entry> </entry></row><row><entry>589490</entry><entry>rs363088</entry><entry>TCACAGCTATCTTCTCA</entry><entry>eeekk-d7-kkeee</entry><entry>451</entry></row><row><entry> </entry></row><row><entry>589489</entry><entry>rs363088</entry><entry>TTCACAGCTATCTTCTC</entry><entry>eeekk-d7-kkeee</entry><entry>452</entry></row><row><entry> </entry></row><row><entry>589684</entry><entry>rs363088</entry><entry>CAGCTATCTTCTCATCA</entry><entry>eekek-d7-kekee</entry><entry>453</entry></row><row><entry> </entry></row><row><entry>589683</entry><entry>rs363088</entry><entry>ACAGCTATCTTCTCATC</entry><entry>eekek-d7-kekee</entry><entry>454</entry></row><row><entry> </entry></row><row><entry>589682</entry><entry>rs363088</entry><entry>CACAGCTATCTTCTCAT</entry><entry>eekek-d7-kekee</entry><entry>455</entry></row><row><entry> </entry></row><row><entry>589681</entry><entry>rs363088</entry><entry>TCACAGCTATCTTCTCA</entry><entry>eekek-d7-kekee</entry><entry>456</entry></row><row><entry> </entry></row><row><entry>589680</entry><entry>rs363088</entry><entry>TTCACAGCTATCTTCTC</entry><entry>eekek-d7-kekee</entry><entry>457</entry></row><row><entry> </entry></row><row><entry>589598</entry><entry>rs363088</entry><entry>AGCTATCTTCTCATCAA</entry><entry>eekk-d8-kkeee</entry><entry>458</entry></row><row><entry> </entry></row><row><entry>589597</entry><entry>rs363088</entry><entry>CAGCTATCTTCTCATCA</entry><entry>eekk-d8-kkeee</entry><entry>459</entry></row><row><entry> </entry></row><row><entry>589594</entry><entry>rs363088</entry><entry>TCACAGCTATCTTCTCA</entry><entry>eekk-d8-kkeee</entry><entry>460</entry></row><row><entry> </entry></row><row><entry>589593</entry><entry>rs363088</entry><entry>TTCACAGCTATCTTCTC</entry><entry>eekk-d8-kkeee</entry><entry>461</entry></row><row><entry> </entry></row><row><entry>589734</entry><entry>rs363088</entry><entry>AGCTATCTTCTCATCAA</entry><entry>ekek-d8-kekee</entry><entry>462</entry></row><row><entry> </entry></row><row><entry>589733</entry><entry>rs363088</entry><entry>CAGCTATCTTCTCATCA</entry><entry>ekek-d8-kekee</entry><entry>463</entry></row><row><entry> </entry></row><row><entry>589732</entry><entry>rs363088</entry><entry>ACAGCTATCTTCTCATC</entry><entry>ekek-d8-kekee</entry><entry>464</entry></row><row><entry> </entry></row><row><entry>589731</entry><entry>rs363088</entry><entry>CACAGCTATCTTCTCAT</entry><entry>ekek-d8-kekee</entry><entry>465</entry></row><row><entry> </entry></row><row><entry>589730</entry><entry>rs363088</entry><entry>TCACAGCTATCTTCTCA</entry><entry>ekek-d8-kekee</entry><entry>466</entry></row><row><entry> </entry></row><row><entry>589729</entry><entry>rs363088</entry><entry>TTCACAGCTATCTTCTC</entry><entry>ekek-d8-kekee</entry><entry>467</entry></row><row><entry> </entry></row><row><entry>589502</entry><entry>rs362271</entry><entry>TGTGTACAGAACCTGCC</entry><entry>eeekk-d7-kkeee</entry><entry>468</entry></row><row><entry> </entry></row><row><entry>589501</entry><entry>rs362271</entry><entry>GTGTGTACAGAACCTGC</entry><entry>eeekk-d7-kkeee</entry><entry>469</entry></row><row><entry> </entry></row><row><entry>589500</entry><entry>rs362271</entry><entry>CGTGTGTACAGAACCTG</entry><entry>eeekk-d7-kkeee</entry><entry>470</entry></row><row><entry> </entry></row><row><entry>589499</entry><entry>rs362271</entry><entry>ACGTGTGTACAGAACCT</entry><entry>eeekk-d7-kkeee</entry><entry>471</entry></row><row><entry> </entry></row><row><entry>589498</entry><entry>rs362271</entry><entry>CACGTGTGTACAGAACC</entry><entry>eeekk-d7-kkeee</entry><entry>472</entry></row><row><entry> </entry></row><row><entry>589694</entry><entry>rs362271</entry><entry>TGTGTACAGAACCTGCC</entry><entry>eekek-d7-kekee</entry><entry>473</entry></row><row><entry> </entry></row><row><entry>589693</entry><entry>rs362271</entry><entry>GTGTGTACAGAACCTGC</entry><entry>eekek-d7-kekee</entry><entry>474</entry></row><row><entry> </entry></row><row><entry>589692</entry><entry>rs362271</entry><entry>CGTGTGTACAGAACCTG</entry><entry>eekek-d7-kekee</entry><entry>475</entry></row><row><entry> </entry></row><row><entry>589691</entry><entry>rs362271</entry><entry>ACGTGTGTACAGAACCT</entry><entry>eekek-d7-kekee</entry><entry>476</entry></row><row><entry> </entry></row><row><entry>589690</entry><entry>rs362271</entry><entry>CACGTGTGTACAGAACC</entry><entry>eekek-d7-kekee</entry><entry>477</entry></row><row><entry> </entry></row><row><entry>589610</entry><entry>rs362271</entry><entry>GTGTACAGAACCTGCCG</entry><entry>eekk-d8-kkeee</entry><entry>478</entry></row><row><entry> </entry></row><row><entry>589609</entry><entry>rs362271</entry><entry>TGTGTACAGAACCTGCC</entry><entry>eekk-d8-kkeee</entry><entry>479</entry></row><row><entry> </entry></row><row><entry>589608</entry><entry>rs362271</entry><entry>GTGTGTACAGAACCTGC</entry><entry>eekk-d8-kkeee</entry><entry>480</entry></row><row><entry> </entry></row><row><entry>589607</entry><entry>rs362271</entry><entry>CGTGTGTACAGAACCTG</entry><entry>eekk-d8-kkeee</entry><entry>481</entry></row><row><entry> </entry></row><row><entry>589606</entry><entry>rs362271</entry><entry>ACGTGTGTACAGAACCT</entry><entry>eekk-d8-kkeee</entry><entry>482</entry></row><row><entry> </entry></row><row><entry>589605</entry><entry>rs362271</entry><entry>CACGTGTGTACAGAACC</entry><entry>eekk-d8-kkeee</entry><entry>483</entry></row><row><entry> </entry></row><row><entry>589746</entry><entry>rs362271</entry><entry>GTGTACAGAACCTGCCG</entry><entry>ekek-d8-kekee</entry><entry>484</entry></row><row><entry> </entry></row><row><entry>589745</entry><entry>rs362271</entry><entry>TGTGTACAGAACCTGCC</entry><entry>ekek-d8-kekee</entry><entry>485</entry></row><row><entry> </entry></row><row><entry>589744</entry><entry>rs362271</entry><entry>GTGTGTACAGAACCTGC</entry><entry>ekek-d8-kekee</entry><entry>486</entry></row><row><entry> </entry></row><row><entry>589743</entry><entry>rs362271</entry><entry>CGTGTGTACAGAACCTG</entry><entry>ekek-d8-kekee</entry><entry>487</entry></row><row><entry> </entry></row><row><entry>589742</entry><entry>rs362271</entry><entry>ACGTGTGTACAGAACCT</entry><entry>ekek-d8-kekee</entry><entry>488</entry></row><row><entry> </entry></row><row><entry>589741</entry><entry>rs362271</entry><entry>CACGTGTGTACAGAACC</entry><entry>ekek-d8-kekee</entry><entry>489</entry></row><row><entry> </entry></row><row><entry>589517</entry><entry>rs363099</entry><entry>TGAGCGGAGAAACCCTC</entry><entry>eeekk-d7-kkeee</entry><entry>490</entry></row><row><entry> </entry></row><row><entry>589516</entry><entry>rs363099</entry><entry>CTGAGCGGAGAAACCCT</entry><entry>eeekk-d7-kkeee</entry><entry>491</entry></row><row><entry> </entry></row><row><entry>589515</entry><entry>rs363099</entry><entry>GCTGAGCGGAGAAACCC</entry><entry>eeekk-d7-kkeee</entry><entry>492</entry></row><row><entry> </entry></row><row><entry>589514</entry><entry>rs363099</entry><entry>GGCTGAGCGGAGAAACC</entry><entry>eeekk-d7-kkeee</entry><entry>493</entry></row><row><entry> </entry></row><row><entry>589513</entry><entry>rs363099</entry><entry>AGGCTGAGCGGAGAAAC</entry><entry>eeekk-d7-kkeee</entry><entry>494</entry></row><row><entry> </entry></row><row><entry>589628</entry><entry>rs363099</entry><entry>GAGCGGAGAAACCCTCC</entry><entry>eekk-d8-kkeee</entry><entry>495</entry></row><row><entry> </entry></row><row><entry>589627</entry><entry>rs363099</entry><entry>TGAGCGGAGAAACCCTC</entry><entry>eekk-d8-kkeee</entry><entry>496</entry></row><row><entry> </entry></row><row><entry>589626</entry><entry>rs363099</entry><entry>CTGAGCGGAGAAACCCT</entry><entry>eekk-d8-kkeee</entry><entry>497</entry></row><row><entry> </entry></row><row><entry>589625</entry><entry>rs363099</entry><entry>GCTGAGCGGAGAAACCC</entry><entry>eekk-d8-kkeee</entry><entry>498</entry></row><row><entry> </entry></row><row><entry>589624</entry><entry>rs363099</entry><entry>GGCTGAGCGGAGAAACC</entry><entry>eekk-d8-kkeee</entry><entry>499</entry></row><row><entry> </entry></row><row><entry>589623</entry><entry>rs363099</entry><entry>AGGCTGAGCGGAGAAAC</entry><entry>eekk-d8-kkeee</entry><entry>500</entry></row><row><entry> </entry></row><row><entry>589531</entry><entry>rs363064</entry><entry>AGAATACGGGTAACATT</entry><entry>eeekk-d7-kkeee</entry><entry>501</entry></row><row><entry> </entry></row><row><entry>589530</entry><entry>rs363064</entry><entry>GAGAATACGGGTAACAT</entry><entry>eeekk-d7-kkeee</entry><entry>502</entry></row><row><entry> </entry></row><row><entry>589529</entry><entry>rs363064</entry><entry>GGAGAATACGGGTAACA</entry><entry>eeekk-d7-kkeee</entry><entry>503</entry></row><row><entry> </entry></row><row><entry>589528</entry><entry>rs363064</entry><entry>TGGAGAATACGGGTAAC</entry><entry>eeekk-d7-kkeee</entry><entry>504</entry></row><row><entry> </entry></row><row><entry>589644</entry><entry>rs363064</entry><entry>AGAATACGGGTAACATT</entry><entry>eekk-d8-kkeee</entry><entry>505</entry></row><row><entry> </entry></row><row><entry>589643</entry><entry>rs363064</entry><entry>GAGAATACGGGTAACAT</entry><entry>eekk-d8-kkeee</entry><entry>506</entry></row><row><entry> </entry></row><row><entry>589642</entry><entry>rs363064</entry><entry>GGAGAATACGGGTAACA</entry><entry>eekk-d8-kkeee</entry><entry>507</entry></row><row><entry> </entry></row><row><entry>589522</entry><entry>rs16843804</entry><entry>AACCGTGGCATGGGCAG</entry><entry>eeekk-d7-kkeee</entry><entry>508</entry></row><row><entry> </entry></row><row><entry>589521</entry><entry>rs16843804</entry><entry>TAACCGTGGCATGGGCA</entry><entry>eeekk-d7-kkeee</entry><entry>509</entry></row><row><entry> </entry></row><row><entry>589520</entry><entry>rs16843804</entry><entry>TTAACCGTGGCATGGGC</entry><entry>eeekk-d7-kkeee</entry><entry>510</entry></row><row><entry> </entry></row><row><entry>589519</entry><entry>rs16843804</entry><entry>TTTAACCGTGGCATGGG</entry><entry>eeekk-d7-kkeee</entry><entry>511</entry></row><row><entry> </entry></row><row><entry>589518</entry><entry>rs16843804</entry><entry>CTTTAACCGTGGCATGG</entry><entry>eeekk-d7-kkeee</entry><entry>512</entry></row><row><entry> </entry></row><row><entry>589634</entry><entry>rs16843804</entry><entry>ACCGTGGCATGGGCAGT</entry><entry>eekk-d8-kkeee</entry><entry>513</entry></row><row><entry> </entry></row><row><entry>589633</entry><entry>rs16843804</entry><entry>AACCGTGGCATGGGCAG</entry><entry>eekk-d8-kkeee</entry><entry>514</entry></row><row><entry> </entry></row><row><entry>589632</entry><entry>rs16843804</entry><entry>TAACCGTGGCATGGGCA</entry><entry>eekk-d8-kkeee</entry><entry>515</entry></row><row><entry> </entry></row><row><entry>589631</entry><entry>rs16843804</entry><entry>TTAACCGTGGCATGGGC</entry><entry>eekk-d8-kkeee</entry><entry>516</entry></row><row><entry> </entry></row><row><entry>589630</entry><entry>rs16843804</entry><entry>TTTAACCGTGGCATGGG</entry><entry>eekk-d8-kkeee</entry><entry>517</entry></row><row><entry> </entry></row><row><entry>589629</entry><entry>rs16843804</entry><entry>CTTTAACCGTGGCATGG</entry><entry>eekk-d8-kkeee</entry><entry>518</entry></row><row><entry> </entry></row><row><entry>589512</entry><entry>rs3121419</entry><entry>ACTATAGCACCCAGATT</entry><entry>eeekk-d7-kkeee</entry><entry>519</entry></row><row><entry> </entry></row><row><entry>589511</entry><entry>rs3121419</entry><entry>GACTATAGCACCCAGAT</entry><entry>eeekk-d7-kkeee</entry><entry>520</entry></row><row><entry> </entry></row><row><entry>589510</entry><entry>rs3121419</entry><entry>AGACTATAGCACCCAGA</entry><entry>eeekk-d7-kkeee</entry><entry>521</entry></row><row><entry> </entry></row><row><entry>589509</entry><entry>rs3121419</entry><entry>GAGACTATAGCACCCAG</entry><entry>eeekk-d7-kkeee</entry><entry>522</entry></row><row><entry> </entry></row><row><entry>589508</entry><entry>rs3121419</entry><entry>AGAGACTATAGCACCCA</entry><entry>eeekk-d7-kkeee</entry><entry>523</entry></row><row><entry> </entry></row><row><entry>589704</entry><entry>rs3121419</entry><entry>ACTATAGCACCCAGATT</entry><entry>eekek-d7-kekee</entry><entry>524</entry></row><row><entry> </entry></row><row><entry>589703</entry><entry>rs3121419</entry><entry>GACTATAGCACCCAGAT</entry><entry>eekek-d7-kekee</entry><entry>525</entry></row><row><entry> </entry></row><row><entry>589702</entry><entry>rs3121419</entry><entry>AGACTATAGCACCCAGA</entry><entry>eekek-d7-kekee</entry><entry>526</entry></row><row><entry> </entry></row><row><entry>589701</entry><entry>rs3121419</entry><entry>GAGACTATAGCACCCAG</entry><entry>eekek-d7-kekee</entry><entry>527</entry></row><row><entry> </entry></row><row><entry>589700</entry><entry>rs3121419</entry><entry>AGAGACTATAGCACCCA</entry><entry>eekek-d7-kekee</entry><entry>528</entry></row><row><entry> </entry></row><row><entry>589622</entry><entry>rs3121419</entry><entry>CTATAGCACCCAGATTT</entry><entry>eekk-d8-kkeee</entry><entry>529</entry></row><row><entry> </entry></row><row><entry>589621</entry><entry>rs3121419</entry><entry>ACTATAGCACCCAGATT</entry><entry>eekk-d8-kkeee</entry><entry>530</entry></row><row><entry> </entry></row><row><entry>589620</entry><entry>rs3121419</entry><entry>GACTATAGCACCCAGAT</entry><entry>eekk-d8-kkeee</entry><entry>531</entry></row><row><entry> </entry></row><row><entry>589619</entry><entry>rs3121419</entry><entry>AGACTATAGCACCCAGA</entry><entry>eekk-d8-kkeee</entry><entry>532</entry></row><row><entry> </entry></row><row><entry>589618</entry><entry>rs3121419</entry><entry>GAGACTATAGCACCCAG</entry><entry>eekk-d8-kkeee</entry><entry>533</entry></row><row><entry> </entry></row><row><entry>589617</entry><entry>rs3121419</entry><entry>AGAGACTATAGCACCCA</entry><entry>eekk-d8-kkeee</entry><entry>534</entry></row><row><entry> </entry></row><row><entry>589758</entry><entry>rs3121419</entry><entry>CTATAGCACCCAGATTT</entry><entry>ekek-d8-kekee</entry><entry>535</entry></row><row><entry> </entry></row><row><entry>589757</entry><entry>rs3121419</entry><entry>ACTATAGCACCCAGATT</entry><entry>ekek-d8-kekee</entry><entry>536</entry></row><row><entry> </entry></row><row><entry>589756</entry><entry>rs3121419</entry><entry>GACTATAGCACCCAGAT</entry><entry>ekek-d8-kekee</entry><entry>537</entry></row><row><entry> </entry></row><row><entry>589755</entry><entry>rs3121419</entry><entry>AGACTATAGCACCCAGA</entry><entry>ekek-d8-kekee</entry><entry>538</entry></row><row><entry> </entry></row><row><entry>589754</entry><entry>rs3121419</entry><entry>GAGACTATAGCACCCAG</entry><entry>ekek-d8-kekee</entry><entry>539</entry></row><row><entry> </entry></row><row><entry>589753</entry><entry>rs3121419</entry><entry>AGAGACTATAGCACCCA</entry><entry>ekek-d8-kekee</entry><entry>540</entry></row><row><entry> </entry></row><row><entry>589527</entry><entry>rs2298967</entry><entry>TTTTCTATTGTCTGTCC</entry><entry>eeekk-d7-kkeee</entry><entry>541</entry></row><row><entry> </entry></row><row><entry>589526</entry><entry>rs2298967</entry><entry>CTTTTCTATTGTCTGTC</entry><entry>eeekk-d7-kkeee</entry><entry>542</entry></row><row><entry> </entry></row><row><entry>589525</entry><entry>rs2298967</entry><entry>GCTTTTCTATTGTCTGT</entry><entry>eeekk-d7-kkeee</entry><entry>543</entry></row><row><entry> </entry></row><row><entry>589524</entry><entry>rs2298967</entry><entry>TGCTTTTCTATTGTCTG</entry><entry>eeekk-d7-kkeee</entry><entry>544</entry></row><row><entry> </entry></row><row><entry>589523</entry><entry>rs2298967</entry><entry>TTGCTTTTCTATTGTCT</entry><entry>eeekk-d7-kkeee</entry><entry>545</entry></row><row><entry> </entry></row><row><entry>589640</entry><entry>rs2298967</entry><entry>TTTCTATTGTCTGTCCC</entry><entry>eekk-d8-kkeee</entry><entry>546</entry></row><row><entry> </entry></row><row><entry>589639</entry><entry>rs2298967</entry><entry>TTTTCTATTGTCTGTCC</entry><entry>eekk-d8-kkeee</entry><entry>547</entry></row><row><entry> </entry></row><row><entry>589638</entry><entry>rs2298967</entry><entry>CTTTTCTATTGTCTGTC</entry><entry>eekk-d8-kkeee</entry><entry>548</entry></row><row><entry> </entry></row><row><entry>589637</entry><entry>rs2298967</entry><entry>GCTTTTCTATTGTCTGT</entry><entry>eekk-d8-kkeee</entry><entry>549</entry></row><row><entry> </entry></row><row><entry>589636</entry><entry>rs2298967</entry><entry>TGCTTTTCTATTGTCTG</entry><entry>eekk-d8-kkeee</entry><entry>550</entry></row><row><entry> </entry></row><row><entry>589635</entry><entry>rs2298967</entry><entry>TTGCTTTTCTATTGTCT</entry><entry>eekk-d8-kkeee</entry><entry>551</entry></row><row><entry> </entry></row><row><entry>589507</entry><entry>rs34315806</entry><entry>TTTTCCGTGCTGTTCTG</entry><entry>eeekk-d7-kkeee</entry><entry>552</entry></row><row><entry> </entry></row><row><entry>589506</entry><entry>rs34315806</entry><entry>CTTTTCCGTGCTGTTCT</entry><entry>eeekk-d7-kkeee</entry><entry>553</entry></row><row><entry> </entry></row><row><entry>589505</entry><entry>rs34315806</entry><entry>ACTTTTCCGTGCTGTTC</entry><entry>eeekk-d7-kkeee</entry><entry>554</entry></row><row><entry> </entry></row><row><entry>589504</entry><entry>rs34315806</entry><entry>AACTTTTCCGTGCTGTT</entry><entry>eeekk-d7-kkeee</entry><entry>555</entry></row><row><entry> </entry></row><row><entry>589503</entry><entry>rs34315806</entry><entry>AAACTTTTCCGTGCTGT</entry><entry>eeekk-d7-kkeee</entry><entry>556</entry></row><row><entry> </entry></row><row><entry>589699</entry><entry>rs34315806</entry><entry>TTTTCCGTGCTGTTCTG</entry><entry>eekek-d7-kekee</entry><entry>557</entry></row><row><entry> </entry></row><row><entry>589698</entry><entry>rs34315806</entry><entry>CTTTTCCGTGCTGTTCT</entry><entry>eekek-d7-kekee</entry><entry>558</entry></row><row><entry> </entry></row><row><entry>589697</entry><entry>rs34315806</entry><entry>ACTTTTCCGTGCTGTTC</entry><entry>eekek-d7-kekee</entry><entry>559</entry></row><row><entry> </entry></row><row><entry>589696</entry><entry>rs34315806</entry><entry>AACTTTTCCGTGCTGTT</entry><entry>eekek-d7-kekee</entry><entry>560</entry></row><row><entry> </entry></row><row><entry>589695</entry><entry>rs34315806</entry><entry>AAACTTTTCCGTGCTGT</entry><entry>eekek-d7-kekee</entry><entry>561</entry></row><row><entry> </entry></row><row><entry>589616</entry><entry>rs34315806</entry><entry>TTTCCGTGCTGTTCTGA</entry><entry>eekk-d8-kkeee</entry><entry>562</entry></row><row><entry> </entry></row><row><entry>589615</entry><entry>rs34315806</entry><entry>TTTTCCGTGCTGTTCTG</entry><entry>eekk-d8-kkeee</entry><entry>563</entry></row><row><entry> </entry></row><row><entry>589614</entry><entry>rs34315806</entry><entry>CTTTTCCGTGCTGTTCT</entry><entry>eekk-d8-kkeee</entry><entry>564</entry></row><row><entry> </entry></row><row><entry>589613</entry><entry>rs34315806</entry><entry>ACTTTTCCGTGCTGTTC</entry><entry>eekk-d8-kkeee</entry><entry>565</entry></row><row><entry> </entry></row><row><entry>589612</entry><entry>rs34315806</entry><entry>AACTTTTCCGTGCTGTT</entry><entry>eekk-d8-kkeee</entry><entry>566</entry></row><row><entry> </entry></row><row><entry>589611</entry><entry>rs34315806</entry><entry>AAACTTTTCCGTGCTGT</entry><entry>eekk-d8-kkeee</entry><entry>567</entry></row><row><entry> </entry></row><row><entry>589752</entry><entry>rs34315806</entry><entry>TTTCCGTGCTGTTCTGA</entry><entry>ekek-d8-kekee</entry><entry>568</entry></row><row><entry> </entry></row><row><entry>589751</entry><entry>rs34315806</entry><entry>TTTTCCGTGCTGTTCTG</entry><entry>ekek-d8-kekee</entry><entry>569</entry></row><row><entry> </entry></row><row><entry>589750</entry><entry>rs34315806</entry><entry>CTTTTCCGTGCTGTTCT</entry><entry>ekek-d8-kekee</entry><entry>570</entry></row><row><entry> </entry></row><row><entry>589749</entry><entry>rs34315806</entry><entry>ACTTTTCCGTGCTGTTC</entry><entry>ekek-d8-kekee</entry><entry>571</entry></row><row><entry> </entry></row><row><entry>589748</entry><entry>rs34315806</entry><entry>AACTTTTCCGTGCTGTT</entry><entry>ekek-d8-kekee</entry><entry>572</entry></row><row><entry> </entry></row><row><entry>589747</entry><entry>rs34315806</entry><entry>AAACTTTTCCGTGCTGT</entry><entry>ekek-d8-kekee</entry><entry>573</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0020" level="1">Example 4: 300 &#x3bc;g ICV Bolus 8 Week Study with Mice</heading><p id="p-0432" num="0553">Oligos were screened in human patient fibroblasts (either GM4022 or GM2173B) at 4 &#x3bc;M with electroporation (2 mm multiwell, 115V, 6 mS, 1 pulse, 3.5e5 cells per well). Target message was measured with an allele specific ABI primer probe set 24-hours post electroporation. Results were normalized to Ribogreen. The half maximal inhibitory concentration (IC<sub>50</sub>) of each oligonucleotide is presented in the Table below and was calculated by plotting the concentrations of oligonucleotides used versus the percent inhibition of HTT mRNA expression achieved at each concentration, and noting the concentration of oligonucleotide at which 50% inhibition of HTT mRNA expression was achieved compared to the control. The IC<sub>50 </sub>at which each oligonucleotide inhibits the mutant HTT mRNA expression is denoted as &#x2018;mut IC<sub>50</sub>&#x2019;. The IC<sub>50 </sub>at which each oligonucleotide inhibits the wild-type HTT mRNA expression is denoted as &#x2018;wt IC<sub>50</sub>&#x2019;. &#x201c;ND&#x201d; means data not available.</p><p id="p-0433" num="0554">Mice were separated into groups of 4 mice. Each mouse in each group of mice was administered a single 300 &#x3bc;g ICV dose of each of the oligonucleotides in the table below. At 3 hours post injection, each mouse was evaluated according to 7 different criteria. The 7 criteria are (1) the mouse was bright, alert, and responsive; (2) the mouse was standing or hunched without stimuli; (3) the mouse shows any movement without stimuli (4) the mouse demonstrates forward movement after it is lifted; (5) the mouse demonstrates any movement after it is lifted; (6) the mouse responds to a tail pinch; (7) the mouse has a regular respiratory rate. For each of the 7 different criteria, each mouse was given a sub-score of 0 if it met the criteria or 1 if it did not. After each of the 7 criteria were evaluated, the sub-scores were summed for each mouse and then averaged for each group. For example, if a mouse was bright, alert, and responsive 3 hours after the 300 &#x3bc;g ICV dose, and met all other other criteria, it would get a summed score of 0. If another mouse was not bright, alert, and responsive 3 hours after the 300 &#x3bc;g ICV dose but met all other criteria, it would receive a score of 1. Saline treated mice generally receive a score of 0. A score of at the top end of the range would be suggestive of acute toxicity. In the table below, a subscript 1&#x2032; indicates an (S)-cEt modification; a subscript &#x2018;e&#x2019; indicates a MOE modification; a subscript indicates a 2&#x2032;-deoxynucleoside and an &#x201c;N&#x201d; without a subscript also indicates a 2&#x2032;-deoxynucleoside. In the table below, an &#x201c;x&#x201d; represents a 2-thiothymine. Subscripts &#x201c;s&#x201d; and &#x201c;o&#x201d; refer to phosphorothioate and phosphodiester internucleoside bonds, respectively.</p><p id="p-0434" num="0555">Each mouse was then evaluated weekly by a trained observer for 8 weeks and examined for adverse events. Adverse events are defined as any behavior not typical in a naive matched control animal. Animals were evaluated for adverse events including, but not limited to: limb clasping, abnormal limb splay, abnormal gait, tremors, abnormal respiration, paralysis, spasticity, impaired righting reflex, hyperactivity and lethargy. For each group, the number of animals that exhibited any adverse events during any of the 8 weekly observations was calculated. For example, a group of animals where no animals exhibited any adverse events is given a score of 0.</p><p id="p-0435" num="0000"><tables id="TABLE-US-00030" num="00030"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 28</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>300 &#x3bc;g ICV Bolus 8 Week Study With Mice</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="6"><colspec colname="1" colwidth="35pt" align="center"/><colspec colname="2" colwidth="35pt" align="left"/><colspec colname="3" colwidth="21pt" align="center"/><colspec colname="4" colwidth="28pt" align="center"/><colspec colname="5" colwidth="49pt" align="center"/><colspec colname="6" colwidth="49pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry/><entry/><entry/><entry># of Mice</entry></row><row><entry/><entry/><entry/><entry/><entry/><entry>in group with</entry></row><row><entry/><entry/><entry>Mut</entry><entry>Wt</entry><entry>Score at</entry><entry>one or more</entry></row><row><entry/><entry/><entry>IC<sub>50</sub></entry><entry>IC<sub>50</sub></entry><entry>3 hours</entry><entry>adverse events</entry></row><row><entry>Isis No.</entry><entry>SNP</entry><entry>(&#x3bc;M)</entry><entry>(&#x3bc;M)</entry><entry>post injection</entry><entry>for 8 weeks</entry></row><row><entry namest="1" nameend="6" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="6"><colspec colname="1" colwidth="35pt" align="char" char="."/><colspec colname="2" colwidth="35pt" align="left"/><colspec colname="3" colwidth="21pt" align="center"/><colspec colname="4" colwidth="28pt" align="center"/><colspec colname="5" colwidth="49pt" align="center"/><colspec colname="6" colwidth="49pt" align="center"/><tbody valign="top"><row><entry>540083</entry><entry>rs7685686</entry><entry>ND</entry><entry>ND</entry><entry>ND</entry><entry>4</entry></row><row><entry>540094</entry><entry>rs7685686</entry><entry>0.31</entry><entry>4.8</entry><entry>4.3</entry><entry>2</entry></row><row><entry>540095</entry><entry>rs7685686</entry><entry>0.69</entry><entry>8.3</entry><entry>6</entry><entry>4</entry></row><row><entry>540096</entry><entry>rs7685686</entry><entry>0.65</entry><entry>10</entry><entry>3.5</entry><entry>2</entry></row><row><entry>540108</entry><entry>rs7685686</entry><entry>0.41</entry><entry>&#x3e;10</entry><entry>0.8</entry><entry>4</entry></row><row><entry>550913</entry><entry>rs7685686</entry><entry>0.12</entry><entry>0.6</entry><entry>2</entry><entry>3</entry></row><row><entry>551429</entry><entry>rs7685686</entry><entry>0.24</entry><entry>&#x3e;10</entry><entry>0.3</entry><entry>0</entry></row><row><entry>566267</entry><entry>rs7685686</entry><entry>0.34</entry><entry>&#x3e;15</entry><entry>1.5</entry><entry>0</entry></row><row><entry>568876</entry><entry>rs7685686</entry><entry>0.1</entry><entry>&#x3e;10</entry><entry>1.3</entry><entry>4</entry></row><row><entry>571036</entry><entry>rs7685686</entry><entry>0.17</entry><entry>&#x3e;10</entry><entry>1</entry><entry>4</entry></row><row><entry>571037</entry><entry>rs7685686</entry><entry>0.11</entry><entry>&#x3e;10</entry><entry>0</entry><entry>4</entry></row><row><entry>575007</entry><entry>rs7685686</entry><entry>0.67</entry><entry>&#x3e;10</entry><entry>1.8</entry><entry>0</entry></row><row><entry>585246</entry><entry>rs7685686</entry><entry>0.6</entry><entry>&#x3e;10</entry><entry>4.5</entry><entry>4</entry></row><row><entry>571069</entry><entry>rs7685686</entry><entry>0.29</entry><entry>&#x3e;10</entry><entry>0</entry><entry>4</entry></row><row><entry>572771</entry><entry>rs7685686</entry><entry>0.54</entry><entry>&#x3e;10</entry><entry>0</entry><entry>3</entry></row><row><entry>572772</entry><entry>rs7685686</entry><entry>0.57</entry><entry>&#x3e;10</entry><entry>0</entry><entry>0</entry></row><row><entry>575008</entry><entry>rs7685686</entry><entry>0.18</entry><entry>&#x3e;10</entry><entry>0</entry><entry>1</entry></row><row><entry>460209</entry><entry>rs7685686</entry><entry>0.34</entry><entry>1.7</entry><entry>1.3</entry><entry>0</entry></row><row><entry>476333</entry><entry>rs7685686</entry><entry>0.32</entry><entry>1.6</entry><entry>0</entry><entry>1</entry></row><row><entry>540108</entry><entry>rs7685686</entry><entry>0.41</entry><entry>&#x3e;10</entry><entry>0.3</entry><entry>2</entry></row><row><entry>593199</entry><entry>rs7685686</entry><entry>ND</entry><entry>ND</entry><entry>0</entry><entry>3</entry></row><row><entry>593200</entry><entry>rs7685686</entry><entry>ND</entry><entry>ND</entry><entry>0.5</entry><entry>0</entry></row><row><entry>593201</entry><entry>rs7685686</entry><entry>ND</entry><entry>ND</entry><entry>0</entry><entry>4</entry></row><row><entry>593202</entry><entry>rs7685686</entry><entry>ND</entry><entry>ND</entry><entry>0</entry><entry>4</entry></row><row><entry>593203</entry><entry>rs7685686</entry><entry>ND</entry><entry>ND</entry><entry>0</entry><entry>3</entry></row><row><entry>593204</entry><entry>rs7685686</entry><entry>ND</entry><entry>ND</entry><entry>0</entry><entry>4</entry></row><row><entry>558257</entry><entry>rs7685686</entry><entry>0.6</entry><entry>&#x3e;10</entry><entry>0</entry><entry>ND</entry></row><row><entry>571039</entry><entry>rs7685686</entry><entry>0.34</entry><entry>&#x3e;10</entry><entry>2.5</entry><entry>ND</entry></row><row><entry>598229</entry><entry>rs7685686</entry><entry>ND</entry><entry>ND</entry><entry>0</entry><entry>ND</entry></row><row><entry>598300</entry><entry>rs7685686</entry><entry>ND</entry><entry>ND</entry><entry>1.3</entry><entry>ND</entry></row><row><entry>598301</entry><entry>rs7685686</entry><entry>ND</entry><entry>ND</entry><entry>2.3</entry><entry>ND</entry></row><row><entry>598302</entry><entry>rs7685686</entry><entry>ND</entry><entry>ND</entry><entry>0.3</entry><entry>ND</entry></row><row><entry>598303</entry><entry>rs7685686</entry><entry>ND</entry><entry>ND</entry><entry>1.5</entry><entry>ND</entry></row><row><entry>598304</entry><entry>rs7685686</entry><entry>ND</entry><entry>ND</entry><entry>1.5</entry><entry>ND</entry></row><row><entry>598305</entry><entry>rs7685686</entry><entry>ND</entry><entry>ND</entry><entry>0</entry><entry>ND</entry></row><row><entry>598306</entry><entry>rs7685686</entry><entry>ND</entry><entry>ND</entry><entry>0.5</entry><entry>ND</entry></row><row><entry>598307</entry><entry>rs7685686</entry><entry>ND</entry><entry>ND</entry><entry>0.8</entry><entry>ND</entry></row><row><entry>598308</entry><entry>rs7685686</entry><entry>ND</entry><entry>ND</entry><entry>1.8</entry><entry>ND</entry></row><row><entry>606560</entry><entry>rs7685686</entry><entry>ND</entry><entry>ND</entry><entry>1.5</entry><entry>ND</entry></row><row><entry>606578</entry><entry>rs7685686</entry><entry>ND</entry><entry>ND</entry><entry>2.8</entry><entry>ND</entry></row><row><entry>435871</entry><entry>rs363088</entry><entry>ND</entry><entry>ND</entry><entry>4.8</entry><entry>3</entry></row><row><entry>525366</entry><entry>rs363088</entry><entry>0.6</entry><entry>2.88</entry><entry>ND</entry><entry>4</entry></row><row><entry>525368</entry><entry>rs363088</entry><entry>0.8</entry><entry>6.88</entry><entry>.3</entry><entry>4</entry></row><row><entry>575172</entry><entry>rs363088</entry><entry>0.9</entry><entry>5.0</entry><entry>0</entry><entry>4</entry></row><row><entry>575175</entry><entry>rs363088</entry><entry>0.4</entry><entry>2.64</entry><entry>0</entry><entry>4</entry></row><row><entry>582658</entry><entry>rs363088</entry><entry>0.8</entry><entry>6.9</entry><entry>0</entry><entry>4</entry></row><row><entry>582661</entry><entry>rs363088</entry><entry>0.4</entry><entry>3.0</entry><entry>0</entry><entry>4</entry></row><row><entry>589595</entry><entry>rs363088</entry><entry>1.2</entry><entry>9.6</entry><entry>0</entry><entry>4</entry></row><row><entry>589596</entry><entry>rs363088</entry><entry>1.4</entry><entry>&#x3e;10</entry><entry>0</entry><entry>4</entry></row><row><entry>591416</entry><entry>rs363088</entry><entry>ND</entry><entry>ND</entry><entry>0</entry><entry>3</entry></row><row><entry>589450</entry><entry>rs6446723</entry><entry>1.3</entry><entry>&#x3e;10</entry><entry>3.8</entry><entry>0</entry></row><row><entry>589532</entry><entry>rs363064</entry><entry>2.5</entry><entry>&#x3e;10</entry><entry>5.8</entry><entry>2</entry></row><row><entry>589537</entry><entry>rs7685686</entry><entry>0.8</entry><entry>4.8</entry><entry>2.8</entry><entry>2</entry></row><row><entry>589546</entry><entry>rs6446723</entry><entry>1.3</entry><entry>&#x3e;10</entry><entry>1.8</entry><entry>0</entry></row><row><entry>589547</entry><entry>rs6446723</entry><entry>1.5</entry><entry>&#x3e;10</entry><entry>2.3</entry><entry>1</entry></row><row><entry>589567</entry><entry>rs6446723</entry><entry>0.8</entry><entry>9.6</entry><entry>6</entry><entry>3</entry></row><row><entry>589601</entry><entry>rs362273</entry><entry>1.3</entry><entry>7</entry><entry>6</entry><entry>4</entry></row><row><entry>589602</entry><entry>rs362273</entry><entry>1.4</entry><entry>&#x3e;10</entry><entry>6</entry><entry>3</entry></row><row><entry>589645</entry><entry>rs363088</entry><entry>1.5</entry><entry>&#x3e;10</entry><entry>5.7</entry><entry>2</entry></row><row><entry>589646</entry><entry>rs363088</entry><entry>3.2</entry><entry>&#x3e;10</entry><entry>4.3</entry><entry>0</entry></row><row><entry>589718</entry><entry>rs6446723</entry><entry>1.4</entry><entry>&#x3e;10</entry><entry>3.3</entry><entry>1</entry></row><row><entry>589737</entry><entry>rs363088</entry><entry>1.3</entry><entry>4.8</entry><entry>5.8</entry><entry>4</entry></row><row><entry>556845</entry><entry>rs7685686</entry><entry>ND</entry><entry>ND</entry><entry>3</entry><entry>ND</entry></row><row><entry>598309</entry><entry>rs7685686</entry><entry>ND</entry><entry>ND</entry><entry>0.5</entry><entry>ND</entry></row><row><entry>598310</entry><entry>rs7685686</entry><entry>ND</entry><entry>ND</entry><entry>0.3</entry><entry>ND</entry></row><row><entry>606561</entry><entry>rs7685686</entry><entry>ND</entry><entry>ND</entry><entry>1.5</entry><entry>ND</entry></row><row><entry>606562</entry><entry>rs7685686</entry><entry>ND</entry><entry>ND</entry><entry>2.3</entry><entry>ND</entry></row><row><entry>598299</entry><entry>rs7685686</entry><entry>ND</entry><entry>ND</entry><entry>1</entry><entry>ND</entry></row><row><entry namest="1" nameend="6" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0021" level="1">Example 5: 300 &#x3bc;g ICV Bolus Study with Mice</heading><p id="p-0436" num="0556">Additional oligonucleotides, shown in the table below, were administered to mice at a single 300 &#x3bc;g ICV dose. The mice were evaluated according to the procedures in Example 4 above.</p><p id="p-0437" num="0000"><tables id="TABLE-US-00031" num="00031"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="392pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;29</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>300&#x2003;ug&#x2003;ICV&#x2003;Bolus&#x2003;Study&#x2003;With&#x2003;Mice</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="6"><colspec colname="1" colwidth="42pt" align="left"/><colspec colname="2" colwidth="49pt" align="left"/><colspec colname="3" colwidth="168pt" align="left"/><colspec colname="4" colwidth="63pt" align="left"/><colspec colname="5" colwidth="42pt" align="center"/><colspec colname="6" colwidth="28pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry/><entry/><entry>Score&#x2003;at</entry><entry/></row><row><entry/><entry/><entry/><entry/><entry>3&#x2003;hours</entry><entry/></row><row><entry/><entry/><entry/><entry/><entry>post</entry><entry>SEQ</entry></row><row><entry>ISIS&#x2003;NO.</entry><entry>SNP</entry><entry>Sequence&#x2003;(5&#x2032;&#x2003;to&#x2003;3&#x2032;)</entry><entry>Sugar&#x2003;Motif</entry><entry>injection</entry><entry>ID&#x2003;NO</entry></row><row><entry namest="1" nameend="6" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="6"><colspec colname="1" colwidth="42pt" align="center"/><colspec colname="2" colwidth="49pt" align="left"/><colspec colname="3" colwidth="168pt" align="left"/><colspec colname="4" colwidth="63pt" align="left"/><colspec colname="5" colwidth="42pt" align="char" char="."/><colspec colname="6" colwidth="28pt" align="center"/><tbody valign="top"><row><entry>551429</entry><entry>rs7685686</entry><entry>T<sub>e</sub>A<sub>e</sub>A<sub>e</sub>A<sub>k</sub>T<sub>k</sub>TGTCATCA<sub>k</sub>C<sub>k</sub>C<sub>e</sub></entry><entry>5-7-3</entry><entry>.3</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry> </entry></row><row><entry>571037</entry><entry>rs7685686</entry><entry>A<sub>e</sub>T<sub>e</sub>A<sub>e</sub>A<sub>e</sub>A<sub>k</sub>T<sub>k</sub>TG<u style="single">T</u><sup>m</sup>CAT<sup>m</sup>CA<sub>k</sub><sup>m</sup>C<sub>e</sub><sup>m</sup>C<sub>k</sub>A<sub>e</sub></entry><entry>6-7-4</entry><entry>0</entry><entry>&#x2003;11</entry></row><row><entry> </entry></row><row><entry>540108</entry><entry>rs7685686</entry><entry>A<sub>e</sub>T<sub>e</sub>A<sub>e</sub>A<sub>k</sub>A<sub>k</sub>TTG<u style="single">T</u><sup>m</sup>CAT<sup>m</sup>C<sub>k</sub>A<sub>k</sub><sup>m</sup>C<sub>e</sub><sup>m</sup>C<sub>e</sub>A<sub>e</sub></entry><entry>5-7-5</entry><entry>.3</entry><entry>&#x2003;11</entry></row><row><entry> </entry></row><row><entry>571036</entry><entry>rs7685686</entry><entry>A<sub>e</sub>T<sub>k</sub>A<sub>e</sub>A<sub>k</sub>A<sub>e</sub>T<sub>k</sub>TG<u style="single">T</u><sup>m</sup>CAT<sup>m</sup>CA<sub>k</sub><sup>m</sup>C<sub>e</sub><sup>m</sup>C<sub>k</sub>A<sub>e</sub></entry><entry>6-7-4</entry><entry>1</entry><entry>&#x2003;11</entry></row><row><entry> </entry></row><row><entry>568876</entry><entry>rs7685686</entry><entry>A<sub>k</sub>A<sub>k</sub>A<sub>k</sub>A<sub>k</sub>AkTTG<u style="single">T</u>CATC<sub>k</sub>A<sub>k</sub>C<sub>k</sub>C<sub>k</sub>A<sub>k</sub></entry><entry>5-7-5</entry><entry>1.3</entry><entry>&#x2003;11</entry></row><row><entry> </entry></row><row><entry>566267</entry><entry>rs7685686</entry><entry>T<sub>e</sub>A<sub>k</sub>A<sub>k</sub>AT<sub>z</sub>TG<u style="single">T</u><sup>m</sup>CAT<sup>m</sup>CAk<sup>m</sup>C<sub>k</sub><sup>m</sup>C<sub>e</sub></entry><entry>3-9-3&#x2003;or&#x2003;5-7-3</entry><entry>1.5</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry> </entry></row><row><entry>575007</entry><entry>rs7685686</entry><entry>T<sub>e</sub>A<sub>k</sub>A<sub>k</sub>AT<sub>k</sub>TG<u style="single">T</u><sup>m</sup>CAT<sup>m</sup>CA<sub>k</sub><sup>m</sup>C<sub>k</sub><sup>m</sup>C<sub>e</sub></entry><entry>3-9-3&#x2003;or&#x2003;5-7-3</entry><entry>1.8</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry> </entry></row><row><entry>550913</entry><entry>rs7685686</entry><entry><u style="single">A<sub>k</sub>A<sub>k</sub></u>T<sub>e</sub>A<sub>k</sub>A<sub>k</sub>ATTGTCATCA<sub>k</sub>C<sub>k</sub>C<sub>e</sub><u style="single">T<sub>k</sub>T<sub>k</sub></u></entry><entry>5-9-5</entry><entry>2</entry><entry>&#x2003;12</entry></row><row><entry> </entry></row><row><entry>540096</entry><entry>rs7685686</entry><entry>A<sub>e</sub>A<sub>k</sub>TTG<u style="single">T</u>CATCAC<sub>k</sub>C<sub>k</sub>A<sub>k</sub>G<sub>e</sub></entry><entry>2-9-4</entry><entry>3.5</entry><entry>&#x2003;&#x2003;7</entry></row><row><entry> </entry></row><row><entry>585246</entry><entry>rs7685686</entry><entry>T<sub>e</sub>A<sub>e</sub>A<sub>e</sub>A<sub>k</sub>T<sub>k</sub>TG<u style="single">T</u>CATCA<sub>k</sub>C<sub>k</sub>C<sub>e</sub>A<sub>e</sub>G<sub>e</sub></entry><entry>5-7-5</entry><entry>4.5</entry><entry>&#x2003;31</entry></row><row><entry> </entry></row><row><entry>540094</entry><entry>rs7685686</entry><entry>T<sub>e</sub>T<sub>k</sub>G<u style="single">T</u><sup>m</sup>CAT<sup>m</sup>CA&#x2003;<sup>m</sup>C<sup>m</sup>CA<sub>k</sub>G<sub>k</sub>A<sub>k</sub>A<sub>e</sub></entry><entry>2-9-4</entry><entry>4.3</entry><entry>&#x2003;&#x2003;8</entry></row><row><entry> </entry></row><row><entry>540095</entry><entry>rs7685686</entry><entry>A<sub>e</sub>T<sub>k</sub>TG<u style="single">T</u>CATCACC<sub>k</sub>A<sub>k</sub>G<sub>k</sub>A<sub>e</sub></entry><entry>2-9-4</entry><entry>6</entry><entry>&#x2003;48</entry></row><row><entry> </entry></row><row><entry>540083</entry><entry>rs7685686</entry><entry>A<sub>e</sub>A<sub>k</sub>T<sub>k</sub>T<sub>k</sub>G<u style="single">T</u>CATCACCA<sub>k</sub>G<sub>e</sub></entry><entry>4-9-2</entry><entry>ND</entry><entry>&#x2003;&#x2003;7</entry></row><row><entry> </entry></row><row><entry>593200</entry><entry>rs7685686</entry><entry>A<sub>es</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;mCA<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;mC<sub>ds</sub></entry><entry>2-9-4</entry><entry>0.5</entry><entry>&#x2003;48</entry></row><row><entry/><entry/><entry>mC<sub>ko</sub>&#x2003;A<sub>ko</sub>&#x2003;G<sub>ks</sub>&#x2003;A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>593202</entry><entry>rs7685686</entry><entry>A<sub>es</sub>&#x2003;T<sub>ko</sub>&#x2003;A<sub>ko</sub>&#x2003;A<sub>ko</sub>&#x2003;A<sub>ks</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ds</sub></entry><entry>6-7-4</entry><entry>0</entry><entry>&#x2003;4</entry></row><row><entry/><entry/><entry>Tas&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ko</sub>&#x2003;mC<sub>ko</sub>&#x2003;mC<sub>ks</sub>&#x2003;A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>476333</entry><entry>rs7685686</entry><entry>A<sub>es</sub>&#x2003;T<sub>ks</sub>&#x2003;A<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub></entry><entry>4-9-4</entry><entry>0</entry><entry>&#x2003;&#x2003;4</entry></row><row><entry/><entry/><entry>mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>es</sub>&#x2003;mC<sub>ks</sub>&#x2003;A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>571039</entry><entry>rs7685686</entry><entry>A<sub>es</sub>&#x2003;T<sub>ks</sub>&#x2003;A<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;xT<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ds</sub></entry><entry>4-9-4</entry><entry>2.5</entry><entry>&#x2003;&#x2003;4</entry></row><row><entry/><entry/><entry>T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>es</sub>&#x2003;mC<sub>ks</sub>&#x2003;A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>598229</entry><entry>rs7685686</entry><entry>A<sub>es</sub>&#x2003;T<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;mC<sub>ks</sub>&#x2003;A<sub>ds</sub></entry><entry>6-7-4</entry><entry>0</entry><entry>&#x2003;&#x2003;4</entry></row><row><entry/><entry/><entry>T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>es</sub>&#x2003;mC<sub>ks</sub>&#x2003;A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>593203</entry><entry>rs7685686</entry><entry>T<sub>ks</sub>&#x2003;A<sub>ko</sub>&#x2003;A<sub>ko</sub>&#x2003;A<sub>ko</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub></entry><entry>5-7-5</entry><entry>0</entry><entry>&#x2003;31</entry></row><row><entry/><entry/><entry>mC<sub>ds</sub>&#x2003;A<sub>ko</sub>&#x2003;mC<sub>ko</sub>&#x2003;mC<sub>ko</sub>&#x2003;A<sub>ks</sub>&#x2003;G<sub>k</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>593204</entry><entry>rs7685686</entry><entry>A<sub>ks</sub>&#x2003;T<sub>ko</sub>&#x2003;A<sub>ko</sub>&#x2003;A<sub>ko</sub>&#x2003;A<sub>ko</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ds</sub></entry><entry>5-7-5</entry><entry>0</entry><entry>&#x2003;&#x2003;4</entry></row><row><entry/><entry/><entry>T<sub>ds</sub>mC<sub>ko</sub>&#x2003;A<sub>ko</sub>&#x2003;mC<sub>ko</sub>&#x2003;mC<sub>ko</sub>&#x2003;A<sub>k</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>598305</entry><entry>rs7685686</entry><entry>A<sub>es</sub>&#x2003;T<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub></entry><entry>4-9-4&#x2003;or</entry><entry>0</entry><entry>&#x2003;&#x2003;4</entry></row><row><entry/><entry/><entry>mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;mC<sub>es</sub>&#x2003;A<sub>e</sub></entry><entry>6-7-4</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>598306</entry><entry>rs7685686</entry><entry>A<sub>es</sub>&#x2003;T<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub></entry><entry>4-9-4&#x2003;or</entry><entry>0.5</entry><entry>&#x2003;4</entry></row><row><entry/><entry/><entry>mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>es</sub>&#x2003;mC<sub>es</sub>&#x2003;A<sub>e</sub></entry><entry>6-7-4</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>598307</entry><entry>rs7685686</entry><entry>A<sub>es</sub>&#x2003;T<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ks</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub></entry><entry>4-9-4&#x2003;or</entry><entry>0.8</entry><entry>&#x2003;&#x2003;4</entry></row><row><entry/><entry/><entry>mC<sub>ds</sub>&#x2003;A<sub>es</sub>&#x2003;mC<sub>es</sub>&#x2003;mC<sub>es</sub>&#x2003;A<sub>e</sub></entry><entry>6-7-4</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>606560</entry><entry>rs7685686</entry><entry>A<sub>es</sub>&#x2003;T<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;xT<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ds</sub></entry><entry>4-9-4</entry><entry>1.5</entry><entry>&#x2003;&#x2003;4</entry></row><row><entry/><entry/><entry>T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>es</sub>&#x2003;mC<sub>ks</sub>&#x2003;A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>606561</entry><entry>rs7685686</entry><entry>A<sub>es</sub>&#x2003;T<sub>ks</sub>&#x2003;A<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;XT<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ds</sub></entry><entry>4-9-4</entry><entry>1.5</entry><entry>&#x2003;&#x2003;4</entry></row><row><entry/><entry/><entry>Tas&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>es</sub>&#x2003;mC<sub>es</sub>&#x2003;A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>606562</entry><entry>rs7685686</entry><entry>A<sub>es</sub>&#x2003;T<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;xT<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ds</sub></entry><entry>4-9-4</entry><entry>2.3</entry><entry>&#x2003;&#x2003;4</entry></row><row><entry/><entry/><entry>Tas&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>es</sub>&#x2003;mC<sub>es</sub>&#x2003;A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>606578</entry><entry>rs7685686</entry><entry>A<sub>es</sub>&#x2003;T<sub>ks</sub>&#x2003;A<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>fs</sub>&#x2003;T<sub>ds</sub></entry><entry>4-9-4</entry><entry>2.8</entry><entry>&#x2003;&#x2003;4</entry></row><row><entry/><entry/><entry>mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>es</sub>&#x2003;mC<sub>ks</sub>&#x2003;A<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>617107</entry><entry>rs363064</entry><entry>A<sub>es</sub>&#x2003;A<sub>eo</sub>&#x2003;T<sub>ko</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>ds</sub>&#x2003;<u style="single">G</u><sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub>&#x2003;A<sub>ds</sub></entry><entry>4-8-5</entry><entry>1.25</entry><entry>108</entry></row><row><entry/><entry/><entry>mC<sub>ds</sub>&#x2003;A<sub>ko</sub>&#x2003;T<sub>ko</sub>&#x2003;T<sub>es</sub>&#x2003;T<sub>es</sub>&#x2003;T<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>617110</entry><entry>rs363064</entry><entry>G<sub>es</sub>&#x2003;A<sub>es</sub>&#x2003;A<sub>eo</sub>&#x2003;T<sub>ko</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>ds</sub>&#x2003;<u style="single">G</u><sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;A<sub>ds</sub></entry><entry>5-7-5</entry><entry>1.75</entry><entry>&#x2003;89</entry></row><row><entry/><entry/><entry>A<sub>ds</sub>m&#x2003;C<sub>ko</sub>&#x2003;T<sub>ko</sub>&#x2003;T<sub>es</sub>&#x2003;T<sub>es</sub>&#x2003;T<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry namest="1" nameend="6" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0022" level="1">Example 6: Modified Oligonucleotides Targeting HTT SNP Rs7685686 or Rs6446723</heading><p id="p-0438" num="0557">The modified oligonucleotides described in the previous examples were tested in vitro targeting HTT SNP rs7685686 or rs6446723. Human patient fibroblasts GM04022 cell line was used. Cultured GM04022 cells at a density of 35,000 cells per well were transfected using electroporation at 130V with 0.37, 1.1, 3.3 and 10 &#x3bc;M concentrations of modified oligonucleotides. After a treatment period of approximately 24 hours, RNA was isolated from the cells and mRNA levels were measured by quantitative real-time PCR using ABI assay C_2229297_10 which measures at dbSNP rs362303. The HTT mRNA levels were adjusted according to total RNA content, as measured by RIBOGREEN and the results are presented in Table 30.</p><p id="p-0439" num="0558">The IC<sub>50 </sub>of each modified oligonucleotide is presented in the table below and was calculated by plotting the concentrations of oligonucleotides used versus the percent inhibition of HTT mRNA expression achieved at each concentration, and noting the concentration of oligonucleotide at which 50% inhibition of HTT mRNA expression was achieved compared to the control. The IC<sub>50 </sub>at which each oligonucleotide inhibits the mutant HTT mRNA expression is denoted as &#x2018;mut IC<sub>50</sub>&#x2019;. The IC<sub>50 </sub>at which each oligonucleotide inhibits the wild-type HTT mRNA expression is denoted as &#x2018;wt IC<sub>50</sub>&#x2019;. Selectivity was calculated by dividing the IC<sub>50 </sub>for inhibition of the wild-type HTT versus the IC<sub>50 </sub>for inhibiting expression of the mutant HTT mRNA.</p><p id="p-0440" num="0559">ISIS 141923 (C<sub>e</sub>C<sub>e</sub>T<sub>e</sub>T<sub>e</sub>C<sub>e</sub>CCTGAAGGTTC<sub>e</sub>C<sub>e</sub>T<sub>e</sub>C<sub>e</sub>C<sub>e</sub>, 5-10-5 MOE (SEQ ID NO: 575)) was included in the study as a negative control and is denoted as &#x201c;neg control&#x201d;. A non-allele specific antisense oligonucleotide, ISIS 387916 (T<sub>e</sub>C<sub>e</sub>T<sub>e</sub>C<sub>e</sub>T<sub>e</sub>ATTGCACATTC<sub>e</sub>C<sub>e</sub>A<sub>e</sub>A<sub>e</sub>G<sub>e</sub>, 5-10-5 MOE (SEQ ID NO: 576)) was used as a positive control and is denoted as &#x201c;pos control&#x201d;. ISIS 460209 or 572772 was also included in the study for comparison.</p><p id="p-0441" num="0000"><tables id="TABLE-US-00032" num="00032"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="343pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;30</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Modified&#x2003;oligonucleotides&#x2003;targeting&#x2003;Huntingtin&#x2003;(HTT)&#x2003;SNP&#x2003;rs7685686&#x2003;or&#x2003;rs6446723</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="7"><colspec colname="1" colwidth="42pt" align="left"/><colspec colname="2" colwidth="49pt" align="left"/><colspec colname="3" colwidth="28pt" align="center"/><colspec colname="4" colwidth="28pt" align="center"/><colspec colname="5" colwidth="56pt" align="center"/><colspec colname="6" colwidth="84pt" align="left"/><colspec colname="7" colwidth="56pt" align="left"/><tbody valign="top"><row><entry/><entry/><entry>IC<sub>50</sub></entry><entry>&#x3bc;M)</entry><entry>Selectivity</entry><entry/><entry/></row><row><entry>Isis&#x2003;No.</entry><entry>SNP</entry><entry>Mut</entry><entry>Wt</entry><entry>(wt&#x2003;vs&#x2003;mut)</entry><entry>Motif</entry><entry>SEQ&#x2003;ID.&#x2003;NO.</entry></row><row><entry namest="1" nameend="7" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="7"><colspec colname="1" colwidth="42pt" align="center"/><colspec colname="2" colwidth="49pt" align="left"/><colspec colname="3" colwidth="28pt" align="char" char="."/><colspec colname="4" colwidth="28pt" align="char" char="."/><colspec colname="5" colwidth="56pt" align="char" char="."/><colspec colname="6" colwidth="84pt" align="left"/><colspec colname="7" colwidth="56pt" align="center"/><tbody valign="top"><row><entry>&#x2003;460209<sup>1</sup></entry><entry>rs7685686</entry><entry>&#x3c;0.4</entry><entry>2.25</entry><entry>5.6</entry><entry>ekk-d9-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry> </entry></row><row><entry>&#x2003;572772<sup>2</sup></entry><entry>rs7685686</entry><entry>0.27</entry><entry>&#x3e;10</entry><entry>&#x3e;37</entry><entry>eeeekk-d7-kke</entry><entry>&#x2003;24</entry></row><row><entry> </entry></row><row><entry>551429</entry><entry>rs7685686</entry><entry>&#x3c;0.4</entry><entry>&#x3e;10</entry><entry>&#x3e;25</entry><entry>eeekk-d7-kke</entry><entry>&#x2003;13</entry></row><row><entry> </entry></row><row><entry>556845</entry><entry>rs7685686</entry><entry>&#x3c;0.4</entry><entry>&#x3e;10</entry><entry>&#x3e;25</entry><entry>ekk-d9-kke</entry><entry>&#x2003;14</entry></row><row><entry> </entry></row><row><entry>617425</entry><entry>rs7685686</entry><entry>1.3</entry><entry>&#x3e;10</entry><entry>&#x3e;8</entry><entry>eeeeek-d7-eee</entry><entry>&#x2003;75</entry></row><row><entry> </entry></row><row><entry>617115</entry><entry>rs7685686</entry><entry>&#x3c;0.4</entry><entry>&#x3e;10</entry><entry>&#x3e;25</entry><entry>eeeeek-d7-kke</entry><entry>&#x2003;70</entry></row><row><entry> </entry></row><row><entry>617116</entry><entry>rs7685686</entry><entry>&#x3c;0.4</entry><entry>&#x3e;10</entry><entry>&#x3e;25</entry><entry>eeeekk-d7-kee</entry><entry>&#x2003;71</entry></row><row><entry> </entry></row><row><entry>617117</entry><entry>rs7685686</entry><entry>0.7</entry><entry>&#x3e;10</entry><entry>&#x3e;14</entry><entry>eeeeek-d7-kee</entry><entry>&#x2003;72</entry></row><row><entry> </entry></row><row><entry>617118</entry><entry>rs7685686</entry><entry>0.4</entry><entry>&#x3e;10</entry><entry>&#x3e;25</entry><entry>eeeeek-d7-kee</entry><entry>&#x2003;73</entry></row><row><entry> </entry></row><row><entry>617119</entry><entry>rs7685686</entry><entry>0.8</entry><entry>&#x3e;10</entry><entry>&#x3e;13</entry><entry>eeeeek-d7-eee</entry><entry>&#x2003;74</entry></row><row><entry> </entry></row><row><entry>617111</entry><entry>rs7685686</entry><entry>&#x3c;0.4</entry><entry>&#x3e;10</entry><entry>&#x3e;25</entry><entry>ekek-d9-keke</entry><entry>&#x2003;91</entry></row><row><entry> </entry></row><row><entry>613581</entry><entry>rs7685686</entry><entry>0.9</entry><entry>&#x3e;10</entry><entry>&#x3e;11</entry><entry>eeeeedk-d7-eeeee</entry><entry>&#x2003;76</entry></row><row><entry> </entry></row><row><entry>613582</entry><entry>rs7685686</entry><entry>0.4</entry><entry>&#x3e;10</entry><entry>&#x3e;25</entry><entry>eeeeek-d7-eeeeee</entry><entry>&#x2003;77</entry></row><row><entry> </entry></row><row><entry>613583</entry><entry>rs7685686</entry><entry>0.7</entry><entry>&#x3e;10</entry><entry>&#x3e;14</entry><entry>eeeek-d7-eeeeeee</entry><entry>&#x2003;78</entry></row><row><entry> </entry></row><row><entry>613584</entry><entry>rs7685686</entry><entry>0.4</entry><entry>&#x3e;10</entry><entry>&#x3e;25</entry><entry>eeek-d7-eeeeeeee</entry><entry>&#x2003;79</entry></row><row><entry> </entry></row><row><entry>613585</entry><entry>rs7685686</entry><entry>0.4</entry><entry>&#x3e;10</entry><entry>&#x3e;25</entry><entry>eek-d7-eeeeeeeee</entry><entry>&#x2003;80</entry></row><row><entry> </entry></row><row><entry>613586</entry><entry>rs7685686</entry><entry>0.7</entry><entry>&#x3e;10</entry><entry>&#x3e;14</entry><entry>ek-d7-eeeeeeeeee</entry><entry>&#x2003;81</entry></row><row><entry> </entry></row><row><entry>613588</entry><entry>rs7685686</entry><entry>0.7</entry><entry>&#x3e;10</entry><entry>&#x3e;14</entry><entry>eeeeeeek-d7-eeee</entry><entry>&#x2003;82</entry></row><row><entry> </entry></row><row><entry>613589</entry><entry>rs7685686</entry><entry>1.2</entry><entry>&#x3e;10</entry><entry>&#x3e;8</entry><entry>eeeeeeeek-d7-eee</entry><entry>&#x2003;83</entry></row><row><entry> </entry></row><row><entry>617105</entry><entry>rs7685686</entry><entry>&#x3c;0.4</entry><entry>5.9</entry><entry>15</entry><entry>eekk-d8-kkeee</entry><entry>&#x2003;90</entry></row><row><entry> </entry></row><row><entry>606561</entry><entry>rs7685686</entry><entry>&#x3c;4</entry><entry>&#x3e;10</entry><entry>25</entry><entry>ekek-d9-keee</entry><entry>&#x2003;67</entry></row><row><entry> </entry></row><row><entry>606562</entry><entry>rs7685686</entry><entry>0.7</entry><entry>&#x3e;10</entry><entry>25</entry><entry>eeek-d9-keee</entry><entry>&#x2003;68</entry></row><row><entry> </entry></row><row><entry>611714</entry><entry>rs7685686</entry><entry>0.6</entry><entry>4.7</entry><entry>8</entry><entry>eeekk-d7-kke</entry><entry>164</entry></row><row><entry/><entry>(G)</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>611715</entry><entry>rs7685686</entry><entry>0.6</entry><entry>5.6</entry><entry>9</entry><entry>ekek-d9-keke</entry><entry>165</entry></row><row><entry/><entry>(G)</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>611717</entry><entry>rs7685686</entry><entry>0.8</entry><entry>4.7</entry><entry>6</entry><entry>eeeekk-d7-kke</entry><entry>167</entry></row><row><entry/><entry>(G)</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>611718</entry><entry>rs7685686</entry><entry>0.8</entry><entry>7.0</entry><entry>9</entry><entry>ekk-d-k-d7-kke</entry><entry>168</entry></row><row><entry/><entry>(G)</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>611719</entry><entry>rs7685686</entry><entry>0.9</entry><entry>3.2</entry><entry>4</entry><entry>ekkkk-d7-kke</entry><entry>169</entry></row><row><entry/><entry>(G)</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>611720</entry><entry>rs7685686</entry><entry>&#x3c;0.4</entry><entry>2.5</entry><entry>6</entry><entry>ek-d9-kkke</entry><entry>170</entry></row><row><entry/><entry>(G)</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>611721</entry><entry>rs7685686</entry><entry>0.9</entry><entry>&#x3e;10</entry><entry>&#x3e;11</entry><entry>eeeek-d7-keee</entry><entry>171</entry></row><row><entry/><entry>(G)</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>611722</entry><entry>rs7685686</entry><entry>1.5</entry><entry>&#x3e;10</entry><entry>&#x3e;7</entry><entry>eeee-d-k-d7-keee</entry><entry>172</entry></row><row><entry/><entry>(G)</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>611723</entry><entry>rs7685686</entry><entry>2.7</entry><entry>9.6</entry><entry>4</entry><entry>eeeek-d7-keeee</entry><entry>173</entry></row><row><entry/><entry>(G)</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>617104</entry><entry>rs6446723</entry><entry>&#x3c;0.4</entry><entry>6.8</entry><entry>17</entry><entry>eeekk-d7-kkeee</entry><entry>&#x2003;84</entry></row><row><entry> </entry></row><row><entry>617106</entry><entry>rs6446723</entry><entry>&#x3c;0.4</entry><entry>5.7</entry><entry>14</entry><entry>eekk-d8-kkeee</entry><entry>&#x2003;85</entry></row><row><entry> </entry></row><row><entry>617108</entry><entry>rs6446723</entry><entry>&#x3c;0.4</entry><entry>5.8</entry><entry>14</entry><entry>ekek-d8-kekee</entry><entry>&#x2003;86</entry></row><row><entry namest="1" nameend="7" align="center" rowsep="1"/></row><row><entry namest="1" nameend="7" align="left" id="FOO-00001"><sup>1</sup>IC<sub>50 </sub>measured from average of 2 independent assays</entry></row><row><entry namest="1" nameend="7" align="left" id="FOO-00002"><sup>2</sup>IC<sub>50 </sub>measured from average of 3 independent assays</entry></row></tbody></tgroup></table></tables></p><heading id="h-0023" level="1">Example 7: Modified Oligonucleotides Targeting HTT SNP Rs7685686</heading><p id="p-0442" num="0560">The modified oligonucleotides were designed to target SNP positions associated with the HTT gene. In Table 31, the &#x2018;k&#x2019; subscript indicates an (S)-cEt modification; &#x2018;e&#x2019; subscript indicates MOE modification; the &#x2018;y&#x2019; subscript indicates a tricyclo DNA (tcDNA) modification; the &#x2018;z&#x2019; subscript indicates a 2&#x2032;-(ara)-F modification; the &#x2018;f&#x2019; subscript indicates a 2&#x2032;-F modification; &#x2018;m&#x2019; before the cytosine residue indicates a 5-methylcytosine; number along with&#x2032;d&#x2032; indicates the number of deoxyribose nucleosides; &#x2018;s&#x2019; subscript after the nucleoside indicates a phosphorothioate internucleoside linkage. The underlined nucleoside indicates the position on the modified oligonucleotide opposite to the SNP position.</p><p id="p-0443" num="0000"><tables id="TABLE-US-00033" num="00033"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="406pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;31</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Modified&#x2003;oligonucleotides&#x2003;targeting&#x2003;HTT&#x2003;SNP&#x2003;rs7685686</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="6"><colspec colname="1" colwidth="42pt" align="center"/><colspec colname="2" colwidth="42pt" align="left"/><colspec colname="3" colwidth="133pt" align="left"/><colspec colname="4" colwidth="70pt" align="left"/><colspec colname="5" colwidth="70pt" align="left"/><colspec colname="6" colwidth="49pt" align="center"/><tbody valign="top"><row><entry>Isis&#x2003;No.</entry><entry>SNP</entry><entry>Sequence&#x2003;(5&#x2032;&#x2003;to&#x2003;3&#x2032;)</entry><entry>Gap&#x2003;Chemistry</entry><entry>Motif</entry><entry>SEQ&#x2003;ID&#x2003;NO</entry></row><row><entry namest="1" nameend="6" align="center" rowsep="1"/></row><row><entry>460209</entry><entry>rs7685686</entry><entry>T<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;mC<sub>ds</sub></entry><entry>Full&#x2003;deoxy</entry><entry>ekk-d9-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry/><entry/><entry>A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>582670</entry><entry>rs7685686</entry><entry>T<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;mC<sub>ds</sub></entry><entry>Full&#x2003;deoxy</entry><entry>ekk-d7-kkeee</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry/><entry/><entry>A<sub>ds</sub>&#x2003;T<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;A<sub>es</sub>&#x2003;mC<sub>es</sub>&#x2003;mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>566270</entry><entry>rs7685686</entry><entry>T<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>zs</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;mC<sub>ds</sub></entry><entry>Deoxy/2&#x2032;-(ara)-F</entry><entry>ekk-d-z-d7-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry/><entry/><entry>A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>566271</entry><entry>rs7685686</entry><entry>T<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>zs</sub>&#x2003;G<sub>ds</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;mC<sub>ds</sub></entry><entry>Deoxy/2&#x2032;-(ara)-F</entry><entry>ekk-d2-z-d6-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry/><entry/><entry>A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>581400</entry><entry>rs7685686</entry><entry>T<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;U<sub>fs</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;mC<sub>ds</sub></entry><entry>Deoxy/2&#x2032;-F</entry><entry>ekk-d-f-d7-kke</entry><entry>577</entry></row><row><entry/><entry/><entry>A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>581401</entry><entry>rs7685686</entry><entry>T<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;U<sub>fs</sub>&#x2003;G<sub>ds</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;mC<sub>ds</sub></entry><entry>Deoxy/2&#x2032;-F</entry><entry>ekk-d2-f-d6-kke</entry><entry>578</entry></row><row><entry/><entry/><entry>A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>539557</entry><entry>rs7685686</entry><entry>T<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;<u style="single">T<sub>ys</sub></u>&#x2003;mC<sub>ds</sub></entry><entry>Deoxy/Tricyclo</entry><entry>ekk-d4-y-d4-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry/><entry/><entry>A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;mC<sub>e</sub></entry><entry>DNA&#x2003;(tcDNA)</entry><entry/><entry/></row><row><entry namest="1" nameend="6" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0024" level="1">Example 8: Selectivity of Modified Oligonucleotides Targeting HTT SNP Rs7685686</heading><p id="p-0444" num="0561">Several modified oligonucleotides presented in Table 31 were tested in vitro targeting HTT SNP rs7685686. Heterozygous fibroblast GM04022 cell line was used (from Coriell Institute). Cultured GM04022 cells at a density of 400,000 cells per well were transfected using electroporation (Harvard Apparatus ECM830, 115 V, 6 ms) with 0.06, 0.19, 0.56, 1.7, 5.0 and 15 &#x3bc;M concentrations of ISIS 460209, 566270, 566271, 581400, or 581401 or 0.027, 0.082, 0.25, 0.7, 2.2, 6.7 and 20 &#x3bc;M concentrations of ISIS 582670. Treated cells were maintained at 37&#xb0; C. and 5% CO<sub>2 </sub>in minimal essential medium containing 15% fetal bovine serum, non-essential amino acids and penicillin/streptomycin. Approximately 24 hours post-transfection, the cells were washed with DPBS buffer and lysed. RNA was extracted using the Qiagen RNeasy96 kit and levels of the human HTT mRNA alleles were determined using the qPCR assay C_2231945_10 at SNP rs362331 from Life Technologies. The mutant and wild-type HTT mRNA levels were measured simultaneously by using two different fluorophores, FAM for mutant allele and VIC for wild-type allele. Quantitative RT-PCR reactions were run on the ABI 7900HT instrument using the Quantitect Probe RT-PCR kit following the manufacturer's instructions. The HTT mRNA levels were normalized to total RNA content, as measured by RIBOGREEN. The IC<sub>50 </sub>and selectivity were calculated using methods described previously in Example 6 and the results are presented in Table 32. ISIS 460209 was included in the study for comparison.</p><p id="p-0445" num="0000"><tables id="TABLE-US-00034" num="00034"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="350pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;32</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Selectivity&#x2003;of&#x2003;modified&#x2003;oligonucleotides&#x2003;targeting&#x2003;Huntingtin&#x2003;(HTT)&#x2003;SNP&#x2003;rs7685686</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="6"><colspec colname="1" colwidth="49pt" align="left"/><colspec colname="2" colwidth="56pt" align="left"/><colspec colname="3" colwidth="49pt" align="center"/><colspec colname="4" colwidth="70pt" align="center"/><colspec colname="5" colwidth="91pt" align="left"/><colspec colname="6" colwidth="35pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry>Mut&#x2003;IC<sub>50</sub></entry><entry>Selectivity</entry><entry/><entry>SEQ</entry></row><row><entry>Isis&#x2003;No.</entry><entry>SNP</entry><entry>(&#x3bc;M)</entry><entry>(wt&#x2003;vs&#x2003;mut)</entry><entry>Motif</entry><entry>ID&#x2003;No.</entry></row><row><entry namest="1" nameend="6" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="6"><colspec colname="1" colwidth="49pt" align="center"/><colspec colname="2" colwidth="56pt" align="left"/><colspec colname="3" colwidth="49pt" align="char" char="."/><colspec colname="4" colwidth="70pt" align="char" char="."/><colspec colname="5" colwidth="91pt" align="left"/><colspec colname="6" colwidth="35pt" align="center"/><tbody valign="top"><row><entry>460209</entry><entry>rs7685686</entry><entry>0.29</entry><entry>6.9</entry><entry>ekk-d9-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry> </entry></row><row><entry>566270</entry><entry>rs7685686</entry><entry>0.14</entry><entry>7.4</entry><entry>ekk-d7-kkeee</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry> </entry></row><row><entry>566271</entry><entry>rs7685686</entry><entry>0.11</entry><entry>7.1</entry><entry>ekk-d-z-d7-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry> </entry></row><row><entry>581400</entry><entry>rs7685686</entry><entry>0.6</entry><entry>&#x3e;25</entry><entry>ekk-d2-z-d6-kke</entry><entry>577</entry></row><row><entry> </entry></row><row><entry>581401</entry><entry>rs7685686</entry><entry>0.77</entry><entry>&#x3e;19</entry><entry>ekk-d-f-d7-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry> </entry></row><row><entry>582670</entry><entry>rs7685686</entry><entry>0.42</entry><entry>&#x3e;47</entry><entry>ekk-d7-kkeee</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry namest="1" nameend="6" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0025" level="1">Example 9: Tm and Selectivity of Modified Oligonucleotide Containing Tricyclo DNA (tcDNA) Modification Targeting HTT SNP Rs7685686</heading><p id="p-0446" num="0562">ISIS 539557 from Table 31 was tested for thermal stability. Its potency and selectivity targeting HTT SNP rs7685686 were also evaluated in vitro. ISIS 460209 was included in the study for comparison.</p><heading id="h-0026" level="2">Thermal Stability Assay</heading><p id="p-0447" num="0563">The T<sub>m </sub>for ISIS 539557 was measured using the method described herein. The modified oligonucleotide and RNA was mixed in a 1:1 ratio (4 &#x3bc;M duplex) in buffer containing 10 mM phosphate, 100 mM NaCl and 10 mM EDTA at pH 7.0. The duplex was denatured at 85&#xb0; C. and slowly cooled to the starting temperature of the experiment (15&#xb0; C.). Thermal denaturation temperatures (T<sub>m </sub>values) were measured in quartz cuvettes (pathlength 1.0 cm) on a Cary 100 UV/VIS spectrophotometer equipped with a Peltier temperature controller. Absorbance at 260 nm was measured as a function of temperature using a temperature ramp of 0.5&#xb0; C. per min. T<sub>m </sub>value was determined using the hyperchromicity method incorporated into the instrument software. The results for T<sub>m </sub>versus matched and mismatched RNA are presented in Table 33.</p><heading id="h-0027" level="2">Cell Culture, Transfection and Selectivity Analysis</heading><p id="p-0448" num="0564">Heterozygous fibroblast GM04022 cell line was used (from Coriell Institute). Cultured GM04022 cells at a density of 400,000 cells per well were transfected using electroporation (Harvard Apparatus ECM830, 115 V, 6 ms) with 2 &#x3bc;M concentrations of ISIS 460209 or 539557. Treated cells were maintained at 37&#xb0; C. and 5% CO<sub>2 </sub>in minimal essential medium containing 15% fetal bovine serum, non-essential amino acids and penicillin/streptomycin. Approximately 24 hours post-transfection, the cells were washed with DPBS buffer and lysed. RNA was extracted using the Qiagen RNeasy96 kit and levels of the human HTT mRNA alleles were determined using the qPCR assay C_2231945_10 at SNP rs362331 from Life Technologies. The mutant and wild-type HTT mRNA levels were measured simultaneously by using two different fluorophores, FAM for mutant allele and VIC for wild-type allele. Quantitative RT-PCR reactions were run on the ABI 7900HT instrument using the Quantitect Probe RT-PCR kit following the manufacturer's instructions. The HTT mRNA levels were normalized to total RNA content, as measured by RIBOGREEN. The percent of HTT mRNA reduction, relative to untreated control levels was measured. The results for selectivity in Table 33 are presented as the ratio of wt HTT/mut HTT mRNA reduction in GM4022 fibroblasts.</p><p id="p-0449" num="0000"><tables id="TABLE-US-00035" num="00035"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="343pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;33</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Tm&#x2003;and&#x2003;selectivity&#x2003;of&#x2003;ISIS&#x2003;582670&#x2003;targeting&#x2003;HTT&#x2003;SNP&#x2003;rs7685686&#x2003;in&#x2003;GM4022&#x2003;cells</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="8"><colspec colname="1" colwidth="42pt" align="left"/><colspec colname="2" colwidth="49pt" align="left"/><colspec colname="3" colwidth="35pt" align="center"/><colspec colname="4" colwidth="35pt" align="center"/><colspec colname="5" colwidth="35pt" align="center"/><colspec colname="6" colwidth="56pt" align="center"/><colspec colname="7" colwidth="63pt" align="left"/><colspec colname="8" colwidth="28pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry>mut&#x2003;T<sub>m</sub></entry><entry>wt&#x2003;T<sub>m</sub></entry><entry>&#x2003;&#x394;&#x2003;T<sub>m</sub></entry><entry>Ratio</entry><entry/><entry>SEQ</entry></row><row><entry>Isis&#x2003;No.</entry><entry>SNP</entry><entry>(&#xb0;&#x2003;C.)</entry><entry>(&#xb0;&#x2003;C.)</entry><entry>mut-wt</entry><entry>(wt&#x2003;vs&#x2003;mut)</entry><entry>Motif</entry><entry>ID&#x2003;NO</entry></row><row><entry namest="1" nameend="8" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="8"><colspec colname="1" colwidth="42pt" align="center"/><colspec colname="2" colwidth="49pt" align="left"/><colspec colname="3" colwidth="35pt" align="center"/><colspec colname="4" colwidth="35pt" align="center"/><colspec colname="5" colwidth="35pt" align="center"/><colspec colname="6" colwidth="56pt" align="center"/><colspec colname="7" colwidth="63pt" align="left"/><colspec colname="8" colwidth="28pt" align="center"/><tbody valign="top"><row><entry>460209</entry><entry>rs7685686</entry><entry>53.7</entry><entry>52.2</entry><entry>1.5</entry><entry>2.6</entry><entry>ekk-d9-kke</entry><entry>3</entry></row><row><entry> </entry></row><row><entry>582670</entry><entry>rs7685686</entry><entry>53.8</entry><entry>51.7</entry><entry>2.1</entry><entry>3.3</entry><entry>ekk-d7-kkeee</entry><entry>3</entry></row><row><entry namest="1" nameend="8" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0028" level="1">Example 10: Duration of Action of Modified Oligonucleotides</heading><p id="p-0450" num="0565">Mice were given a single ICV injection of modified oligonucleotides targeted to mutant HTT nucleic acid transcripts. The modified oligonucleotides had either 2&#x2032;-MOE modifications or cEt modifications. After the initial ICV injection, mice from each group were sacrificed at 1, 2, 4, 8, 12, and 16 weeks and the among of mutant HTT protein was analyzed. It was found that the modified oligonucleotides having cEt modifications reduced mutant HTT protein for up to 16 weeks after a single ICV dose. It was found that 2&#x2032;-MOE modified oligonucleotides reduced mutant HTT protein for 4-8 weeks, after which point in time mutant HTT levels began to rise and approach mutant HTT levels found in animals treated with PBS control. This example shows that a single dose of modified oligonucleotides targeted to mutant huntingtin transcript can inhibit mutant HTT protein expression for greater than 16 weeks.</p><heading id="h-0029" level="1">Example 11: Modified Oligonucleotides Targeting HTT SNP Rs7685686</heading><p id="p-0451" num="0566">The modified oligonucleotides were designed to target SNP positions associated with the HTT gene. In Table 31, the &#x2018;k&#x2019; subscript indicates an (S)-cEt modification; &#x2018;e&#x2019; subscript indicates MOE modification; the &#x2018;y&#x2019; subscript indicates a tricyclo DNA (tcDNA) modification; the &#x2018;z&#x2019; subscript indicates a 2&#x2032;-(ara)-F modification (shown below); the &#x2018;f&#x2019; subscript indicates a 2&#x2032;-F modification in the ribo orientation (shown below); the &#x2018;h&#x2019; subscript indicates a F-CeNA modification; &#x2018;m&#x2019; before the cytosine residue indicates a 5-methylcytosine; number along with &#x2018;d&#x2019; indicates the number of deoxyribose nucleosides; &#x2018;s&#x2019; subscript after the nucleoside indicates a phosphorothioate internucleoside linkage; &#x2018;<sup>s5</sup>&#x2019; before a residue indicates an S-5&#x2032;-Me-DNA modification, e.g. &#x201c;<sup>s5</sup>T&#x201d;; &#x201c;<sup>r5</sup>&#x201d; before a residue indicates an S-5&#x2032;-Me-DNA modification, e.g. &#x201c;<sup>r5</sup>T.&#x201d; The underlined nucleoside indicates the position on the modified oligonucleotide opposite to the SNP position.</p><p id="p-0452" num="0567">Examples of the 2&#x2032;-(ribo)-fluoro (f), 2&#x2032;-(ara)-fluor (z), and F-CeNA (h) modifications are provided below:</p><p id="p-0453" num="0000"><chemistry id="CHEM-US-00006" num="00006"><img id="EMI-C00006" he="116.25mm" wi="56.64mm" file="US20230002763A1-20230105-C00006.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0454" num="0568">Examples of R-5 &#x2018;-Me-DNA and S-5&#x2019;-Me-DNA modifications are provided below:</p><p id="p-0455" num="0000"><chemistry id="CHEM-US-00007" num="00007"><img id="EMI-C00007" he="30.73mm" wi="65.02mm" file="US20230002763A1-20230105-C00007.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0456" num="0000"><tables id="TABLE-US-00036" num="00036"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="441pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;34</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Modified&#x2003;oligonucleotides&#x2003;targeting&#x2003;HTT&#x2003;SNP&#x2003;rs7685686</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="6"><colspec colname="1" colwidth="49pt" align="left"/><colspec colname="2" colwidth="42pt" align="left"/><colspec colname="3" colwidth="147pt" align="left"/><colspec colname="4" colwidth="77pt" align="left"/><colspec colname="5" colwidth="77pt" align="left"/><colspec colname="6" colwidth="49pt" align="center"/><tbody valign="top"><row><entry>Isis&#x2003;No.</entry><entry>SNP</entry><entry>Sequence&#x2003;(5&#x2032;&#x2003;to&#x2003;3&#x2032;)</entry><entry>Gap&#x2003;Chemistry</entry><entry>Motif</entry><entry>SEQ&#x2003;ID&#x2003;NO</entry></row><row><entry namest="1" nameend="6" align="center" rowsep="1"/></row><row><entry>460209</entry><entry>rs7685686</entry><entry>T<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;mC<sub>ds</sub></entry><entry>Full&#x2003;deoxy</entry><entry>ekk-d9-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry/><entry/><entry>A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>582670</entry><entry>rs7685686</entry><entry>T<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;mC<sub>ds</sub></entry><entry>Full&#x2003;deoxy</entry><entry>ekk-d7-kkeee</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry/><entry/><entry>A<sub>ds</sub>&#x2003;T<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;A<sub>es</sub>&#x2003;mC<sub>es</sub>&#x2003;mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>566270</entry><entry>rs7685686</entry><entry>T<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>zs</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;mC<sub>ds</sub></entry><entry>Deoxy/2&#x2032;-(ara)-F</entry><entry>ekk-d-z-d7-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry/><entry/><entry>A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>566271</entry><entry>rs7685686</entry><entry>T<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>zs</sub>&#x2003;G<sub>ds</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;mC<sub>ds</sub></entry><entry>Deoxy/2&#x2032;-(ara)-F</entry><entry>ekk-d2-z-d6-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry/><entry/><entry>A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>581400</entry><entry>rs7685686</entry><entry>T<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;U<sub>fs</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;mC<sub>ds</sub></entry><entry>Deoxy/2&#x2032;-F</entry><entry>ekk-d-f-d7-kke</entry><entry>577</entry></row><row><entry/><entry/><entry>A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>581401</entry><entry>rs7685686</entry><entry>T<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;U<sub>fs</sub>&#x2003;G<sub>ds</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;mC<sub>ds</sub></entry><entry>Deoxy/2&#x2032;-F</entry><entry>ekk-d2-f-d6-kke</entry><entry>578</entry></row><row><entry/><entry/><entry>A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>539557</entry><entry>rs7685686</entry><entry>T<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;<u style="single">T<sub>ys</sub></u>&#x2003;mC<sub>ds</sub></entry><entry>Deoxy/Tricyclo</entry><entry>ekk-d4-y-d4-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry/><entry/><entry>A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;mC<sub>e</sub></entry><entry>DNA&#x2003;(tcDNA)</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>575837</entry><entry>rs7685686</entry><entry>T<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>fs</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;mC<sub>ds</sub></entry><entry>Deoxy/2&#x2032;-F</entry><entry>ekk-f-d8-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry/><entry/><entry>A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>575831</entry><entry>rs7685686</entry><entry>T<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>zs</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;mC<sub>ds</sub></entry><entry>Deoxy/2&#x2032;-(ara)-F</entry><entry>ekk-z-d8-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry/><entry/><entry>A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>XXXX1</entry><entry>rs7685686</entry><entry>T<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>hs</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;mC<sub>ds</sub></entry><entry>Deoxy/F-CeNA</entry><entry>ekk-h-d8-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry/><entry/><entry>A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>582981</entry><entry>rs7685686</entry><entry>T<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;Ths&#x2003;G<sub>ds</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;mC<sub>ds</sub></entry><entry>Deoxy/F-CeNA</entry><entry>ekk-d2-h-d6-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry/><entry/><entry>A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>582980</entry><entry>rs7685686</entry><entry>T<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>hs</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;mC<sub>ds</sub></entry><entry>Deoxy/F-CeNA</entry><entry>ekk-d-h-d7-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry/><entry/><entry>A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>575840</entry><entry>rs7685686</entry><entry>T<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>fs</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;mC<sub>ds</sub></entry><entry>Deoxy/2&#x2032;-F</entry><entry>ekk-d3-f-d5-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry/><entry/><entry>A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>566272</entry><entry>rs7685686</entry><entry>T<sub>e</sub>s&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>zs</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;mC<sub>ds</sub></entry><entry>Deoxy/2&#x2032;-(ara)-F</entry><entry>ekk-d3-z-d5-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry/><entry/><entry>A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>XXXX2</entry><entry>rs7685686</entry><entry>T<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>hs</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;mC<sub>ds</sub></entry><entry>Deoxy/F-CeNA</entry><entry>ekk-d3-h-d5-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry/><entry/><entry>A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>586156</entry><entry>rs7685686</entry><entry>T<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;mC<sub>ds</sub></entry><entry>Deoxy/F-CeNA</entry><entry>ekk-d4-h-d4-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry/><entry/><entry>A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>581402</entry><entry>rs7685686</entry><entry>T<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;<u style="single">T</u><sub>hs</sub>&#x2003;mC<sub>fs</sub></entry><entry>Deoxy/2&#x2032;-F</entry><entry>ekk-d5-f-d3-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry/><entry/><entry>A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>566273</entry><entry>rs7685686</entry><entry>T<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;<u style="single">T</u><sub>zs</sub>&#x2003;mC<sub>ds</sub></entry><entry>Deoxy/2&#x2032;-(ara)-F</entry><entry>ekk-d5-z-d3-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry/><entry/><entry>A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>582982</entry><entry>rs7685686</entry><entry>T<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;<u style="single">T</u><sub>hs</sub>&#x2003;mC<sub>ds</sub></entry><entry>Deoxy/F-CeNA</entry><entry>ekk-d5-h-d3-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry/><entry/><entry>A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>575842</entry><entry>rs7685686</entry><entry>T<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;mC<sub>ds</sub></entry><entry>Deoxy/2&#x2032;-F</entry><entry>ekk-d6-f-d2-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry/><entry/><entry>Af<sub>S</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>566274</entry><entry>rs7685686</entry><entry>T<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;mC<sub>ds</sub></entry><entry>Deoxy/2&#x2032;-(ara)-F</entry><entry>ekk-d6-z-d2-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry/><entry/><entry>A<sub>zs</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>XXXX3</entry><entry>rs7685686</entry><entry>T<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;mC<sub>ds</sub></entry><entry>Deoxy/F-CeNA</entry><entry>ekk-d6-h-d2-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry/><entry/><entry>Ais&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>581403</entry><entry>rs7685686</entry><entry>T<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;mC<sub>ds</sub></entry><entry>Deoxy/2&#x2032;-F</entry><entry>ekk-d7-f-d-kke</entry><entry>579</entry></row><row><entry/><entry/><entry>A<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>566275</entry><entry>rs7685686</entry><entry>T<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;mC<sub>ds</sub></entry><entry>Deoxy/2&#x2032;-(ara)-F</entry><entry>ekk-d7-z-d-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry/><entry/><entry>A<sub>ds</sub>&#x2003;T<sub>zs</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>582983</entry><entry>rs7685686</entry><entry>T<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;mC<sub>ds</sub></entry><entry>Deoxy/F-CeNA</entry><entry>ekk-d7-h-d-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry/><entry/><entry>A<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>581404</entry><entry>rs7685686</entry><entry>T<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;mC<sub>ds</sub></entry><entry>Deoxy/2&#x2032;-F</entry><entry>ekk-d8-f-dkke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry/><entry/><entry>A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>fs</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>578228</entry><entry>rs7685686</entry><entry>T<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;mC<sub>ds</sub></entry><entry>Deoxy/2&#x2032;-(ara)-F</entry><entry>ekk-d8-z-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry/><entry/><entry>A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>zs</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>582984</entry><entry>rs7685686</entry><entry>T<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;mC<sub>ds</sub></entry><entry>Deoxy/F-CeNA</entry><entry>ekk-d8-h-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry/><entry/><entry>A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;mC<sub>e</sub></entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>XXXX4</entry><entry>rs7685686</entry><entry>T<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;Ads<sup>r5</sup>T<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;mC<sub>ds</sub></entry><entry>Deoxy/R-5&#x2032;-Me</entry><entry>ekk-d9-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry/><entry/><entry>A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;mC<sub>e</sub></entry><entry>DNA</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>XXXX5</entry><entry>rs7685686</entry><entry>T<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;<sup>s5</sup>T<sub>ds</sub>T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;mC<sub>ds</sub></entry><entry>Deoxy/S-5&#x2032;-Me</entry><entry>ekk-d9-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry/><entry/><entry>A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;mC<sub>e</sub></entry><entry>DNA</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>XXXX6</entry><entry>rs7685686</entry><entry>T<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;<sup>r5</sup>T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;mC<sub>ds</sub></entry><entry>Deoxy/R-5&#x2032;-Me</entry><entry>ekk-d9-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry/><entry/><entry>A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;mC<sub>e</sub></entry><entry>DNA</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>XXXX7</entry><entry>rs7685686</entry><entry>T<sub>es</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ks</sub>&#x2003;A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;<sup>s5</sup>T<sub>ds</sub>&#x2003;G<sub>ds</sub>&#x2003;<u style="single">T</u><sub>ds</sub>&#x2003;mC<sub>ds</sub></entry><entry>Deoxy/S-5&#x2032;-Me</entry><entry>ekk-d9-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry/><entry/><entry>A<sub>ds</sub>&#x2003;T<sub>ds</sub>&#x2003;mC<sub>ds</sub>&#x2003;A<sub>ks</sub>&#x2003;mC<sub>ks</sub>&#x2003;mC<sub>e</sub></entry><entry>DNA</entry><entry/><entry/></row><row><entry namest="1" nameend="6" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0030" level="1">Example 12: Selectivity of Modified Oligonucleotides Targeting HTT SNP Rs7685686</heading><p id="p-0457" num="0569">Several modified oligonucleotides presented in Table 31 were tested in vitro targeting HTT SNP rs7685686. Heterozygous fibroblast GM04022 cell line was used (from Coriell Institute). Cultured GM04022 cells at a density of 400,000 cells per well or 450,000 cells per well were transfected using electroporation (Harvard Apparatus ECM830, 115 V, 6 ms) with 0.06, 0.19, 0.56, 1.7, 5.0 and 15 &#x3bc;M concentrations of the modified oligonucleotides presented in Table 31, except for ISIS 582670, in which concentrations of 0.027, 0.082, 0.25, 0.7, 2.2, 6.7 and 20 &#x3bc;M were used. Treated cells were maintained at 37&#xb0; C. and 5% CO<sub>2 </sub>in minimal essential medium containing 15% fetal bovine serum, non-essential amino acids and penicillin/streptomycin. Approximately 24 hours post-transfection, the cells were washed with DPBS buffer and lysed. RNA was extracted using the Qiagen RNeasy96 kit and levels of the human HTT mRNA alleles were determined using the qPCR assay C_2231945_10 at SNP rs362331 from Life Technologies. The mutant and wild-type HTT mRNA levels were measured simultaneously by using two different fluorophores, FAM for mutant allele and VIC for wild-type allele. Quantitative RT-PCR reactions were run on the ABI 7900HT instrument using the Quantitect Probe RT-PCR kit following the manufacturer's instructions. The HTT mRNA levels were normalized to total RNA content, as measured by RIBOGREEN. The IC<sub>50 </sub>and selectivity were calculated using methods described previously in Example 6 and the results are presented in Table 32. ISIS 460209 was included in the study for comparison.</p><p id="p-0458" num="0570">In certain embodiments, a modification at position 4 from the 5&#x2032;-end increases selectivity. In certain embodiments, a modification at position 5 from the 5&#x2032;-end increases selectivity. In certain embodiments, a modification at position 7 from the 5&#x2032;-end increases selectivity. In certain embodiments, a modification at position 8 from the 5&#x2032;-end increases potency and selectivity. In certain embodiments, a modification at position 9 from the 5&#x2032;-end increases potency. In certain embodiments, a modification at position 10 from the 5&#x2032;-end increases selectivity. In certain embodiments, a modification at position 11 from the 5&#x2032;-end increases selectivity. In certain embodiments, a modification at position 12 from the 5&#x2032;-end increases potency. In certain embodiments, an S-5&#x2032;-Me-DNA modification increases allele selectivity.</p><p id="p-0459" num="0000"><tables id="TABLE-US-00037" num="00037"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="294pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;35</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Selectivity&#x2003;of&#x2003;modified&#x2003;oligonucleotides&#x2003;targeting</entry></row><row><entry>Huntingtin&#x2003;(HTT)&#x2003;SNP&#x2003;rs7685686</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="6"><colspec colname="1" colwidth="35pt" align="left"/><colspec colname="2" colwidth="49pt" align="left"/><colspec colname="3" colwidth="35pt" align="center"/><colspec colname="4" colwidth="56pt" align="center"/><colspec colname="5" colwidth="70pt" align="left"/><colspec colname="6" colwidth="49pt" align="left"/><tbody valign="top"><row><entry/><entry/><entry>Mut&#x2003;IC<sub>50</sub></entry><entry>Selectivity</entry><entry/><entry/></row><row><entry>Isis&#x2003;No.</entry><entry>SNP</entry><entry>(MM)</entry><entry>(wt&#x2003;vs&#x2003;mut)</entry><entry>Motif</entry><entry>SEQ&#x2003;ID&#x2003;No.</entry></row><row><entry namest="1" nameend="6" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="6"><colspec colname="1" colwidth="35pt" align="left"/><colspec colname="2" colwidth="49pt" align="left"/><colspec colname="3" colwidth="35pt" align="center"/><colspec colname="4" colwidth="56pt" align="char" char="."/><colspec colname="5" colwidth="70pt" align="left"/><colspec colname="6" colwidth="49pt" align="center"/><tbody valign="top"><row><entry>460209</entry><entry>rs7685686</entry><entry>.31</entry><entry>9</entry><entry>ekk-d9-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry> </entry></row><row><entry>575837</entry><entry>rs7685686</entry><entry>.28</entry><entry>15</entry><entry>ekk-f-d8-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry> </entry></row><row><entry>575831</entry><entry>rs7685686</entry><entry>.21</entry><entry>19</entry><entry>ekk-z-d8-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry> </entry></row><row><entry>XXXX1</entry><entry>rs7685686</entry><entry>ND</entry><entry>ND</entry><entry>ekk-h-d8-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry> </entry></row><row><entry>582981</entry><entry>rs7685686</entry><entry>.35</entry><entry>&#x3e;29</entry><entry>ekk-d2-h-d6-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry> </entry></row><row><entry>582980</entry><entry>rs7685686</entry><entry>.34</entry><entry>7</entry><entry>ekk-d-h-d7-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry> </entry></row><row><entry>575840</entry><entry>rs7685686</entry><entry>.94</entry><entry>&#x3e;11</entry><entry>ekk-d3-f-d5-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry> </entry></row><row><entry>566272</entry><entry>rs7685686</entry><entry>.07</entry><entry>27</entry><entry>ekk-d3-z-d5-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry> </entry></row><row><entry>XXXX2</entry><entry>rs7685686</entry><entry>ND</entry><entry>ND</entry><entry>ekk-d3-h-d5-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry> </entry></row><row><entry>586156</entry><entry>rs7685686</entry><entry>.39</entry><entry>5</entry><entry>ekk-d4-h-d4-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry> </entry></row><row><entry>581402</entry><entry>rs7685686</entry><entry>.16</entry><entry>5</entry><entry>ekk-d5-f-d3-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry> </entry></row><row><entry>566273</entry><entry>rs7685686</entry><entry>.09</entry><entry>18</entry><entry>ekk-d5-z-d3-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry> </entry></row><row><entry>582982</entry><entry>rs7685686</entry><entry>.23</entry><entry>13</entry><entry>ekk-d5-h-d3-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry> </entry></row><row><entry>575842</entry><entry>rs7685686</entry><entry>.20</entry><entry>50</entry><entry>ekk-d6-f-d2-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry> </entry></row><row><entry>566274</entry><entry>rs7685686</entry><entry>.20</entry><entry>&#x3e;50</entry><entry>ekk-d6-z-d2-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry> </entry></row><row><entry>XXXX3</entry><entry>rs7685686</entry><entry>ND</entry><entry>ND</entry><entry>ekk-d6-h-d2-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry> </entry></row><row><entry>581403</entry><entry>rs7685686</entry><entry>.35</entry><entry>18</entry><entry>ekk-d7-f-d-kke</entry><entry>579</entry></row><row><entry> </entry></row><row><entry>566275</entry><entry>rs7685686</entry><entry>.22</entry><entry>28</entry><entry>ekk-d7-z-d-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry> </entry></row><row><entry>582983</entry><entry>rs7685686</entry><entry>.30</entry><entry>17</entry><entry>ekk-d7-h-d-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry> </entry></row><row><entry>581404</entry><entry>rs7685686</entry><entry>.07</entry><entry>18</entry><entry>ekk-d8-f-dkke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry> </entry></row><row><entry>578228</entry><entry>rs7685686</entry><entry>.10</entry><entry>32</entry><entry>ekk-d8-z-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry> </entry></row><row><entry>582984</entry><entry>rs7685686</entry><entry>.06</entry><entry>10</entry><entry>ekk-d8-h-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry> </entry></row><row><entry>XXXX4</entry><entry>rs7685686</entry><entry>.15</entry><entry>6.9</entry><entry>ekk-d9-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry> </entry></row><row><entry>XXXX5</entry><entry>rs7685686</entry><entry>.38</entry><entry>16.3</entry><entry>ekk-d9-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry> </entry></row><row><entry>XXXX6</entry><entry>rs7685686</entry><entry>.31</entry><entry>5.7</entry><entry>ekk-d9-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry> </entry></row><row><entry>XXXX7</entry><entry>rs7685686</entry><entry>.40</entry><entry>&#x3e;38</entry><entry>ekk-d9-kke</entry><entry>&#x2003;&#x2003;3</entry></row><row><entry namest="1" nameend="6" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><?detailed-description description="Detailed Description" end="tail"?></description><us-sequence-list-doc id="SEQLST-1"><sequence-list file="US20230002763A1-20230105-S00001.XML" carriers="internal-electronic" seq-file-type="ST.25"/></us-sequence-list-doc><us-chemistry idref="CHEM-US-00001" cdx-file="US20230002763A1-20230105-C00001.CDX" mol-file="US20230002763A1-20230105-C00001.MOL"/><us-chemistry idref="CHEM-US-00002" cdx-file="US20230002763A1-20230105-C00002.CDX" mol-file="US20230002763A1-20230105-C00002.MOL"/><us-chemistry idref="CHEM-US-00003" cdx-file="US20230002763A1-20230105-C00003.CDX" mol-file="US20230002763A1-20230105-C00003.MOL"/><us-chemistry idref="CHEM-US-00004" cdx-file="US20230002763A1-20230105-C00004.CDX" mol-file="US20230002763A1-20230105-C00004.MOL"/><us-chemistry idref="CHEM-US-00005" cdx-file="US20230002763A1-20230105-C00005.CDX" mol-file="US20230002763A1-20230105-C00005.MOL"/><us-chemistry idref="CHEM-US-00006" cdx-file="US20230002763A1-20230105-C00006.CDX" mol-file="US20230002763A1-20230105-C00006.MOL"/><us-chemistry idref="CHEM-US-00007" cdx-file="US20230002763A1-20230105-C00007.CDX" mol-file="US20230002763A1-20230105-C00007.MOL"/><claims id="claims"><claim id="CLM-01-20" num="01-20"><claim-text><b>1</b>.-<b>20</b>. (canceled)</claim-text></claim><claim id="CLM-00021" num="00021"><claim-text><b>21</b>. A compound comprising a modified oligonucleotide consisting of 12 to 30 linked nucleosides, wherein the nucleobase sequence of the modified oligonucleotide comprises at least 8 contiguous nucleobases of the nucleobase sequence recited in SEQ ID NOs: 40, 41, 45, 117, 122, 202, 251, 254, 265, 268, 271, 281, 429-447, or 490-500.</claim-text></claim><claim id="CLM-00022" num="00022"><claim-text><b>22</b>. The compound of <claim-ref idref="CLM-00021">claim 21</claim-ref>, wherein the nucleobase sequence of the modified oligonucleotide is 100% complementary to SEQ ID NO: 1.</claim-text></claim><claim id="CLM-00023" num="00023"><claim-text><b>23</b>. The compound of <claim-ref idref="CLM-00021">claim 21</claim-ref>, wherein the modified oligonucleotide has the nucleobase sequence recited in SEQ ID NOs: 40, 41, 45, 117, 122, 202, 265, 281, or 429-447.</claim-text></claim><claim id="CLM-00024" num="00024"><claim-text><b>24</b>. The compound of <claim-ref idref="CLM-00021">claim 21</claim-ref>, wherein the modified oligonucleotide has the nucleobase sequence recited in SEQ ID NOs: 40, 41, 45, 117, or 122.</claim-text></claim><claim id="CLM-00025" num="00025"><claim-text><b>25</b>. The compound of <claim-ref idref="CLM-00021">claim 21</claim-ref>, wherein the modified oligonucleotide has the nucleobase sequence recited in SEQ ID NOs: 251, 268, or 490-500.</claim-text></claim><claim id="CLM-00026" num="00026"><claim-text><b>26</b>. The compound of <claim-ref idref="CLM-00021">claim 21</claim-ref>, wherein the modified oligonucleotide has the nucleobase sequence recited in SEQ ID NO: 254 or 271.</claim-text></claim><claim id="CLM-00027" num="00027"><claim-text><b>27</b>. The compound of <claim-ref idref="CLM-00021">claim 21</claim-ref>, wherein the modified oligonucleotide has a sugar motif selected from eeeee-d9-eeeee, ekk-d9-kke, eekk-d8-kkeee, ekek-d8-kekee, ekk-d8-kkeee, eeekk-d7-kkeee, or eekek-d7-kekee; wherein k is a cEt sugar moiety, e is a 2&#x2032;-OCH<sub>2</sub>CH<sub>2</sub>OCH<sub>3 </sub>ribosyl sugar moiety, and d is a 2&#x2032;-deoxyribosyl sugar moiety.</claim-text></claim><claim id="CLM-00028" num="00028"><claim-text><b>28</b>. The compound of <claim-ref idref="CLM-00027">claim 27</claim-ref>, wherein the modified oligonucleotide has a eeeee-d9-eeeee sugar motif.</claim-text></claim><claim id="CLM-00029" num="00029"><claim-text><b>29</b>. The compound of <claim-ref idref="CLM-00027">claim 27</claim-ref>, wherein the modified oligonucleotide has a ekk-d9-kke sugar motif.</claim-text></claim><claim id="CLM-00030" num="00030"><claim-text><b>30</b>. The compound of <claim-ref idref="CLM-00027">claim 27</claim-ref>, wherein the modified oligonucleotide has a eekk-d8-kkeee sugar motif.</claim-text></claim><claim id="CLM-00031" num="00031"><claim-text><b>31</b>. The compound of <claim-ref idref="CLM-00027">claim 27</claim-ref>, wherein the modified oligonucleotide has a ekek-d8-kekee sugar motif.</claim-text></claim><claim id="CLM-00032" num="00032"><claim-text><b>32</b>. The compound of <claim-ref idref="CLM-00027">claim 27</claim-ref>, wherein the modified oligonucleotide has a ekk-d8-kkeee sugar motif.</claim-text></claim><claim id="CLM-00033" num="00033"><claim-text><b>33</b>. The compound of <claim-ref idref="CLM-00027">claim 27</claim-ref>, wherein the modified oligonucleotide has a eeekk-d7-kkeee sugar motif.</claim-text></claim><claim id="CLM-00034" num="00034"><claim-text><b>34</b>. The compound of <claim-ref idref="CLM-00027">claim 27</claim-ref>, wherein the modified oligonucleotide has a eekek-d7-kekee sugar motif.</claim-text></claim><claim id="CLM-00035" num="00035"><claim-text><b>35</b>. The compound of <claim-ref idref="CLM-00021">claim 21</claim-ref>, wherein the modified oligonucleotide comprises at least one phosphorothioate internucleoside linkage.</claim-text></claim><claim id="CLM-00036" num="00036"><claim-text><b>36</b>. The compound of <claim-ref idref="CLM-00021">claim 21</claim-ref>, wherein the compound is conjugated.</claim-text></claim><claim id="CLM-00037" num="00037"><claim-text><b>37</b>. A pharmaceutical composition comprising the compound of <claim-ref idref="CLM-00021">claim 21</claim-ref> and a pharmaceutically acceptable carrier or diluent.</claim-text></claim><claim id="CLM-00038" num="00038"><claim-text><b>38</b>. The pharmaceutical composition of <claim-ref idref="CLM-00037">claim 37</claim-ref>, wherein the pharmaceutically acceptable diluent is phosphate-buffered saline (PBS).</claim-text></claim><claim id="CLM-00039" num="00039"><claim-text><b>39</b>. A method of ameliorating a symptom of Huntington's disease, comprising administering the compound of <claim-ref idref="CLM-00021">claim 21</claim-ref> to a subject in need thereof.</claim-text></claim></claims></us-patent-application>